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Amino acids containing quaternary centres can be accessed by the alkylation or arylation of tertiary 
amino acid enolates. The arylation of tertiary amino acid enolates, however, has proved problematic 
due to the challenging Csp3–Csp2 coupling. Many of the methods available for the arylation of 
tertiary amino acid enolates are not general and many of them give racemic products or rely on 
heavy metal catalysis. -Aryl quaternary amino acids form components of several bioactive 
compounds; hence the need for a general, metal free route towards their enantioselective synthesis. 
 
In this work, the intramolecular arylation of amino acid enolates employing either phase transfer 
catalysis (PTC), self-regeneration of stereocentres (SRS) or a chiral auxiliary approach in inducing 
enantioselectivity has been developed. All the methods take advantage of the unusual ability of 
metallated Nꞌ-aryl,N-benzyl ureas to undergo aryl migration from the urea distal nitrogen to the 
benzylic methylene. For the first time, N to C aryl migration in tertiary amino acid-derived Nꞌ-aryl 
ureas was facilitated by the use of mild inorganic bases, and this led to the formation of new 
quaternary amino acid derivatives arylated at the -carbon. In addition, the mild conditions of 
photoredox catalysis was used to initiate radical conjugate addition to Nꞌ-aryl urea derivatives of 
dehydroalanine (Dha) and subsequent intramolecular arylation of the enolate formed. To the best 
of the author’s knowledge, illustrated in this thesis, is the first example of the synthesis of -aryl 
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1.1 Amino Acids 
Amino acids, as the name implies, are compounds containing an amine (NH2) group and a 
carboxylic acid (CO2H) group; other functional groups might be present in them as well.1 There 
exists 21 naturally occurring -amino acids that form components of protein in living organisms,2 
these amino acids have as a general formula: NH2CHRCO2H (Figure 1). The side chain, which is 
the substituent R bonded to the -carbon, varies from one amino acid to the other. When R is a 
substituent other than H, a stereogenic carbon centre is formed. -Amino acids exist in nature as 
the single L-enantiomers.3,4 
 
Figure 1: General structure of an -amino acid 
The conformational properties of amino acids allow them to finely modulate the precise chemical 
architectures required for biological functions.5,6 Amino acids are synthesised for use as drugs, 
supplements, flavour enhancers and preservatives. The most common methods for making them are 
the Strecker synthesis, alkylation of an acetamidomalonate and the nucleophilic substitution 
reaction of ammonia with a -haloacid.7,8 
1.2 Quaternary Amino Acids 
A quaternary amino acid manifests when the -carbon of an amino acid has four substituents 
bonded to it (Figure 2).9 When R1 ≠ R2, the quaternary amino acid has potential for optical purity. 
 
Figure 2: General structure of a quaternary amino acid 
In the past few decades, the synthesis of quaternary amino acids has enjoyed significant interest; 
this is because they have different properties from their tertiary amino acid homologues.5 
Incorporation of these quaternary amino acids into peptides induces a more robust helical secondary 
structure due to greater steric constraints and results in higher protein stability.10 An example are 
the -alkyl quaternary amino acids which have played an important role in the construction of 
peptides with more stable conformations.11–14 Quaternary amino acids have been shown to be 





acids, the cyclic quaternary amino acids, incorporate greater conformational restrictions into the 
structure of proteins because the amino acid is contained within a ring.16 
1.3 Synthesis of Quaternary Amino Acids 
Extensive research has been carried out on the synthesis of quaternary amino acids; as a result, 
several synthetic routes, both asymmetric (stereoselective) and non-asymmetric (non-
stereoselective), now exist towards these useful compounds.10,15,16 It is noteworthy that several 
methods exist for the stereoselective alkylation of amino acids; the stereoselective arylation of 
amino acids, on the other hand, remains challenging, due to the unreactivity of aromatic coupling 
partners as electrophiles towards enolates (Csp3–Csp2 bond formation). The most representative 
synthetic routes towards quaternary amino acids are reviewed in this report. 
1.3.1 The Chiral Auxiliary Approach 
Chiral auxiliary methodology has been particularly useful in the synthesis of -alkyl quaternary 
amino acids. It involves the alkylation of an amino acid enolate derivative. A chiral auxiliary is first 
incorporated into the amino acid derivative and a diastereoselective enolate alkylation is carried 
out.10 A disadvantage of this method is that two additional steps are required – the step required to 
insert the chiral auxiliary and the step required to remove it after the reaction. One significant 
example of the chiral auxiliary approach is Schöllkopf’s bis lactim ether methodology.17–19 The 
methodology involves the condensation of a racemic amino acid and enantiopure amino acid to 
form a heterocyclic intermediate. The enantiopure amino acid component in the heterocycle serves 
as the chiral auxiliary and induces diastereoselective -alkylation of the other amino acid 
component. On hydrolysis of the alkylated product, the chiral auxiliary is recovered along with the 






Scheme 1: Enantioselective alkylation of lactim ethers of cyclo-(L-Ala-L-Ala) 
In 1979, Schöllkopf et al. reported the enantioselective alkylation of lactim ethers of cyclo-(L-Ala-
L-Ala) (Scheme 1).20 The heterocycle 2 was built up from condensation of 2 molecules of methyl 
L-alaninate 1. Methyl L-alaninate served as both the chiral auxiliary component and the body of the 
new quaternary amino acid that would be formed. Heterocycle 2 was converted to the bis-methoxy 
lactim ether 3 by treatment with trimethyloxonium tetrafluoroborate. Treatment of 3 with nbutyl 
lithium gave the lithiated intermediate 4, which reacted with a variety of electrophiles to give the 
adducts 5. Hydrolysis of 5 liberated the new quaternary amino methyl ester 6 and the chiral auxiliary 
1. The chiral auxiliary 1 and the quaternary amino methyl ester 6 could be separated by distillation 
if they differ sufficiently in boiling point. They could also be hydrolysed to their respective amino 
acids, and the amino acids then separated by chromatography. One disadvantage of using a single 
amino acid in the construction of the bis lactim ether is that only half of the chiral auxiliary 1 is 
recovered, because the remaining is incorporated in the quaternary amino acid formed. To avoid 
this, Schöllkopf et al. carried out the alkylation of a bis lactim ether built up from two different 
amino acids (Scheme 2).21  
 





The bis lactim ether 7 was made from methyl D,L-alaninate and methyl L-valinate 9, of which 
methyl L-valinate served as the chiral auxiliary. Deprotonation and subsequent alkylation of 7 
occurred regioselectively, at the alanine residue. Hydrolysis of 8 led to full recovery of the chiral 
auxiliary 9 and the formation of 6. Higher levels of stereoselectivity were obtained with methyl L-
valinate as chiral auxiliary than with methyl L-alaninate. This was due to the steric hindrance created 
by the bulkier isopropyl group in valine. The electrophile enters 10 trans to the isopropyl group at 
C-6. With the bulkier isopropyl group, the facial differentiation is more pronounced than with a 
methyl group because the isopropyl group offers more shielding of one of the diastereotopic faces. 
The use of methyl D-valinate as chiral auxiliary led to the formation of the (S)-enantiomer. The bis 
lactim ether methodology has also been exploited to access optically active -methyl serine,22 -
alkenyl alanines,23 -methylphenylalanine, -methyldopa, -methyl--allylglycines21 and -
methyltryptophan.24  
Meyer et al. reported the diastereoselective alkylation of imino methyl alaninate 11 (Scheme 3).25 
The alaninate 11 was formed from condensation of an aldehyde chiral auxiliary and a racemic 
methyl alaninate. Deprotonation of 11 with LDA followed by alkylation using 3,4-dimethoxybenzyl 
bromide afforded the alkylated imino methyl alaninate 12 as a single diastereoisomer. On hydrolysis 
of 12, quaternary amino methyl ester hydrochloride salt 13, an enantiomerically pure derivative of 
(R)--methyldopa was obtained with excellent enantioselectivity.  
 
Scheme 3: Diastereoselective alkylation of alanine methyl ester using an aldehyde chiral auxiliary 
In a similar study, aldimines 14 obtained from amino esters and chiral aldehydes of a pyridoxal 
model were stereoselectively alkylated (Scheme 4).26 A range of aldimine substrates and bases were 
used in this study. Even though the chiral auxiliary component was located on the side chain of the 
aldimines, the reaction still proceeded with good stereoselectivity. The stereoselectivity of the 
reaction depended on the metal ion in the base and the side chain of the aldimines. Best yields and 
stereoselectivity were generally obtained when R2X in 14 was a 2-naphthylmethoxy group. NaH 






Scheme 4: Diastereoselective alkylation of amino esters using a pyridoxal type chiral auxiliary 
It was suggested that the Na+ counter ion of the base played an important role in stereoselectivity. 
Perhaps, it coordinates to the oxygen atoms of the chiral auxiliary, bringing them closer to the 
reactive centre (Scheme 5). Coordination of the sodium ion to the enolate of substrate 14 (R2X = 2-
naphCH2O) provides two possible transition states T1 and T2, in which the 2-naphthyl group 
shields one of the diastereomeric faces of the enolate. The transition state T1 offers more stability 
than T2 due to an extra coordination by the sodium ion to the oxygen of the 2ꞌ-methoxy moiety. In 
addition, steric repulsion between the 2ꞌ-methoxy moiety and the pyridine 2-methyl substituent in 
T2 causes instability of that transition state. Approach of the electrophile at the Re face in T1 and 
subsequent hydrolysis affords the major isomer.  
 





In the use of a chiral auxiliary, the amino acid synthesis is not always achieved by alkylation of 
amino acid derivatives. A requirement of the amino acid precursor is that it possesses functionality 
that can be converted to an amino acid after quaternisation. An example is the functionalisation of 
oxazolidine ester enolate 20 to produce 21 (Scheme 6).27 The chiral auxiliary is the amino alcohol 
17 which was converted to 20 by a sequence of reactions illustrated in Scheme 6. Direct hydrolysis 
of 21 revealed the serine side chain in 22. X-ray analysis of 22 (E = Me) showed that the alkylation 
occurred at the Si face of the enolate. Subsequent hydrogenolysis of 22 produced enantiopure -
substituted serine tert-butyl esters 23. 
 
Scheme 6: Asymmetric functionalisation of an oxazolidine ester enolate 
Many other examples exist in the literature on the synthesis of enantiopure quaternary amino acids 
through the diastereoselective alkylation of amino acid derivatives (Figure 3). Some of these 
examples include the use of an oxazolidinone chiral auxiliary as seen in 24,28 glycine derived chiral 
auxiliaries such as 25 and 27,29–32 a phenylethyl chiral auxiliary as seen in morpholinone 2633,34 and 
chiral auxiliaries built up into oxazinones as seen in 28 and 29.35–40 In all of these cases, alkylation 
is always followed by hydrolysis to produce enantiopure ,-disubstituted amino acids and recover 






Figure 3: Examples of amino acid derivatives diastereoselectively functionalised in the literature  
1.3.2 Self-Regeneration of Stereocentres 
The term ‘Self–Regeneration of Stereocentres’ (SRS)41 is used to describe the destruction and 
subsequent re-generation of a chiral centre present within an enantiopure molecule. Before the 
destruction of the chiral centre, a temporary chiral centre is diastereoselectively generated. The 
original chiral centre is then destroyed by the removal of a substituent. The temporary chiral centre 
then directs a diastereoselective introduction of another substituent at the previously destroyed 
chiral centre, hence reproducing chirality at that centre. The temporary chiral centre is then 
destroyed by hydrolysis, leaving behind the reproduced chiral centre without racemisation. The 
SRS protocol was developed by Dieter Seebach and has been applied to the synthesis of a variety 
of enantiopure compounds.42–44 For the asymmetric synthesis of quaternary amino acids, a chiral 
cyclic intermediate is usually formed from an enantiopure amino acid. On deprotonation of this 
intermediate, a chiral enolate having diastereomeric faces is formed; this can then be 






Scheme 7: Alkylation of oxazolidinones via SRS 
One of the earliest examples of the “SRS” principle in the synthesis of enantiopure quaternary 
amino acids is the functionalisation of the -carbon of proline 30 (Scheme 7).45,46 Direct 
introduction of a substituent to the -carbon of proline would ordinarily lead to a racemic 34. To 
prevent this, 30 was condensed with pivaldehyde to give a new chiral centre labelled with a pink 
asterisk in 31. The configuration of this new chiral centre was induced by the single chiral centre 
in 30. After crystallisation, the product 31 was obtained as a single diastereoisomer, in which the 
tert-butyl group was in the exo position having a cis relationship with the -proton in the proline 
residue. Treatment of 31 with LDA led to trigonalisation of the original chiral centre to produce the 
enolate 32. The enolate was able to react with a variety of electrophiles to produce 33 as essentially 
single diastereoisomers and with retention of configuration. The direction of entry of the 
electrophilic substituent was induced by the single chiral centre in the enolate 32 and occurs from 
the Re face of the enolate. This placed both the tert-butyl and the new substituent cis to each other 
and on the exo side of the bicycle. Hydrolysis of 33 (E = Me) led to the enantiopure -methyl 






Scheme 8: Synthesis of cis- or trans-imidazolidinones 
The original SRS protocol illustrated with proline in Scheme 7 could not be achieved with acyclic 
amino acids, as they did not readily form acetals under the conditions used. As a result of this 
shortcoming, another route was developed towards achieving chiral cyclic -amino acid derivatives 
that could be diastereoselectively -functionalised to attain enantiopure quaternary amino acids 
(Scheme 8).47 This route involves the conversion of an amino acid methyl or ethyl ester 
hydrochloride 35 to the methylamide 36. The methylamide is then condensed with pivaldehyde to 
afford the imine 37. Depending on the conditions used, 37 could be transformed to give 
predominantly the cis- or trans-imidazolidinones 38. These products could however be crystallised 
to obtain the single cis- or trans-isomers. This imidazolidinone route was later exploited for the 
synthesis of enantiopure quaternary amino acids (Scheme 9).48 
 





The cis- and trans-imidazolidinone derivatives of alanine, valine and methionine were converted to 
their respective quaternary amino acid derivatives 39 and 41, by deprotonation and subsequent 
alkylation. In all cases, ≥ 95% diastereoselectivity of 39 and 41 were observed by 1H NMR of the 
crude mixture. Relative and absolute configurations of selected examples of 39 and 41 were 
assigned by NOE analysis. Hydrolysis using several harsh acidic conditions led to the production 
of -alkylated -amino acids 40 and 42. The cis-imidazolidinone (cis-38) led to amino acids 40, in 
which the configuration of the tertiary amino acid precursor was retained while the trans-
imidazolidinone (trans-38) led to inversion of configuration in the amino acids 42. This strategy is 
valuable because opposite enantiomers of a quaternary amino acid are accessible by starting from 
a single enantiomer of the precursor tertiary amino acid. For example, (S)--methyldopa which 
shows antihypertensive activity,49,50 was exclusively accessed, without contamination by its 
biologically inactive (R)-enantiomer. 
Recently, Clayden et al. reported a completely diastereoselective method for making trans-
imidazolidinones (Scheme 10).51 The imines 43 were made from the corresponding tertiary amino 
acids through Seebach’s methyl amide protocol illustrated in Scheme 8. On treatment with 
phosgene and pyridine, the imines 43 underwent cyclisation and concomitant acylation, offering 
the trans-N-chloroformylimidazolidinones 44 with >99:1 dr in most cases. The acylated 
imidazolidinones 44 were considerably stable under basic conditions, hence they were -alkylated 
with several electrophiles to afford the quaternary amino acid derivatives 45. Hydrolysis to the 
quaternary amino acid was exemplified by treating selected examples of 45 with HCl/TFA to afford 
the quaternary amino acid 46a or the N-methyl amide 46b. 
 





Seebach’s imidazolidinone strategy was useful in the synthesis of a variety of important compounds 
such as derivatives of aspartic and glutamic acids52 and BIRT 377 63, a hydantoin used in the 
treatment of various inflammatory and immune disorders.42,43 However, the imidazolidinones 
usually require harsh conditions to be hydrolysed to the amino acids, hence limiting the incoming 
electrophiles to acid stable substituents. 
 
Scheme 11: Alkylation of acyclic amino acid derived oxazolidinones 
While investigating alternative scaffolds for the diastereoselective functionalisations, Seebach et 
al. found out that it was indeed possible to achieve the acetalisation of acyclic amino acids.53–55 
Going back to the original oxazolidinone route, the sodium salts of 47 were condensed with 
pivaldehyde to furnish the imines 48 (Scheme 11). Treatment of 48 with PhCOCl at or below room 
temperature led to diastereoisomers 49, in which the cis was the major diastereoisomer. 
Surprisingly, treating cis-49 with LDA and subsequent reaction with electrophiles led to low yields 
of 50. Using the less sterically hindered lithium diethylamide LDEA, 50 was obtained with good 
yields and diastereoselectivity of >90% before crystallisation. The hydrolysis of oxazolidinone 50 
(R = CH3, E = Bn) occurred under milder conditions than the corresponding imidazolidinone 
derivative.55 Seebach also extended the oxazolidinone strategy to reactions with aldehyde and 





acetaldehyde diastereoselectively to produce the hydroxyamide 53. Desulfurisation and hydrolysis 
of 53 produced -ethylthreonine 54. The (2S),(3R)-configuration of 54 was obtained by comparison 
with the 1H NMR of its known diastereoisomer.56 
 
Scheme 12: Functionalisation of an oxazolidinone with an aldehyde 
In 2001, Zhang et al.57 reported the synthesis of (2S)--(hydroxymethyl) glutamate (HMG) 57 
(Scheme 13). HMG exhibits metabotropic glutamate receptor agonist activity. After several 
disappointing results with formyl and Boc N-protecting groups, they decided to try serine-derived 
oxazolidine with a methoxy carbonyl N-protecting group 55. Using LDA as base, oxazolidine 55 
was subjected to a Michael addition with ethyl acrylate to afford the bicycle 56 as a single 
diastereoisomer. The bicycle was then hydrolysed to afford HMG 57 in high yield. 
 
Scheme 13: Synthesis Of (2S)--(hydroxymethyl) glutamate (HMG) through SRS 
Pivaldehyde has been widely used as auxiliary in “SRS” reactions. This is because the tert-butyl 
group induces good diastereoselectivity due to its bulkiness, it is easily hydrolysed, it is unreactive 
and quite easy to identify by 1H NMR, as it gives just a singlet in a clearly defined area of the 
spectrum.41 Notwithstanding the use of other auxiliaries have been reported. Kapadia et al. adopted 
the SRS principle in the enantioselective synthesis of -(4-bromo benzyl) alanine ethyl ester 62 
through an oxazolidinone (Scheme 14). 58 The oxazolidinone 60 was synthesised predominantly as 
the cis-diastereoisomer by the reaction of the acylated alanine 58 with benzaldehyde dimethyl acetal 
59. Both zinc chloride and thionyl chloride were necessary for the reaction to occur, as reduced 
equivalents of either of them led to incomplete reaction. Addition of a mixture of 60 and 4-
bromobenzyl bromide in THF to KHMDS afforded the alkylated product 61. The alkylation was 
stereoselective and occurred trans to the phenyl ring. Hydrolysis of 61 was then carried out using 
hydrogen bromide in acetic acid to give the amino acid hydrobromide which was stirred in ethanol 
at 70 °C in the presence of HCl gas to afford the amino ester 62 with greater than 99% ee. The 






Scheme 14: Alkylation of an oxazolidinone through SRS 
Another class of heterocyclic system through which quaternary amino acids could be accessed using 
the SRS principle is the tetrahydropyrimidinones (Scheme 15). Tetrahydropyrimidinone 65 was 
obtained from (S)-asparagine 64, isobutyraldehyde and benzoyl chloride. It was then converted to 
the enantiopure pyrimidinone imino ester 66. The lithium enolate of 66 was then alkylated by 
various electrophiles to afford the trans alkylated product 67 with >97% de. The authors suggested 
that the high stereoselectivity in the reaction of the lithium enolate of 66 with the electrophiles 
might be due to the steric hindrance produced by the isopropyl group. Hence, the electrophiles were 
directed to the face of the enolate opposite the isopropyl group. Hydrolysis of 67 afforded 
enantiopure -alkyl aspartic acids 68.59 
 





In a case similar to the SRS strategy, quaternary (R)-(2-trialkylstannyl)vinyl amino acids were 
synthesised through cyclic oxazoline intermediates (Scheme 16).60 A temporary chiral centre was 
first introduced into the N-benzoyl-protected L-vinyl glycine 69 through an episelenonium ion-
mediated 5-exo-trig cyclisation. The L and D isomers of 70 produced were easily separated by SiO2 
chromatography. Both isomers were separately subjected to alkylation to produce the new 
quaternary centre in 71 with >95% de. The temporary chiral centre was destroyed, and the original 
vinyl moiety unmasked by basic hydrolysis to yield 72. The ring opening reaction was 
stereoselective, producing only the E-isomer of 72. Substitution reaction of 72 with Bu3SnH 
followed by protodestannylation afforded the -alkyl vinyl amino acids 74. 
 
Scheme 16: Synthesis of -alkyl,-vinyl amino acids through the SRS principle 
To investigate the effect of substituents on the -position of the neurokinin-1 receptor antagonist 
CI 1021 (82), Ashwood et al.61 carried out the alkylation of tryptophan through a 
tetrahydropyrroloindole intermediate (Scheme 17). Allyl esterification of 75 afforded 76 with slight 
racemisation when DMAP was used as catalyst. There was no racemisation in the absence of 
DMAP, but the reaction was slower. 76 was subjected to a cyclisation reaction catalysed by TFA 
to afford 77, which was isolated as a single diastereoisomer. The indolinyl nitrogen of 77 was 
protected with a benzyloxycarbonyl (Cbz) group to afford 78 in excellent yield. Alkylation of 78 
proceeded in good yield and was diastereoselective at the -carbon. Ring opening reaction of 79 to 





yield the free quaternary amino acids 81. The amino acid 81 was finally used to make several -
substituted derivatives of the neurokinin-1 receptor antagonist CI 1021 (82). 
 
Scheme 17: Alkylation of tetrahydropyrroloindoles through the SRS principle 
1.3.3 Memory of Chirality 
The term “Memory of Chirality” (MOC) is used to describe reactions in which the stereochemistry 
of a reactant having one chiral centre is retained temporarily in an intermediate formed from 
destruction of the single chiral centre, and as a result, products formed from reaction with this 
intermediate retain the stereochemistry of the reactant. It is noteworthy that this process occurs 
without the influence of an external source of chirality.62 In the synthesis of quaternary amino acids, 
the intermediate formed is an enolate and reaction of this enolate with non-chiral electrophiles 
proceeds enantiospecifically without any other chiral influence.62,63 This is remarkable because 
deprotonation of the -carbon of the only chiral centre in a carbonyl compound should in principle 
lead to the loss of stereochemical information in the enolate intermediate, hence leading to the 






Scheme 18: Alkylation of the only chiral centre present in a molecule without complete loss of optical 
purity 
In 1981, while investigating the -alkylation of the enantiopure aspartic acid derivative 83, Seebach 
et al. observed that -alkylated product 85 was formed with a 60% enantiomeric excess (Scheme 
18). Surprised at the result, they attributed the enantioretention to either complexes of achiral 
enolate 84 to the chiral enolate 8641,64 or the enolate 84 itself existing in a sufficiently stable 
conformation that possesses axial chirality.65–67 Kawabata et al. explained that it was possible for 
an enolate to exist in a conformationally chiral form, whose lifetime is dependent on the temperature 
of reaction (Scheme 19). The enolate conformations 88 and ent-88 interconvert rapidly and may 
not be differentiated at elevated temperatures. At lower temperatures, the enolate could persist 
sufficiently in one conformation for it to get quenched by the electrophile in that conformation.68 
 
Scheme 19: Interconversion between two conformational forms of an enolate 
To demonstrate the explanation above, Kawabata carried out some variable-temperature alkylations 
of 90. Enolate formation at −78 °C produced an enantiomeric excess of 82% in 91 (Scheme 20).68 
Enolate formation at −78 °C and subsequent warming to −40 °C led to a significant reduction in the 





produced racemic 91. These experiments indicate that racemisation of the enolate intermediate 
occurs with increase in temperature. 
 
Scheme 20: Enantiospecific alkylation of an L-phenylalanine derivative through memory of chirality 
To demonstrate the generality of the MOC strategy in enantioselective quaternary amino acid 
synthesis, Kawabata et al. investigated the methylation of derivatives of amino acids such as phenyl 
alanine, histidine, valine, leucine, tryptophan, tyrosine and dopa (Scheme 21).69 Prior investigations 
showed that having a MOM group as substituent on the nitrogen as seen in 92 produced better 
results than a methyl group.68 The methylation of 92 occurred stereoselectively and with 
comparable enantioretention for all the amino acids used. 
 
Scheme 21: (a) Direct enantiospecific -methylation of -amino acid derivatives (b) A chiral C1-N axis 
Further investigations into the source of enantioretention revealed that there is hindered rotation 
about the C1-N bond which produces axial chirality in the enolate. The stereochemical outcome of 
the reaction was explained using 92 (R = Bn). The substrate 92 (R = Bn) can exist as two 
conformers. Deprotonation of the more stable conformer (Cs) leads to formation of the N-chiral 
enolate 94. The half-life of racemisation of 94 at −78 °C was calculated to be 22 h, which is enough 
time for the enolate to attack the electrophile. The methyl electrophile approaches 94 at the direction 






Scheme 22: Proof of the presence of an axially chiral enolate intermediate 
Since axial chirality will not exist with two identical groups on the nitrogen, the methylation of 95 
occurring with complete racemisation (Scheme 22) was proof that the alkylation of amino acids 
through the MOC strategy takes place through an axially chiral enolate intermediate.69 
 
Scheme 23: Intramolecular alkylation of amino acid derivatives through a MOC strategy 
Kawabata et al. later developed an enantioselective intramolecular alkylation of amino acid 
derivatives 97 at ambient temperature (Scheme 23).70 From the outcome of previous investigations, 
it was assumed that a MOC strategy at ambient temperature would result in diminished 
enantioselectivities. However, excellent enantioselectivity was observed. It was proposed that this 
was due to the intramolecular nature of the reaction. Because both alkylating agent and enolate were 
within the same molecule, the rate of alkylation was able to outcompete the rate of racemisation of 
the chiral enolate. The enolate formation step was found to be the rate-determining step and it was 
calculated that after formation of this enolate, it would have to undergo cyclisation within 
approximately 10 ms at 20 °C to produce an ee of ≥88%. The excellent enantioselectivities implied 
cyclisation occurred as soon as the enolate was formed. The smaller the ring, the faster the rate of 
cyclisation; hence four-membered cyclic amino acids were obtained faster and with better 
enantioselectivities than the corresponding 6-membered ring amino acids. 
 





Synthesis of quaternary amino acids by aldol reactions using the MOC strategy has been reported. 
Oxazolidinone 100 obtained from L-alanine71 underwent condensation with aldehydes, with 
retention of configuration to produce -hydroxy quaternary -amino acid derivatives 101 (Scheme 
24). Hydrolysis of some examples of 101 led to -hydroxy quaternary -amino acids 102 in up to 
99% ee.72 The retention of configuration in 101 was due to the dynamic axial chirality in the tertiary 
aromatic amide of 100.71,73 The derivative 101 was obtained as a mixture of two separable 
diastereoisomers. The temperature, rate, and order of addition of 100, the aldehyde and KHMDS 
was relevant to obtaining good diastereoselectivity. The ee of the major diastereoisomer of 101 was 
80 – 94%, but upon crystallisation, an ee of 99% was obtained. 
 
Scheme 25: Observed stereoselectivity in the synthesis of 101 
The major diastereoisomer formed in each reaction was dependent on the structural component of 
the aldehyde used (Scheme 25).72 Sterically hindered aldehydes such as ortho-substituted 
benzaldehydes were selective towards the transition state 103, hence producing 104. Aldehydes 
containing electron donor atoms such as furaldehyde favoured the transition state 105. This is 
probably because donor atoms in the pseudo axial position will stabilise the transition state 105 
more by coordinating with the metal. 
1.3.4 Addition of Nucleophiles to C=N Bond 
The Strecker synthesis, which involves the reaction of an aldehyde with ammonia and a cyanide, 
with subsequent cyanide hydrolysis, has been an attractive tool for the synthesis of tertiary amino 
acids.74,75 In the enantioselective synthesis of quaternary amino acids through the Strecker route, an 





two groups attached to the carbonyl of the ketone become the two side chains of the quaternary 
amino acid. An example is the construction of -methyl phenylglycine derivatives from -aryl 
ketones, phenyl glycinol and TMSCN (Scheme 26).76 
 
Scheme 26: Asymmetric Strecker-type synthesis of alkylated phenylglycine amino esters 
-Aryl ketone 107 was heated with the amine (R)-phenylglycinol 108 in toluene to obtain a mixture 
of imine 109 and oxazolidine 110. The mixture of 109 and 110 might exist as an equilibrium. The 
mixture was subjected to treatment with trimethylsilyl cyanide in methanol to obtain the amino 
nitrile which was then treated with saturated methanolic HCl to obtain the amino ester 111 as a 
mixture of two diastereoisomers. The diastereoisomers, which were obtained as a 2:1 mixture for 
amino ester 111a and a 2.5:1 mixture for amino ester 111b, were not easily separable by column 
chromatography. Protection with a benzyloxycarbonyl group made it possible to separate the 
diastereoisomers by column chromatography. The major diastereoisomer 113b was isolated and 
used in the synthesis of (S)--M4CPG 11477–79 and (S)-MPPG 115 (Figure 4).80 The synthesis of 
114 and 115 confirmed that the stereochemistry of the major diastereoisomer of 111 was (R,S). The 
method was also extended to the synthesis of (S)-AIDA 11681 and (S)-APICA 117 (Figure 4)82 






Figure 4: Antagonists of metabotropic glutamate receptor 
Sulfinimines are good chiral directing groups for the diastereoselective synthesis of quaternary 
amino acids and can be cleaved under acidic conditions.83–85 The stereoselective addition of a 
cyanide to enantiopure N-sulfinyl ketimine was carried out (Scheme 27).86 
 
Scheme 27: Synthesis of (R)--phenylserine through an asymmetric Strecker reaction 
N-Sulfinyl ketimine (R)-120, obtained from condensation of silyl protected 2-hydroxy 
acetophenone 119 with the amine (R)-tert-butanesulfinamide, was subjected to an addition reaction 
with ethyl aluminium cyanoisopropoxide to afford 121 in an 81:19 mixture of the two 
diastereoisomers. The major diastereoisomer (R,R)-121 was isolated through column 
chromatography. Hydrolysis of (R,R)-121 with 12 M HCl, followed by reflux with propylene oxide 
in ethanol liberated the free amino acid (S)-122 in 93% yield. (R)--Phenylserine (R)-122 was 






Scheme 28: Synthesis of (R)-(-)-2-methylserine through stereoselective addition of Grignard reagent to a 
chiral nitrone; LA = Lewis acid 
In the Strecker method discussed, the carboxylic acid group was introduced through a cyanide. 
Alternatively, the side chain of the amino acid could be introduced by the addition of organometallic 
reagents to an imine. An example was that reported by Portolés et al. (Scheme 28).87 A Grignard 
reagent was used to introduce the side chain of the amino acid. Nitrone 124, obtained from the 
reaction of silylated L-erythrulose acetonide 123 with N-benzyl hydroxyl amine was initially 
reacted with several Grignard reagents to afford N-acetoxyamine derivatives such as 125 as a 
mixture of two diastereoisomers. The results showed that the diastereomeric ratio depended on the 
Grignard reagent used. Allyl and phenyl Grignard reagents were particularly stereoselective. It was 
observed that the presence of a Lewis acid in the Grignard reaction favoured one diastereoisomer 
over the other. ZnBr2, for example, favoured the diastereoisomer with an (R)-configuration at the 
new stereocentre while Et2AlCl showed poor diastereoselectivity or in some cases, complete 
reversal in diastereoselectivity in favour of the diastereoisomer having a (S)-configuration at the 
new stereocentre. In the synthesis of (R)-(-)-2-methyl serine 128, sequential treatment of 125 with 
periodic acid, sodium chlorite and diazomethane afforded the N-acetoxy--amino esters 126. 
Deprotection of 126 with TBAF/THF afforded 127, which on hydrogenolysis followed by 
hydrolysis furnished (R)-(-)-2-methyl serine 128. 
1.3.5 Phase Transfer Catalysis 
The term “phase transfer catalysis” (PTC)1 was introduced by Stark in 1971 to describe the role of 
tetra-alkylammonium or phosphonium salts in the reaction between substances at the interface 
between immiscible phases.88 A reaction is inhibited when the reactants are separated by solvation 
 






in two different immiscible phases. The reaction, however, can be made possible using a phase 
transfer catalyst, due to the ability of the catalyst to transfer a reactant from one phase to another. 
Organic-soluble quaternary ammonium or phosphonium cations are effective in transferring anions 
from aqueous phases to organic phases.89 An example is the phosphonium salt-catalysed SN2 
reaction of 1-chlorooctane 129 and aqueous sodium cyanide (Scheme 29). 
 
Scheme 29: SN2 reaction of 1-chlorooctane with aqueous sodium cyanide under phase transfer catalysis 
There was no reaction without the phosphonium catalyst 130; however, when 130 was introduced, 
the reaction proceeded with 94% yield. The generation of quaternary phosphonium cyanide makes 
the cyanide anion organic soluble, facilitating the reaction.88 
PTC has enjoyed significant attention in both industrial and academic research, this is because of 
the simplicity of the process. The process eliminates the use of expensive and environmentally 
unfriendly reactants/solvents, it employs the use of mild reaction conditions and has the possibility 
of being performed on a large scale. Asymmetric phase transfer catalysis involves the use of a chiral 
catalyst for the transfer of a reactant from one phase to the other where reaction can occur. The 
chirality of the catalyst interacts with a reactive intermediate, hence inducing enantioselectivity in 
the product formed from the intermediate. PTC has been applied to a variety of reactions such as 
the asymmetric alkylation of amino acid derived imines, Michael addition, aldol reaction and 
Mannich reaction.90 The most widely used catalysts in the synthesis of quaternary amino acids under 
PTC are the cinchona-derived ammonium salts.91 
 





In 1992, O’Donnel et al. carried out the solid-liquid phase catalytic alkylation of alanine-derived 
imines 132 (Scheme 30).92 Of all the bases examined, best enantioselectivities and yields were 
obtained with a ground mixture of potassium hydroxide and potassium carbonate. Investigation of 
several aryl groups in 132, revealed 132a (Ar = 4-ClC6H4) as the optimal in achieving good yields 
and enantioselectivities of 133. Other aryl groups made 132 significantly inactive under the 
KOH:K2CO3 system. By using epimers 135a or 136, either enantiomer of 133 could be accessed as 
the major product. However, 136 induced better enantioselectivity than 135a in the alkylation of 
132a. The use of catalyst 136 in the alkylation afforded the alkylated products 133 in up to 50% ee 
in favour of the (R)-enantiomer. As expected, alkylation of enantiopure 132 derived from L-alanine 
with an achiral catalyst afforded racemic product while alkylation of racemic 132 derived from D,L-
alanine with the chiral catalyst 136 afforded enantioenriched product. Though the alkylated 
products 133 were obtained in moderate to good enantioselectivities, a pure enantiomer could be 
obtained by crystallisation of the racemate.93 For example, the amino acid 134 was obtained in 
greater than 97% ee by hydrolysis of enantiopure 133 (R = 4-ClC6H4CH2), which was obtained by 
two recrystallisations to remove racemic product from the corresponding racemate. 
N-9-anthracenyl-bearing cinchona salts such as 138 were independently designed by the groups of 
Lygo94 and Corey.95 Corey explained that the quinuclidinyl nitrogen of cinchona-derived salts could 
be likened to the centre of a tetrahedron and effective shielding of three faces of the tetrahedron 
could be relevant to obtaining excellent enantioselectivities. The quinuclidine ring already offers 
effective shielding of one of the three tetrahedral faces. The introduction of a bulky substituent such 
as a 9-anthracenyl on the nitrogen of the quinuclidine serves as a shield for a second face and 
provides an additional advantage of positional rigidity. The third face may be shielded by the 
introduction of an allyl or benzyl on the hydroxyl group as seen in 139. Hence, substrate interaction 
with the cinchona salt at those 3 faces becomes difficult, thus leaving the fourth face of the 






Scheme 31: -Alkylation of alanine using a 9-anthracenyl-bearing cinchona salt 
Application of N-9-anthracenylmethyl dihydrocinchonidinium bromide 138 as catalyst in the 
alkylation of the alanine-derived imine 132a was performed (Scheme 31).97 The chloride analogue 
of 138 was reportedly used as catalyst in the alkylation of a glycine derived imine under phase 
transfer catalytic conditions, inducing an enantioselectivity of 94%.94 It should be noted that the 
active catalyst in the alkylation of amino acids using cinchona salts bearing a free hydroxyl group 
at the C-9 position is the O-alkylated form which is generated in situ; Hence, a new active catalyst 
is formed with each change in the R-group of RX.94,98 Research showed that the nature of the 
alkylating group has an influence on the enantioselectivity. A 22% increase in ee was observed 
when a pre-formed C9-O-benzyl cinchona salt was used in place of a pre-formed C9-O-
methoxymethyl cinchona salt in the benzylation of glycine derived imines. Nevertheless, the pre-
formed C9-O-benzyl cinchona salt gave the same er as the in situ formed equivalent.99 Similar 
conditions to that used by O’Donnel in Scheme 30 were used in the alkylation of 132a. The 
potassium carbonate/hydroxide mixture had to be freshly ground because the use of a moisture 
absorbed base led to decrease in rate and enantioselectivity. The tert-butyl ester 132a gave best 
enantioselectivities than other esters. Alkylation of 132a with alkyl halides, followed by subsequent 
hydrolysis afforded 137 in moderate to good enantioselectivities. The best ees were obtained with 
benzylhalides such as benzyl bromide. Investigations into the reaction revealed that there were some 
background uncatalysed alkylations occurring, rationalising low ees observed in some cases. 
Optimisation of the reaction to minimise the background alkylations could improve the 







Figure 5: Influence of electronics of the catalyst on enantioselectivity; Conditions: alkylation of a glycine 
derived imine in PhMe:CHCl3 (7:3) with 50% KOH at 0 °C, 10 mol% of catalyst used in each case 
Jew et al. studied the electronic influence of the quinuclidine N-substituents on the 
enantioselectivity in the alkylation of a glycine derived imine.91,100 Since enantioinduction is 
facilitated by coordination of the chiral ammonium cation of the catalyst with the enolate formed 
on deprotonation of the amino acid, it is expected that the electronic effects of the N-substituents 
might have an influence on enantioselectivity. Ortho-substituted benzylic N-substituents generally 
produced better enantioselectivities than the para and meta substituted. Additionally, bulky ortho 
substituents on the benzyl gave reduced ees relative to the less bulky ones. Particularly, the ortho-
fluorobenzyl derivative 140 gave a significantly better ee than the unsubstituted benzyl derivative 
141 (Figure 5). Further investigations with cinchona-based catalysts having differential fluorine 
substitutions on the N-benzyl revealed that a single fluorine atom at the ortho position of the N-
benzyl substituent was significant in obtaining enhanced enantioselectivities in the alkylation. This 
could be due to the ability of the fluorine atom to hydrogen bond with the hydroxyl group through 
water present in the solvent (see 147). This intramolecular hydrogen bonding produces a more rigid 
catalyst conformation. Catalysts 144 and 146, which have hydrogen-bond acceptor atoms on the 





acceptor atoms. This further supported the hypothesis that the potential for intramolecular hydrogen 
bonding within the catalyst could be the source of enhanced ees in the alkylation. 
 
Scheme 32: -Alkylation of alanine using a 2,3,4-trifluorobenzyl-bearing cinchona salt 
The use of catalyst 151c, having a 2,3,4-trifluorobenzyl N-substituent, induced excellent 
enantioselectivities in the alkylation of the alanine derived imine 148 in favour of the (S)-
enantiomer (Scheme 32).101 The unsubstituted N-benzyl derivative 151a gave a significantly 
reduced ee relative to 151c. The 9-anthracenyl derivative 151b also gave a reduced ee relative to 
151c but an improved ee relative to 151a. These reactions further show the influence of the sterics 
and electronics of the catalyst on the enantioselectivity of the alkylation. It was also observed that 
improved enantioselectivities were obtained at cryogenic temperatures.  
The general mechanism for arylation or alkylation of amino acids under liquid-liquid phase transfer 
catalysis involves the deprotonation of the amino acid derivative 152 at the solvent-solvent interface 
by the base 153 to give the enolate 154 (Scheme 33).102 The enolate is transported into the organic 
layer by coordinating with quaternary ammonium ion (Q+) from the catalyst 156. The chiral 







Scheme 33: Mechanism of alkylation of -amino acids under PTC conditions 
In the mechanism, the step involving the coordination of the enolate to the chiral quaternary 
ammonium ion of the catalyst is the step necessary to induce asymmetry. Computational studies of 
the quaternary ammonium ion 159 and the glycine-derived enolate 160 revealed that the catalyst 
fragments, in order of relevance, for binding to the enolate are the quinuclidine (A) > the benzyl 
(E) > the hydroxyl (C) fragment (Figure 6).102 The positive charge on the quinuclidine nitrogen is 
dispersed over fragment A and E, hence A and E interact with the enolate through coulomb 
attractions while fragment C interacts with the enolate through hydrogen bonding. Hence, to 
improve enantioselectivity in the alkylation reactions, the fragments A, C and E might be the 
fragments to consider for synthetic modification. The vinyl (B) and quinoline (D) fragments do not 
bind to the enolate, rather they tend to repel the enolate as it interacts with fragments A and E. The 
vinyl fragment plays no role in enantioselectivity; However, the quinoline fragment, even though 
it does not bind to the enolate, plays an important role by acting as a platform for the enolate to bind 
to the relevant fragments. The catalyst interacts with all labelled fragments of the enolate, but it is 
mostly attracted to fragments H and I. 
 






Apart from the cinchona alkaloids, another class of catalysts that has been used in the asymmetric 
alkylation of -amino acids are the C2-symmetric chiral ammonium salts designed by Maruoka.103–
105 The one pot double alkylation of the tert-butyl ester of glycine-derived imine 161 using the C2-
symmetric catalysts 162a and 162b was investigated.106 The enantioselectivity induced by 162b, 
bearing fluorine substituents on the aryl group, was significantly higher than that induced by 162a, 
bearing a naphthyl group. These results suggest that in the design of new catalysts for asymmetric 
alkylation, modification of the electronic nature of the catalyst might be more important than steric 
factors. Catalyst 162b was later used in the double alkylation with several alkyl halides (Scheme 
34). 
 
Scheme 34: Double alkylation of glycine-derived imine using a C2-symmetric chiral catalyst 
The first alkyl halide was added at −10 °C, and left for 2 to 3.5 hours before adding the second alkyl 
halide at 0 °C. The quaternary amino acids 163 were obtained in up to 98% ee. The generality in 
the use of 162b was demonstrated in the alkylation of alanine and phenylalanine-derived aldimines 
164 and 166 (Scheme 35). Excellent yields and enantioselectivities of the alkylated amino acids 






Scheme 35: (a.) Alkylation of an alanine-derived imine using 162b (b.) Alkylation of a phenylalanine-
derived imine using 162b 
In 2014, Maruoka et al. reported the highly enantioselective catalysed -arylation of amino acid 
derivatives 168 using nitrofluoroarenes 169 as electrophiles (Scheme 36).107 The arylation was 
however limited to electron-deficient arenes. A chloride on 169 was not effective enough a leaving 
group, hence the best leaving groups were found to be a fluoride or triflate. The catalyst (S)-171 
induced better enantioselectivities than 162b, hence it was used in the arylation scope. The arylation 
was tolerant of various amino acids such as alanine, ethylglycine, methionine and phenylalanine. 
When an electron-donating group such as a methyl was introduced as a substituent on 169, the rate 
and yield of the reaction reduced drastically. 
 





To overcome the challenge of the arylation being limited to electron-deficient arenes and 
consequently expanding the scope of the reaction, the arylation of -amino acids with fluoroarene 
chromium complexes as the electrophilic source was investigated (Scheme 37).108 It was hoped that 
the arene, no matter how electron-rich, would be activated towards a nucleophilic aromatic 
substitution through coordination to Cr(CO)3. 
 
Scheme 37: (a) -arylation of alanine with fluoroarene chromium complexes by phase transfer catalysis (b) 
-arylation of other amino acids with fluoroarene chromium complexes by phase transfer catalysis 
Optimisation of the arylation reaction with different catalysts revealed catalyst (R)-175 as optimal. 
Arylation of the alanine derivative 172 with several electron-rich arenes proceeded smoothly with 
good yields and excellent enantioselectivities (Scheme 37a). The arylation was also tolerant of a 
variety of amino acids, affording the arylated amino acids 178 in excellent yields and 
enantioselectivities (Scheme 37b). This arylation strategy is one of the few reported methods for 
the arylation of -amino acids. Other existing methods will be discussed in the next section. 
1.3.6 -Arylation of Amino Acid Derivatives 
-Aryl quaternary amino acids and their congeners have been found to exhibit bioactivity, a 
selection of which are illustrated in Figure 7. The direct arylation of tertiary amino acids using 
nucleophilic aromatic substitution of haloarenes would seem like the easiest route towards -aryl 





anionic carbon centre with an electron-rich sp2 carbon. Nonetheless, a handful of methods have 
been developed for the racemic and enantioselective -arylation of -amino acid derivatives. 
 
Figure 7: Some biologically active -aryl quaternary amino acids and their congeners109–112 
O’Connor and Liu disclosed the direct arylation of racemic amino acid-derived imine 180.113 
Several amino acid derivatives were arylated using 2-nitrofluorobenzene (Scheme 38). No yields 
were reported except that of the arylation of the alanine-derived substrate, which gave an overall 
yield of 41%. The arylated amino acids 181 were actually synthesised for their direct conversion to 
3-amino-2-oxindoles, which are important structural motifs found in biologically potent 
compounds.114,115 
 
Scheme 38: Arylation of -amino acids with 2-nitro fluorobenzene 
A similar arylation with nitro(hetero)arenes 183 was performed on O-protected serine derivative 
182.116 On treatment of 182 with tBuOK, it underwent oxidative nucleophilic addition to the 
nitroarene to produce the dearomatised adduct 184, which on treatment with DDQ produced the -
arylated species 185 (Scheme 39). The addition occurred even with an electron-donating or 
electron-neutral substituent on the nitroarene. Hydrolysis of 185 (Z = H, X = CH) furnished -4-







Scheme 39: Arylation of a serine derivative with nitro(hetero)arenes 
Arynes are reactive intermediates that undergo electrophilic addition with nucleophiles, resulting 
in aryl carbanions that are capable of reacting with electrophiles.118,119 Barett and co-workers 
employed the reactivity of arynes and Schöllkopf’s bis lactim ether chiral auxiliary approach (see 
section 1.3.1) to a multicomponent coupling reaction with electrophiles (Scheme 40).120 The aryne 
was developed in situ from 188. Nucleophilic attack of the secondary anion 191 on the aryne formed 
the anionic adduct 192, which underwent a proton exchange to give the tertiary ion 193. The tertiary 
ion 193 reacts with several electrophiles to give the new ,-disubstituted quaternary species 189 
with excellent diastereoselectivities. 1H NMR NOESY experiments revealed that the preferentially 
formed diastereoisomer was the result of electrophile approach from opposite the sterically 
demanding isopropyl group. The reaction was tolerant of a variety of electrophiles such as alkyl 






Scheme 40: Electrophilic addition of arynes to bis lactim ethers of chiral amino acids 
Penso et al. utilised the MOC strategy (see section 1.3.3) for the enantioselective intramolecular 
arylation of N-(4-nitro-benzene)sulfonyl--amino acid tert-butyl esters 194 (Scheme 41a).121 A 
control experiment showed that 194 did not rearrange in the absence of the alkyl bromide indicating 
that N-alkylation of 194 was necessary for the rearrangement to occur. Mechanistic investigations 
also revealed that the stereochemical retention of the rearrangement was influenced directly by N-
alkylated 194 through the non-racemic enolate 196, formed from deprotonation of the most stable 
conformer of N-alkylated 194. Hence the proposed mechanism for the rearrangement was N-
alkylation of 194, followed by deprotonation of the -carbon to afford the enolate 196. Attack of 
the electrophile on the Re face of 196 led to the formation of the chiral spirocyclic Meisenheimer 
intermediate 197, which collapses to expel sulfur dioxide and produce the -arylated species 195 






Scheme 41: (a) Enantioselective intramolecular arylation of sulfonyl amino acid derivatives via MOC (b) 
Spirocyclic Meisenheimer intermediate expels sulfur dioxide to give rearranged products 
The authors extended the intramolecular arylation strategy to the N-sulfonyl proline derivatives 198 
(Scheme 42).122 The use of NaNH2 as base was found to be more effective than NaH. It is thought 
that the ammonia produced in the use of sodium amide solvates the sodium ion, so that the ion 
forms a loose ion-pair with the carbanion generated from 198. This results in a faster reaction rate 
and better yields relative to when sodium hydride was used. An electron-withdrawing group on 
either the para or ortho position of the aryl ring was crucial for efficient stabilisation of the 
Meisenheimer intermediate. No reaction occurred with electron-donating substituents at the para 
position of the ring. 
 
Scheme 42: Enantioselective intramolecular arylation of sulfonyl proline derivatives via MOC 
The mechanism of the reaction is like that of the acyclic amino acid derivatives in Scheme 41. The 





198a. Intramolecular attack of the enolate on the aryl ring generates the spirocyclic Meisenheimer 
intermediate 201, which subsequently undergoes aryl migration to produce 199a with retention of 
stereochemistry (Scheme 43).  
 
Scheme 43: Proposed mechanism for arylation of sulfonyl proline derivatives via MOC 
In 1983, Seebach demonstrated a transition metal-catalysed -phenylation of proline via the self-
regeneration of stereocentres (SRS) strategy (Scheme 44).45 Direct -alkylation of the proline 
derivative 202 with several alkyl halides was achievable, but in the case of arylation, phenylation 
of 202 was achieved with the use of (benzene)(tri-carbonyl)chromium. The electron-withdrawing 
property of the Cr(CO)3 has been shown to permit nucleophilic attack even on electron-rich aryl 
rings coordinated to it.123 The product 204 was obtained as a single diastereoisomer with retention 
of configuration. Extension of this arylation strategy to other amino acids was later reported by 
Lavergne (Scheme 45).124 
 
Scheme 44: -Phenylation of a proline derivative via the SRS strategy 
Imine 205 was made from condensation of a chiral auxiliary 2-hydroxypinan-3-one with the desired 
amino acid methyl ester.125 Treatment of 205 with the fluorobenzene chromium complex 177 at −75 
°C led to -phenylation and concomitant cyclisation to afford the -phenylated lactones 206 with 





with no cyclisation. The stereochemistry at the new quaternary centre (indicated with a pink 
asterisk) of the major or only diastereoisomer of 206 and 207 was found to be either R or S, 
depending on the steric bulk of the side chain R of the amino acid used. There was evidence of 
strong interaction between the anion formed on deprotonation of 205 and the electrophile, which is 
suspected to be the result of coordination of the anion to chromium, by displacement of one CO 
ligand. Decomplexation, followed by hydrolysis of 206 afforded (R)- or (S)-208 depending on the 
amino acid used. 
 
Scheme 45: -Phenylation of -amino acid derivatives by a chiral auxiliary approach 
The first palladium-catalysed intramolecular arylation of -amino acid derivatives was reported by 
Gaertzen and Buchwald (Scheme 46).126 Treatment of amino acid derivatives 209 with LiOtBu, 
Pd2(dba)3 and either ligand 211 or 212 afforded isoindoline 210 (n = 1) and tetrahydroisoquinoline 
210 (n = 2) in good to excellent yields. Coordination of the aryl bromide in 209 to the palladium 
complex, formed from coordination of the ligand to Pd2(dba)3, enables the aryl group to react with 
the anion formed on deprotonation of the -proton of 209. This reaction occurred even when R1 
and R2 were electron-donating and it was tolerant of a variety of -amino acids such as 
phenylglycine, alanine, valine, and proline. In addition, it was tolerant of several different N-
substituents such as a phenyl, alkyl, and ester groups. The cyclic -aryl amino acid derivatives 210 






Scheme 46: Palladium-catalysed intramolecular arylation of -amino acid derivatives 
A similar palladium-catalysed intramolecular arylation was reported by Marsden et.al (Scheme 
47).127 A racemic version was initially disclosed, employing a combination of Pd(OAc)2 and 
HPCy3.BF4 as catalyst and affording 16 examples of the arylated products in 61 – 89% yield.128 For 
the asymmetric version, a combination of Pd(dba)2 and the imidazolinium (R,R)-215 was used as 
catalyst, affording the arylated products 214 in up to 90% ee. The cyclic -aryl amino acid 
derivatives 214 are known as 3-aminooxindoles and constitute a number of biologically active 
compounds.129,130 
 
Scheme 47: Palladium catalysed asymmetric intramolecular arylation  
Amino acid-derived azlactones 217 were arylated under palladium catalysis to afford the -aryl 
amino acid derivatives 218.131 Whilst so many combinations of palladium source and ligand gave 
good yields, arylations carried out with a combination of Pd(OAc)2 and Ad2P(tBu) as catalyst and 
K3PO4 as base generally gave best yields (Scheme 48). The arylation was tolerant of electron-
neutral, electron-donating and electron-withdrawing groups on the aryl bromide. As with many 
palladium-catalysed reactions, the mechanism of the arylation probably incorporates an oxidative 
addition,132 transmetalation and reductive elimination.133 218 could be hydrolysed to reveal racemic 






Scheme 48: Palladium-catalysed intermolecular arylation of azlactones 
In 2015, Clayden et al. reported the palladium-catalysed intermolecular arylation of amino acid-
derived hydantoins 219 (Scheme 49).135 Optimisation of the reaction conditions using alanine-
derived hydantoin 219 (R = Me) and iodobenzene revealed a combination of 
palladium(II)trifluoroacetate and xantphos as the optimal catalyst. Furthermore, the addition of 
ZnF2 to the reaction improved the yield, probably due to the formation of a zinc enolate via 
transmetalation. Using the optimal conditions, several amino acid-derived hydantoins 219 were 
successfully arylated. The reaction was tolerant of electron-neutral, electron-withdrawing and 
donating groups on the aryl iodide. Selected examples of the arylated hydantoins 220 were 
deprotected and subsequently hydrolysed to their corresponding -aryl quaternary amino acids 221. 
 
Scheme 49: Palladium catalysed intermolecular arylation of tertiary amino acid-derived hydantoins 
The chiral cyclic nitrone 222 is a derivative of glycine,136–138 hence -arylation will lead to a tertiary 
-aryl glycine derivative. However, the ability of the nitrone to undergo ortho addition to Grignard 
reagents137 makes it possible for a second substituent to be introduced to the tertiary centre, thus 
generating a new quaternary centre. Taking advantage of this, Blandin and co-workers performed 
the C- arylation of cyclic nitrones 222 under palladium catalysis (Scheme 50).139 The active 





studies and other experimental investigations, it was presumed that the mechanism for the arylation 
involved a metalation-deprotonation, which might be a concerted process. Subsequent addition of 
MeMgCl to 223 afforded 224, having the new methyl group anti to the bulky isopropyl. Reduction 
of the N-O bond in 224 with zinc in acetic acid, followed by acid hydrolysis and esterification 
afforded the -aryl,-methyl glycine derivative 225 in greater than 98% ee. 
 
Scheme 50: Palladium catalysed arylation of cyclic nitrones 
Iron-catalysed -C(sp3)-H functionalisation of amino acid derivatives 226 with nucleophiles was 
disclosed by You et al. (Scheme 51).140 In this method, the aryl group was not introduced to the 
tertiary carbon using an aryl halide, but rather through an oxidative C-H/C-H coupling reaction of 
an aryl nucleophile and the sp3 tertiary carbon centre of the amino acid derivative. The reaction was 
found to be general for a range of natural and unnatural tertiary amino acids such as benzyl, allyl, 
5-cyano, 4-benzoyl and 4-hydroxylphenylalanine, as well as tyrosine, tryptophan, naphthylalanine 
and acetyl glycine. The reaction was also tolerant of several nucleophiles such as indoles, electron-
rich heteroarenes and 1,2,4,5-tetramethylbenzene. 
 





As addition of radical inhibitors to the coupling reaction led to reduced yields, it was proposed that 
the reaction followed a single electron pathway (Scheme 52). A suggested mechanism for the 
coupling is coordination of the metal ion to both the nitrogen of the pyridine and the NH in 226 to 
produce the metal complex 228. Hydrogen atom abstraction from 228 by a tert-butoxy radical, 
generated from DTBP 229, produces the metal complex radical 230. An intramolecular single 
electron transfer in 230 produces the ketimine 231, which undergoes addition with a nucleophile to 
produce the -arylated--amino acid ester 227. 
 
Scheme 52: Proposed mechanism for the oxidative coupling of aryl nucleophiles to tertiary amino acid 
derivatives 
1.3.7 -Arylation of Amino Acid Derivatives via Intramolecular N→C Migration 
In 2007, Clayden et al. reported an intramolecular arylation through the rearrangement of lithiated 
ureas (Scheme 53).141 While investigating the regioselective lithiation of N-benzyl urea 232 (R = 
2,6-dimethyl, R1 = Ph ), it was observed that aryl migration from the distal nitrogen of the urea to 
the benzylic CH2 carbon had rapidly taken place after deprotonation, affording the rearranged diaryl 
methyl urea 233, after an aqueous quench. The reaction involved a nucleophilic aromatic 
substitution which is atypical for aromatic compounds, which usually undergo electrophilic 
aromatic substitution. To test the limit of the rearrangement, it was extended to N-benzyl ureas 
having different migratory aryl rings. Surprisingly, the rearrangement successfully occurred 






Scheme 53: Discovery of N to C aryl migration in lithiated benzyl ureas 
As an enantioselective version of the aryl migration of 232 seemed impractical, the substrates 232 
were modified. Enantiomerically pure -methylbenzylureas 234 were made and subjected to the 
aryl migration (Scheme 54). The rearrangement occurred more slowly than it did with the lesser 
substituted substrates 232; However, addition of DMPU significantly improved the rate and yield 
of the reaction probably due to activation of the organolithium nucleophile through the generation 
of a reactive ionic pair.142,143 The reaction also proceeded with retention of stereochemistry 
affording the products 235 with minimal loss of optical purity. In addition, the aryl migration yet 
occurred with both electron-rich and deficient rings. 
 
Scheme 54: Stereospecific rearrangement via N to C aryl migration in lithiated -methyl benzylureas  
Further studies on the aryl migration unveiled that the reaction was not limited to ureas but could 
also be employed in the rearrangement of carbamates142,144–146 and thiocarbamates.147–149 The 
migratory groups have also been extended to include both sterically hindered and unhindered 
alkenyls.150,151 Of more pertinence is the rearrangement of tertiary amino acid-derived Nꞌ-arylureas, 
which has been employed to achieve both racemic and enantioenriched -aryl quaternary amino 
acids. For example, Clayden and co-workers carried out the intramolecular arylation of amino acid-
derived ureas 237 (Scheme 55).152 By coupling an aryl group to a tertiary amino acid through a urea 
linkage as seen in 237, they were able to achieve quaternary amino acid derivatives 241 through 
base-mediated translocation of the aryl group to the -carbon of the amino acid and subsequent 
cyclisation on quenching with methanol. The aryl migration was tolerant of both electron-





yields. ReactIR studies of the aryl migration of 237 (Ar = Ph, R = R1 = Me) revealed the three 
species 238, 239 and 240 but showed no evidence of the Meisenheimer intermediate 242. The 
hydantoin 241 (Ar = Ph, R = R1 = Me) was not observed until after the reaction was quenched with 
MeOH. The cyclisation of 240 to 241 occurred quickly, with no non-cyclised product 243 detected. 
 
Scheme 55: Rearrangement of amino acid derived Nꞌ-arylureas via N to C aryl migration 
Employing the chiral auxiliary approach (see section 1.3.1), Clayden et al. performed the 
enantioselective version of the arylation of ureas 237 (Scheme 56).153 By coupling (S,S)-
pseudoephedrine 247 to analogues of 237, the ureas 244 were obtained as single diastereoisomers. 
Intramolecular -arylation of the derivative 244 (Ar = Ph, R = R1 = Me) using LDA and LiCl alone 
afforded the doubly N-methylated hydantoin 245 (Ar = Ph, R = R1 = Me) with good 
enantioselectivity. However, it was difficult to hydrolyse to the corresponding -aryl quaternary 
amino acid derivative. Repeating the reaction with the N-unsubstituted analogue 244 (Ar = Ph, R = 
Me, R1 = H) led to the formation of racemic 245 (Ar = Ph, R = Me, R1 = H), indicating that N-
substitution was conducive to enantioselectivity. Further optimisation revealed that the addition of 
two equivalents of trimethylsilyl chloride led to in situ silylation of the NH, ultimately affording 
the enantioenriched hydantoin. The reaction was extended to a variety of amino acid-derived ureas 
244 (R1 = H), bearing several migratory aryl groups. A sequence of silylation, enolisation, N to C 
aryl migration, cyclisation with expulsion of the chiral auxiliary and proto-desilylation offered the 
hydantoins (R)-245 in good yields and enantioselectivities. The scope of the migratory aryl group 
was inclusive of both electron-rich and electron-deficient arenes, with best enantioselectivities 
obtained with electron-rich migratory aryl rings. The scope of the amino acid was limited to less 
sterically hindered R-substituents, as no rearrangement was observed with valine and phenylglycine 
derived ureas, while leucine-derived urea rearranged but with low yield. The hydantoins could 







Scheme 56: Synthesis of -aryl quaternary amino acids via a chiral auxiliary directed N to C aryl migration 
Employing N to C aryl migration within ureas, Kawabata and co-workers performed the 
enantioselective intramolecular arylation of amino acid derived ureas 249 (Scheme 57).154 The 
MOC strategy was employed for stereocontrol in the arylation. The ureas 249 were synthesised 
according to the protocol by Clayden et al.141 Treatment of 249 with either LiHMDS or KHMDS 
led to migration of the aryl group from the distal urea nitrogen to the -carbon, resulting in a 
nitrogen-centred anionic urea intermediate 250, which underwent cyclisation to afford quaternary 
amino acid derivatives 251. The migration was limited to only electron-withdrawing and electron-
neutral groups on the migrating aryl ring. 
 
Scheme 57: Stereoselective N to C aryl migration in ureas via MOC 
It was found that aryl migration in valine-derived ureas 249 afforded the quaternary products with 
inversion of configuration. Hence, it was assumed that aryl migration proceeded with inversion of 
configuration for the phenylglycine and methionine-derived ureas as well. A conformational search 
for substrate 249 (valine, Ar = 4-nitrophenyl) revealed two stable conformers, 249C1 and 249C2 
(Scheme 58). A possible explanation for the inversion of configuration might be that deprotonation 
of the -proton in conformer 249C1 was thermodynamically preferred to that of 249C2,155–157 





to be 5 minutes at −60 °C. Intramolecular attack of the enolate on the aryl ring leads to formation 
of the Meisenheimer-type complex 253, which collapses by N-acylation to produce 254 with 
inversion of configuration. 
 
Scheme 58: Stereochemical rationale for inversion of configuration 
It was previously demonstrated that intramolecular arylation and subsequent cyclisation of proline 
derived ureas 255 (R = R1 = R2 = H) offered racemic -arylated hydantoins 256.152 Subsequent 
investigations revealed that introduction of a chiral centre either at the 3, 4 or 5-position of the 
proline ring in 255 offers enantioenriched hydantoins 256 on aryl migration and ensuing cyclisation 
(Scheme 59).158 Most likely, diastereoselectivity in the rearrangement is induced by migration of 
the aryl group to the less hindered face of the enolate. Hindered, electron-rich and electron-deficient 
aryl rings migrated successfully. In corroboration with a similar report,153 lower 
diastereoselectivities were obtained in the migration of electron-deficient rings. This is presumably 
due to reversibility in the migration of electron-deficient rings.159 N-methyl hydantoins 256 (R3 = 
Me) were resistant to hydrolysis; However, hydrolysis of the N-MOM derivatives 256 (R3 = 







Scheme 59: Synthesis of -aryl prolines via N to C aryl migration in proline urea derivatives 
Recently the asymmetric intramolecular arylation of amino acids via SRS was disclosed by Clayden 
and co-workers (Scheme 60).160 The method employed the use of Seebach’s imidazolidinone 
strategy in inducing enantioselectivity in the aryl migration of imidazolidinone bearing Nꞌ-
arylureas. This strategy allows the formation of either enantiomer of the -aryl quaternary amino 
acid from a single enantiomer of the tertiary amino acid precursor. Condensation of amino acid-
derived methyl amide 258 with pivaldehyde and subsequent acylation of 259 with the desired 
carbamoyl chloride 260 provided the imidazolidinone urea 261 as the cis-isomer. Treatment of 261 
with KHMDS afforded the rearranged product 262 in up to greater than 98% ee. Alternatively, 
condensation of 258 with pivaldehyde under acidic conditions and subsequent acylation with 
triphosgene offered the N-chloroformylimidazolidinone 264, predominantly as the trans-isomer. 
Treatment of 264 with an excess of KHMDS and the desired N-methylaniline derivative led to one-
pot attainment of the rearranged product ent-262. In the formation of both enantiomers of the -
aryl quaternary amino acids, the stereochemistry at the quaternary centre is directed by the bulky 
tertbutyl group. The reaction was general for a variety of tertiary amino acids, both functionalised 
and unfunctionalised. Rearrangement of phenylglycine derived ureas generally suffered from 
diminished enantioselectivities. Hydrolysis of the arylated products 262 furnished the 






Scheme 60: Stereoselective N to C aryl migration in Imidazolidinone ureas via SRS. MW = microwave 
irradiation. 
1.4 N→C Aryl Migration – Mechanistic Discussions 
The N→C aryl migration developed by Clayden and co-workers is similar to the Smiles and Truce-
Smiles rearrangements; but unlike these rearrangements, it is not limited to electron-deficient aryl 
rings, as even electron-rich aryl rings were successfully migrated. The originally proposed 
mechanism for the aryl migration is exemplified by the urea 234 in Scheme 61 .161,162 The -methyl-
benzylurea 234 is deprotonated at the benzylic methylene. Coordinated lithium cations and their 
translocation in the reaction were revealed by DFT calculations to be of importance in the 
mechanism. Movement of a solvated lithium cation from the organo lithium to the deprotonated 
benzylic methylene, and ensuing coordination of the lithium ion to the carbonyl oxygen provides 
265. The complex 265 is unreactive, but rotation of the C-N bond in 265 affords the reactive 
conformation 266, whose lithiated carbon centre is sufficiently close to the N-aryl ring, allowing 
enantioretentive nucleophilic attack on the ring and resulting in the dearomatised Meisenheimer 
intermediate 267 in the case of a migrating 1-naphthyl ring. Movement of the lithium cation to the 
N-aryl ring of 267 stabilises the developing negative charge. Ring opening of 267 restores 
aromaticity and provides the product 268, which on aqueous quench affords the arylated products 
235. The lithiated species 266 is stable with respect to the addition timescale, hence the 
stereochemistry of the starting material 234 is retained in the product 235. The presence of 
dearomatised intermediate 267 in the case of a migrating 1-naphthyl ring was confirmed by the x-
ray structure of enone 270, which was obtained by exposing the migration of a 1-naphthyl ring to 
air after the reaction had been stirring for 2 hours.163 The intramolecular mechanism of the reaction 






Scheme 61: Originally proposed mechanism of N to C aryl migration in lithiated ureas 
Mechanistic investigations using in situ 1H NMR spectroscopy further confirmed the presence of 
the dearomatised intermediate 267 in the migration of a 1-naphthyl ring. There was however no 
evidence of this intermediate with other aryl migratory groups. Other possible reaction pathways 
such as migration with inversion of stereochemistry or attack of the lithiated carbon centre in 266 
on the carbonyl carbon, resulting in a 1,2-acyl shift were shown from DFT calculations to require 
higher energy transition states.161 Though the aryl migration of acyclic -methylbenzylureas 234 
(Scheme 54) was stereospecific, aryl migration of the cyclic analogues produced the racemic 
rearranged products. It is thought that racemisation of the organolithium intermediate outcompetes 
aryl migration.164 
 
Scheme 62: Recent mechanistic investigations into N to C aryl migration in lithiated ureas 
The question of whether a dearomatised intermediate truly exists for other migratory aryl rings 
other than the 1-naphthyl was recently investigated by Clayden and co-workers.160 The use of 
ReactIR and Hammett plot construction gave new insight into the mechanism of the aryl migration. 
ReactIR studies of the conversion of 261 (X = H) to 262 (X = H) using the optimised conditions in 
Scheme 60 revealed no reaction intermediate, suggesting that aryl migration was faster than enolate 





and intermediates which were identified to be enolate 271 (X = H) and anion 272 (X = H) were 
observed. A plot of absorbances against time for the aryl migration of 261 bearing different aryl 
groups revealed that the formation of the anion 272 from the enolate 271 followed first order 
kinetics. A Hammett plot of log of rate constants against the aryl substituent constants revealed that 
the formation of the enolate is the rate-limiting step for the aryl migration of electron-deficient 
rings. Hence, after formation of the enolate, the rearrangement occurred so fast, it was not possible 
to identify a dearomatised intermediate between 271 and 272. This however does not prove the non-
existence of a dearomatised intermediate, as electron-withdrawing groups on the aryl migratory 
ring can stabilise the intermediate. For the electron-rich aryl rings, the value of the Hammett 
coefficient  was +4.5, which indicates that there is a development of negative charge on the arene 
during the rearrangement. This value was however smaller than that of a typical nucleophilic 
aromatic substitution,165,166 probably indicating the absence of a Meisenheimer intermediate.167–170 
It is proposed that the reaction was tolerant of electron-rich aryl migratory groups because the 
restricted conformation of the urea171 brings the reactive enolate centre close enough to the aryl 
ring, so that the electrostatic force of repulsion between the negatively charged enolate and the 
electron-rich aryl ring is overcome, hence attack of the enolate on the aryl ring occurs. 
In summary, N to C aryl migration within metallated ureas has provided a powerful means for C-
arylation through intramolecular nucleophilic attack of an enolate on the ipso position of an arene. 
The reaction has offered access to both racemic and enantioenriched quaternary amino acids. The 
reaction is indeed unique because it enables nucleophilic attack of enolates on electron-rich arenes 
without the mediation of a heavy metal. However, the aryl migrations require the use of strong 
bases such as LiHMDS, KHMDS and LDA (see section 1.3.7). It is therefore important that 
advances continue to be made, especially in the development of milder conditions for the 






2 Results and Discussion 
2.1 Aims of the Project 
From the review of the various synthetic routes towards quaternary amino acids, it is evident that 
several methods exist for the synthesis of -alkyl quaternary amino acids. As discussed in section 
1.3.6, many biologically active targets or their precursors contain -aryl quaternary amino acids or 
their congeners,9,172–175 yet only a few methods are available for their synthesis. Many of these 
methods are not general and some require the use of heavy metal catalysis, which could be 
problematic in drug synthesis; furthermore, only a few of them give enantiomerically enriched -
aryl quaternary amino acids.126,131,135,176 This thesis explores several synthetic routes towards 
enantiomerically enriched -aryl quaternary amino acids exploiting the unusual urea reactivity.141 
It provides a detailed description of the work that has been done by the author in developing or 
improving already existing methods towards these compounds. The first method discussed is the 
use of chiral phase transfer catalysis (PTC); The aim is to provide the first truly catalytic method 
for accessing -aryl quaternary amino acids, as Marouka’s PTC method (Scheme 37) required the 
use of stoichiometric amounts of chromium. To the best of the author’s knowledge, there is no 
phase transfer catalysed intramolecular nucleophilic aromatic substitution yet reported. 
2.2 Arylation of Amino Acid Enolates employing Phase Transfer Catalysis 
2.2.1 Previous Work 
Preliminary work within the Clayden group established that it was possible to carry out urea 
rearrangements under the mild conditions of PTC (Scheme 63). The hydantoin scaffold (pka of 
hydantoin = 9.16)177 was chosen for investigation to allow ready formation of the enolate. 
Phenylglycine-derived hydantoin urea 273a was treated with simple inorganic bases such as 
Cs2CO3. The rearrangement failed to occur in the absence of a catalyst. However, in the presence 
of the PTCs 135, (S)-175 or 276, the rearrangement occurred. 273a underwent intramolecular aryl 
migration to give N-methyl hydantoin urea 274a. The hydantoin 275a was then obtained by treating 
274a with a strong base such as KHMDS. All the PTCs gave racemic products, except 276 which 






Scheme 63: Urea rearrangement under PTC conditions 
2.2.2 Synthesis of Hydantoin Ureas 
From preliminary studies discussed in the previous section, it is obvious that the rearrangement of 
the hydantoin urea employing chiral PTC shows a propensity for achieving stereoselectivity. 
Nevertheless, the rearrangement needs further optimisation, with the goal being higher 
enantioselectivity, reactivity and a broad scope of amino acids and arenes. To achieve this, a series 
of amino acid-derived hydantoin ureas were made. 
Table 1: Synthesis of hydantoins 279 
 
Entry Amino acid R Product 
Yield (%) 
278 279 
1 Phg Ph a 92 75 
2 Ala Me b >99 85 
3 4-Cl-Phg 4-ClC6H4 c >99 65
a 
4 4-OMe-Phg 4-OMeC6H4 d >99 18
a 
5 Gly H e 87 57 





Readily available amino acid methyl ester hydrochlorides 277 were reacted with tert-butyl 
isocyanate to give the amino ester ureas 278. The ureas 278, on treatment with potassium tert-
butoxide, underwent cyclisation to give hydantoins 279 (Table 1). The cyclisation reaction of 278a, 
278c and 278d must not be left for more than an hour, as this leads to side reactions, resulting in a 
lower yield of the cyclisation products. The yield of 279d was significantly increased when the 
cyclisation was performed with sodium hydride at 0 °C (Scheme 64). 
 
Scheme 64: Alternative synthesis of 279d 
Hydantoins 279 were treated with triphosgene at −78 °C to room temperature to yield carbamoyl 
chlorides 280 (Table 2). Earlier work within the Clayden group showed that the carbamoyl chlorides 
were capable of hydrolysing back to the hydantoins if worked up under basic or acidic conditions.178 
To avoid this, work up of the reaction was performed simply by washing with saturated brine. The 
acylation of 279d occurred slowly, with starting material remaining after 16 hours. This is probably 
because the methoxy substituent is sigma withdrawing due to the electronegativity of the oxygen 
atom. 
Table 2: Synthesis of carbamoyl chlorides 280 
 
Entry Product Amino acid R Yield (%) 
1 280a Phg Ph 89 
2 280b Ala Me >99 
3 280c 4-Cl-Phg 4-ClC6H4 >99 
4 280d 4-OMe-Phg 4-OMeC6H4 nd
a 
5 280e Gly H 93 





To obtain hydantoin ureas 273, carbamoyl chlorides 280 were coupled with N-methylanilines 
bearing a range of electron-deficient substituents. The crude products were purified by column 
chromatography to afford 273 in good to excellent yields (Table 3). 273e was difficult to purify 
chromatographically because it had the same retention factor as its N-methyl-4-nitroaniline 
precursor. To overcome this issue, 0.9 equivalent of N-methyl-4-nitroaniline was used, instead of 
1.0, to achieve complete consumption of the aniline in the coupling reaction. Acidic work up was 
avoided with 273d to prevent protonation of the pyridyl group. 
Table 3: Synthesis of hydantoin ureas 273 
 
Entry Product Amino acid R Ar Yield (%) 
1 273a Phg Ph 4-CNC6H4 96 
2 273b Phg Ph 3-CNC6H4 79 
3a 273c Phg Ph 2-CNC6H4 58 
4 273d Phg Ph 4-Pyridyl 70 
5b 273e Phg Ph 4-NO2C6H4 78 
6 273f Phg Ph 2-NO2C6H4 0 
7c 273g Phg Ph 3-NO2C6H4 95 
8 273h Phg Ph 4-CF3C6H4 66 
9 273i Phg Ph 3-CF3,4-CNC6H4 79 
10 273j Ala Me 4-ClC6H4 61 
11 273k Ala Me 4-CNC6H4 77 
12 273l 4-Cl-Phg 4-ClC6H4 4-CNC6H4 60 
14 273m Gly H Ph 70 
a Reaction left on overnight; b 0.9 eq. of N-methyl-4-nitroaniline was used in reaction 
 c Reaction performed in CH3CN 
The coupling of N-methyl-2-nitro aniline with 280a to yield 273f failed in DCM at room 
temperature (Table 3, entry 6). This was likely due to the steric hindrance from the 2-NO2 
substituent. On refluxing the coupling reaction overnight in anhydrous acetonitrile (Scheme 65), 
273f was obtained in moderate yield due to resulting intramolecular aryl migration in 273f to 
produce 274f. The same steric hindrance issue was encountered with the coupling reaction to yield 





65), the coupling reaction to yield 273c was not heated, but carried out at room temperature 
overnight (Table 3, entry 3). 
 
Scheme 65: Synthesis of hydantoin urea 273f 
To investigate if it were possible to obtain 279 from aryl migration of glycine derived hydantoin 
ureas such as 273m, rearrangement of 273m was attempted (Table 4). Under all conditions tried, 
the hydantoin 279a was not observed, but instead a cleavage of 273m to N-methyl aniline. This was 
quite disappointing because the possibility of aryl migration within glycine derived hydantoin ureas 
would allow facile access to hydantoins 279 bearing different aryl substituents on the -carbon, 
saving time and effort needed to source amino acids with the required aryl sidechains. 
Table 4: Attempted aryl migration of 273m 
 
Entry T (°C) Base Solvent Time (h) 
1 rt KOH CH3CN 16 
2 −78 – 0 KHMDS THF 4 
3 −78 Cs2CO3 THF 6 
4 −78 – rt LDA THF 16 
 
2.2.3 Optimisation of Aryl Migration 
With the amino acid hydantoin ureas successfully made, a route towards achieving enantioselective 
rearrangements could now be investigated. As discussed in Scheme 63, the chiral ammonium salt 
276 (Figure 8) produced a crude er of 85:15 in the aryl migration reaction of 273a. Hence, this PTC 






Figure 8: O-Allyl-N-(9-anthracenylmethyl) cinchonidinium bromide 276 
Toluene is non-polar so favours ion-pairing; It is also a commonly used solvent for phase transfer 
catalysed reactions in precedent literature.104,106 Hence, it was employed in these optimisation 
studies. Other solvents were also trialled for insight into the influence of solvents on 
enantioselectivity. For those substrates insoluble in the investigated solvent, CHCl3 was added to 
aid dissolution. CHCl3 also aids dissolution of the catalysts, which are usually insoluble in non-
polar solvents like toluene.179 Bases were chosen based on control experiments and previous work 
within the group.178,180,181 Inorganic bases used in PTC reactions are usually poorly soluble in the 
organic phase; hence there should be no or minimal reaction occurring in the absence of the PTC.182 
In the presence of the PTC, the cation of the PTC is thought to coordinate with the anion of the 
base, thus transferring it into the organic phase for substrate deprotonation (see Scheme 75). 
Table 5: PTC aryl migration of 273a 
 
Entry T (°C) Solvent Base Time 
Yield (%) 
er (274a) 
273a 281ad 274a 
1 0 PhMe:CHCl3
a Cs2CO3 6 d 29 0 9 37:63 
2 0 CH3CN
b Cs2CO3 <5 h 0 16 46 53:47 
3 −20 CH3CN
b Cs2CO3 1 d 0 44 11 54:46 
4 −20 TBME/CHCl3
a KOH 3 d 0 30 13 46:54 
5 −20 – 0 TBME/CHCl3
a Cs2CO3 7 d 14 9 32 40:60 
6 0 TBME/CHCl3
a K2CO3 4 d 53 0 20 45:55 
7 0 – rt PhMe:CHCl3
a K2CO3 2 d 12 0 62 44:56 
8 0 – 70 PhMe:CHCl3
a 282 3 d >99c 0 0 - 
a 1:0.7 ratio; b Anhydrous; c Only 273a observed by 1H NMR; Other yields obtained by 1H NMR and compared  





As prior investigations showed that a crude er of 80:20 was obtained in the aryl migration reaction 
of 273a using Cs2CO3 base at 0 °C, it was expedient to repeat the reaction under the same 
conditions. Hydantoin urea 273a was subjected to the same conditions (Table 5, entry 1). HPLC 
analysis of purified 274a revealed an er of 37:63. The yield of 274a was low and the reaction slow, 
with starting material remaining after 6 days. A control experiment with 273a using Cs2CO3 in a 
PhMe:CHCl3 solvent system showed there was no background reaction occurring (Table 6, entry 
1). When anhydrous acetonitrile was used as solvent at 0 °C, the reaction was complete in only 5 
hours, but the transformation was not enantioselective (Table 5, entry 2). This was in accordance 
with various literature reports183,184 which report a faster phase transfer catalysed reaction in polar 
solvents in detriment of enantioselectivity, due to polar stabilisation of the enolate by the solvent 
and not by formation of an ionic pair with the chiral cation of the catalyst. This suggests that non-
polar solvents might be required to achieve higher enantioselectivities, perhaps at expense of 
reactivity. Racemic products were still obtained when the temperature of the reaction was lowered 
to −20 ° C (Table 5, entry 3). There was also an increased decomposition of 273a to 4-
(methylamino)benzonitrile 281a when the reaction temperature was decreased from 0 to −20 °C 
(Table 5, entry 2 vs 3). At this point, it was deduced that acetonitrile was not a suitable solvent for 
achieving enantioselectivity in these reactions. 
Table 6: Control experiments for 273a 
 
Entry T (°C) Solvent Base Comments 
1 rt PhMe:CHCl3
a Cs2CO3 274a not observed181 
2 −20 – 0 TBME/CHCl3
a Cs2CO3 274a not observed at −20 °C; observed at 0 °C 
3 −20 TBME/CHCl3
a KOH 274a observed; 281a observed 
4 0 TBME/CHCl3
a K2CO3 274a not observed 
a 1:0.7 ratio 
Following conditions used by Dixon and co-workers in their enantioselective nitro Mannich 
reactions,185 KOH/tert-butyl methyl ether (TBME) at −20 °C was used in the aryl migration reaction 
of substrate 273a (Table 5, entry 4). The product 274a obtained was practically racemic, and there 
was evidence of decomposition. A control reaction showed that there was some background 
uncatalysed arylation, as well as decomposition of the starting material (Table 6, entry 3). For an 





Cs2CO3 as base. There was no reaction at −20 °C; however, at 0 °C, the product 274a was formed 
with an er of 40:60 (Table 5, entry 5). A control reaction showed that there was a degree of 
uncatalysed arylation with Cs2CO3/ TBME at 0 °C (Table 6, entry 2). This suggested that if a base 
that was inactive without the catalyst was used, the er could be improved. To probe this, the weaker 
base K2CO3 was trialled (Table 5, entry 6). Surprisingly, the er reduced from 40:60 to 45:55. The 
decrease in er was unexpected because a control reaction showed no uncatalysed migration taking 
place with K2CO3 (Table 6, entry 4). Perhaps, racemisation of the chiral ammonium enolate 
occurred due to the prolonged reaction time. The use of K2CO3 was also attempted in toluene (Table 
5, entry 7). There was no rearrangement at 0 °C; however, when the temperature was raised to room 
temperature, 62% rearrangement occurred albeit with poor enantioselectivity. The organic base 1,8-
bis(dimethylamino)naphthalene 282 was also trialled. The aryl migration reaction showed no 
conversion to the product, even when the reaction was heated to 70 °C (Table 5, entry 8). It appears 
that the decomposition product 281a is mostly observed at lower temperatures, and with increasing 
polarity of solvents used. This might be because polar solvents readily absorb water, which is 
suspected to be the cause of decomposition.  
Table 7: PTC aryl migration of 273b 
  
Entry Base Time Yield (%) 
1 Cs2CO3 6 d 0 
2 CsOH 2 h 0 
Anhydrous PhMe used 
To compare the migration of 3- and 4-cyano substituted rings, the reaction was carried out with 
273b (Table 7). There was no reaction at 0 °C with either Cs2CO3 or CsOH in toluene. When the 
reaction was allowed to warm to room temperature, decomposition of 273b to the corresponding 
N-methyl aniline 281b occurred (Table 7, entries 1 and 2). The 3-cyano substituent most likely fails 





Table 8: PTC aryl migration of 273e 
 
Entry T (°C) Time 
Yield (%) 
er (274e) 
273e 281e 274e 
1 0 <17 h 0 0 48 55:45 
2 −40  2 d 75 0 22 58:42 
Yields obtained by 1H NMR and compared with hexamethylbenzene internal standard. 
At 0 °C, the aryl migration of 273e was complete in less than 17 hours, with a slight enantiomeric 
excess noted (Table 8, entry 1). As enantioselectivity is improved at lower temperatures,101 the aryl 
migration was repeated at −40 °C. Unfortunately, at this temperature, the reaction did not go to 
completion after two days, although the er improved slightly (Table 8, entry 2). A control reaction 
with substrate 273e showed that background uncatalysed arylation could be observed at −20 °C but 
not at −40 °C (Scheme 66). This may explain the reason for the slight increase in er at −40 °C. 
 
Scheme 66: Control experiment for 273e 
There was no reaction when Cs2CO3 was used as base for the aryl migration of 273h (Table 9, entry 
1). However, when a stronger base (CsOH) was used at room temperature (Table 9, entry 2), the 
reaction proceeded to form the hydantoin 275h, but with no enantioinduction. It is likely the 
reaction was not enantioselective because the chiral catalyst played no role in the reaction. When 
the temperature of the reaction was reduced to 0 °C (Table 9, entry 3), decomposition of the 





Table 9: PTC aryl migration of 273h 
 
Entry T (°C) Solvent Base Time 
Yield (%) er 
(275h) 273h 281h 275h 
1 0 – rt PhMe:CHCl3
a Cs2CO3 7 d 273h
c 281hc 0 - 
2 rt PhMeb CsOH 1 d 0 20 39 50:50 
3 0 PhMeb CsOH 1 d 0 >99d 0 - 
a 1:0.7 ratio; b Anhydrous; c Mixture of 273h and 281h observed by 1H NMR; d Only 281h observed by 1H NMR; Other 
yields obtained by 1H NMR and compared with hexamethylbenzene internal standard. 
To investigate the participation of the catalyst in the reaction, a control experiment was carried out 
with substrate 273h using CsOH in toluene at room temperature (Scheme 67); decomposition of 
273h to 281h was observed. This suggested that whilst the catalyst must have played a role in the 
formation of 275h at room temperature, it did not confer any enantioselectivity. 
 
Scheme 67: Control reaction for 273h 
The aryl migration failed to occur with hydantoin urea 273j (Table 10). This is likely due to lack of 





Table 10: PTC aryl migration of 273j 
 
Entry T (°C) Solvent Time 
Yields (%) 
273j 281j 274j 
1 rt – 40 PhMe:CHCl3
a 3 d >99c 0 0 
2 rt PhMeb 1 d 0 >99c 0 
a 1:0.7 ratio; b Anhydrous; c Only compound observed by 1H NMR. 
The PTC aryl migration was investigated further by screening other PTCs (Figure 9). Since the best 
er was obtained for the aryl migration of 273a (Table 5, entry 1), this substrate was selected for 
screening of the catalysts. The results of the screening are given in Table 11. The PTCs: 285, 286, 
287, 288 and 291 gave the hydroxylated product 297a (Table 11, entries 3 – 6 and 9). As 
hydroxylation likely results from oxidation of the enolate by oxygen in the reaction mixture, the 
reaction with PTC 291 was repeated using degassed solvent. However, the hydroxylated product 








Figure 9: PTCs screened in the aryl migration of 273a1 
 





With PTCs 283 and 284; quinine-derived PTCs 289 and 290; and PTCs 293 – 295, there was no 
reaction at 0 °C after 1 day. When the reactions were warmed to room temperature, the products 
274a and 275a were formed with practically no enantioselectivity. Decomposition to the N-
methylaniline 281a was also observed in many cases. The difference in the results obtained for 284 
(Table 11, entry 2) and 285 (Table 11, entry 3) suggests that a thiourea catalyst might be more 
favourable towards these reactions than a urea. At room temperature, PTC 292 gave the product 
274a along with the corresponding N-methylaniline 281a (Table 11, entry 10). When the reaction 





Table 11: Screening of PTCs in the aryl migration of 273a 
 
Entry PTC T (°C) Time 
Yield (%) 
er (274a) 273a 281a 274a 275a 
1 283 0 – rt 2 d 0 15 5 48 54:46 
2 284 0 – rt 2 d 0 8 6 18 52:48 
3 285 0 2 d 0 0 0 0 - 
4 286 0 3 d 0 0 0 0 - 
5 287 0 16 h 0 0 0 0 - 
6 288 0 4 d 0 0 0 0 - 
7 289 0 – rt 4 d 0 21 9 18 54:46 
8 290 0 – rt 4 d 0 25 5 8 53:47 
9 291 0 3 d 0 0 0 0 - 
10 292 rt 16 h 0 20 11 0 51:49 
11 292 0 7 d 23 8 8 0 54:46 
12 293 0 – rt 4 d 0 0 40 21 52:48 
13 294 0 – rt 2 d 0 18 12 51 50:50 
14 295 0 – rt 2 d 0 0 44 14 52:48 
15 296 0 – rt 2 d 0 0 58 trace 45:55 
PTC – 10 mol%; Yields obtained by 1H NMR and compared with hexamethylbenzene internal standard. 
Wu and co-workers showed that a phosphonium-based catalyst gave good enantioselectivity when 
used in the phase transfer catalysed addition reaction of oxindoles to vinyl ketones.186 The excellent 
enantioselectivities obtained by them and other authors187,188 who have worked independently on 
the use of phosphonium based salts for enantioselective phase transfer catalysis prompted the author 






Scheme 68: Synthesis of alcohol 300 
Following the procedure used by Wu and co-workers, the phosphonium catalyst 296 was 
synthesised in a 3-step procedure. The first step was the nucleophilic addition of the amino alcohol 
298 to acyl chloride 299 to afford the addition and concomitant elimination product 300 (Scheme 
68). In the second step, 300 was treated with tetrabromomethane and triphenylphosphine to produce 
halide 301. Finally, 301 was treated with triphenylphosphine to produce the phosphonium salt 296 
(Scheme 69). 
 
Scheme 69: Synthesis of phosphonium salt 296 
The phosphonium salt 296 was applied in the aryl migration of 273a (Table 11, entry 15). 
Disappointingly, 296 gave a poor er of 45:55. 
As all attempts to improve the enantioselectivity using non-cinchona-derived catalysts proved 
unsuccessful, attention reverted to the cinchona-derived catalysts. Catalysts 303 – 304 were 
synthesised following literature protocol.100,189 (-)-Cinchonidine was heated with the desired alkyl 
halide in either toluene or a mixture of ethanol, DMF and chloroform to obtain the ammonium salts 
303. The ammonium salt 303a was later converted to its O-allylated form 304a by treating 303a 






Scheme 70: Synthesis of cinchona-derived catalysts 
PTC 303a was prepared to investigate if having a single hydrogen bonding site as opposed to 
multiple hydrogen bonding sites (compare PTC 290) was detrimental or beneficial to the 
enantioselectivity. Carrying out the aryl migration using PTC 303a (Table 12, entry 1) indicated 
that having multiple hydrogen bonding sites on the PTC made no contribution to the 
enantioselectivity of the aryl migration. This result was not surprising as it was not possible to 
achieve enantioselectivity with the previously used bifunctional urea and thiourea PTCs (Table 11). 
Literature reports, however, suggest that enantioselectivity can be significantly increased using 
PTCs with multiple hydrogen bonding sites.190,191 Beyond the influence of hydrogen bonding, 
perhaps the structures of 290 and 303a exert no stereodiscrimination in the rearrangement. 
PTC 304a showed that the presence of an O-allyl group at the C-9 position of the catalyst had no 
significant influence on the enantioselectivity as a similar er (Table 12, entry 2) was obtained to 
that of 303a (Table 12, entry 1). Previous studies showed that there was improved enantioselectivity 
in the -benzylation of a glycine-derived imine when the cinchona-derived catalyst was C9-O-allyl 
substituted.91 The benzylation was however intermolecular and not intramolecular. Belyk and 
Ronchi independently reported a significant reduction in enantioselectivity when a C9-O-allylated 
cinchona-derived PTC was used in place of its unallylated form in certain intramolecular 
transformations.192,193 This suggests that a free hydroxyl group at the C-9 position might be crucial 
to obtaining enantioselective transformations in intramolecular reactions. The reduction in 
enantioselectivity from 37:63 (Table 5, entry 1) to 43:57 (Table 12, entry 3) corroborates literature 





PTC increases enantioselectivity.194 Disappointingly, PTC 303c bearing a pyren-1-yl group at the 
quaternary nitrogen showed only 15% conversion to 274a after 2 days, with a er of only 44:56 
(Table 12, entry 4). 
Table 12: PTC optimisation 
 
Entry PTC T (°C) Time 
Yield (%) 
er (274a) 273a 281aa 274a 275a 
1 303a 0 2 d 31 10 27 0 44:56 
2 304a 0 3 d 20 8 35 0 45:55 
3 303b 0 5 d 30 8 15 0 43:57 
4 303c 0 2 d 48 trace 15 0 44:56 
5 305 0 3 d 0 8 56 0 60:40 
6 307a 0 1 d 5 7 76 0 51:49 
7 307b 0 – rt 2 d 0 3 65 0 50:50 
8 308 0 – rt 2 d 0 0 5 48 57:43 
Yields obtained by 1H NMR and compared with hexamethylbenzene internal standard; a 4-(methylamino)benzonitrile 
When commercially available bis(hydrocinchonidine)-derived PTC 305 (Figure 10) was used in the 
aryl migration, an er of 60:40 (Table 12, entry 5) was obtained. The reaction was faster and the 
yield higher relative to previously used single cinchona unit PTCs. Unlike the monomeric cinchona 
derived catalyst 303b, there is hindered rotation of the naphthyl in 305, hence the dimeric cinchona-
derived catalyst would offer a more rigid conformation of the ammonium/enolate ion-pair. The use 
of bicinchona catalysts was explored further. 
 





Bicinhona catalysts 307a and 307b were synthesised via the 1 step procedure described in Scheme 
71.194 (DHQD)2-PHAL 306 was refluxed with the desired alkyl bromide in toluene to afford 307a 
and 307b in a 99% and 31% yield respectively. 
 
Scheme 71: Synthesis of Bicinchona catalysts 
PTC 307a showed a remarkable increase in the rate and yield of the aryl migration; however, the 
product 274a was racemic (Table 12, entry 6). PTC 307b showed no conversion to the product at 0 
°C, hence the reaction was warmed to room temperature. A good yield of 65% was obtained at 
room temperature but the product 274a was found to be racemic (Table 12, entry 7). It is uncertain 
why the catalysts 307a and 307b confer no enantioselectivity in the reaction. Jeong and co-workers 
also reported a 0% ee when 307a was used as PTC in the -benzylation of a benzophenone glycine 
derived imine at room temperature.179 Like 305, the dimeric cinchona catalyst 307a significantly 
improved the rate of the reaction, suggesting that the added cinchona unit provides an additional 
stabilization of the enolate. Steric clashes between the naphthyl and quinoline ring in 307b might 
lead to an unfavourable transition state conformation. This might explain why no reaction occurred 
at 0 °C. 
To get more insight into the influence of polymeric cinchona salts on the rearrangement, tricinchona 
catalyst 308 was synthesised via the 1 step protocol illustrated in Scheme 72 and used in the aryl 
migration. No aryl migration occurred at 0 °C; when the reaction was heated to room temperature, 
274a and 275a were observed in a 5% and 48% yield respectively (Table 12, entry 8). The 
enantioselectivity of 274a was disappointingly poor. This result suggests that whilst sterically 
hindered catalysts are useful in reducing flexibility in the conformation of the ammonium enolate, 
excessive steric hindrance could lead to high energy transition states and lose ion-pairing of the 






Scheme 72: Synthesis of tricinchona catalyst 308 
Past research showed that cinchona salts having a perfluorinated benzyl group at the quaternary 
ammonium centre are effective catalysts for inducing excellent enantioselectivities in many 
transformations.195–197 It is postulated that an electron-withdrawing group like fluorine results in a 
more compact ammonium/anion pair, thus improving enantioselectivity.95,198,199 Furthermore a 
fluorine atom provides additional stabilisation through stereoelectronic and electrostatic effects; 
and could also take part in hydrogen bonding.200,201 Maruoka also observed that the introduction of 
a 3,4,5-trifluorophenyl substituent on the 3,3ꞌ position of his binaphthyl PTCs led to significantly 
increased enantioselectivities in the double alkylation of glycine-derived imines.106,202 On the basis 
of these findings, the cinchona salts 309 – 316 were made by refluxing a mixture of the desired 






Figure 11: Cinchona-derived PTCs bearing fluorobenzyl groups 
PTCs 309 – 316 (Figure 11) bearing different fluorine substitution patterns on the N-benzyl group 
were independently trialled in the aryl migration reaction (Table 13). Delightfully, PTC 314 with 
3,4,5-trifluorobenzyl substitution produced an enantiomeric ratio of 78:22 in the aryl migration 
(Table 13, entry 6). The poor enantioselectivities obtained with all the ortho-substituted N-benzyl 
derivatives (Table 13, entries 1 – 5 and 7 – 8) indicated that a H-atom at the ortho position is crucial 
to obtaining good enantioselectivities, perhaps due to aromatic C-H/ interactions with 273a.203 
The better enantioselectivity obtained with PTC 315 relative to PTC 309 indicates the importance 
of the methoxy substituent on the quinoline ring (Table 13, entry 7 vs entry 1). The oxygen atom of 
the methoxy group likely takes part in hydrogen bonding interactions with 273a; this implies that 
an hydroxyl group on the quinoline ring would also take part in hydrogen bonding interactions with 
273a. Proceeding with PTC 314, the effect of water on the enantioselectivity of the aryl migration 
was investigated. The use of a mixture of anhydrous toluene and wet (non-anhydrous) chloroform 
(Table 13, entry 9) decreased the er from 78:22 to 69:31, indicating that the presence of water in 





this might explain the improved enantioselectivity in the presence of water. As expected, the 
enantioselectivity decreased at higher temperatures, from 69:31 at 0 °C (Table 13, entry 9) to 62:38 
at room temperature (Table 13, entry 10). 
Table 13: PTC optimisation 
 
Entry PTC1 T (°C) Time 
Yield (%) 
er (274a) 273a 281a 274a 
1 309 0 3 d 21 15 19 56:44 
2 310 0 3 d 10 17 22 54:46 
3 311 0 3 d 40 13 13 49:51 
4 312 0 3 d 21 19 18 54:46 
5 313 0 2 d 10 14 35 53:47 
6 314 0 2 d 9 15 47 78:22 
7 315 0 3 d 39 16 11 60:40 
8 316 0 5 d > 90 nd trace 55:45a 
9b 314 0 2 d 32 10 19 69:31 
10b 314 rt 16 h 0 0 80c 62:38 
Except otherwise stated, the reactions were performed in wet solvents; Except otherwise stated, yields were obtained by 
1H NMR and compared with hexamethylbenzene internal standard; PTC – 10 mol%; a HPLC trace of crude; b Reaction 
carried out in a mixture of anhydrous toluene and wet chloroform; c Isolated yield 
As solvents have been found to significantly alter enantioselectivity in asymmetric reactions,196,197 
the influence of solvents on the enantioselectivity of the aryl migration was probed (Table 14). 
When a mixture of THF and toluene was used as solvent at 0 °C, incomplete conversion to 274a 
with significantly reduced enantioselectivities were observed after 24 hours (Table 14, entries 2 and 
3). The use of THF alone increased the rate of the aryl migration but to the detriment of the 
enantioselectivity (Table 14, entry 4). With the rationale that a weaker base might produce good 
enantioselectivity in THF, K2CO3 was trialled in the reaction (Table 14, entry 9). Disappointingly, 
no conversion was observed after 96 h. 
 





Table 14: Solvent optimisation1 
 
Entry T (°C) Solvents (ratio) Base Time (h) Comments er 
1 0 PhMe:CHCl3 (0.6:0.4) Cs2CO3 48  47%
b 78:22c 
2 0 PhMe:THF (1:1)a Cs2CO3 24  Incomplete conversion 54:46 
3 0 PhMe:THF (0.9:0.1)a Cs2CO3 24  trace conversion 63:37
c 
4 0 THFa Cs2CO3 24  100% conversion 52:48
c 
5 0 CF3Ph
a Cs2CO3 60  100% conversion 60:40 
6 0 PhMe:CHCl3 (0.9:0.1) Cs2CO3 72  No conversion - 
7 rt PhMe:CHCl3 (0.9:0.1) Cs2CO3 20  Incomplete conversion 60:40 
8 0 CHCl3 Cs2CO3 72  100% conversion 70:30 
9 0 THF K2CO3 96  No conversion - 
Except otherwise stated, the reactions were carried out in wet solvents; a Reaction carried out in anhydrous solvent        
b Yield was obtained by 1H NMR and compared with hexamethylbenzene internal standard; c HPLC trace of pure 
product 
Complete conversion was observed with trifluoro toluene at 0 °C but the enantioselectivity was 
reduced (Table 14, entry 5). As expected, no conversion was observed when the amount of PhMe 
in the PhMe:CHCl3 solvent mixture was increased (compare Table 14, entry 6 to 1); However, when 
the aryl migration reaction was warmed to room temperature in the same solvent mixture (Table 
14, entry 7), some conversion was observed after 20 hours with moderate enantioselectivity. The 
use of chloroform alone made the reaction faster but the enantioselectivity reduced from 78:22 to 
70:30 (Table 14, entry 8 vs 1). Amongst the solvent systems screened, a 0.6:0.4 mixture of 
PhMe:CHCl3 (Table 14, entry 1) was the optimal solvent system for enantioselectivity, but 
considering the slower rate of reaction relative to using CHCl3 alone (Table 14, entry 8), the latter 
was chosen for further optimisations. 
 





Table 15: Further optimisations1 
 
Entry T (°C) Base x Time Comments er 
1 0 Cs2CO3 10 72 h 100% conversion 70:30 
2 0 Cs2CO3 20 17 h 100% conversion 77:23 
3 −10 Cs2CO3 20 23 h 100% conversion 82:18 
4 −20 Cs2CO3 20 36 h 100% conversion 85:15 
5 −20 – 0 Rb2CO3 20 15 h Incomplete conversion 73:27 
6 −20 Cs2CO3 30 24 h 100% conversion 87:13 
7 0 Cs2CO3 30 22 h 100% conversion 80:20 
Wet CHCl3 was used as solvent in all cases  
When the catalyst loading was increased from 10 to 20 mol% (Table 15, entry 2), the aryl migration 
was complete in 17 hours and the er improved from 70:30 to 77:23. Reducing the temperature of 
the aryl migration from 0 to −10 °C slowed down the reaction but improved the er from 77:23 to 
82:18 (Table 15, entry 3). A further reduction in temperature to −20 °C slowed down the reaction 
further but improved the er to 85:15 (Table 15, entry 4). Using the same conditions as entry 4, a 
weaker base, Rb2CO3 was used instead of Cs2CO3 (Table 15, entry 5). There was no conversion at 
−20 °C, hence the reaction was warmed to 0 °C. The reaction showed slight conversion to 274a 
after 15 hours with an er of 73:27. Going back to Cs2CO3 as base and increasing the catalyst loading 
from 20 to 30 mol%, the aryl migration occurred with an er of 87:13 at −20 °C (Table 15, entry 6). 
Using this same catalyst loading at 0 °C, the er of the aryl migration product 274a reduced from 
87:13 to 80:20 (Table 15, entry 7). 
 





Table 16: Further solvent optimisations1 
 












30 Cs2CO3 18 h Incomplete conversion 79:21 
4 −20 THFa 20 Rb2CO3 60 h Incomplete conversion 57:43 
5 0 HFIPa 20 Cs2CO3 48 h No conversion - 
Except otherwise stated, the reactions were carried out in wet solvents; a Anhydrous solvent.  
The rate of the aryl migration was faster in chloroform than toluene; However, a non-polar solvent 
like toluene was needed to promote tighter interactions between the catalyst and the enolate, 
consequently leading to better enantioselectivity. To obtain an optimal PhMe:CHCl3 solvent 
system, further investigations were done. A 1:1 ratio of the two solvents (Table 16, entry 1) 
produced an er of 77:23. Decreasing the ratio of toluene to CHCl3 (Table 16, entry 2) produced a 
comparable er of 79:21. Though the rate of the aryl migration reduces with increasing ratio of 
PhMe:CHCl3, it was thought that increasing the catalyst loading to 30 mol% (Table 16, entry 3) 
might increase the rate and enantioselectivity of the reaction even when a greater percentage of 
toluene was used in the solvent mixture. Disappointingly, a comparable rate and enantioselectivity 
to that obtained in Table 14, entry 1 was noted. From these results, it was inferred that toluene could 
only solvate a small amount of the catalyst; and this might explain why increasing the catalyst 
loading to 30 mol% had no significant effect on the enantioselectivity. Chloroform, on the other 
hand, can solvate the catalyst well even at a low temperature of −20 °C (Table 15, entry 4).  
Using 20 mol% catalyst loading, additional optimisations were carried out with the aim of obtaining 
a better enantioselectivity than 85:15. The use of Rb2CO3 in THF at −20 °C gave some conversion 
to 274a, but with a low level of enantioenrichment (Table 16, entry 4). No conversion was observed 
 





in hexafluoro-2-propanol at 0 °C (Table 16, entry 5). At this point, it was concluded that further 
catalyst optimisations should be carried out with Cs2CO3 as base and chloroform as solvent. 
 
Figure 12: Modification of PTC 314 
To gain further insights into the components of PTC 314 that contribute to enantioselectivity 
through interaction with the enolate, structural modifications were made to afford PTCs 317 – 323 
(Figure 12). It is now known from previous optimisations (Table 13, entry 1 vs 7) that the OMe 
group on the quinoline is relevant to obtaining improved enantioselectivity. Nonetheless, out of 
inquisitiveness, 317 bearing an OTIPS instead of an OMe, was tested. No conversion was observed 
at either −20 or 0 °C, with only starting material observed by 1H NMR after 24 hours (Table 17, 
entry 2). As noted earlier, a bulky group such as a triisopropylsilyl (TIPS) could lead to the 
generation of an unfavourable high energy ammonium enolate transition state. The importance of 
the hydroxyl group in PTC 314 was exemplified by PTC 318 and 319, both having a substituent on 





respectively obtained when the reaction was warmed to 0 °C (Table 17, entries 3 and 4). The failure 
of PTCs 318 and 319 to catalyse the reaction at −20 °C indicates that the hindrance posed by the 
bulky O-substituents is more obvious at lower temperature, but raising the temperature of the 
reaction to 0 °C, supplies just enough energy for the reaction to occur at a slow rate. With PTC 320, 
only starting material was observed by 1H NMR after 18 hours at 0 °C (Table 17, entry 5). This 
suggests that fluorine substitution at carbon 5 of the benzyl in PTC 314 is pertinent to reactivity. 
PTC 321 gave a similar er to 314 at −10 °C (Table 17, entry 6 vs Table 15, entry 3), indicating that 
fluorine substitution at carbon 4 of the benzyl in 314 is inconsequential to the enantioselectivity. 
Fluorine substitution at the meta positions (carbon 3 and 5) of the benzyl ring certainly provides a 
high level of stereodiscrimination that becomes disturbed with further introduction of fluorine to 
other positions on the ring apart from the para position. PTC 322 gave similar enantioselectivity 
and yield to its dehydrogenated form 314 (Table 17 entry 7 vs entry 1). This corroborates a 1991 
literature finding that the vinyl group in a cinchona alkaloid-based catalyst makes no contribution 
to the enantioselectivity of the reaction in which it is used.102 PTC 323 having a 3,5-difluoro 
substitution also gave similar enantioselectivity and yield to both 322 and 314 (Table 17, entry 8), 






Table 17: PTC optimisation1,2 
 
Entry PTC T (°C) Time Comments er 
1 314 −20 36 h 100% conversion 85:15 
2 317 −20 – 0 24 h No conversion - 
3 318 −20 – 0 22 h Incomplete conversion 73:27 
4 319 −20 – 0 18 h Incomplete conversion 75:25 
5 320 0 18 h No conversion - 
6 321 −10 23 h Incomplete conversion 79:21 
7 322 −20 36 h 100% conversion 85:15 
8 323 −20 36 h 100% conversion 85:15 
All reactions were carried out in wet chloroform; PTC: 20 mol%. 
PTC 322 was used for further optimisation of the reaction conditions (Table 18). The use of the 
stronger KOH base led to decreased enantioselectivity (Table 18, entry 4 vs 1). Both aqueous and 
powdered K3PO4.H2O gave no conversion, as observed by 1H NMR (Table 18, entries 5 and 6). 
Ag2CO3 gave no conversion at either −20 or +40 °C (Table 18, entry 7). Changing the solvent to 
xylene or mesitylene also gave no conversion (Table 18, entries 8 and 9).  
It is known from optimisations presented in Table 13, entries 6 and 9 that the use of non-anhydrous 
solvents enhances enantioselectivity. The influence of water on the reaction was further 
investigated. Using both anhydrous CHCl3 and Cs2CO3 at −20 °C gave no conversion (Table 18, 
entry 10), indicating that the presence of water was not only relevant to enantioselectivity but also 
reactivity. Increasing the temperature to −10 °C gave some conversion but with reduced er (Table 
18, entry 11). Direct addition of water into the reaction (Table 18, entries 12 and 13) made no 
difference to the enantioselectivity, however, the rate of the reaction was significantly reduced. It 
appears a minimal amount of water is needed to increase the solubility of the catalyst, hence 
enhancing the enantioselectivity of the reaction. An excess of water, on the other hand, leads to 
slow reaction rates due to solvation of the enolate. 
 
1 Joint work of the author and Dr Rakesh K. Saunthwal 





Table 18: Further optimisations1 
 
Entry T (°C) Solvent Base x Time Comments er 
1 −20 CHCl3 Cs2CO3 5 36 h 100% conversion 85:15 
2 −10 CHCl3 KOH 3 18 h Incomplete 70:30 
3 −10 CHCl3 KOH 1.2 18 h 100% conversion 77:23 
4 −20 CHCl3 KOH 1.2 18 h 100% conversion 77:23 
5 −10 CHCl3 K3PO4.H2O 3 18 h No conversion - 
6 −10 CHCl3 K3PO4.H2O
a 2 18 h No conversion - 
7 −20 – 40 CHCl3 Ag2CO3 5 36 h No conversion - 
8 0 Xylene Cs2CO3 5 22 h No conversion - 
9 0 Mesitylene Cs2CO3 5 22 h No conversion - 
10 −20 CHCl3
b Cs2CO3
 b 5 22 h No conversion - 
11 −10 CHCl3
b Cs2CO3
 b 5 23 h Incomplete 72:28 
12 −20 CHCl3
c Cs2CO3 5 42 h 100% conversion 85:15 
13 −20 CHCl3
d Cs2CO3 5 42 h 100% conversion 85:15 
a 30% aqueous; b Anhydrous; c 1l/10ml(H2O/CHCl3); d 3l/10ml(H2O/CHCl3) 
In 2004, Nájera et al. reported that the counterion of a cinchona salt could influence the 
enantioselectivity of a PTC reaction. In their study, the hexafluorophosphate counterion, in 
particular, gave slightly improved er to the bromide counterion.204 To investigate this effect on the 
aryl migration, 324 and 325 were made by an anion exchange reaction involving 322 and the 
respective salts (Scheme 73). 
 






Scheme 73: Anion exchange synthesis of 324 and 3251 
Both 324 and 325 were tested in the aryl migration reaction (Table 19). They both produced the 
same enantioselectivity as 322, albeit with a significant reduction in the rate of the reaction. Nájera 
et al. also observed a general reduction in reaction rates with the hexafluorophosphate counterion 
relative to the bromide counterion. It is imaginable that the ammonium ion is tightly bound to the 
hexafluorophosphate or tetrafluoroborate counterion, thus leading to slow ion exchange between 
the PTC and caesium enolate, consequentially leading to slow reaction rates (see PTC mechanism 
in Scheme 74).  
Table 19: Counterion investigation 
 
Entry PTC Time Yield (%) er 
1 322 36 h (67) 85:15 
2 324 4 d 33a 85:15 
3 325 2 d 37a 85:15 
a Yields obtained by 1H NMR and compared with hexamethylbenzene internal standard  
Wet solvent used; Parenthesis indicate isolated yield 
From the optimisation results presented above; and similar reports on PTC rearrangements205 and 
solid-liquid PTC,206 a mechanism is suggested for the PTC rearrangement of hydantoin ureas 
(Scheme 74). Deprotonation of 273a by the base (M2CO3) occurs at the interface to produce the 
metal enolate pair 326. At this stage, there are two possibilities for 326. The metal enolate 326 could 
undergo rearrangement directly at the interface, ultimately leading to racemic 274a (pathway A). 
Alternatively, 326 could undergo ion exchange with the chiral PTC Q+X− to give the chiral 
ammonium enolate pair 328 (pathway B). The chiral ammonium enolate 328 could undergo 
 





rearrangement directly at the interface or it could migrate to the organic phase, where it rearranges 
to enantioenriched 329.  
 
Scheme 74: Proposed mechanism for intramolecular PTC aryl migration; Q+X− = quaternary ammonium 
halide, M = Metal 
Finally, an aqueous quench produces the rearranged product 274a whilst regenerating the catalyst. 
Rearrangement of 328 in the organic phase would be more favoured than at the interface because 
the enolate is desolvated on its extraction to the organic phase.207,208 This probably accounts for the 
reduction in reaction rate when water was added to the reaction (Table 18, entries 12 and 13). Based 
on previous studies done in the Clayden group and other nucleophilic aromatic substitution 





formed from attack of the enolate on the aryl ring in 326 or 328. Collapse of this intermediate gives 
327 or 329, which gains a proton from the aqueous quench to give 274a. It is uncertain if the 
intermediate 330 exists in this reaction. Nonetheless, the presence of this intermediate is feasible as 
the electron-withdrawing cyano group is able to stabilise 330. 
The mechanism described for this intramolecular PTC arylation is speculative and requires further 
mechanistic investigations. In intermolecular reactions, where the nucleophile and electrophile are 
separate molecules (see Scheme 33), the ammonium enolate must migrate to the organic phase to 
react with the electrophile. As the electrophile is mostly in the organic phase, it is logical that there 
is minimal or no reaction without the PTC, because the ammonium counterion of the PTC extracts 
the enolate into the organic phase by formation of an ion-pair with the enolate. In intramolecular 
reactions, the implication of both electrophile and nucleophile being in the same molecule is that a 
reaction could happen in the absence of the PTC leading to racemic products even when a chiral 
PTC is used (Scheme 74, pathway A). This is not the case, as seen in the optimisations presented. 
In many cases, the rearrangement did not occur or occurred slowly in the absence of the PTC. The 
formation of enantioenriched products is also evidence that the PTC plays a role in the reaction. 
Furthermore, reported intramolecular PTC reactions showed that the rates and enantioselectivities 
of the reactions were influenced by the catalyst.192,193,209,210 One rationale is that the ammonium 
enolate 328 exhibits more ionic character than the metal enolate 326. Hence, rearrangement of the 
ammonium enolate occurs faster than the metal enolate, thus minimizing uncatalysed 
rearrangements.207,211 Another rationale is that the active base carrying out the interfacial 
deprotonation might not be the metal carbonate 332, but a chiral ammonium carbonate 333 
generated from extraction of the carbonate ion from the metal carbonate 332 (Scheme 75). This 
rationale was corroborated by studies that showed that quaternary ammonium ions could influence 
substrate deprotonation by an extraction mechanism.212–216 In cases where no products were formed 
in the absence of the PTC, but racemic products were formed in the presence of the PTC, it could 
be that the PTC aided deprotonation of the substrate but did not have the required structure to induce 
enantioselectivity in the rearrangements. 
 
Scheme 75: Generation of proposed active base 333; QX = quaternary ammonium salt, M2CO3 = metal 
carbonate base 
In summary, non-polar solvents promoted enantioselectivity but were detrimental to the rate of the 
rearrangement. Non-anhydrous conditions are required for enhanced enantioselectivities. There was 
a general reduction in the rate of the reaction, with increasing steric hindrance of catalysts used. 
The enantioselectivity of the aryl migration is highly sensitive to the structural composition of the 





ring was crucial to enhancing stereodiscrimination. This was probably due to the stereoelectronic 
effect produced by the fluorine atom at the position. The optimal catalyst was found to be cinchona 
salts bearing a 3,4,5 or 3,5-perfluorobenzyl substituent, producing an er of 85:15 in the migration 
of a 4-cyanophenyl (Figure 13). 
 
Figure 13: HPLC trace of near-racemic and scalemic 274a 
2.2.4 Attempted Scope for the Aryl migrations 
To establish the migratory group tolerance of the phase transfer catalysed aryl migrations, the 
rearrangement was performed on hydantoin ureas bearing other migratory aryl rings apart from 4-
cyanophenyl. The optimal condition: 20 mol% of PTC 322 in non-anhydrous chloroform was used 
in the reactions. 
Table 20: Attempted PTC aryl migration of 273b  
 
Entry T (°C) Solvent Time Comments 
1 −20 Cs2CO3 16 h No conversion 
2 −10 Cs2CO3 16 h No conversion 
3 0 Cs2CO3 16 h No conversion 
4 rt Cs2CO3 16 h No conversion 
5 40 Cs2CO3 16 h No conversion 







Aryl migration was attempted on hydantoin urea 273b containing a 3-cyanophenyl migratory ring. 
Disappointingly, starting material 273b was observed by 1H NMR when Cs2CO3 was used as base 
at various temperatures (Table 20, entries 1 – 5). The use of KOH at −20 ° C only led to 
decomposition of 273b to the corresponding N-methyl aniline 281b (Table 20, entry 6). The 3-
cyanophenyl ring is probably not electron-deficient enough. A Similar failure to migrate this ring 
was experienced in earlier optimisations (see Table 7). 
 
Scheme 76: PTC aryl migration of 273c 
Hydantoin urea 273c bearing a 2-cyanophenyl migratory ring gave incomplete conversion to 274c 
after 24 hours (Scheme 76). HPLC analysis of the crude reaction mixture revealed an er of 52:48.  
Table 21: PTC aryl migration of 273d 
 
Entry T (°C) Base x  Time 
Yield (%) er 
(274d) 274d 275d 
1 −20 Cs2CO3 5 18 h 0 0 - 
2 0 Cs2CO3 5 16 h Incomplete conversion 0 68:32 
3 −20 KOH 3 25 h 51 20 70:30 
Yields obtained by 1H NMR and compared with hexamethylbenzene internal standard. 
Hydantoin urea 273d bearing an electron-deficient 4-pyridyl group was subjected to the aryl 
migration reaction (Table 21). No conversion was observed using Cs2CO3 as the base at −20 °C 
(Table 21, entry 1). On warming the reaction to 0 °C (Table 21, entry 2), partial conversion to 274d 
was observed by TLC with a crude HPLC analysis revealing an er of 68:32. The stronger KOH 
base gave 51% and 20% conversion to 274d and 275d respectively by 1H NMR (Table 21, entry 





Table 22: PTC aryl migration of 273e 
 
Entry T (°C) Solvent PTC Time Comments er 
1 −20 CHCl3 322 18 h 100% conversion 55:45 
2 −40  CHCl3 322 24 h 100% conversion 55:45 
3 −40  PhMe:CHCl3
a 322 24h 100% conversion 54:46 
4 −40  CHCl3 314 23 h 100% conversion 53:47 
5 −40  CHCl3 323 23 h 100% conversion 53:47 
a 0.6:0.4 ratio of PhMe:CHCl3 
The aryl migration was performed on hydantoin urea 273e containing a 4-nitrophenyl migratory 
ring (Table 22). PTC 322 gave 100% conversion to 274e at both −20 and −40 °C; nevertheless, a 
poor er of 55:45 was obtained in both reactions (Table 22, entries 1 and 2). A change in solvent to 
a 0.6:0.4 mixture of PhMe:CHCl3 at −40°C made only a minor difference to the reactivity and 
enantioselectivity (Table 22, entry 2 vs 3). PTC 314 and 323, which also offered a good er of 85:15 
in the aryl migration of substrate 273a in CHCl3 (Table 17, entries 1 and 8), were tested on the aryl 
migration of 273e at −40 °C. Both PTCs gave 100% conversion to 274e; however, a poor er of 
53:47 was obtained in both cases (Table 22, entries 4 and 5). 
 





Aryl migration of the 2-nitrophenyl group in hydantoin urea 273f went on smoothly at −20 °C, with 
complete conversion to 274f observed by TLC after 72 hours (Scheme 77). The enantiomeric ratio 
obtained, however, was poor (47:53). The 4- and 2-nitrophenyl migratory aryl rings are quite 
electron-deficient. The occurrence of background uncatalysed arylation leading to racemic products 
is plausible in the migration of these rings.  
 
Scheme 78: Attempted PTC aryl migration of 273g 
Unlike the 4- and 2-nitrophenyl examples, aryl migration was not achieved with the 3-nitrophenyl 
migrating group (Scheme 78). Instead, attack of the enolate on the ortho position of the ring was 
observed, leading to the dearomatised intermediate 336 that rearomatises to produce the tricycle 
337. It is presumed that this nucleophilic substitution of hydride was likely caused by oxygen in the 






Table 23: Attempted PTC aryl migration of 273n1 
 
Entry T (°C) Base x eq. Time Comments 
1 −20 Cs2CO3 5 96 h No conversion 
2 0 Cs2CO3 5 24 h No conversion 
3 rt – 40 Cs2CO3 5 48 h No conversion 
4 rt KOHa 1.5 20 h No conversion 
5 rt – 40 CsOH.H2O 5 50 h No conversion 
a 30% aqueous 
The 4-tolyl group of hydantoin urea 273n failed to migrate under all conditions trialled (Table 23). 
This is likely due to the 4-tolyl group being electron-rich. Migration of the 4-tolyl group has been 
reported, but a strong base, KHMDS was used to achieve the transformation.153 
 
Scheme 79: PTC aryl migration of 273i 
The 3-CF3,4-CN substituted aryl group in 273i underwent migration to afford 274i in a 59% isolated 
yield; however, the enantioselectivity produced was poor (Scheme 79). 
As the PTC 322 seemed to offer good enantioselectivity only in the migration of a 4-cyanophenyl 
group, alanine-derived hydantoin urea 273k bearing a 4-cyanophenyl group on the distal urea 
nitrogen was subjected to the aryl migration conditions (Table 24). As also observed in Table 10, 
every attempt made to achieve aryl migration of 273k was not forthcoming. Deprotonation of the 
less acidic -proton of 273k is likely disfavoured because of the instability of the resulting enolate 
due to the hyperconjugation effect of the methyl group at the -carbon. Notwithstanding, aryl 
 





migration within alanine derived ureas have been reported but with the use of strong organic bases 
for deprotonation of the -proton.153,217 
Table 24: Attempted PTC aryl migration of 273k 
 
Entry T (°C) Base x Time Comments er 
1 rt KH 2 18 h No conversion - 
2 rt – 50 KOHa 2 18 h No conversion - 
3 0 – 50 Cs2CO3 5 22 h trace -
b 
4 rt KOH 3 24 h No conversion - 
5 0 KOH 4 17 h No conversion - 
6 rt CsOH.H2O 3 24 h trace -
b 
a 50% aqueous; b Not enough material for an HPLC analysis 
To investigate the influence of another enolate stabilising group on the reactivity and 
enantioselectivity of the aryl migration, hydantoin urea 273l with a 4-ClC6H4 stabilising group on 
the -carbon was subjected to the aryl migration reaction (Scheme 80). 
 
Scheme 80: Aryl migration of 273l 
After 46 h, 66% of 274l was isolated. Though the yield is similar to that obtained in the aryl 
migration of 273a, the rate of reaction for the chlorinated substrate was much faster. TLC analysis 
of the aryl migration of 273l after 22 hours showed almost complete consumption of the starting 
material compared to the aryl migration of 273a which still showed a significant amount of starting 
material after 18 hours. As such, this increase in reaction rate can be directly linked to the formation 





274a. The reduced enantioselectivity suggests that an electron-withdrawing group on the -phenyl 
ring could be detrimental to enantioselectivity. This cannot be ascertained without performing the 
aryl migration of an hydantoin urea bearing an electron-rich -aryl substituent.  
2.2.5 Alternative Directing Groups 
Several hydantoin N-protecting groups have been investigated in N to C aryl migrations within 
ureas.152,158 One important factor considered in the choice of protecting groups is the ease of 
removability. Another factor considered, particularly in asymmetric reactions, is the ability of the 
protecting group to also act as a directing group to confer selectivity. Amongst many other reasons, 
the tert-butyl is a common protecting group because it is easily removed and is known to enhance 
stereoselectivity in asymmetric reactions.41,218 
 
Scheme 81: Synthesis of urea 338 
One alternative to the tert-butyl group chosen for investigation is the benzyl group; Methods for 
removal of the group has been reported.219–221 Hence it was worth examining if this group would 
induce a better enantioselectivity than the tert-butyl. Following the established procedure, D-
phenylglycine methyl ester hydrochloride 277 was treated with benzyl isocyanate to afford the urea 
338 in 84% yield (Scheme 81). 
 
Scheme 82: Synthesis of hydantoin 342 
Treatment of 338 with potassium tert-butoxide led to deprotonation of one of the benzylic protons 





instead of the intended product 342. Formation of 340 was avoided by treatment of 338 with the 
milder triethylamine base, affording 342 in a 55% yield (Scheme 82).222  
Table 25: Attempted acylation of 342 
 
Entry T (°C) Base Acylating agent Solvent Time (h) 
1 −78 – rt Pyridine Triphosgene DCM 72 
2 0 – rt Et3N Triphosgene DCM 16 
3 0 – 100 Et3N Triphosgene PhMe 16 
4 rt − Phosgene THF 3 
 
Unfortunately, all attempts to acylate 342 proved unsuccessful. Unreacted 342 was recovered in 
each case (Table 25). Ethyl and tert-octyl are not commonly used directing groups in asymmetric 
reactions. Nevertheless, they were chosen for further investigation to determine the effect of steric 
hindrance on the yields and enantioselectivity of the aryl migration. It was anticipated that a bulkier 
tert-octyl group would confer better enantioselectivity than the tert-butyl group 
 
Scheme 83: (a) Synthesis of hydantoins bearing an ethyl or tert-octyl directing group (b) Synthesis of 





Synthesis of the hydantoin ureas 350 and 351 proceeded smoothly using the established conditions 
(Scheme 83). The stereochemistry in 346 and 347 is not indicated because racemisation could have 
occurred in the use of potassium tert-butoxide as base. Using the optimal PTC 322, hydantoin ureas 
350 and 351 were subjected to the aryl migration (Table 26). The aryl migration of 350 took place 
at a comparative rate to substrate 273a, but the er was reduced from 85:15 to 77:23 (Table 26, entry 
2). The aryl migration of 351 occurred at a significantly slower rate than 273a. Incredibly, starting 
material remained even after the reaction had been left to stir for 144 hours (Table 26, entry 3), 
owing to the increased steric hindrance of the tert-octyl group in 351. Disappointingly, the er 
induced by the tert-octyl group was lower than that induced by the tert-butyl group.  
Table 26: Aryl migration of 350 and 351 
 
Entry Starting material R Time (h) Yield (%) Product er 
1 273a tert-Butyl 40  (67) 274a 85:15 
2 350 Ethyl 48 (61) 352 77:23 
3 351 tert-Octyl 144 36a 353 72:28 
aYield obtained by 1H NMR and compared with hexamethylbenzene internal standard  
Parentheses indicate isolated yields 
The optimal PTC 322 seem to be highly substrate-specific producing good stereodiscrimination 
only for the migration of a 4-cyanophenyl and 4-pyridyl. The fact that 322 is stereoselective only 
for the migration of these rings implies that one of the sites of interaction of the catalyst with the 
hydantoin ureas 273 is the fragment E (Figure 14). The implication of this is that a PTC optimisation 
would be required for each change in the migratory aryl ring. The PTC 322 likely interacts with the 
fragment E by - stacking, C-H/ interactions or by hydrogen bonding between the hydroxyl 
fragment B and the nitrogen of the cyano substituent. Other plausible interactions between the PTC 
and 273 are hydrogen bonding between the fragment B and any of the carbonyls (fragment F or G); 
C-H/ interaction between the ortho-H in fragment D and the arene fragment E or H, this would 
account for why racemic products were obtained with ortho-fluoro N-benzyl analogues of 322; An 
unclassical C−H∙∙∙∙O hydrogen bond interaction between the OMe of fragment A and the aromatic 





used in the aryl migration as opposed to PTC 315 (Table 13, entries 1 vs 7); and electrostatic 
attraction between the ammonium ion (fragment C) and the enolate (fragment I).  
 
Figure 14: Proposed interaction sites between the PTC and the enolate 
It is remarkable how the introduction of fluorine substituents on the N-benzyl ring of the cinchona 
salt led to a dramatic rise in the enantioselectivity. The high electronegativity of the fluorine atom 
makes the C-F bond highly polarised. As a result of this, the fluorine atom of the C-F bond can 
engage in dipole-dipole and charge-dipole electrostatic interactions. In addition, the highly 
polarised C-F bond leads to a hyperconjugation effect due to the low energy *C-F antibonding 
orbital accepting electron density from adjacent non-bonding electron pairs. The interactions and 
hyperconjugation effect produced by the presence of fluorine in a molecule can significantly 
stabilise one transition state or reactive intermediate conformation over another, thus leading to 
good stereodiscrimination in asymmetric reactions.200,224 It is uncertain why the fluorine 
substituents had to be on specific positions of the N-benzyl ring for good stereodiscrimination to 
occur. It could be that the stereoelectronic and electrostatic effects of the fluorine atom is more 
pronounced at certain positions of the N-benzyl ring.  
2.2.6 Conclusion and Future Work 
The investigations have shown that N to C aryl migration in ureas under the mild conditions of 
phase transfer catalysis is achievable. An acidified -proton, hence the use of -phenyl substituted 
hydantoin ureas; and migratory aryl groups bearing electron-withdrawing substituents are important 
features for these reactions to occur. This is likely due to the mild basic conditions used. The 
rearrangement also shows potential for enantioselectivity with the migration of a 4-cyano and 4-
pyridyl giving an er of 85:15 and 70:30, respectively. 
Future work should focus on varying the electronics of the cinchona catalyst at the N-benzyl 
position (Figure 15). Previous studies by other authors (see section 1.3.5) showed that H-atom 
acceptors at the ortho position of the N-benzyl ring were crucial to obtaining good 
enantioselectivities in the -alkylation of amino acids; Cinchona catalysts bearing a 2-fluorophenyl 





than analogues bearing the H-atom acceptor at other positions of the aryl ring.225 The opposite was 
observed in the studies presented in this work – cinchona catalysts bearing a 2-fluoro substituent 
on the N-benzyl ring gave poor enantioselectivities while those bearing a fluorine at the meta and 
para position i.e. 3,5- or 3,4,5-perfluoro substitution on the N-benzyl ring gave good 
enantioselectivities. 
 
Figure 15: Varying the electronics of cinchona-based PTCs 
It is worth investigating the effect of the 3-substituted cinchona-derived salts 354, 355 and 356 on 
the enantioselectivity of the aryl migrations. The meta substituted N-benzyl cinchona derivatives 
354, 355 and 356 can easily be made by the reaction of quinidine with the respective arylmethyl 
halides (see Scheme 70). The para substituted analogues of 354, 355 and 356 could be investigated 
as well to determine if the enantioselectivity induced by the optimal PTC 322 is a joint contribution 
of having a fluorine substituent on both the meta and para position. 
The scope of the reaction should also be broadened to include other migratory arenes such as doubly 
substituted and heterocyclic arenes. Catalyst and base optimisations would likely be required for 
each reaction substrate. Additionally, conditions for hydrolysis of the aryl migration products 274 








2.3 Photoredox-Catalysed Alkylarylation of Dehydroalanine Derivatives for 
the Preparation of Enantiopure -Quaternary Amino Acids 
2.3.1 Introduction 
Photoredox Catalysis is a process in which a photocatalyst (PC) gets excited by absorption of 
photons of light and in this excited state becomes able to facilitate chemical transformations by 
engaging in single electron transfer with organic or organometallic compounds.226 Metal 
polypyridyl complexes and organic dyes have been found to absorb visible light and convert it to 
chemical energy. These molecules can behave both as an oxidant and a reductant in the excited 
state, hence they have been widely used as PCs to effect several chemical transformations under 
mild reaction conditions, which would not have be attainable by alternative two electron 
transformation pathways.227–232 A PC induced chemical transformation can follow either an 
oxidative or reductive quenching cycle, depending on what happens to the excited PC (Scheme 84). 
The first step in the catalytic cycle is the excitation of the PC by absorption of light. The excited 
PC is remarkable, in that it is both more oxidizing and reducing than the corresponding ground state 
PC. In the oxidative quenching cycle, the excited photocatalyst PC* is oxidised by transferring an 
electron to an acceptor molecule A. This results in the generation of the radical anion A●− and the 
oxidised photocatalyst PC+. To complete the catalytic cycle, PC+ is reduced by accepting an 
electron from a donor molecule D. This leads to formation of the radical cation D●+ and regeneration 
of the ground state PC. Alternatively, in the reductive quenching cycle, PC* is reduced by accepting 
an electron from a donor molecule D. The products of this electron transfer are the radical cation 
D●+ and the reduced photocatalyst PC−. The catalytic cycle is closed by transfer of an electron from 
PC− to an acceptor molecule A, thus producing the radical anion A●− and regenerating the ground 
state PC. The ability of the excited PC to be quenched by either oxidation or reduction is defined 
by the standard reduction potentials. In the oxidative quenching cycle, the excited PC must have a 
lower reduction potential (propensity to be reduced) than the acceptor molecule A, while in the 







Scheme 84: Oxidative and reductive pathways of PCs 
A photoredox reaction could be net reductive, where the presence of a stoichiometric amount of an 
electron donor leads to net reduction in the reaction or it could be net oxidative, where the presence 
of a stoichiometric amount of an electron acceptor leads to net oxidation in the reaction. It could 
also be redox neutral where both oxidation and reduction occur at various stages of the reaction, 
resulting in no net change in oxidation state.234 
Recent advances in the use of photoredox catalysis in organic chemistry has led to the development 
of several synthetic transformations,235–237 one of which is the addition of radicals to olefins.238–240 
Dehydroalanine (Dha) derivatives such as 358 are potent radical acceptors; conjugate addition of 
radicals to Dha derivatives have been used to access a variety of unnatural amino acids which can 
potentially be used in the synthesis of new bioactive peptides.241,242 
 
Scheme 85: Conjugate addition of heteroaryls to a Dha derivative 
In 2017, Jui et al. disclosed the first radical approach to heteroaryl amino acids through conjugate 
addition to a Dha derivative (Scheme 85).243 The [Ir(ppy)2(dtbbpy)PF6-mediated addition of 





ester 359 as terminal reductant. It was found that 1 mol% of the iridium PC and 1.5 equivalents of 
the Hantzsch ester in aqueous DMSO was able to promote conjugate addition of heteroaryl radicals 
to the electron-poor alkene 358 upon irradiation with visible light. The amino acid derivatives 360 
were obtained in good yields and diastereoselectivity in favour of the energetically stable cis-
isomer. Hydrolysis of 360a afforded the free amino acid in 98% yield and 97% ee. The reaction 
was also applicable to a variety of acyclic Dha derivatives and several electron-deficient and rich 
halopyridines and pyrimidines, exhibiting good regiospecificity and chemoselectivity. No reaction 
occurred in the absence of light, the Hantzsch ester or the PC. Stern-Volmer quenching studies 
revealed that of the components 357, 358 and 359 present in the reaction, the Hantzsch ester 359 
was the most significant excited state quencher, hence it was not surprising that no product was 
afforded in the absence of the Hantzsch ester. The process is net reductive and a proposed 
mechanism using the acyclic Dha derivative 366 is detailed in Scheme 86. 
 
Scheme 86: A proposed mechanism for conjugate addition of heteroaryl radicals to a Dha derivative 
As with all photoredox reactions, the mechanism starts with absorption of visible light by the PC 
361, resulting in promotion of the PC from the ground state to the excited state 362. The excited 
state PC gets quenched by single electron transfer from Hantzsch ester 359, resulting in the oxidised 





it transfers an electron to the bromo-heteroarene 357a causing mesolytic cleavage to give the 
bromide ion and the heteroaryl radical 365a. The ground state PC 361 is regenerated in this step. 
The heteroaryl radical 365a behaves as a nucleophile in aqueous DMSO.245 It undergoes radical 
conjugate addition to 366, providing the reactive radical 367, which on single electron transfer from 
363 is reduced to the enolate 369. Evidence for 369 was shown using D2O as co-solvent instead of 
H2O. The amino acid derivative 370 was revealed with 94% deuterium incorporation in the -
proton. 
 
Scheme 87: Addition of -aminoalkyl radicals to a Dha derivative 
The same authors later reported the redox neutral addition of -aminoalkyl radicals to 358 catalysed 
by the iridium-based PC Ir[(dFCF3)ppy]2dtbbpy+ 373 (Scheme 87).242 The amine 371 was capable 
of directly reducing the excited state PC 374 to obtain the amine radical cation 376 and the reduced 
PC 375. The amine radical cation 376 is deprotonated at the -position to give the -aminoalkyl 
radical 377.246,247 -Aminoalkyl radicals are potent nucleophiles,234 377 undergoes conjugate 
addition to 358 to obtain the radical 378. Reduction of 378 by 375 regenerates the ground state PC 
373 and subsequent protonation provides 372. The adducts 372 were generally obtained in good 





reaction was tolerant of both electron-withdrawing and donating groups as substituents on the amine 
nitrogen. 
More recently, Schubert et al. disclosed the visible light-mediated addition of carboxylic acid 
derived alkyl radicals to 358 using the non-metal based PC 4CzIPN (379) (Scheme 88).248 It was 
found that 2 mol% of the PC was sufficient, upon irradiation with visible light, to promote efficient 
addition of alkyl radicals to 358. The K2HPO4 base was needed to promote deprotonation of the 
carboxylic acid. Control reactions revealed that light, the PC, and the base were necessary for the 
reaction to occur. As with all the mechanisms discussed above, the reaction follows a reductive 
quenching pathway. Photoexcitation of 379 generates the oxidizing species 381, which is 
subsequently reduced to 382 by a single electron transfer from the carboxylic acid 383. This single 
electron transfer causes the acid to expel CO2 and, in the process, produce the radical 384. Conjugate 
addition to 358 by the radical 384 affords the radical adduct 385, which is reduced by 382 to the 
enolate 386. The enolate is finally protonated to afford the products 380.249 The products 380 were 
formed in good yields and as the single cis-diastereoisomer. Functional groups like esters, ketones, 
ethers, amines, and aromatics on the alkyl radical were well tolerated. Sterically hindered alkyl 
radicals like the adamantyl radical were also well tolerated. 
 





Yajima and Ikegami described a procedure for the stereoselective addition of perfluoroalkyl radicals 
to a Dha derivative using Eosin Y 387 as the PC (Scheme 89).250 By coupling a chiral auxiliary to 
the Dha derivative (as seen in 392), the highly diastereoselective hydroperfluoroalkylation of 392 
was achieved by using 1 to 5mol% of the PC. 5 equivalents of aqueous sodium thiosulfate was 
employed as the terminal reductant and acetonitrile as solvent. The mechanism was proposed to go 
through an oxidative quenching pathway. Single electron oxidation of the photoexcited PC 388 by 
the perfluoroalkyl iodide 389 generated the perfluoroalkyl radical 390 and the oxidised PC 391. 
Addition of 390 to 392 produced the radical 393, which was reduced to the enolate 394 by sodium 
thiosulfate. On the basis that quenching with D2O gave the product 395 with 66% -deuterium 
incorporation, it was deduced that protonation of the enolate 394 was achieved by water in the 
reaction. Meanwhile, single electron reduction of 391 by either sodium thiosulfate or iodide 
regenerated the ground state PC 387 and closed the catalytic cycle. The authors submitted that 
iodine radical transfer to 393 was unfavourable because the radical 393 was stable and sterically 
hindered. 
 
Scheme 89: Hydroperfluoroalkylation of a chiral auxiliary coupled Dha derivative via an oxidative 
quenching pathway 
The above reactions represent examples of tertiary amino acid synthesis through radical conjugate 
addition to Dha. No example yet exists in the literature for the synthesis of quaternary amino acids 
through this method. Perhaps the unusual reactivity of metallated ureas could be exploited in 
bridging this gap through photoredox radical conjugate addition and subsequent aryl migration in 






2.3.2 Project Proposal 
In 2010, Clayden and co-workers reported the -arylation of amines by carbolithiation and 
concomitant rearrangement in vinyl ureas (Scheme 90).251 The reaction allowed 1,2 alkylarylation 
of vinyl ureas 396 affording ,-diaryl quaternary amines 399 on hydrolysis. Both carbolithiation 
and aryl migration were possible with organolithiums such as nBuLi, sBuLi, iPrLi, PhLi and 
CH2=CH2Li. However, with the bulky tBuLi, only carbolithiation was observed.  
 
Scheme 90: Carbolithiation and subsequent aryl migration of vinyl ureas 
Due to the success of the carbolithiation and ensuing aryl migration in vinyl ureas 396 (Scheme 
90), the Clayden group attempted the carbolithiation and aryl migration of tertiary amino acid-
derived imidazolidinone vinyl urea 400a (Scheme 91).252 The addition of several organometallics 
to the vinyl urea 400a was unsuccessful. Surprisingly, with tBuLi, addition to the vinyl 
accompanied by aryl migration occurred affording the arylation product 401 in a yield of 7%. 
 
Scheme 91: Carbolithiation and subsequent aryl migration of imidazolidinone vinyl ureas 
More recently, Clayden and Abrams reported the alkylation with subsequent aryl migration of non-
amino acid-derived vinyl ureas, by photoredox catalysis (Scheme 92).253 Practically, this method 
uses the organo PC 4CzIPN (379) to facilitate the redox cycle and utilises sodium sulfinate radical 
precursors to yield -quaternary ureas 403, which may be simply converted into -quaternary 
amines 404 by solvolysis. The proposed mechanism of this photoredox alkylarylation starts with 
photo excitation of 4CzIPN, which then facilitates the oxidative decomposition of sodium sulfinate 
salts, generating electrophilic radical that in turn add into the electron-rich olefin of vinyl ureas. 





metallated urea by the radical anion of 4CzIPN formed in sodium sulfinate decomposition, closing 
the photoredox cycle. The newly formed -metallated urea then undergoes N to C aryl migration, 
delivering an alkylarylation. 
 
Scheme 92: Photoredox catalysed N to C aryl migration in vinyl ureas 
It was envisaged that merging the imidazolidinone SRS protocol (see section 1.3.2) with photoredox 
catalysis in urea Dha derivatives might provide a useful means of accessing enantiopure -aryl 
quaternary amino acids under mild conditions (Scheme 93). In addition, both side chains of the 
newly formed -aryl quaternary amino acid would not be limited to the commercially available 
enantiopure tertiary amino acids.  
 





A suggested mechanism for the proposed addition and ensuing aryl migration in imidazolidinone 
vinyl urea Dha derivatives is illustrated in Scheme 93. Excitation of the PC by visible light occurs 
to produce the excited photocatalyst PC*. The excited PC is quenched by accepting an electron 
from the radical precursor RP, resulting in formation of the radical R● and the reduced photocatalyst 
PC●⁻. The radical R● undergoes radical attack on the vinyl urea 400 resulting in the formation of 
the C-centred radical 407. In a radical polar cross-over pathway, 407 accepts an electron from the 
reduced photocatalyst PC●⁻ producing the enolate 408 and recovering the PC. The enolate 408 then 
undergoes intramolecular nucleophilic attack on the N-aryl ring leading to transfer of the aryl ring 
from the nitrogen to the -carbon resulting in the new quaternary centre in 409. 
2.3.3 Synthesis of Imidazolidinone Vinyl Ureas  
Using a synthetic route established within the Clayden group,160 the imidazolidinone vinyl ureas 
were made. (S)-benzyl-L-Cysteine methyl ester hydrochloride 410 was reacted with methylamine 
to afford the methylamide 411 (Scheme 94).  
 
Scheme 94: Synthesis of methylamide 411 
Condensation of 411 with pivaldehyde produced imine 412 (Scheme 95). The reactions affording 
the methylamide 411 and imine 412 were quantitative and had no need for further purification. 
 
Scheme 95: Synthesis of imine 412 
Reaction of 412 with the desired carbamoyl chloride 260, obtained from phosgenation of the 
corresponding N-methyl aniline 413, led to the formation of the imidazolidinone urea 414, in which 





Table 27: Synthesis of imidazolidinone ureas 414 
 
Entry a-e Ar 
Yield (%) 
260 414 
1 a C6H4 n/a1 35 
2 b 4-CNC6H4 n/a2 40 
3 c 4-CF3C6H4 >99 39 
4 d 4-ClC6H4 >99 53 
5 e 4-MeC6H4 n/a2 45 
6 f 2-pyridyl n/a3 n/a3 
 
The reaction producing the imidazolidinone ureas 414 involves a cyclisation and concomitant 
acylation step, which was low yielding with significant formation of 415, presumably resulting 
from nucleophilic attack of the N-methylaniline 413, formed from decomposition of the carbamoyl 
chloride 260. Co-elution of 414 with some other product suspected to be non-acylated 
imidazolidinone 416 was also observed. 
 
1 Commercially available 
2 Thanks to Dr Daniel Leonard for making this compound 





Table 28: Elimination to achieve vinyl ureas 400 
 
Entry Ar Product Yield (%) 
1 C6H4 400a 85 
2 4-CNC6H4 400b 62 
3 4-CF3C6H4 400c 0 
4 4-ClC6H4 400d 71 
5 4-MeC6H4 400e 73 
6 2-pyridyl 400f >99 
 
Treatment of 414 with KHMDS led to elimination of the S-benzyl group to afford the desired vinyl 
ureas 400 in good yields (Table 28). The elimination reaction of 414c proved challenging (Table 
28, entry 3). Complete recovery of 414c was obtained even after the reaction had been left ongoing 
for 26 hours. To circumvent this, a similar protocol to that used by Jui et al. for the synthesis of 
vinyl oxazolidines was adopted.242 The sulfide group in 414c was successfully oxidised to a sulfone 
in a moderate yield of 48% (Scheme 96a). Attempted elimination of the sulfone proved difficult 
with starting material observed by 1H NMR after 24 h. The elimination of 414c with KHMDS was 
attempted again; however, the reaction was refluxed at 75 °C for 16 hours to afford 400c in a 
moderate yield (Scheme 96b). 
 





As the malodorous benzyl mercaptan is produced as a by-product in the elimination reaction of 
cysteine, it was decided that serine would be an operationally safer option, since benzyl alcohol 
would be produced. The synthesis of the vinyl urea bearing a 4-bromophenyl group on the distal 
nitrogen of the urea was performed using O-benzyl-L-serine methyl ester hydrochloride 418.  
 
Scheme 97: Synthesis of imine 420 
Using already established conditions, the reaction gave excellent yields for the synthesis of the 
methylamide 419 and imine 420 (Scheme 97). The cyclisation and concomitant acylation of 420 
with 260g gave the product 421g along with side product 415, which was also observed when 
cysteine was used as starting amino acid (see Table 27). Side product 422 resulting from 
adventitious hydrolysis of the imine was also isolated (Scheme 98). 
 
Scheme 98: Synthesis of imidazolidinone urea 421g 
The elimination reaction of 421g gave a low yield of 400g due to competing nucleophilic attack of 





an equal proportion to 400g (Scheme 99). Though the use of serine is more operationally convenient 
than cysteine, the latter is necessary to obtain good yields of the elimination product. 
 
Scheme 99: Elimination reaction of serine-derived imidazolidinone urea 421g 
2.3.4 Attempted Aryl Migration employing Photoredox catalysis 
With the desired vinyl ureas now accessible, a photoredox mediated radical addition with 
subsequent intramolecular arylation employing the “SRS” principle could now be investigated with 
the aim of making enantiopure -aryl quaternary amino acids. The PC used in this investigation is 
1,2,3,5-tetrakis(carbazol-9-yl)-4,6-dicyanobenzene (4CzIPN). As shown in Scheme 92, 4CzIPN 
(379) has already been used as an amenable PC to facilitate the alkylarylation of styryl based vinyl 
ureas. Furthermore, 379 is a precious metal free catalyst that is preparable in an inexpensive fashion 
by performing a quadruple SNAr substitution reaction of tetrafluoroisophthalonitrile 425 by 
carbazole 424 (Scheme 100).254 
 
Scheme 100: Synthesis of 4CzIPN 379. All potentials are given in volts vs the saturated calomel electrode (SCE) 
4CzIPN 379 has a high photoluminescence quantum yield and a long-lived excited state (5 s) – 
long enough to engage in single electron transfer reactions with organic molecules. It is both a 
powerful oxidant and reductant in the excited state. In addition, 379 has similar excited state redox 
potentials to commonly used iridium-centred metal based PCs. This makes 379 an inexpensive 
alternative to these PCs.255 Sodium trifluoromethylsulfinate, also known as Langlois reagent 426a 
was chosen as radical precursor to the trifluoromethyl radical, because it is commercially available 





V vs. SCE).256 Hence, 4CzIPN is capable of single electron oxidation of Langlois reagent255 to 
produce trifluoromethyl radical after expulsion of sulfur dioxide. Trifluoromethyl radical has been 
well established to add to a variety of electron-rich alkenes.257–259 A potential short coming of the 
use of Langlois reagent in photoredox manifolds can be that the SO2 by-product, formed in 
trifluoromethyl radical formation, demonstrates a reduction potential of –0.7 V.260 As such, it is 
possible the radical anion of 4CzIPN can engage in single electron reduction of sulfur dioxide, 
leading to formation of net-oxidative side product with respect to the vinyl urea. Addition of Cs2CO3 
has been shown to suppress the occurrence of net-oxidative side products when using Langlois 
reagent, presumably by adsorption of sulfur dioxide. 253,261,262  
Investigations began with the use of 400a in optimisation studies towards the alkylarylated product 
405aa. Since the photochemical alkylarylation of styryl based vinyl ureas had already been 
established in solvents such as CH3CN, DMF and acetone, it seemed rational to begin optimisation 
with these solvents (Table 29).  





1 CH3CN 66 0 
2 Acetone 65 0 
3 DMF 65 0 
All yields obtained by 19F NMR and compared with α,α,α-trifluoro toluene internal standard 
Light source: 24 W blue LED strips 
Disappointingly, in the three solvents, the addition product 427aa was solely obtained and not the 
desired alkylarylated product 405aa. The formation of 427aa was however encouraging because it 









400a 427ab 405ab 
1 DMF 100 0 0 
2 acetone 100 0 0 
3 CH3CN 100 0 0 
Light source: 24 W blue LED strips 
Several radical precursors were tested in the alkylarylation of 400a. The radical precursor BnBF
3
K 
426b (E1/2 = +1.10 V vs. SCE) is capable of reducing photo excited 379 to produce a benzyl 
radical.263,264 -Amino radicals such as 4-methylmorpholine radical have been formed from single 
electron oxidation with concurrent deprotonation of their amine precursors using PCs with similar 
potentials to 379.242 




400a 427ac 405ac 
1 DMF 100 0 0 
2 acetone 100 0 0 
3 CH3CN 100 0 0 
Light source: 24 W blue LED strips 
These nucleophilic benzyl and -amino radicals have been reported to add to olefins substituted 
with electron-withdrawing ester groups.242,247,264 The olefin of the vinyl urea 400a is not as electron-
deficient as those olefins substituted with ester groups; the proximal nitrogen of the urea in 400a 





why starting material was recovered when BnBF
3
K 426b and 4-methylmorpholine 426c were used 
as radical precursors in the reaction (Table 30 and Table 31). 
Table 32: Radical precursor investigation 
 
Entry 426 R Product Yield (%) 
1 426d C4H9 427ad 0 
2 426e C2H3F2 427ae (64) 
3 426f CHF2 427af (91) 
Light source: 24 W blue LED strips; Parenthesis indicate isolated yields 
Unlike with Langlois reagent, use of C4H9SO2Na radical precursor 426d resulted in only starting 
material being recovered (Table 32, entry 1). The fluorine containing radical precursors, 
C2H3F2SO2Na 426e and CHF2SO2Na 426f were attempted in CH3CN alone, affording addition 
product 427ae and 427af in a 64% and 91% isolated yield, respectively. No product of aryl 
migration 405ae or 405af was observed in both cases. The configuration of the addition products 
was determined to be cis by 1D NOE experiments (see section 4.4). The screening of the radical 
precursors gives key information that the vinyl urea used in the reaction is not electron-deficient 
enough to react with nucleophilic radicals. Therefore, further investigation would be done with 
electrophilic radicals such as fluorine substituted carbon centred radicals. 
With the photochemical alkylation of 400a by sodium sulfinate radical precursors firmly 
established, attention was directed towards the question of why the subsequent N to C aryl transfer 
was inhibited? One theory may be that the phenyl group is not electrophilic enough for attack by 
the enolate of 408aa, resulting in protonation from water impurities in starting materials used or 
upon work up (Scheme 101). As an alternative hypothesis to why aryl transfer may not occur, the 
urea radical 407aa could abstract an H-atom from a H-atom source, such as solvent, before its 






Scheme 101: Proposed reaction pathways for obtaining addition product 
To get some insight into the proton or H-atom source, deuterium experiments were carried out. 
Though acetone is more acidic than acetonitrile, acetone-D6 was used in the study due to 
availability. The addition reaction of 400a with the radical precursor 426e was repeated under 
anhydrous conditions using acetone-D6 as solvent (Scheme 102). 
 
Scheme 102: Deuterium experiments with acetone-D6 
11% deuterium incorporation was observed by NMR analysis of the -proton in 427ae. This gives 
tentative indication that the enolate formed may be protonated by acetone, but because of the low 
D incorporation other pathways towards the addition product appear to be more significant. When 
the reaction was repeated with acetone-D6 and quenched with D2O, the deuterium incorporation 
was increased to 32%, indicating that the -proton of 427ae can originate from an aqueous quench. 
To investigate if a proton source might be the presence of water, the reaction was repeated using 
non-deuterated DMF as solvent. 5 equivalents of D2O was added from the start of the reaction and 
NMR analysis of the -proton showed 34% deuterium incorporation. This indicated that water 
present in the reaction could lead to protonation as well. Due to the low D incorporation, there is a 
possible occurrence to a certain degree of deprotonation of solvent, water present in and water used 





reaction in DMF-d7. Using this information, more electron-deficient aryl migratory rings were 
investigated in the reaction. 
Table 33: Attempted 1,2-alkylarylation of 400b 
 
Entry 426 R Solvent Product 
Yield (%) 
427 405 
1 426e C2H3F2 DMF be 4 35 
2 426e C2H3F2 CH3CN be 4 44 (32) 
3 426f CHF2 CH3CN bf 26 45 (42) 
Yields obtained by 19F NMR and compared with α,α,α-trifluoro toluene internal standard 
Parentheses indicate isolated yields; Light source: 24 W blue LED strips 
Using 426e as radical precursor, the addition and subsequent arylation reaction was attempted on 
400b (Table 33). Delightfully, in DMF, a 35% conversion to the arylation product 405be was 
observed by 1H and 19F NMR (Table 33, entry 1). When the same reaction was repeated in 
acetonitrile, a 44% conversion to 405be was observed by 1H and 19F NMR (Table 33, entry 2). 
Since comparative yields were obtained in both solvents, acetonitrile was used for further 
investigations. With the radical precursor 426f, a 45% conversion of 400b to 405bf was observed 
by 1H and 19F NMR (Table 33, entry 3). 
Table 34: Attempted 1,2-alkylarylation of 400c 
 
Entry 426 R Product 
Yield (%) 
427 405 
1 426a CF3 ca 54 (39) 2 
2 426e C2H3F2 ce 47 17 
3a 426e C2H3F2 ce 60 10 
4 426f CHF2 cf 67 8 
Yields obtained by 19F NMR and compared with α,α,α-trifluoro toluene internal standard 





With 426a as radical precursor, 400c, having a lesser electron-deficient migratory ring relative to 
400b gave a poor conversion to 405ca (Table 34, entry 1). With the radical precursor 426e, a 17% 
conversion of 400c to 405ce was observed (Table 34, entry 2). In a bid to increase the yield of 
405ce, the reaction was repeated using a more powerful LED at 35 °C (Table 34, entry 3), which 
disappointingly gave a slightly lower yield of the product 405ce.With 426f as radical precursor, an 
8% conversion of 400c to 405cf was observed (Table 34, entry 4). 
Table 35: Attempted 1,2-alkylarylation of 400d and 400g 
 
Entry 400 X 426 R Product Yield (%) 
1 400d Cl 426a CF3 427da 74 (56) 
2 400d Cl 426e C2H3F2 427de 67 
3 400d Cl 426f CHF2 427df (88) 
4 400g Br 426a CF3 427ga (65) 
Yields obtained by 19F NMR and compared with α,α,α-trifluoro toluene internal standard 
Parentheses indicate isolated yields; Light source: 24 W blue LED strips. 
Other electron-deficient migratory rings such as 4-ClC6H4 and 4-BrC6H4 gave exclusively addition 
products with all radical precursors used (Table 35). As expected, 400e having an electron-rich 4-
tolyl migratory ring gave only addition product with the two radical precursors used (Table 36). 
Table 36: Attempted 1,2-alkylarylation of 400e 
 
Entry 426 R Product Yield (%) 
1 426e C2H3F2 427ee 85 (57) 
2 426f CHF2 427ef (75) 
Yields obtained by 19F NMR and compared with α,α,α-trifluoro toluene internal standard 





In the formation of the radical addition with subsequent aryl migration product 405, one of two 
reaction pathways may be possible (Scheme 103). The difluoromethane radical 428f is produced 
by single electron reduction of 381 by CHF2SO2Na 426f. The radical then adds to 400b to produce 
the radical addition adduct 407bf. In a radical polar cross-over pathway, 407bf can accept an 
electron from the reduced PC 382, hence turning over the catalytic cycle. The resulting enolate 
408bf can then undergo an intramolecular nucleophilic attack on the N-aryl ring, resulting in 
migration of the aryl group from N to C to give the new quaternary centre in 409bf. On quenching 
with water, 409bf accepts a proton to give 405bf. Alternatively, the C-centred radical 407bf may 
facilitate the intramolecular abstraction of the 4-cyanophenyl from the distal urea nitrogen, resulting 
in the formation of the nitrogen centred radical 429bf. To turn over the photocatalytic cycle, 429bf 
may accept an electron from the reduced PC 382, followed by protonation to give 405bf. 
 
Scheme 103: Possible reaction pathways for the formation of aryl migration product 405 
Though no mechanistic investigation has been done to refute the N to C aryl migration by a radical 
manifold pathway, the deuterium experiments done previously give evidence of radical polar cross-
over, since deuteration of the -carbon on quenching with D2O indicates the presence of an anion 









427fa 430fa 431f 405fa 
1 1.5 28 18 9 0 
2 2.5 39 9 1 6 
                  All yields obtained by 19F NMR and compared with α,α,α -trifluoro toluene internal standard 
            Light source: 24 W blue LED strips. Wavy bond in 430fa and 431f represents unknown stereochemistry 
In order to investigate the scope of the addition and ensuing arylation further, in terms of electron-
deficient aryl migratory rings, the electron-deficient 2-pyridyl substrate 400f was subjected to the 
established photoredox conditions (Table 37). Surprisingly, the net oxidation product 430fa and 
product of acid catalysed Friedel-Crafts cyclisation of 400f (431f) were observed, alongside the 
addition product 427fa (Table 37, entry 1). Presence of net-oxidative side product 430fa may be 
due to either the adventitious presence of oxygen in the reaction mixture or insufficient quantities 
of Cs2CO3 to completely sequester SO2; either or both gases in theory are able to oxidise the radical 
anion of 4CzIPN 382 resulting in a net oxidative photoredox cycle. To test this supposition, the 
reaction was repeated with an extra equivalent of Cs2CO3 and degassed for 10 – 15 mins. There was 
a decrease in the yields of 430fa and 431f and increase in the yield of the addition product 427fa. 
The alkylarylated product 405fa was also afforded in a 6% 19F NMR yield. The decrease in net 
oxidation products due to the use of an extra equivalent of Cs2CO3 shows the importance of Cs2CO3 
in the alkylarylation reaction. It is however unclear why both net oxidation and addition products 
are favoured in this reaction. It is even more unclear why aryl migration is not efficiently occurring, 
even with such an electron-deficient migratory ring. The fact that 427fa is formed indicates that 
addition to the vinyl urea is occurring. The electrophilic radical 407fa (Scheme 104) is just the same 
as in previous substrates, the only difference is the electron-deficient 2-pyridyl ring. A proposed 






Scheme 104: Proposed mechanism for formation of 430fa and 431f 
The trifluoromethyl radical 428a is generated by single electron reduction of the excited PC 381 by 
Langlois reagent 426a. The reduced PC 382 could reduce an oxidant present in the reaction, thereby 
regenerating the PC 379 and closing the first catalytic cycle. Addition of 428a to vinyl urea 400f 
occurs to produce the radical addition adduct 407fa. The radical 407fa enters a second photoredox 
cycle and does a single electron reduction of the excited PC 381 to produce an intermediary cation 
which loses acid (H+) to afford 432fa. The substrates 432fa and 400f could then undergo an acid 
catalysed Friedel-Crafts cyclisation to produce 430fa and 431f, respectively. The second catalytic 
cycle is then closed by reduction of an oxidant present in the reaction by 382 to regenerate 379. The 
likely oxidants responsible for the net oxidation photoredox manifold could be either of SO2 or O2 







2.3.5 Base-mediated Aryl Migration 
Next an investigation into whether the addition products 427 can undergo base facilitated 
intramolecular aryl migration was performed. The addition product 427ae was treated with 1.5 
equivalents of KHMDS (Table 38, entry 1). Surprisingly, aryl migration did not only occur but 1,2-
elimination of a fluorine to produce the new quaternary centre having an aryl and vinyl fluoride 
group as seen in 433ae, and elimination of both fluorines to produce the bicycle 434ae. However, 
obtaining just the aryl migration product 405ae was pertinent. When the number of equivalents of 
the base was reduced to 1.0 (Table 38, entry 2), only starting material was observed. 
Table 38: Attempted base facilitated aryl migration of 427ae 
 
Entry x Time 
Yield (%) 
427ae 433ae 434ae 
1 1.5 2 h 0 (26) (18) 
2 1.0 2.30 h 100 0 0 
Parentheses indicate isolated yields 
Addition product 427af having a difluoromethyl substituent at the -carbon of the amide carbonyl 
furnished exclusively the aryl migration and subsequent elimination product 433af (Table 39, entry 
1). Pleasingly, addition product 427df having a 4-chlorophenyl migratory ring afforded the aryl 
migration and subsequent elimination product 433df alongside the desired aryl migration product 





Table 39: Attempted base facilitated aryl migration of 427af and 427df 
 
Entry 427 Ar Time 
Yield (%) 
405 433 
1 427af C6H5 2.15 h 0 97(54) 
2 427df 4-ClC6H4 1 h 32 31 
Yields obtained by 19F NMR and compared with α,α,α-trifluoro toluene internal standard 
Parentheses indicate isolated yields 
The addition product 427df seemed promising in furnishing the aryl migration product; hence, it 
was used for optimisation of the aryl migration and elimination reactions. The reaction was 
optimised for both the formation of 405df and 433df exclusively (Table 40). TLC analysis at 
various times of the reaction revealed that 405df was formed before being converted to 433df. This 
meant that 433df might be formed exclusively if the reaction was left for longer than an hour. As 
anticipated, a minimal amount of 405df was observed when the reaction was left for 3 hours (Table 
40, entry 2). When the number of equivalents of KHMDS was increased to 2.5, the aryl migration 
and subsequent elimination product 433df was formed exclusively after approximately 3 hours 
(Table 40, entry 3). Satisfied with this result, attention was drawn towards optimising the reaction 
for just the aryl migration product 405df. It was supposed that performing the reaction with 1.5 
equivalents of KHMDS for less than 1 hour would lead to the formation of 405df exclusively. 
Nevertheless, some amount of 433df was observed by 1H NMR about 20 mins into the reaction. To 
slow down the rate of the aryl migration and consequently the elimination, the reaction was carried 
out at −20 °C. After 1 hour, 51% of 405df was observed along with a trace amount of 433df (Table 








Table 40: Optimisation of reaction conditions 
 
Entry Base eq. T (°C) Time 
Yield (%) 
427df 405df 433df 
1 KHMDS 1.5 0 – rt 1 h 0 32 31 
2 KHMDS 1.5 0 – rt 3 h 0 7 61 
3 KHMDS 2.5 0 – rt 2.45 h 0 0 (81) 
4 KHMDS 1.5 −20 1 h 0 51 trace 
5 LDA 2.0 −20 1.75 h 4 28 0 
6 LiHMDS 1.5 −20 3.25 h 26 20 0 
7 LiHMDS 1.5 0 2 h 0 67 0 
Yields obtained by 19F NMR and compared with α,α,α-trifluoro toluene internal standard 
Parentheses indicate isolated yields 
Another base, LDA was tested on the aryl migration reaction at −20 °C. There was still starting 
material left after about 2 hours. Notwithstanding 28% of 405df was observed by 1H and 19F NMR 
alongside some unidentified product (Table 40, entry 5). A weaker lithium base, LiHMDS, was 
utilised at −20 °C. The aryl migration product 405df was observed exclusively; however, there was 
still starting material left after approximately 3 hours (Table 40, entry 6). Satisfactorily, when the 
reaction was repeated with LiHMDS at 0 °C, the aryl migration product 405df was observed 






Scheme 105: (a) Proposed mechanism for aryl migration and subsequent elimination reaction  
(b) Experimental evidence for deprotonation by KHMDS 
The formation of 405df exclusive of 433df was favoured by lithium bases such as LDA and 
LiHMDS, while the formation of 433df exclusive of 405df was favoured by KHMDS. It was 
postulated that the lithium cation, due to its smaller size, coordinates more to the oxygen anion in 
435df than the potassium cation does (Scheme 105a). The implication of this, for the use of 
KHMDS, is that the nitrogen anion in 409df will be more available to abstract a -proton, leading 
to elimination of a fluorine to afford 433df. This rationale is made, however, on the assumption that 
the nitrogen anion in 409df is responsible for the deprotonation of the -proton and not KHMDS. 
To prove/disprove this rationale, methylated 405df (437df) was treated with KHMDS (Scheme 
105b), the elimination product 438df was observed by 1H and 19F NMR, as well as some other 
product of hydrolysis which is suspected to be 439df. Starting material 437df was also recovered 
in the reaction of Scheme 105b. This experiment indicates that KHMDS can carry out deprotonation 
of the -proton in 405df but LiHMDS and LDA cannot. However, it may also be that some 
deprotonation by the nitrogen ion may be occurring and this might be the reason the reaction was 






Scheme 106a: Scope of aryl migration reaction; Yields obtained by 19F NMR and compared with α,α,α-
trifluoro toluene internal standard; Parenthesis indicate isolated yields 
The scope of the aryl migration was explored (Scheme 106a). For the aryl migration, substrates 
bearing a CHF2 or CF2CH3 on the -carbon of the amide carbonyl rearranged smoothly furnishing 
the aryl migration products (405df, 405de and 405af) exclusively. Substrate 427ef having an 
electron-donating 4-methyl group underwent the aryl migration at a slower rate: about an equal 
proportion of starting material to the arylation product remained, even when the reaction was treated 
with 3.0 equivalents of LiHMDS and left overnight. To increase the rate of the aryl migration 
reaction of 427ef, it was heated up to 40 °C. Unfortunately, total conversion to the elimination 
product 433ef was observed (not shown in scheme). The aryl migration of 427da and 427ga both 
having a CF3 on the -carbon, led to the formation of the bicyclic product 434da and 434ga 






Scheme 106b: Scope of aryl migration and subsequent elimination reaction; Yields obtained by 19F NMR 
and compared with α,α,α-trifluoro toluene internal standard; Parenthesis indicate isolated yields  
The scope of the aryl migration and subsequent elimination reaction seemed limited to substrates 
bearing a CHF2 or CF2CH3 on the -carbon of the amide carbonyl (Scheme 106b). Substrates 
bearing a CHF2 group (427df, 427af and 427ef) smoothly underwent the aryl migration and 
concomitant elimination to produce the elimination products 433df, 433af and 433ef, respectively. 
The substrate bearing a CF2CH3 group (427ae) furnished the elimination product 433ae alongside 
the bicyclic side-product 434ae. For the substrate bearing a CF3 group (427da), the bicyclic product 
434da was furnished exclusively. From the reactions, it is speculated that the presence of the CF3 
group in a substrate promotes the formation of the bicyclic product 434. While the presence of the 
CF2CH3 group promotes the formation of the bicyclic product only when KHMDS is used as base. 
In all cases, the aryl migration and elimination products were isolated as single diastereoisomers. 
The new quaternary centre formed is assumed to be R based on previous work done within the 
Clayden group that showed that aryl migration in similar imidazolidinone ureas occurred at the face 





on their 3JH-F coupling constants (3JH-F = 20 – 22 Hz for the E isomer and 33 – 39 Hz for the Z 
isomer).265–267  
 
Scheme 107: Proposed mechanism for formation of bicyclic side-product 
It is proposed that the bicyclic product 434 is formed by nucleophilic attack of the urea distal 
nitrogen in 433 on the vinyl, resulting in substitution of a fluorine to produce 434 (Scheme 107 
pathway 1).  The substitution reaction in pathway 1 is unusual, and no literature precedent could be 
found for the reaction. An alternative mechanistic proposal is pathway 2, which has an intermediary 
fluoroalkyne 440. Nucleophilic attack of the urea distal nitrogen on the alkyne in 440, followed by 
protonation of the resulting anion results in formation of the bicycle 434 (Scheme 107 pathway 2). 
It is noteworthy that no elimination product 433da or 433ga was isolated in the aryl migration 






Scheme 108: Failed aryl migration and elimination reaction 
Aryl migration failed to occur with substrate 427cf (Scheme 108). Decomposition was observed 
with the use of KHMDS and LDA. This was not surprising as previous studies within the group 
also observed decomposition for the migration of a 4-CF3C6H4 using KHMDS.268 With the weaker 
KOtBu base, starting material was recovered. Nevertheless, the 4-CF3C6H4 ring was migrated under 
the mild conditions of phase transfer catalysis (see section 2.2.3). 
2.3.6 Attempted Hydrolysis to Amino Acids 
To show the practicality of the method in affording enantioenriched -aryl quaternary amino acids 
containing fluorinated carbon side-chains, the hydrolysis of the aryl migration product 405bf was 
attempted. Previous work within the group showed that similar compounds could be cleanly 
hydrolysed to the respective amino acids using a 10:1 HCl:ethanol solvent system.160 
 





The urea NH in 405bf was methylated to prevent cyclisation of the urea unto the carboxylic acid 
that would be revealed on hydrolysis. Treatment of 437bf with 10:1 6M HCl:ethanol mixture at 160 
°C in a microwave reactor afforded the decarboxylated product 441bf (Scheme 109). Delightfully, 
when the reaction was repeated at 120 °C, a mixture of hydrolysed products 406bf and 442bf was 
observed by 13C NMR. 
 
Scheme 110: Attempted methylation of 405ga 
Due to unavailability of substrate 405bf and insufficient time to make more, an attempt was made 
to carry out the hydrolysis on 405ga (Scheme 110). Unfortunately, the attempted methylation of 
405ga led to the formation of the bicyclic product 434ga. To circumvent this, the one pot aryl 
migration and N-methylation of 427da was performed (Scheme 111). Favourably, the N,N-
dimethylated urea 437da could be separated from the bicyclic product 434da. The urea 437da was 
finally subjected to the previous hydrolysis conditions for 4 hours in a microwave reactor. A mixture 
of the amino acid 406da, amino amide 443da, and the N,N-dimethylated urea starting material 
437da was observed by 13C, 1H and 19F NMR.  
 





Though the optimal hydrolysis conditions have not been achieved yet, these investigations have 
laid a foundation for further work. 
2.3.7 Conclusion and Future Work 
The synthesis of -aryl quaternary amino acids containing fluorinated carbon side-chains has been 
discussed. The methodology incorporates three important tools: Photoredox catalysis for 
introducing the fluorocarbon side-chain of the new amino acid; N to C aryl migration of -
metallated ureas for introducing the aryl side-chain of the new amino acid and Seebach’s self-
regeneration of stereocentres for inducing diastereoselectivity in the aryl migration (Scheme 112). 
 
Scheme 112: Summary of work 
This method provides a useful route for making fluorinated small molecules. These molecules are 
important to the field of pharmaceutical industry, as many of them show anti-malarial, anti-ulcer 
and anti-diabetic activity.269 In addition, the presence of a C-F bond in peptide-based drugs is known 
to improve their lipophilicity, metabolic stability and bioavailability.270,271 
Future work should focus on expanding the scope of the reaction to include additional electron-
deficient aryl rings, as well as electron-rich and doubly substituted aryl migratory rings. Further 
radical precursors should also be considered for the radical conjugate addition step. An example 
includes phosphinoyl radicals, which have been reported to undergo conjugate addition to styryl 
based vinyl ureas.253 Further hydrolysis optimisations to obtain exclusively the amino acid should 
also be performed. 
As discussed in section 2.3.1, radical addition to oxazolidinone Dha derivatives is already known. 
It might be possible to access analogous oxazolidinone vinyl ureas 447 using similar methodology 





oxazolidinone vinyl ureas could then be subjected to radical addition and ensuing N to C aryl 
migration under the photoredox conditions to afford 448, which on hydrolysis should furnish the 
enantioenriched -aryl quaternary amino acids 406 (Scheme 113).  
 
Scheme 113: Oxazolidinone vinyl ureas towards achieving -aryl quaternary amino acids 
A chiral auxiliary approach could also be considered in achieving diastereoselectivity in the radical 
conjugate addition and ensuing N to C aryl migrations. The use of chiral auxiliaries would not only 
induce stereoselectivity but also alter reactivity, hopefully leading to a broader substrate scope. 
Several pathways could be explored towards attaining the starting chiral vinyl ureas. Coupling of 
the carbamoyl chloride 260 with amino ester hydrochloride 410 should afford the singly N-
methylated urea 449.152 This urea could then be treated with KHMDS and quenched with methyl 
iodide to afford the N,Nꞌ-dimethylated vinyl urea 450. To introduce the chiral auxiliary component, 
450 could be reacted with a chiral amine; An example of a chiral amine is the camphorsultam 451, 
which was used by Yajima and Ikegami in similar radical conjugate addition reactions.250 Following 
similar procedure to that used by Metz and co-workers,272 the vinyl urea 450 could be reacted with 
451 to obtain the final vinyl urea 452. Tert-butanesulfinamide could also be used in place of 
camphorsultam in the reaction sequence. An alternative pathway is to introduce the chiral auxiliary 
component directly to the amine residue of the amino acid. Both enantiomers of the aldehyde 453 
are easily accessible on a large-scale from the inexpensive (R)-Methyl 2-hydroxypropanoate and 
(S)-Ethyl 2-hydroxypropanoate.273 Reductive amination of 453 with 454, obtained from treating 
410 with KHMDS, should afford the amine 455 as NaBH4 alone is incapable of reducing olefins or 
esters. Finally, coupling of 455 with carbamoyl chlorides 260 should afford the final vinyl ureas 






Scheme 114: Synthesis of chiral vinyl ureas employing either camphorsultam or tert-butanesulfinamide as 
chiral auxiliary 
Another methodology that could be investigated is introducing the chiral auxiliary component 
through the commercially available and inexpensive chiral isocyanate 457 (Scheme 115). 
Treatment of 454 with the isocyanate 457 should afford the urea 458. To avoid racemisation, 
cyclisation of 458 to 459 is facilitated by the weak triethylamine base.222 The cyclised product 459 
could then be coupled with carbamoyl chlorides 260 to afford the final vinyl ureas 460. 
 





Ultimately, the mechanism of the aryl migration in all the vinyl urea scaffolds would be probed. As 
stated earlier, the mechanism for the photoredox catalysed N to C aryl migration in the 
imidazolidinone vinyl ureas can either be by a radical manifold or by a radical polar crossover (see 
Scheme 103). Further deuterium experiments would have to be carried out to ascertain which. 
Performing the reaction in DMF-d7 and doing a deuterium analysis of the proton bonded to the urea 
distal nitrogen in 405 will give some insight into this (Scheme 116). If analysis of the said proton 
reveals deuterium incorporation, it indicates the occurrence of H-atom abstraction, signifying that 
the aryl migration could be going through a radical manifold. 
 
Scheme 116: Mechanistic investigation by a deuterium experiment 
Similar deuterium experiments could be applied to the other vinyl urea scaffolds suggested above. 
Additionally, Stern-Volmer studies would have to be done to investigate which substrate in the 
photoredox reaction is actively quenching the excited PC. 
 
Scheme 117: Attempted aryl migration of 427da 
It was presented in section 2.3.5 that attempted aryl migration of the addition product 427da gave 
exclusively the bicyclic product 434da in a 78% yield (Scheme 117). The product 434da has the 
potential of exhibiting bioactivity as similar pyrimidine analogues such as fluorouracil and 
Floxuridine, are used in the treatment of cancer.274,275 As 434da was formed cleanly and easily in 





2.4 Decarboxylative Arylation of Urea Malonic Acid Half Esters 
2.4.1 Introduction 
Decarboxylative enantioselective C-C or C-H bond formation employing the use of chiral bases is 
a developing area of modern organic chemistry.276 The process generally involves the base-
mediated extrusion of CO2 from a carboxylic acid-bearing substrate to produce an anion. The anion 
can either be quenched by a proton or undergo reaction with electrophiles. An example is the 
decarboxylative aldol reaction of malonic acid half thioester 462 with isatin 461 (Scheme 118).277 
Decarboxylation of 462 produces an enolate, which undergoes nucleophilic attack on the C-3 
carbonyl of 461, hence producing a new C-C bond between the -carbon of 462 and carbon 3 of 
461. The reaction was catalysed by the chiral cinchona alkaloid squaramide base 463 and the 
products 464 were obtained with up to 99% yield and 92% ee.  
 
Scheme 118: An example of decarboxylative enantioselective C-C bond formation 
As an example of a C-H bond forming process, Rouden et al. disclosed the decarboxylative 
protonation of amino malonic acid half esters 465 (Scheme 119).278 Stoichiometric amounts of the 
cinchona-derived thioureas 466 or 467 were used to facilitate decarboxylation. As there was no 
available electrophile in the reaction, the enolate formed on decarboxylation was quenched by a 
proton, affording the (R) or (S)-tertiary amino acid derivatives 468 in good yields and 
enantioselectivities. The enantioselectivity of the reaction was reversed simply by inverting the 






Scheme 119: An example of decarboxylative enantioselective C-H bond formation 
2.4.2 Project Proposal 
It was envisaged that if a urea bearing an N-aryl group were introduced into the -position of a 
malonic acid half ester derivative (as in 469), treatment of this derivative with a chiral amine base 
472 would not only lead to decarboxylation, but also attack of the ensuing enolate on the N-aryl 
ring, resulting in aryl migration followed by cyclisation to give an imidazolidinone 470 (Scheme 
120). Interaction of the chiral ammonium ion with the enolate should induce enantioselectivity in 
the formation of the imidazolidinone 470. The imidazolidinone could then be hydrolysed to give 
enantiomerically enriched -aryl quaternary amino acids. 
 





2.4.3 Synthesis of Urea Malonic Acid Half Esters 
To begin the project, the urea malonic acid half esters 469 were synthesised following the 3-step 
procedure illustrated in Scheme 121. On heating amino malonate ester hydrochloride 476 with 
carbamoyl chloride 260 and triethylamine in acetonitrile, nucleophilic attack of the amine of 476 
on the carbonyl of 260, followed by a chloride elimination occurred, affording the urea 477 in good 
to excellent yields. Treatment of 477 with sodium hydride and 5 equivalents of methyl iodide gave 
the doubly methylated product 478. It is noteworthy that methylation of 477 with only 2.2 
equivalents of methyl iodide in THF resulted in only -methylation of 477. Finally, selective basic 
hydrolysis of one ester group of 478 in ethanol and water afforded the urea malonic acid half ester 
469. No double hydrolysis was observed by 1H NMR, however 7% of decarboxylated product 479a 
was isolated when Ar = Ph. 
 
Scheme 121: Synthesis of urea malonic acid half esters 
2.4.4 Attempted Aryl Migration of Urea Malonic Half Esters  
With a route towards the starting ureas established, the proposed aryl migrations could then be 
investigated. Urea 469a, having an electron-neutral phenyl migratory ring was chosen as the model 
substrate. The chiral cinchonidine base 302 was readily available; hence it was chosen for initial 
investigations. Several solvents were tested for the aryl migration using a catalytic amount of 
cinchonidine (Table 41). In THF, decarboxylation and subsequent protonation occurred affording 
the product 480a; there was no trace of the desired rearranged product 470a (Table 41, entry 1). 
Addition of LiCl to the reaction led to a reduction in the formation of 480a, but there was still no 





ether led to a significant decrease in the rate of the reaction (Table 41, entries 3 – 5). There was no 
reaction in chloroform at room temperature, but when the reaction was warmed up to 50 °C, 
conversion to 480a was observed (Table 41, entry 6). Unfortunately, in all the reactions, the enolate 
formed was quenched by a proton before it could undergo nucleophilic attack on the N-phenyl ring. 
It was nevertheless encouraging to know that decarboxylation was occurring. 
Table 41: Attempted aryl migration of 469a 
 
Entry Solvent Additivea T (°C) Time (h) 480a:469ab 
1 THF - rt 20 7:1 
2 THF LiCl rt 20 2:1 
3 PhMe LiCl rt 24 1:10 
4 PhMe: acetone (5:1) LiCl rt 20 1:5 
5 Et2O LiCl rt 24 1:10 
6 CHCl3 LiCl rt – 50 48 1:2 
a 3.0 eq. of additive b Ratio by 1H NMR 
With the notion that an electron-deficient aryl ring on the urea might enable aryl migration to 
outcompete protonation of the enolate, urea 469b, having an electron-withdrawing 4-cyano group, 
was subjected to the rearrangement (Table 42). The use of cinchonidine 302 gave only the 
decarboxylated product 480b (Table 42, entry 1). Addition of LiCl decreased the rate of the reaction 
but gave an encouraging 20% of the desired aryl migration product 470b albeit with poor 
enantioselectivity (Table 42, entry 2). A control reaction showed that LiCl was not capable of 
facilitating the aryl migration on its own (Table 42, entry 3). The presence of LiCl in the reaction 
probably enhances the polarity of the solvent thereby enhancing enolate solubility. Additionally, 
LiCl has been shown to increase the reactivity of enolate aggregates by formation of mixed 





Table 42: Attempted arylation of 469b 
 
Entry Base Additivea Time (h)  Results er (470b) 
1 302 - 26 480bb - 
2 302 LiCl 29 20c;32d 48:52 
3 - LiCl 44 Tracec,d - 
4 481 LiCl 48 Tracec; 39d - 
5 482 LiCl 41 16c;41d 50:50 
6e 302 LiCl 48 470b:480bf,b 50:50 
7 e 302 - 24 470b:480bf,b 52:48 
8g 302 - 24 470b:480bf,b 51:49 
a 3 eq. of additive; b Complete conversion to; c Isolated yield of 470b, trace: observed by 1 H NMR; d Isolated yield of 
480b, trace: observed by 1 H NMR; e 1:4 THF:DMF used as solvent; f 1:1 ratio by 1 H NMR; g DMF used as solvent 
Keeping LiCl as additive, alternative bases were tested for the decarboxylative aryl migration. The 
use of 4-dimethylaminopyridine derivative 481 gave only trace amounts of the desired product 470b 
and about 39% of 480b, contaminated with starting material (Table 42, entry 4), while (DHQD)2-
PHAL 482 gave racemic 470b in a 16% yield and 480b in a 41% yield (Table 42, entry 5). It is 
proposed that the bases 481 and 482 promote the formation of 480b over 470b because of their 
steric bulk. The enolate may be sterically crowded by tight ion-pairing with the ammonium ion of 
these bases, hence promoting enolate attack on the smaller sized-proton rather than the aryl ring. 
Additionally, increased steric bulk of the catalyst could disfavour the necessary conformation of 
the enolate to attack the aryl ring. The less hindered cinchonidine 302 was re-examined using a 
more polar 1:4 (THF:DMF) solvent system. This led to complete conversion to the products 470b 





entries 6 and 7). The same result was obtained with the use of DMF alone in the absence of LiCl 
(Table 42, entry 8). In all cases, poor enantioselectivity was obtained.  
2.4.5 Conclusion and Future Work 
It is now established that aryl migration and subsequent cyclisation to imidazolidinones is possible 
in urea malonic acid half esters. The optimisations presented provide key information for future 
developments – aryl migration is faster and promoted in polar solvents, without the need for an 
additive. Future work should focus on optimising the reactions further: first by increasing the yield 
of the aryl migration pathway (imidazolidinone formation) before continuing the development of 
an enantioselective version. Achiral bases such as triethylamine could be used to achieve a non-
enantioselective transformation.280 Some solvents that have been used effectively in 
decarboxylative C-H or C-C bond formation include acetone278 and chloroform.281,282 Some non-
polar solvents that have been used include tert-butyl methyl ether and cyclopentyl methyl 
ether.283,284 These solvents can be tested in the reaction; however, the non-polar solvents might 
require an additive. In the development of an enantioselective transformation, several chiral bases 
could be tested in the reaction; a number of efficient chiral bases for decarboxylative C-C formation 
have been reported in the literature.276  
In addition, the urea substrate 469 could be modified by introducing other groups apart from a 
methyl to the -carbon of the malonic ester residue and the NH of the urea residue in 477 (Scheme 
122). This will not only alter reactivity, but also help to broaden the substrate scope, since the -
carbon and its substituents are preserved in the final amino acid hydrolysis product.  
 









2.5 Diastereoselective Arylation of -Amino Nitriles1 
2.5.1 Previous work 
Earlier work within the Clayden group had developed the base-mediated intramolecular arylation 
of amino nitriles 485 to afford imino hydantoins 486 (Scheme 123).152 Migration of the N'-aryl 
substituent of the Nꞌ-aryl-N-1-cyanoethyl ureas 485 to the -carbon of its amino nitrile had 
evidently occurred, followed by cyclisation of the urea anion unto the cyano group to reveal 486 in 
good to excellent yields. 
 
Scheme 123: Aryl migration of amino nitrile ureas 
The reaction was tolerant of both electron-neutral and electron-rich migratory rings. A selection of 
imino hydantoins 486 were subsequently hydrolysed to afford 487 as racemic aryl substituted 
hydantoin derivatives of alanine.  
2.5.2 Overview of Route 
The method described in Scheme 123 gives racemic quaternary amino acid derivatives. It has been 
shown within the Clayden group that enantiopure quaternary amino acids can be accessed by the 
intramolecular arylation of amino acids through an imidazolidinone intermediate;160 however, for 
the synthesis of diarylglycines, lower enantioselectivities were obtained due to racemisation 
occurring during synthesis of starting materials.285–287 Hence another method is needed. It was 
proposed that incorporating a chiral auxiliary as R2 (refer to 485 in Scheme 123) in an aryl glycine 
amino nitrile urea 488 (Scheme 124), might cause the intramolecular arylation to take place 
diastereoselectively, thereby affording enantioenriched ,-diarylglycine derivatives 490 on 
hydrolysis. This method would also give access to enantiopure derivatives of phenytoin 490 (Ar1 = 
Ar2 = C6H5), an hydantoin used as an anticonvulsant. 
 






Scheme 124: Proposed route towards enantioenriched ,-diarylglycine derivatives 
In addition, this method will have no racemisation issue since the enantioselectivity is determined 
by the chiral auxiliary and not the amino acid. A wide scope of ,-diarylglycines could also be 
accessed since the method will not be limited to only phenylglycine derivatives. 
Preliminary investigations using (R)-1-(4-methoxyphenyl)ethylamine (indicated in purple) as the 
chiral auxiliary showed that 3 equivalents of LDA in THF was optimal for the migration of a phenyl 




Scheme 125: Optimal condition (Absolute configuration of new stereogenic centre in 489aa not 
determined).1  
Satisfied with a 93% yield of 489aa, the next endeavour was to improve the diastereoselectivity. A 
series of amino nitrile ureas 488 was made, as diastereomeric mixtures, from the corresponding 
enantiopure amines highlighted in purple (refer to Table 43 and Table 44 for synthetic route). 
 






Scheme 126: Optimisation of chiral auxiliary (Absolute configuration of new stereogenic centre in 489 not 
determined).1 
Ureas 488 were subjected to the optimal conditions and O-silyl protected (1R),(2R)-2-amino 
cyclohexanol (491), precursor to 488ea, was found to be the optimal chiral auxiliary producing a 
>95:5 dr of the aryl migration product 489ea (Scheme 126). This was convenient because both 
enantiomers of trans-2-amino cyclohexanol 491 are commercially available. Furthermore, they can 
be easily made by amination of the corresponding meso epoxide.288,289 The OH group also allows 
for variation of the steric and electronic properties of the auxiliary.  
2.5.3 Synthesis of Amino Nitrile Ureas 
With the optimal chiral auxiliary revealed, a selection of amino nitrile ureas 488e was synthesised 
by the 4-step synthesis illustrated in Table 43 and Table 44. (1R),(2R)-2-amino cyclohexanol 491 
was reacted with TMSCN and the desired aldehyde 492 to afford the corresponding -amino nitrile 
493. The amino nitriles were unstable and capable of hydrolysing back to the aldehyde; hence they 
were used immediately in the next step to afford silyl protected alcohols 494 (Table 43). The 
diastereoselectivity at the -carbon is irrelevant as this centre is destroyed in the rearrangement.  
 





Table 43: Synthesis of -amino nitriles 494 
 
Entry Ar1 Product Yield (%) dr 
1 3-furyl 494a 52 65:35 
2 4-FC6H4 494b 38 75:25 
3 Ph 494c 49 70:30 
 
Nitriles 494 were subjected to reaction with triphosgene to afford carbamoyl chlorides 495 (Table 
44). It was observed that treating 495 with KI, 2,6-lutidine and the corresponding N-methylaniline 
413 in a microwave reactor at 110 °C (Method B) led to the removal of the silyl group and 
subsequent attack of the exposed hydroxyl group on the carbonyl of 495, resulting in low yields of 
488e. This issue was resolved by eliminating KI from the reaction and refluxing in acetonitrile for 
24 hours (Method A). 
Table 44: Synthesis of -amino nitrile ureas 488e 
  
Entry Ar1 Ar2 Product Yield (%) dr 
1 3-furyl C6H5 488ea 17
a 50:50 
2 4-FC6H4 C6H5 488eb 11
a 50:50 
3 C6H5 4-FC6H4 488ec 58
b 50:50 
4 C6H5 D5-C6H5 488ed 51
b 50:50 






2.5.4 Aryl Migration of -amino nitrile ureas 
The aryl migration reactions were carried out on substrates 488e (Table 45). Using the optimal 
conditions (method A), both diastereoisomers of 488ea (DA and DB) were independently subjected 
to the aryl migration reaction (Table 45, entries 1 and 2). In both cases, 489ea was obtained in good 
yields and excellent diastereoselectivity. 488eb and 488ed showed good conversion to their 
respective rearranged products 489eb and 489ed with excellent diastereoselectivities (Table 45, 
entries 3 and 5). The substrate 488ed, however, had to be left for more than 3 hours for complete 
conversion to occur. The synthesis of 489ed as a single diastereoisomer shows the usefulness of 
this method in accessing diarylglycines which might ordinarily be difficult to obtain through normal 
resolution methods due to the similarity of the two substituents at the chiral centre.290 Urea 488ec, 
which is a positional isomer of 488eb, surprisingly required more forceful conditions (method B) 
than 488eb for the aryl migration to occur (Table 45, entry 4). It is remarkable that access to 
molecules having an opposite configuration at the -carbon (489eb and 489ec) is possible by 
alternating the positions of Ar1 and Ar2. This would be useful for obtaining opposite enantiomers 
of the final hydantoin. 
Table 45: Aryl migration reactions 
 
Entry 488 489 Ar1 Ar2 Yield (%) dr 
1a 488eaDA 489ea 3-furyl C6H5 68 >95:5 
2a 488eaDB 489ea 3-furyl C6H5 85 >95:5 
3a 488eb 489eb 4-FC6H4 C6H5 93 98:2 
4b 488ec 489ec C6H5 4-FC6H4 51 94:6 
5a,c 488ed 489ed C6H5 D5- C6H5 75 >95:5 
a Method A; b Method B; c Reaction left overnight. The absolute configuration of the new stereogenic centre in  489e 
was assigned by analogy to 489ee (see Scheme 128) 
As described in section 1.4, the mechanism of the intramolecular aryl migration is related to a 
Smiles or Truce-Smiles rearrangement. However, unlike the Smiles rearrangement, the migratory 
aryl group does not require activation by an electron-withdrawing group.291 The well-defined 





reaction centre in 496ea, thereby inducing nucleophilic attack on the aryl group even without an 
electron-withdrawing substituent (Scheme 127). 
 
Scheme 127: Proposed mechanism for intramolecular arylation of -amino nitrile ureas 
Compounds 489e could be hydrolysed to the respective hydantoins. Dr Josep Mas Rosellό 
illustrated this with substrate 489ee (Scheme 128).293 The aryl migration product 489ee was firstly 
refluxed with HCl in methanol to remove the silyl group, resulting in 498ee. The product 498ee 
was then treated with polyphosphoric acid (PPA) to remove the chiral auxiliary, thereby furnishing 
490e. The absolute configuration of 490e was determined to be S based on comparison with the 
HPLC trace of an authentic sample.293 
 










In summary, a method has been developed for the diastereoselective synthesis of phenytoin 
derivatives. This method provides access to diarylglycines without the use of a tertiary amino acid 
having the desired aryl sidechain, which might not be readily available. The method also overcomes 
the problem of racemisation encountered with the use of phenylglycine in the synthesis of starting 
materials.  
 
Scheme 129: Hydrolysis of hydantoins to amino acids 
The C,C-diaryl hydantoins 490 can be potentially hydrolysed to ,-diaryl quaternary amino acids. 
A literature precedent for this is the hydrolysis of C-alkyl,C-aryl hydantoins 499 reported in 2015 
(Scheme 129).153 The hydantoins 499 were hydrolysed to the amino acids 500 which due to 







3.1 Organocatalytic rearrangement using tertiary amines 
In the synthesis of the hydantoin urea starting materials for the PTC aryl migrations (section 2.2.2), 
hydantoin urea 273e was difficult to purify chromatographically because it had the same retention 
factor as its N-methyl-4-nitroaniline precursor. To obtain a pure fraction of 273e, a slight excess of 
the carbamoyl chloride 280a was added to the reaction mixture to consume the left-over N-methyl-
4-nitroaniline. This worked well in consuming the N-methylaniline, however there was left an 
excess of carbamoyl chloride 280a which hydrolysed back to the hydantoin 279a. Unfortunately, 
279a had the same retention factor as 273e; hence, they could not be separated by simple 
chromatography technique. Using a reaction procedure found in Pharm et al.,294 the mixture of 273e 
and 279a was subjected to a reaction with DMAP (catalytic) and Boc anhydride. It was assumed 
that Boc protecting 279a would lead to a change in its retention factor; hence making it possible to 
chromatographically separate 279a from 273e. Surprisingly, this was not the case – Boc anhydride, 
instead reacted with the entire mixture to give the Boc-protected rearranged product 502e (Scheme 
130). 
 
Scheme 130: Attempted protection of 279a with a Boc group 
This was quite remarkable because it was not anticipated that a tertiary amine such as DMAP would 
be able to deprotonate the -H of the hydantoin urea 273e. To investigate the rearrangement, 
substrate 273a (having a 4-CNC6H4 migratory ring) and 273h (having a 4-CF3C6H4 migratory ring) 
were independently subjected to the reaction with DMAP and Boc2O. The substrate 273h was still 
unreacted after 15 hours while 273a gave the product 502a in 65% yield (Table 46, entry 1). It was 
assumed that there was no reaction with substrate 273h because it was less activated towards an 
SNAr reaction than 273e and 273a. The reaction was further investigated with the use of DMAP 
alone (without Boc2O). Hydantoin urea 273a was used as test substrate. After 15 hours, 1H NMR 
showed a 4:1 ratio of starting material 273a to unprotected product 274a (Table 46, entry 2). 
Catalytic amounts of DMAP were continuously added until 1H NMR showed a constant ratio of 2:1 





used in place of DMAP + Boc2O, the unprotected rearranged product 274a was obtained (Table 46, 
entry 4). 
Table 46: Tertiary amine optimisation for rearrangement reaction 
 
Entry Base Boc2O Comments/Yields 
1 DMAP (cat.) Yes 65% of 502aa 
2 DMAP (cat.) - 4:1 273a:274ab 
3 DMAP (non-cat.) - 2:1 273a:274abb 
4 Et3N Yes 274a
c 
5 Et3N - 273a
c 
6 cinchonidine - 273ac 
7 cinchonidine Yes 274ac 
a Isolated yield; b 1H NMR ratio; c Observed by 1H NMR 
When Et3N was used in the reaction without Boc anhydride there was still no reaction after 24 hours 
(Table 46, entry 5), however when Boc anhydride was added to the reaction mixture, the 
unprotected rearranged product 274a was formed. This suggests that Boc2O aids the aryl transfer, 
probably through a deprotonation by tert-butoxide ion; however, a better understanding would be 
obtained by trying Boc2O alone to see if it is enough to make the reaction work. Since tertiary 
amines in the presence of Boc anhydride induced the aryl transfer, it was expedient to check if a 
chiral tertiary amine in the presence of Boc-anhydride would induce stereoselectivity in the 
reaction. When the chiral amine cinchonidine was used as base in the reaction, as expected, there 
was still no reaction after 24 hours (Table 46, entry 6). When Boc anhydride was added to the 
reaction mixture, the unprotected rearranged product 274a was formed (Table 46, entry 7). The 
product 274a was found to be racemic, suggesting again that Boc anhydride must have aided the 







Scheme 131: reaction showing no equilibrium between 273a and 274a 
To investigate the reversibility or irreversibility of the reaction, a catalytic amount of DMAP was 
added to an acetonitrile solution of 274a to see if the reaction would go backwards towards the 
starting material 273a. The rearranged product 274a was still observed by 1H NMR after 15 hours 
indicating that the rearrangement was not an equilibrium reaction (Scheme 131). As a non-catalytic 
amount of DMAP was sufficient to carry out the aryl migration without the influence of Boc2O 
(Table 46, entry 3), it is worth investigating in the future if chiral tertiary amines would be able to 







4.1 General Information 
Reactions requiring anhydrous conditions and inert atmosphere were carried out under dry nitrogen 
in flame-dried apparatus. Air- and moisture-sensitive solvents and reagents were transferred via a 
plastic syringe into the reaction vessels through rubber septa. Reactions carried out in a microwave 
reactor were completed on a Biotage Initiator+. All reagents were bought from chemical suppliers 
and used without further purification. The thiourea catalysts were sent to the group from Johannes 
Kepler University Austria. Some of the fluorinated cinchona-derived catalysts were sent to the 
group from the University of Oxford, United Kingdom. Anhydrous THF, DCM, PhMe and CH3CN 
were dried using an anhydrous Engineering Grubbs-type solvent system. Et3N was stored over KOH. 
Blue LEDs used were LED Strip Light MINGER 16.4ft(5m) RGB SMD 5050 LED Rope Lighting 
Colour Changing Full Kit with 44-Keys IR Remote Controller LED Lighting Strips for Kitchen 
Christmas Decoration (controller was used to set lights to highest blue intensity). The LEDs 
required 12 V direct current and were powered by a 2 A power supply resulting in a power output 
of 24 watts. The LEDs were wrapped around the interior of a glass beaker, with the exterior of the 
glass beaker wrapped in aluminium foil. During the course of the photo reactions, heat generated 
from the LED strip resulted in warming of the reaction mixtures to 30 °C. 
Thin layer chromatography (TLC) was performed using commercially available aluminium 
backed silica plates (0.2 mm, 60 F254). Visualisation was done under UV light (254 nm), or by 
staining with ‘Seebach’ dip or potassium permanganate.  
Flash chromatography was performed on an automated Biotage IsoleraTM Spektra Four using 
gradient elutions on pre-packed silica gel Biotage® SNAP Ultra/ZIP Sphere columns.  
Melting points were measured on a Stuart Scientific melting point SMP 10 apparatus and are 
uncorrected.  
FT-IR spectra were recorded on neat compounds using a Perkin Elmer (Spectrum One) FT-IR 
spectrometer, using a Universal ATR sampling accessory. Only strong and relevant absorptions are 
reported.  
1H NMR spectra were recorded on Jeol ECS or ECZ (400 MHz), Joel ECZ-var (400 MHz), Varian 
VNMR (400 MHz) or Bruker Ultrashield (400 MHz) spectrometers. Chemical shifts δΗ are quoted 
in parts per million (ppm) and referenced to the appropriate NMR residual solvent peak(s). For 
CDCl3 (δΗ: 7.26 ppm), CD3OD (δΗ: 3.31 ppm) and (CD3)2SO (δH: 2.50 ppm). 
13C NMR spectra were recorded on Jeol ECS or ECZ (101 MHz), Joel ECZ-var (101 MHz), Varian 
VNMR (101 MHz) or Bruker Ultrashield (101 MHz or 126 MHz) spectrometers. Chemical shifts 
(δC) are quoted in parts per million (ppm) and referenced to the appropriate NMR residual solvent 
peak(s). For CDCl3 (δC: 77.16 ppm), CD3OD (δC: 49.00 ppm) and (CD3)2SO (δC: 39.52 ppm). 2D-
NMR experiments COSY, HSQC and HMBC were used where necessary to assign NMR spectra. 
Coupling constants (J) are quoted in Hertz (Hz). 
19F NMR spectra were recorded on Jeol ECS or ECZ (377 MHz), Joel ECZ-var (377 MHz), or 
Bruker Ultrashield (377 MHz) instruments. Chemical shifts (δF) are quoted in parts per million 
(ppm) and referenced to an external standard. Spin-spin coupling constants (J) are reported in Hertz 
(Hz). 
High resolution mass spectra were recorded on a Bruker Daltronics MicrOTOF 2 mass 






4.2 General Procedures 
Procedure 1: Synthesis of cinchona salts 
Method A: To a suspension of the cinchona alkaloid (1.0 eq., 0.52 M) in a mixture of EtOH, DMF 
and CHCl3 (2.5:3:1) was added the alkyl bromide (1.1 eq.). The reaction was stirred at 100 °C for 
4 hours. It was then cooled to room temperature, diluted with methanol, and added to diethyl ether 
dropwise with stirring. The solid precipitated was filtered and washed with diethyl ether. The crude 
solid was crystallised from methanol to diethyl ether. 
Method B: To a suspension of the cinchona alkaloid (1.0 eq., 0.1 – 0.5 M) in toluene was added 
the alkyl bromide (1.0 eq.). The reaction was stirred at 100 – 120 °C for 8 – 16 hours. The crude 
solid was purified by crystallisation. 
Procedure 2: Urea formation from amino methyl ester hydrochloride 
Under a dry, inert atmosphere, Et3N (2.0 eq.) and the isocyanate (1.1 eq.) was added to a suspension 
of the amino methyl ester hydrochloride (1.0 eq., 0.5 M) in anhydrous DCM. The reaction was 
stirred for 16 hours at room temperature. The reaction was quenched with HCl (1.0 M, aq.) and the 
organic layer washed with NaHCO3 (sat. aq.) and brine, then dried over MgSO4, filtered and the 
solvent removed under reduced pressure. The crude product was used without further purification. 
Procedure 3: Hydantoin formation from urea 
Under a dry, inert atmosphere, KOtBu (1.1 eq.) was added to a solution of the urea (1.0 eq., 0.4 M) 
in anhydrous THF. The reaction was stirred for not more than 1 hour at room temperature. The 
reaction was quenched with HCl (1.0 M, aq.) and the organic solvent removed under reduced 
pressure. The residue was dissolved in EtOAc and the organic layer separated. The organic layer 
was washed with NaHCO3 (sat. aq.) and brine. Afterwards, it was dried over MgSO4, filtered and 
the solvent removed under reduced pressure. The crude product was purified by flash column 
chromatography. 
Procedure 4: Carbamoyl chloride formation from hydantoin 
Under a dry, inert atmosphere, triphosgene (0.5 eq., 0.2 M) in anhydrous DCM was cooled to −78 
°C and stirred for 5 minutes. Anhydrous pyridine (1.5 eq.) was added dropwise and the reaction 
stirred a further 10 minutes. To the reaction, a solution of hydantoin (1.0 eq., 2.0 M) in anhydrous 
DCM was added dropwise. The solution was allowed to warm to room temperature and stirred for 





dried over MgSO4, filtered, and the solvent removed under reduced pressure. The crude product 
was used without further purification. 
Procedure 5: Hydantoin urea formation from carbamoyl chloride 
Under a dry, inert atmosphere, carbamoyl chloride (1.0 eq., 0.2 M) in anhydrous DCM was stirred 
at room temperature. Et3N (1.2 eq.) and the desired N-methylaniline (1.0 eq. in a solution of DCM, 
if solid) were simultaneously added dropwise over 5 minutes. The reaction was stirred for 2 hours 
before quenching with HCl (1.0 M, aq.). The organic layer was washed with NaHCO3 (sat. aq.) and 
brine, then dried over MgSO4, filtered and the solvent removed under reduced pressure. The crude 
product was purified by flash column chromatography. 
Procedure 6: Phase transfer catalysed aryl migration 
Under an inert atmosphere, hydantoin urea (1.0 eq., 0.1 M) in the desired solvent was cooled down 
to the desired temperature. The PTC (0.1 – 0.2 eq.) and Cs2CO3 (5.0 eq.) or KOH (3.0 eq.) were 
added. The reaction was stirred and left until TLC analysis showed the starting material had been 
completely consumed. The reaction was quenched with NH4Cl (sat. aq.). The organic solvent was 
removed under reduced pressure and the aqueous layer extracted with EtOAc. The organic layer 
was washed with brine, dried over MgSO4, filtered and the solvent removed under reduced pressure. 
The crude product was purified by flash column chromatography. 
Procedure 7: N-Methylamide formation from amino methyl ester hydrochloride 
MeNH2 (33% w/w solution in EtOH, 7.0 eq.) was added to the amino methyl ester hydrochloride 
(1.0 eq.). The mixture was left to stir at room temperature for 24 hours. The solvent was removed 
under reduced pressure, the residue dissolved in NaHCO3 (sat. aq.) and extracted 4 times with 
CHCl3. The combined organic layers were dried over MgSO4, filtered and the solvent removed 
under reduced pressure. The crude product was used without further purification. 
Procedure 8: Imine formation from amino acid N-methylamide 
Under a dry, inert atmosphere, pivalaldehyde (1.3 eq.) was added to a mixture of MgSO4 (1.0 eq.) 
and N-methylamide (1.0 eq., 2.0 M) in anhydrous DCM. The reaction was left to stir at room 
temperature for 16 hours. The reaction was filtered, and the organic filtrate washed with water. The 
washed organic filtrate was collected, and the remaining aqueous layer extracted 3 times with DCM. 
The combined organic layers were dried over MgSO4, filtered and the solvent removed under 






Procedure 9: Carbamoyl chloride formation from N-methylaniline 
Under a dry, inert atmosphere, triphosgene (0.5 eq., 0.4 M) in anhydrous DCM was cooled to −78 
°C and stirred for 5 minutes. Anhydrous pyridine (1.0 eq.) was added dropwise, followed by a 
solution of the desired N-methylaniline (1.0 eq., 16.0 M, if solid) in anhydrous DCM. After 10 mins, 
the reaction was allowed to warm to room temperature and left to stir for 3 hours. The reaction was 
quenched with HCl (1.0 M, aq.). The organic layer was seperated, and the aqueous layer extracted 
3 times with DCM. The combined organic layers were washed with NaHCO3 (sat. aq.), dried over 
MgSO4, filtered and the solvent removed under reduced pressure. The crude product was used 
without further purification. 
Procedure 10: Imidazolidinone urea formation from N-methylamide imine 
Under a dry, inert atmosphere, DMAP (0.05 eq.) and N-alkyl-N-arylcarbamoyl chloride (1.5 eq.) 
were added to a solution of the N-Methylamide imine (1.0 eq., 0.2M) in anhydrous toluene. The 
reaction mixture was stirred at reflux for 48 hours. The reaction was cooled to room temperature 
and quenched with HCl (1.0 M, aq.). The organic solvent was removed under reduced pressure and 
the aqueous layer extracted 3 times with EtOAc. The combined organic layers were dried over 
MgSO4, filtered and the solvent removed under reduced pressure. The crude product was purified 
by flash column chromatography. 
Procedure 11: Vinyl urea formation from imidazolidinone urea 
Under a dry, inert atmosphere, KHMDS (1.0 M/THF, 1.2 – 2.0 eq.) was added to a solution of the 
imidazolidinone urea (1.0 eq., 0.1 M) in anhydrous THF at 0 °C. The reaction was left to stir at 0 
°C for 15 minutes and then allowed to warm to room temperature. The reaction was left stirring at 
room temperature until TLC analysis showed the starting material had been completely consumed. 
The reaction was quenched with NH4Cl (sat. aq.) and the organic solvent removed under reduced 
pressure. The aqueous layer was extracted 3 times with EtOAc. The combined organic layers were 
washed with brine, dried over MgSO4, filtered and the solvent removed under reduced pressure. 
The crude product was purified by flash column chromatography. 
Procedure 12: Conjugate addition and Aryl migration product via Photoredox catalysis 
The vinyl urea (1.0 eq.), caesium carbonate (1.5 eq.), 4CzIPN (5 mol%) and the radical precursor 
(2.0 – 3.0 eq.) were added into a dried microwave vial under an inert atmosphere. The mixture was 
left under vacuum for 10 – 15 mins and then flushed with nitrogen. Anhydrous CH3CN ([vinyl urea] 
= 0.1 M) was added and the mixture stirred and degassed for 10 minutes by bubbling nitrogen in 
through a long needle and oxygen out through a short needle. The reaction mixture was exposed to 





with water and extracted 3 times with EtOAc. The combined organic layers were evaporated under 
reduced pressure and the crude product purified by flash column chromatography. 
Procedure 13: Aryl migration of conjugate addition product 
Under a dry, inert atmosphere, LiHMDS (1.0 M/THF, 1.5 eq.) was added to a solution of the 
conjugate addition product (1.0 eq., 0.1 M) in anhydrous THF at 0 °C. The reaction was left to stir 
at 0 °C until TLC analysis showed the starting material had been completely consumed. The 
reaction was quenched with NH4Cl (sat. aq.) and the organic solvent removed under reduced 
pressure. The aqueous layer was extracted 3 times with EtOAc. The combined organic layers were 
washed with brine, dried over MgSO4, filtered and the solvent removed under reduced pressure. 
The crude product was purified by flash column chromatography. 
Procedure 14: Aryl migration and subsequent 1,2-elimination of conjugate addition product 
Under a dry, inert atmosphere, KHMDS (1.0 M/THF, 1.5 – 2.5 eq.) was added to a solution of the 
conjugate addition product (1.0 eq., 0.1 M)  in anhydrous THF at 0 °C. The reaction was allowed 
to warm to room temperature and left to stir until TLC analysis showed the starting material had 
been completely consumed. The reaction was quenched with NH4Cl (sat. aq.) and the organic 
solvent removed under reduced pressure. The aqueous layer was extracted 3 times with EtOAc. The 
combined organic layers were washed with brine, dried over MgSO4, filtered and the solvent 
removed under reduced pressure. The crude product was purified by flash column chromatography. 
Procedure 15: N-Methylation of aryl migration product 
Under a dry, inert atmosphere, the conjugate addition product (1.0 eq., 0.1 M) in anhydrous THF 
was cooled to 0 °C. LiHMDS (1 M/THF, 1.5 eq.) was added and the reaction stirred at 0 °C until 
TLC analysis showed the starting material had been completely consumed. An additional 1.5 eq. of 
LiHMDS (1 M/THF) was added and the reaction stirred further for 45 minutes at 0 °C, after which 
MeI (2.0 – 5.0 eq.) was added. The reaction was allowed to warm to room temperature and left to 
stir for 16 hours. The reaction was quenched with water; and MeI and THF removed under reduced 
pressure. The residue was partitioned between water and EtOAc, and the organic layer collected. 
The organic layer was washed with brine, before being dried over MgSO4, filtered, and the solvent 
removed under reduced pressure. The crude product was purified by flash column chromatography. 
Procedure 16: Formation of urea malonic acid ester 
Under a dry, inert atmosphere, diethyl amino malonate hydrochloride salt (1.1 eq.) and Et3N (2.2 
eq.) were added to a solution of N-Methyl-N-arylcarbamoyl chloride (1.0 eq., 0.1 M) in anhydrous 





pressure and the residue partitioned between NaHCO3 (sat. aq.) and DCM. The organic layer was 
collected, and the aqueous layer extracted 2 times with DCM . The combined organic layers were 
washed with brine, dried over Na2SO4, filtered and the solvent removed under reduced pressure. 
The crude product was purified by flash column chromatography. 
Procedure 17: N- and -alkylation of urea malonic acid ester 
Under a dry, inert atmosphere, a solution of the urea malonic acid ester (1.0 eq., 0.1 M) in anhydrous 
DMF was cooled to 0 °C, NaH (60% in mineral oil, 3.0 eq.) was added and the reaction left stirring 
for 15 minutes. MeI (5.0 eq.) was added and the reaction left stirring for a further 1 hour at 0 °C. 
The reaction mixture was diluted with EtOAc and quenched by addition of ice and NaOH (1.0 M, 
aq.). The organic layer was collected, and the aqueous layer extracted 2 times with EtOAc. The 
combined organic layers were washed with brine, dried over MgSO4, filtered and the solvent 
removed under reduced pressure. The crude product was purified by flash column chromatography. 
Procedure 18: Mono hydrolysis of alkylated urea malonic acid ester 
A solution of the alkylated urea malonic acid ester (1.0 eq., 0.7 M) in ethanol:water (10:1) was 
cooled to 0 °C. KOH (2.0 eq.) was added and the reaction stirred for 15 hours at room temperature. 
Ethanol was removed under reduced pressure with the temperature of the rotary evaporator set 
below 20 °C. The residue was then dissolved in NaHCO3 (10%, aq.) and washed 3 times with diethyl 
ether. The aqueous layer was acidified with HCl (6.0 M, aq.) at 0 °C, and then extracted 3 times 
with diethyl ether. The combined organic layers were dried over MgSO4, filtered, and the solvent 
removed under reduced pressure. The crude product was purified by flash column chromatography. 
Procedure 19: Formation of -amino nitrile 
Under a dry, inert atmosphere, (1R),(2R)-2-aminocyclohexanol (1.0 eq. 0.17 M) in MeOH was 
reacted with the aldehyde (1.1 eq.) and TMSCN (1.2 eq.) for 16 hours at room temperature. The 
reaction mixture was evaporated under reduced pressure and the crude product used without further 
purification. 
Procedure 20: Silyl protection of -amino nitrile 
Under a dry, inert atmosphere, 2,6-lutidine (1.5 eq.) was added to a solution of the -amino nitrile 
(1.0 eq., 0.22 M) in anhydrous DCM. Upon cooling to −78 °C, TBDMSOTf (1.2 eq.) was added 
dropwise to the reaction. After stirring for 5 minutes, the reaction mixture was warmed to room 
temperature and left to stir for 4 hours. It was then quenched by addition of NaHCO3 (sat. aq.). The 
organic layer was washed with water and brine, dried over Na2SO4, filtered, and the solvent 





Procedure 21: Carbamoyl chloride formation from silyl protected -amino nitrile 
Under a dry, inert atmosphere, triphosgene (0.4 eq., 0.1 M) in anhydrous DCM was cooled to −78 
°C. 2,6-Lutidine (1.2 eq.) was added dropwise and the reaction left to stir for 10 minutes. The silyl 
protected -amino nitrile (1.0 eq.) was then added dropwise as a solution in DCM. The reaction 
was warmed to room temperature and left to stir for 2 hours. The reaction was quenched by addition 
of HCl (1.0 M, aq.). The organic layer was washed with NaHCO3 (sat. aq.) and brine, then dried 
over Na2SO4 and filtered. The solvent was removed under reduced pressure to obtain the crude 
carbamoyl chloride, which was used in the next step without further purification. 
Procedure 22: -Amino nitrile urea formation from carbamoyl chloride and N-methylaniline 
Method A: 2,6-Lutidine (1.2 eq.), the desired N-methylaniline (1.1 eq.) and KI (1.2 eq.) were added 
to a solution of the carbamoyl chloride (1.0 eq., 0.4 M) in anhydrous CH3CN. The reaction was 
heated at 110 °C in a microwave reactor for 4 hours. It was then evaporated under reduced pressure 
and partitioned between EtOAc and HCl (1.0 M, aq.). The aqueous layer was extracted twice with 
EtOAc and the combined organic layers were washed with NaHCO3 (sat. aq.) and brine, then dried 
over Na2SO4, filtered, and the solvent removed under reduced pressure. The crude product was 
purified by flash column chromatography. 
Method B: 2,6-Lutidine (1.2 eq.) and the desired N-methylaniline (1.1 eq.) were added to a solution 
of the carbamoyl chloride (1.0 eq. 0.4 M) in anhydrous CH3CN. The reaction mixture was refluxed 
at 100 °C for 24 hours. The solvent was removed under reduced pressure and partitioned between 
EtOAc and HCl (1.0 M, aq.). The aqueous layer was extracted twice with EtOAc. The combined 
organic layers were washed with NaHCO3 (sat. aq.) and brine, then dried over Na2SO4, filtered, and 
the solvent removed under reduced pressure. The crude product was purified by flash column 
chromatography. 
Procedure 23: Hydantoin formation from aryl migration of -amino nitrile urea  
Method A: Under a dry, inert atmosphere, LDA (2.0 M in THF/heptane/ethylbenzene, 3.0 eq.) was 
added dropwise to a solution of the -amino nitrile urea (1.0 eq., 0.1 M) in anhydrous THF at −78 
°C. The reaction was stirred for 10 minutes before warming to room temperature and stirred for 
another 3 hours. The reaction was quenched by addition of NH4Cl (sat. aq.) and then partitioned 
between water and EtOAc. The aqueous layer was extracted twice with EtOAc. The combined 
organic layers were washed with brine, dried over Na2SO4, filtered, and the solvent removed under 





Method B: Under a dry, inert atmosphere,  DMPU (DMPU:THF, 1:10) was added to a solution of 
the -amino nitrile urea (1.0 eq., 0.11 M) in anhydrous THF. The reaction was cooled to −78 °C 
and LDA (2.0 M in THF/heptane/ethylbenzene, 2.5 eq.) was added dropwise. The reaction was left 
to stir for 10 minutes at −78 °C , after which it was warmed to +40 °C and stirred for 20 hours. The 
reaction was cooled to room temperature and quenched by the addition of NH4Cl (sat. aq.). It was 
then partitioned between water and EtOAc and the aqueous layer extracted twice with EtOAc. The 
combined organic layers were washed with brine, dried over Na2SO4, filtered, and the solvent 
removed under reduced pressure. The crude product was purified by flash column chromatography. 
4.3 Characterisation Data 
4.3.1 Phase Transfer Catalysed Aryl Migration 
4.3.1.1 Synthesis of Phosphonium-based PTC 
(S)-N-(2-Hydroxy-1-phenylethyl)-3,5-bis(trifluoromethyl)benzamide (300) 
 
To a solution of (R-)-(-)-2-Phenylglycinol (1.00 g, 7.29 mmol, 1.00 eq., 0.20 M) in anhydrous THF 
(40.0 mL) was added Et3N (2.00 mL, 14.6 mmol, 2.00 eq.). The reaction was cooled to 0 °C and 
3,5-di(trifluoromethyl)benzoyl chloride (1.40 mL, 8.00 mmol, 1.10 eq.) was added slowly through 
a syringe. Stirring was continued for 2 hours at room temperature. The reaction mixture was then 
concentrated under reduced pressure. The residue was dissolved in EtOAc (40.0 mL) and the 
solution was washed successively with NaHCO3 (sat. aq.), HCl (1M, aq.) and brine. The organic 
layer was dried over MgSO4 and the solvent removed under reduced pressure. The crude product 
was purified by flash column chromatography (SiO2; Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 
80:20) to afford the title compound (1.85 g, 67%) as a white solid. Rf (8:2 Pet.Ether:EtOAc) 0.14; 
mp: 155 – 156 °C; 1H NMR (400 MHz, CD3OD):  8.51 (2H, s, Ar-H), 8.17 (1H, s, Ar-H), 7.42 
(2H, d, J = 7.0, Ar-H), 7.36 (2H, dd, J = 8.5, 6.7, Ar-H), 7.28 (1H, t, J = 7.2, Ar-H), 5.25 (1H, dd, 
J = 7.7, 5.8, CHNH), 3.95 – 3.85 (2H, m, CHAHBOH); 13C NMR (126 MHz, CD3OD): 166.82 
(C=O), 140.87 (CAr), 138.26 (CAr), 133.0 (q, 
2JC-F = 33.6, 2xCAr), 129.26 (q, 3JC-F = 3.78, 2xCArH), 
129.61 (2xCArH), 128.62 (CArH), 128.07 (2xCArH), 125.93 (q, 3JC-F = 3.78, CArH) 124.6 (q, 
1JC-F = 









Triphenylphosphine (4.22 g, 16.1 mmol, 3.30 eq.) was added to a solution of alcohol 300 (1.80 g, 
4.79 mmol, 1.00 eq., 0.30 M) in anhydrous DCM (15.0 mL). The solution was cooled to 0 °C and 
a solution of tetrabromomethane (1.77 g, 5.32 mmol, 1.10 eq., 1.00 M) in DCM (5.00 mL) was 
added slowly through a syringe and stirring was continued for 2 hours at room temperature. The 
reaction mixture was concentrated under reduced pressure. The residue was dissolved in EtOAc 
(30.0 mL) and washed with water (15.0 mL). After separation, the aqueous layer was extracted with 
EtOAc (20.0 mL). The combined organic layers were washed with brine, dried over MgSO4 and 
the solvent removed under reduced pressure. The crude product was purified by flash column 
chromatography (SiO2; Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 99.5:0.5) to afford the title 
compound (1.48 g, 70%) as a white solid. Rf (9.5:0.5 Pet.Ether:EtOAc) 0.12; 1H NMR (400 MHz, 
CD3OD):  8.49 (2H, s, Ar-H), 8.20 (1H, s, Ar-H), 7.46 (2H, d, J = 7.7, Ar-H), 7.40 (2H, t, J = 7.5, 
Ar-H), 7.33 (1H, t, J = 7.2, Ar-H), 5.44 (1H, q, J = 7.5, CHNH), 3.90 – 3.82 (2H, m, CHAHBBr); 
13C NMR (126 MHz, CD3OD): 164.70 (C=O), 133.4 (q, 
2JC-F = 34.0, 2xCAr), 129.17 (q, 3JC-F = 3.78, 
2xCArH), 130.63 (2xCArH), 129.87 (CArH), 128.04 (2xCArH), 129.25 (CAr) 128.36 (CAr) 126.15 (q, 
3JC-F = 3.78, CArH), 124.4 (q, 
1JC-F = 273.4, 2xCF3), 65.88 (CHAHBOH), 57.59 (CHNH); IR 
(vmax/cm-1) (neat): 2935, 2888 (alkyl C-H), 1736 (C=O); HRMS (ESI): m/z calcd for 













A mixture of 301 (1.38 g, 3.14 mmol, 1.00 eq.) and triphenylphosphine (2.29 g, 8.70 mmol, 2.80 
eq.) was refluxed in toluene (10.0 mL) for 12 hours. The resulting solution was allowed to cool to 
room temperature and was concentrated under reduced pressure. Diethyl ether (10.0 mL) was added 
dropwise to the residue while stirring vigorously. The cloudy solution was filtered, and the residue 
washed with diethyl ether to remove all impurities. It was then concentrated under reduced pressure 
to afford the title compound (768 mg, 35%) as a white solid. [
24
D
 = +8.0 (c = 10 mg/ml, CHCl3); 
mp: 130 – 133 °C; 1H NMR (400 MHz, CDCl3):  10.37 (1H, br., s, NH), 8.39 (2H, s, Ar-H), 7.97 
– 7.90 (6H, m, Ar-H), 7.88 (1H, s, Ar-H), 7.76 (2H, d, J = 7.1, Ar-H), 7.73 – 7.63 (3H, m, Ar-H), 
7.66 – 7.56 (6H, m, Ar-H), 7.36 (2H, t, J = 7.5, Ar-H), 7.28 (1H, d, J = 7.3, Ar-H), 6.29 (1H, dt, J 
= 15.9, 11.4, CHAHBPPh3), 5.93 – 5.74 (1H, m, CHNH), 3.19 (1H, dd, J = 15.7, 12.3, CHAHBPPh3); 
13C NMR (126 MHz, CDCl3): 163.98 (C=O), 141.85 (d, 
1JC-P = 13.86, 3xAr), 135.23 (d, JC-P = 3.78, 
3xAr), 134.83 (Ar), 134.25 (d, JC-P = 10.08, 6xAr), 131.44 (q, 2JC-F = 34.02, 2xAr), 130.47 (d, JC-P 
= 12.6, 6xAr), 129.44 (Ar), 129.15 (2xAr), 129.01 (q, 3JC-F = 3.78, 2xAr), 128.55 (Ar), 127.37 
(2xAr), 124.96 (q, 3JC-F = 3.78, Ar), 123.21 (q, 1JC-F = 273.42, 2xCF3), 48.97 (d, 
2JC-P = 3.78, CHNH), 
28.30 (d, 1JC-P = 47.88, CHAHBPPh3); IR (vmax/cm-1) (neat): 2926, 2864 (alkyl C-H), 1661 (C=O); 
HRMS (ESI): m/z calcd for [C35H27F6NOP]+ 622.172897, found 622.173067. 
4.3.1.2 Synthesis of Cinchona-based PTCs 
(1S,2S,4S,5R)-2-((R)-Hydroxy(quinolin-4-yl)methyl)-1-(4-(trifluoromethyl)benzyl)-5-
vinylquinuclidin-1-ium bromide (303a) 
 
Following general procedure 1 (method A): (-)-cinchonidine (1.00 g, 3.40 mmol), 4-





(3.00 mL) and chloroform (1.00 mL). The title compound (1.00 g, 55%) was afforded as a white 
solid after crystallisation. [
22
D
 = –135 (c = 10 mg/ml, CHCl3); mp: 210 – 212 °C; 1H NMR (400 
MHz, CDCl3):  8.79 (1 H, d, J = 4.5, Ar-H), 8.18 – 8.08 (1H, m, Ar-H), 7.87 (2H, d, J = 7.8, Ar-
H), 7.78 (1H, d, J = 4.5, Ar-H), 7.58 – 7.50 (1H, m, Ar-H), 7.41 (2H, d, J = 7.7, Ar-H), 7.07 – 6.98 
(2H, m, Ar-H), 6.53 (1H, d, J = 5.9, CH), 6.48 (1H, br. s, OH ), 6.31 (1H, d, J = 11.9, CHAHBPh), 
5.58 (1H, d, J = 11.9, CHAHBPh), 5.43 – 5.26 (2H, m, CHAHB=CH), 4.91 (1H, dd, J = 9.6, 1.8, 
CHAHB=CH), 4.65 (1H, q, J = 10.4, CH), 4.20 (1H, t, J = 10.0, CH), 3.95 (1H, d, J = 12.9, CH), 
3.07 – 2.86 (2H, m, 2xCH), 2.53 – 2.41 (1H, m, CH), 2.07 (1H, t, d, J = 12.0, CH), 1.92 (1H, s, 
CH), 1.88 – 1.79 (1H, m, CH), 1.59 (1H, q, J = 10.8, CH), 1.05 – 0.94 (1H, m, CH); 13C NMR (126 
MHz, CDCl3): 149.5 (CArH), 147.2 (CAr), 144.2 (CAr), 135.7 (CHAHB=CH), 134.7 (2xCArH), 132.4 
(q, 2JC-F = 32.5, CAr), 131.2 (CAr), 129.8 (CArH), 128.4 (CArH), 127.3 (CArH), 125.5 (q, 
3JC-F = 3.8, 
2xCArH), 123.5 (q, 
1JC-F = 270.8, CF3), 123.4 (CAr), 122.7 (CArH), 119.8 (CArH), 118.2 
(CHAHB=CH), 67.4 (CH), 65.4 (CH), 61.1 (CHAHBPh), 60.2 (CH2), 50.6 (CH2), 37.9 (CH), 26.4 
(CH), 25.20 (CH2), 22.7 (CH2), IR (vmax/cm-1) (neat): 3400 – 3200 (OH, br.) 2953 (alkyl C-H), 
1324 (C-F); MS (ESI): m/z calcd for [C27H28F3N2O]+, found 453.21. 
(1S,2S,4S,5R)-2-((R)-(Allyloxy)(quinolin-4-yl)methyl)-1-(4-(trifluoromethyl)benzyl)-5-
vinylquinuclidin-1-ium bromide (304a)  
 
To a suspension of 303a (687 mg, 1.28 mmol, 1.00 eq., 0.5 M) in DCM (2.70 mL) was added allyl 
bromide (0.33 mL, 3.86 mmol, 3.00 eq.) and 50% aqueous KOH (0.72 mL, 6.44 mmol, 5.00 eq.). 
The resulting mixture was stirred vigorously at room temperature for 4 hours. It was then diluted 
with water (1.70 mL) and extracted with DCM (3x7 mL). The combined organic layers were dried 
over MgSO4, filtered, and the solvent removed under reduced pressure. The crude solid was 




 = –151 (c = 10 mg/ml, CHCl3); mp: 138 – 140 °C; 1H NMR (400 MHz, CDCl3):  8.96 
(1H, d, J = 4.5, Ar-H), 8.87 (1H, d, J = 8.5, Ar-H), 8.18 – 8.08 (3H, m (overlapping), 2xAr-H+Ar-
H), 7.97 – 7.86 (1H, m, Ar-H), 7.77 (1H, t, J = 8.2, Ar-H), 7.73 (2H, d, J = 8.0, 2xAr-H), 6.85 (1H, 
d, J = 11.8, CHAHBPh), 6.16 – 6.02 (1H, m, CHAHB=CHCH2), 5.69 (1H, ddd, J = 17.0, 10.6, 6.3, 
CHAHB=CH), 5.45 – 5.35 (3H, m (overlapping), CHAHB=CHCH2+CHAHB=CH), 5.20 – 5.06 (1H, 
m, CH), 5.03 (1H, d, J = 10.6, CHAHB=CH), 4.81 – 4.70 (1H, m, CH), 4.67 (1H, d, J = 11.8, 





(1H, ddt, J = 12.5, 6.7, 1.2, CHAHB=CHCH2), 3.33 (1H, td, J = 11.1, 10.0, CH), 3.15 (1H, dd, J = 
12.9, 10.5, CH), 2.66 – 2.56 (1H, m, CH), 2.23 – 2.03 (3H, m (overlapping), 3xCH), 1.86 – 1.77 
(1H, m, CH), 1.49 – 1.36 (1H, m, CH); 13C NMR (126 MHz, CDCl3): 149.6 (CArH), 148.7 (CAr), 
139.7 (CAr), 135.9 (CHAHB=CH), 134.8 (2xCArH), 132.8 (q, 
2JC-F = 32.9, CAr), 132.6 
(CHAHB=CHCH2), 131.4 (CAr), 130.6 (CArH), 130.1 (CArH), 129.4 (CArH), 126.2 (q, 
3JC-F = 3.6, 
2xCArH), 124.9 (CArH), 123.7 (q, 
1JC-F = 270.8, CF3), 120.3 (CHAHB=CHCH2), 119.0 (CHAHB=CH), 
70.5 (CHAHB=CHCH2), 66.4 (CH), 61.2 (CHAHBPh), 59.9 (CH2), 51.7 (CH2), 38.0 (CH), 27.0 (CH), 
25.4 (CH2), 23.0 (CH2); IR (vmax/cm-1) (neat): 2948 (alkyl C-H), 1323 (C-F); MS (ESI): m/z calcd 
for [C30H32F3N2O]+, found 493.2. 
(1S,2S,4S,5R)-2-((R)-Hydroxy(quinolin-4-yl)methyl)-1-(naphthalen-2-ylmethyl)-5-
vinylquinuclidin-1-ium bromide (303b) 
 
Following general procedure 1 (method A): (-)-cinchonidine (1.00 g, 3.40 mmol), 2-bromo methyl 
naphthalene (746 mg, 3.37 mmol) and a mixture of ethanol (2.50 mL), DMF (3.00 mL) and 
chloroform (1.00 mL). The title compound (1.02 g, 58%) was afforded as a white solid after 
crystallisation. mp: 218 – 220 °C (decomposes); 1H NMR (400 MHz, (CD3)2SO):  9.00 (1H, d, J 
= 4.4, Ar-H), 8.38 – 8.30 (2H, m, Ar-H), 8.15 – 8.08 (2H, m, Ar-H), 8.05 (2H, dt, J = 7.2, 2.4, Ar-
H), 7.89 – 7.81 (3H, m, Ar-H), 7.75 (1H, ddd, J = 8.3, 6.8, 1.4, Ar-H), 7.69 – 7.61 (2H, m, Ar-H), 
6.79 (1H, br. d, J = 4.4, OH), 6.62 (1H, br. dd, J = 4.4, 2.0, CHOH), 5.69 (1H, ddd, J = 17.2, 10.5, 
6.5, CH2=CH), 5.35 (1H, d, J = 12.4, CHAHB), 5.22 (1H, d, J = 12.4, CHAHB), 5.17 (1H, dt, J = 
17.3, 1.3, CHAHB=CH), 4.96 (1H, dt, J = 10.5, 1.3, CHAHB=CH), 4.43 – 4.29 (1H, m, CH), 4.04 – 
3.97 (1H, m, CH), 3.89 – 3.80 (1H, m, CH), 3.46 – 3.37 (1H, m, CH), 3.36 – 3.31 (1H, m, CH), 
2.65 (1H, br. s, CH), 2.20 – 2.02 (2H, m, CH+CH), 2.00 – 1.98 (1H, br. m, CH), 1.86 – 1.71 (1H, 
m, CH), 1.37 – 1.25 (1H, m, CH); 13C NMR (101 MHz, (CD3)2SO): 150.16 (CArH), 147.63 (CAr), 
145.26 (CAr), 133.27 (CAr), 132.54 (CAr), 138.11 (CH2=CH), 133.92 (CArH), 130.16 (CArH), 129.86 
(CArH), 129.42 (CArH), 128.36 (CArH), 128.32 (CArH), 127.65 (CArH), 127.52 (CArH), 127.19 
(CArH), 126.81 (CArH), 125.44 (CAr), 124.31 (CAr), 123.69 (CArH), 120.07 (CArH), 116.36 
(CHAHB=CH), 67.56 (CH), 64.15 (CHOH), 62.84 (CHAHB), 59.32 (CH2), 50.67 (CH2), 36.92 (CH), 
25.88 (CH), 24.25 (CH2), 20.95 (CH2); (IR (vmax/cm-1) (neat): 3421 – 30857 (OH), 3006 (alkene 






vinylquinuclidin-1-ium bromide (303c) 
 
Following general procedure 1 (method B): (-)-cinchonidine (300 mg, 1.02 mmol) and 4-
(bromomethyl)pyrene (301 mg, 1.02 mmol) in toluene (12.0 mL). The reaction was stirred at 100 
°C for 8 hours. After cooling the reaction mixture to room temperature, it was filtered, and the 
residue dissolved in MeOH (9.00 mL). The cloudy solution was filtered over celite pad, partly 




 = –368 (c = 10 mg/ml, CHCl3); mp: 184 – 186 °C (decomposes); 1H NMR (500 
MHz, CD3OD):  9.00 (1H, d, J = 4.7, Ar-H), 8.63 (1H, d, J = 9.4, Ar-H), 8.48 – 8.44 (2H, m, Ar-
H), 8.42 – 8.36 (4H, m, Ar-H), 8.28 (1H, d, J = 9.0, Ar-H), 8.20 (1H, d, J = 8.9, Ar-H), 8.18 – 8.13 
(2H, m, Ar-H), 8.07 (1H, d, J = 4.5, Ar-H), 7.87 (2H, dddd, J = 19.1, 8.2, 6.8, 1.4, Ar-H), 6.96 (1H, 
br. d, J = 2.5, CHOH), 6.19 (1H, d, J = 13.1, CHAHB), 5.72 (1H, ddd, J = 17.3, 10.5, 6.8, CH2=CH), 
5.64 (1H, d, J = 13.1, CHAHB), 5.15 (1H, dt, J = 17.2, 1.2, CHAHB=CH), 5.01 (1H, dt, J = 10.5, 
1.2, CHAHB=CH), 4.76 (1H, tdt, J = 10.8, 5.5, 3.0, CH), 4.34 – 4.26 (1H, m, CH), 3.95 (1H, ddd, J 
= 12.7, 4.9, 3.1, CH), 3.57 (1H, dd, J = 12.7, 10.7, CH), 3.27 – 3.17 (1H, m, CH), 2.61 (1H, d, J = 
8.9, CH), 2.34 (1H, ddt, J = 12.6, 8.6, 1.9, CH), 2.21 (1H, ddt, J = 12.5, 11.0, 4.4, CH), 2.07 – 2.00 
(1H, m, CH), 1.76 – 1.64 (1H, m, CH), 1.45 (1H, ddt, J = 13.5, 10.1, 3.8, CH); 13C NMR (126 
MHz, CD3OD): 151.09 (CArH), 138.76 (CH2=CH), 133.83 (CArH), 132.59 (CArH), 131.22 (CArH), 
130.43 (CArH), 130.39 (CArH), 129.17 (CArH), 128.28 (CArH), 127.89 (CArH), 127.77 (CArH), 127.37 
(CArH), 125.98 (CArH), 124.14 (CArH), 123.68 (CArH), 121.40 (CArH), 117.53 (CHAHB=CH), 69.66 
(CH), 66.79 (CHOH), 62.60 (CH2), 61.75 (CHAHB), 53.05 (CH2), 39.34 (CH), 27.69 (CH), 26.06 
(CH2), 22.78 (CH2); (IR (vmax/cm-1) (neat): 3608 – 3208 (OH), 2992 (alkyl C-H), 2925 (alkyl C-












vinylquinuclidin-1-ium tribromide (308) 
 
Following a similar procedure to general procedure 1 (method A): (-)-cinchonidine (500 mg, 1.70 
mmol, 1.00 eq.), 1,3,5-tris(bromomethyl) benzene (202 mg, 0.57 mmol, 0.33 eq.) and a mixture of 
ethanol (1.30 mL), DMF (1.50 mL) and chloroform (0.50 mL). The reaction was stirred at 100 °C 
for 6 hours, after which it was cooled to room temperature, diluted with methanol (5.00 mL) and 
diethyl ether (15.0 mL) and stirred for 1 hour. The solids were filtered and washed with diethyl 
ether. The crude solid was recrystallised from methanol to diethyl ether to afford the title compound 
(591 mg, 84%) as a brown solid. [
24
D
 = –236 (c = 10 mg/ml, CHCl3); mp: 226 – 227 °C 
(decomposed);1H NMR (400 MHz, (CD3)2SO):  9.02 (3H, d, J = 4.5, 3xAr-H), 8.38 (3H, d, J = 
8.5, 3xAr-H), 8.28 (3H, br. s, 3xAr-H), 8.15 (3H, d, J = 8.5, 3xAr-H), 7.93 – 7.76 (9H, m (overlap), 
Ar-H), 6.77 (3H, br. d, J = 3.6, 3xOH), 6.65 (3H, br. s, 3xCHOH), 5.73 (3H, ddd, J = 17.1, 10.6, 
6.5, 3xCH2=CH), 5.25 (6H, br. s, 3xCH2(benzyl)), 5.14 (3H, d, J = 17.2, 3xCHAHB=CH), 4.95 (3H, d, 
J = 10.5, 3xCHAHB=CH), 4.29 – 4.13 (6H, m, 6xCH), 4.04 – 3.89 (3H, m, 3xCH), 3.85 – 3.71 (3H, 
m, 3xCH), 3.68 – 3.55 (3H, m, 3xCH), 2.97 – 2.89 (3H, m, 3xCH), 2.19 – 2.09 (3H, m, 3xCH), 
2.04 (3H, br. s, 3xCH), 1.97 – 1.87 (6H, br. s, 3xCH2), 1.42 – 1.28 (3H, m, 3xCH); 13C NMR (126 
MHz, (CD3)2SO): 150.23 (3xCArH), 147.68 (3xCAr), 145.05 (3xCAr), 140.05 (3xCArH), 138.36 
(3xCH2=CH), 130.03 (3xCArH), 129.51 (3xCArH), 129.42 (3xCAr), 127.24 (3xCArH), 124.35 
(3xCAr), 123.52 (3xCArH), 120.12 (3xCArH), 116.11 (3xCHAHB=CH), 67.84 (3xCH), 64.54 
(3xCHOH), 62.41 (3xCH2(benzyl)), 59.33 (3xCH2), 50.45 (3xCH2), 36.72 (3xCH), 25.66 (3xCH), 
24.07 (3xCH2), 21.24 (3xCH2); (IR (vmax/cm-1) (neat): 3678 – 3006 (OH), 3072 (alkene CH), 







vinylquinuclidin-1-ium bromide (314) 
 
Following general procedure 1 (method B): quinidine (1.00 g, 3.08 mmol) in toluene (6.00 mL); 
and 3,4,5-trifluoro benzyl bromide (0.45 mL, 3.39 mmol). The reaction mixture was refluxed at 120 
°C for 16 h. It was then cooled to room temperature and filtered. The residue was washed with 




+192 (c = 10 mg/ml, MeOH); mp: 208 – 210 °C (decomposed); 1H NMR (400 MHz, (CD3)2SO): 
 8.81 (1H, d, J = 4.5, Ar-H), 8.02 (1H, d, J = 9.2, Ar-H), 7.93 – 7.84 (2H, m, Ar-H), 7.76 (1H, d, 
J = 4.5, Ar-H), 7.50 (1H, d, J = 9.4, Ar-H), 7.43 (1H, br. s, Ar-H), 6.77 (1H, br. d, J = 3.6, OH), 
6.47 (1H, br. s, CHOH), 6.03 (1H, ddd, J = 17.4, 10.4, 6.9, CH2=CH), 5.30 – 5.20 (2H, m, 
CHAHB=CH), 5.07 (1H, d, J = 12.7, CHAHB), 4.81 (1H, d, J = 12.6, CHAHB), 4.29 – 4.20 (1H, m, 
CH), 4.07 (3H, s, OCH3), 4.05 – 3.96 (1H, m, CH), 3.83 – 3.73 (1H, m, CH), 3.60 – 3.49 (1H, m, 
CH), 3.12 – 2.96 (1H, m, CH), 2.68 – 2.57 (1H, m, CH), 2.44 – 2.32 (1H, m, CH), 1.91 (1H, br. s, 
CH), 1.86 – 1.71 (2H, m, CH2), 1.19 – 1.07 (1H, m, CH); 13C NMR (126 MHz, (CD3)2SO): 157.55 
(CAr), 150.11 (2xCAr, ddd, 1JC-F = 248.6, 2JC-F = 9.9, 3JC-F = 3.8), 147.36 (CArH), 143.71 (CAr), 143.26 
(CAr), 140.06 (CAr, dt, 1JC-F = 253.1, 2JC-F = 15.3), 137.18 (CH2=CH), 131.40 (CArH), 125.47 (CAr), 
125.05 – 124.67 (CAr, m), 121.24 (CArH), 120.36 (CArH), 118.82 (2xCArH, dd, 2JC-F = 16.8, 3JC-F = 
5.0), 117.01 (CHAHB=CH), 102.33 (CArH), 67.72 (CH), 64.60 (CHOH), 61.44 (CHAHB), 55.92 
(CH2), 55.83 (OCH3), 53.96 (CH2), 36.89 (CH), 26.30 (CH), 23.05 (CH2), 20.59 (CH2); 19F NMR 
(377 MHz, CDCl3) δF –134.46 (2F, d, J = 21.8), –159.42 (1F, t, J = 21.8); (IR (vmax/cm-1) (neat): 
3684 – 3126 (OH), 3013 (alkene CH), 2957, 2907 (alkyl C-H); MS (ESI): m/z calcd for 










5-vinylquinuclidin-1-ium bromide (316) 
 
Following general procedure 1 (method B): quinidine (1.00 g, 3.08 mmol) in toluene (6.00 mL); 
and 2,3,4,5,6-pentafluoro benzyl bromide (0.50 mL, 3.39 mmol). The reaction mixture was refluxed 
at 120 °C for 16 h. It was then cooled to room temperature and filtered. The residue was washed 




+192 (c = 10 mg/ml, MeOH); mp: 215 – 218 °C; 1H NMR (400 MHz, (CD3)2SO):  8.82 (1H, d, J 
= 4.4, Ar-H), 8.02 (1H, d, J = 9.1, Ar-H), 7.77 (1H, d, J = 4.6, Ar-H), 7.53 – 7.45 (2H, m, Ar-H), 
6.97 (1H, br. d, J = 3.3, OH), 6.51 (1H, br. s, CHOH), 6.10 – 5.99 (1H, m, CH2=CH), 5.29 – 5.19 
(2H, m, CHAHB=CH), 5.15 (1H, d, J = 13.9, CHAHB), 4.91 (1H, d, J = 13.9, CHAHB), 4.14 – 4.09 
(2H, m, 2xCH), 4.06 (3H, s, OCH3), 3.91 – 3.75 (1H, m, CH), 3.67 – 3.53 (1H, m, CH), 3.49 – 3.35 
(1H, m, CH), 2.68 – 2.55 (1H, m, CH), 2.41 – 2.27 (1H, m, CH), 1.93 (1H, br. s, CH), 1.90 – 1.74 
(2H, m, CH2), 1.12 – 0.98 (1H, m, CH); 13C NMR (126 MHz, (CD3)2SO): 157.38 (CAr), 147.44 
(CArH), 146.38 (2xCAr, br. d, 1JC-F = 250.7), 143.68 (CAr), 143.00 (CAr), 142.26 (CAr, br. d, 1JC-F = 
250.7), 137.59 (2xCAr, br., dt, 1JC-F = 248.2, 2JC-F = 17.0), 137.00 (CH2=CH), 131.32 (CArH), 125.31 
(CAr), 121.37 (CArH), 120.24 (CArH), 103.17 (CAr, t, 2JC-F = 16.1), 117.19 (CHAHB=CH), 102.55 
(CArH), 67.47 (CH), 65.13 (CHOH), 55.64 (CH2), 55.53 (OCH3), 54.46 (CH2), 51.37 (CHAHB), 
37.28 (CH), 25.74 (CH), 23.39 (CH2), 20.67 (CH2); 19F NMR (377 MHz, CDCl3) δF –135.25 (2F, 
d, J = 22.0), –150.33 (1F, t, J = 22.2), –160.74 (2F, t, J = 19.4); (IR (vmax/cm-1) (neat): 3373 – 
3080 (OH), 3038 (alkene CH), 2946, 2904 (alkyl C-H); HRMS (ESI): m/z calcd for 











vinylquinuclidin-1-ium bromide (321) 
 
Following general procedure 1 (method B): quinidine (1.00 g, 3.08 mmol) in toluene (6.00 mL); 
and 3,5-difluoro benzyl bromide (0.44 mL, 3.42 mmol). The reaction mixture was refluxed at 120 
°C for 16 h. It was then cooled to room temperature and filtered. The residue was washed with 
toluene and isolated to afford the title compound (1.40 g, 85%) as an off-white solid.[
24
D
 = +188 
(c = 10 mg/ml, MeOH); mp: 200 – 202 °C; 1H NMR (400 MHz, (CD3)2SO):  8.81 (1H, d, J = 4.5, 
Ar-H), 8.01 (1H, d, J = 9.2, Ar-H), 7.77 (1H, d, J = 4.5, Ar-H), 7.63 (2H, br. d, J = 5.5, Ar-H), 
7.55 – 7.48 (2H, m, Ar-H), 7.44 (1H, d, J = 2.8, Ar-H), 6.80 (1H, br. d, J = 3.9, OH), 6.49 (1H, br. 
s, CHOH), 6.03 (1H, ddd, J = 17.3, 10.6, 6.9, CH2=CH), 5.29 – 5.22 (2H, m, CHAHB=CH), 5.13 
(1H, d, J = 12.5, CHAHB), 4.83 (1H, d, J = 12.5, CHAHB), 4.28 (1H, ddd, J = 11.7, 8.1, 2.7, CH), 
4.08 (3H, s, OCH3), 4.08 – 4.04 (1H, m, CH), 3.85 – 3.77 (1H, m, CH), 3.55 (1H, ddd, J = 12.3, 
10.5, 1.6, CH), 3.03 (1H, dt, J = 11.5, 9.1, CH), 2.71 – 2.62 (1H, m, CH), 2.43 – 2.35 (1H, m, CH), 
1.90 (1H, br. s, CH), 1.81 – 1.74 (2H, m, CH2), 1.13 (1H, ddd, J = 13.6, 8.7, 5.1, CH); 13C NMR 
(126 MHz, (CD3)2SO): 162.26 (2xCAr, dd, 1JC-F = 247.0, 3JC-F = 13.3), 157.54 (CAr), 147.32 (CArH), 
143.66 (CAr), 143.33 (CAr), 137.20 (CH2=CH), 131.64 (CAr, t, 3JC-F = 9.9), 131.34 (CArH), 125.47 
(CAr), 121.35 (CArH), 120.36 (CArH), 117.13 (2xCArH, d, 2JC-F = 26.2), 116.98 (CHAHB=CH), 105.89 
(CArH, t, 2JC-F = 25.6), 102.28 (CArH), 67.77 (CH), 64.57 (CHOH), 61.71 (CHAHB), 56.07 (CH2), 
55.81 (OCH3), 54.12 (CH2), 36.78 (CH), 26.25 (CH), 23.07 (CH2), 20.62 (CH2); 19F NMR (377 
MHz, CDCl3) δF –108.93 (2F, s); (IR (vmax/cm-1) (neat): 3454 – 3083 (OH), 3028 (alkene CH), 











trifluorobenzyl)quinuclidin-1-ium bromide (322) 
 
Following general procedure 1 (method B): dihydroquinidine (500 mg, 1.53 mmol) in toluene 
(3.00 mL); and 3,4,5-trifluoro benzyl bromide (0.22 mL, 1.68 mmol). The reaction mixture was 
refluxed at 120 °C for 16 h. It was then cooled to room temperature and filtered. The residue was 




 = +188 (c = 10 mg/ml, MeOH); mp: 224 – 227 °C (decomposed); 1H NMR (500 MHz, 
(CD3)2SO):  8.81 (1H, d, J = 4.5, Ar-H), 8.02 (1H, d, J = 9.2, Ar-H), 7.93 – 7.83 (2H, m, Ar-H), 
7.79 (1H, d, J = 4.6, Ar-H), 7.50 (1H, d, J = 8.8, Ar-H), 7.40 (1H, s, Ar-H), 6.73 (1H, br. s, OH), 
6.45 (1H, br. s, CHOH), 5.03 (1H, d, J = 12.6, CHAHB), 4.76 (1H, d, J = 12.6, CHAHB), 4.07 (3H, 
s, OCH3), 4.02 – 3.92 (2H, m, 2xCH), 3.79 – 3.67 (1H, m, CH), 3.56 – 3.45 (1H, m, CH), 3.07 – 
2.93 (1H, m, CH), 2.41 – 2.31 (1H, m, CH), 1.87 (1H, br. s, CH), 1.82 – 1.71 (2H, m, 2xCH), 1.71 
– 1.61 (1H, m, CH), 1.61 – 1.45 (2H, m, CH2), 1.16 – 1.05 (1H, m, CH), 0.88 (3H, t, J = 7.4, CH3); 
13C NMR (126 MHz, (CD3)2SO): 157.55 (CAr), 150.10 (2xCAr, ddd, 1JC-F = 248.2, 2JC-F = 9.8, 3JC-F = 
3.2), 147.35 (CArH), 143.67 (CAr), 143.35 (CAr), 140.04 (CAr, dt, 1JC-F = 252.5, 2JC-F = 15.3), 131.40 
(CArH), 125.43 (CAr), 125.08 – 124.76 (CAr), 121.25 (CArH), 120.39 (CArH), 118.77 (2xCArH, dd, 
2JC-F = 16.7, 3JC-F = 4.5), 102.26 (CArH), 67.83 (CH), 64.47 (CHOH), 61.41 (CHAHB), 56.00 
(2xCH2), 55.82 (OCH3), 34.87 (CH), 24.07 (CH), 23.90 (CH2), 23.59 (CH2), 20.33 (CH2), 11.35 
(CH3); 19F NMR (377 MHz, CDCl3) δF –134.43 (2F, d, J = 21.8), –159.43 (1F, t, J = 21.8); (IR 
(vmax/cm-1) (neat): 3257 – 3123 (OH), 2957, 2900 (alkyl C-H); HRMS (ESI): m/z calcd for 











yl)methyl)quinuclidin-1-ium bromide (323) 
 
Following general procedure 1 (method B): dihydroquinidine (500 mg, 1.53 mmol) in toluene (3 
mL); and 3,5-difluoro benzyl bromide (0.22 mL, 1.68 mmol). The reaction mixture was refluxed at 
120 °C for 16 h. It was then cooled to room temperature and filtered. The residue was washed with 
toluene and isolated to afford the title compound (500 mg, 61%) as an off white solid. [
24
D
 = +116 
(c = 10 mg/ml, CHCl3); mp: 208 – 210 °C (decompose); 1H NMR (400 MHz, (CD3)2SO):  8.81 
(1H, d, J = 4.5, Ar-H), 8.01 (1H, d, J = 9.2, Ar-H), 7.80 (1H, d, J = 4.5, Ar-H), 7.62 (2H, br. d, J 
= 6.1, Ar-H), 7.58 – 7.44 (2H, m, Ar-H), 7.42 (1H, d, J = 2.1, Ar-H), 6.76 (1H, br. d, J = 3.9, OH), 
6.48 (1H, br. s, CHOH), 5.12 (1H, d, J = 12.5, CHAHB), 4.80 (1H, d, J = 12.5, CHAHB), 4.08 (3H, 
s, OCH3), 4.10 – 3.95 (2H, m, 2xCH), 3.84 – 3.72 (1H, m, CH), 3.57 – 3.45 (1H, m, CH), 3.05 – 
2.91 (1H, m, CH), 2.43 – 2.31 (1H, m, CH), 1.87 (1H, br. s, CH), 1.84 – 1.64 (3H, m, CH2+CH), 
1.54 (2H, dq, J = 17.6, 6.8, CH2), 1.10 (1H, ddd, J = 13.7, 9.1, 5.0 CH), 0.88 (3H, t, J = 7.3, CH3); 
13C NMR (126 MHz, (CD3)2SO): 162.24 (2xCAr, dd, 1JC-F = 247.1, 3JC-F = 13.3), 157.54 (CAr), 
147.32 (CArH), 143.65 (CAr), 143.40 (CAr), 131.75 (CAr, t, 3JC-F = 9.9), 131.34 (CArH), 125.44 (CAr), 
121.37 (CArH), 120.40 (CArH), 117.10 (2xCArH, d, 2JC-F = 26.1), 105.86 (CArH, t, 2JC-F = 25.7), 
102.19 (CArH), 67.86 (CH), 64.41 (CHOH), 61.64 (CHAHB), 56.15 (CH2), 56.12 (CH2), 55.81 
(OCH3), 34.79 (CH), 24.00 (CH), 23.86 (CH2), 23.61 (CH2), 20.37 (CH2), 11.33 (CH3); 19F NMR 
(377 MHz, CDCl3) δF –108.91 (2F, s); (IR (vmax/cm-1) (neat): 3333 – 3028 (OH), 2954, 2881 
(alkyl C-H); MS (ESI): m/z calcd for [C27H31F2N2O2]+, found 453.2415. 
4.3.1.3 Synthesis of Hydantoin Ureas 
Methyl 2-(3-(tert-butyl)ureido)-2-phenylacetate (278a) 
 
Following general procedure 2: [R]-[-]-2-phenylglycine methyl ester hydrochloride (4.33 g, 21.5 





mL, 23.6 mmol). The title compound (5.23 g, 92%) was yielded as a white solid and used without 
further purification. Rf (1:1 Pet.Ether:EtOAc) 0.61; mp: 124 – 125 °C; 1H NMR (400 MHz, 
CDCl3):  7.38 – 7.28 (5H, m, Ar-H), 5.46 (1H, d, J =7.2, CHPh), 5.16 (1H, s, NHCH), 4.34 (1H, 
s, (CH3)3CNH), 3.71 (3H, s, OCH3), 1.31 (9H, s, (CH3)3CNH); 13C NMR (101 MHz, CDCl3): 
 (C=O)ester, 156.10 (C=O)urea, 137.63 (CAr), 129.04 (2xCArH), 128.44 (CArH), 127.36 
(2xCArH), 57.12 (CHPh), 52.82 (OCH3), 50.83 ( (CH3)3C), 29.56 ((CH3)3C); IR (vmax/cm-1) 
(neat): 3345 (NH), 2962, 2925 (alkyl C-H), 1746 (ester C=O), 1633 (urea C=O); HRMS (ESI): 
m/z calcd for C14H20N2O3Na [M+Na]+ 287.1366, found 287.1359. Data in agreement with reported 
values.178 
3-(tert-Butyl)-5-phenylimidazolidine-2, 4-dione (279a) 
 
Following general procedure 3: KOtBu (1.77 g, 15.8 mmol) and urea 278a (3.79 g, 14.3 mmol) in 
anhydrous THF (60.0 mL). The crude product was purified by flash column chromatography (SiO2; 
Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 70:30) to afford the title compound (2.48 g, 75%) as a 
white solid. Rf (7:3 Pet.Ether:EtOAc) 0.37; mp: 125 – 126 °C; 1H NMR (400 MHz, CDCl3):  7.47 
– 7.31 (5H, m, Ar-H), 5.46 (1H, s, NH), 4.87 (1H, d, J =1.4, CHPh), 1.61 (9H, s, NC(CH3)3); 13C 
NMR (101 MHz, CDCl3): 173.06 (C=O)amide, 158.83 (C=O)urea, 135.29 (CAr), 129.14 (2xCArH), 
128.96 (CArH), 126.50 (2xCArH), 60.06 (CHPh), 58.12 (C(CH3)3), 28.67 (C(CH3)3); IR (vmax/cm-
1) (neat): 3234 (NH), 2973, 2935 (alkyl C-H), 1765, 1698 (C=O); HRMS (ESI): m/z calcd for 
C13H16N2O2Na [M+Na]+ 255.1104, found 255.1099. Data in agreement with reported values.178 
3-(tert-Butyl)-2-oxo-5-phenylimidazolidine-1-carbonyl chloride (280a) 
 
Following general procedure 4: triphosgene (1.24 g, 4.18 mmol) in anhydrous DCM (21.0 mL), 
anhydrous pyridine (1.00 mL, 12.2 mmol) and hydantoin 279a (1.94 g, 8.35 mmol) in anhydrous 
DCM (4.20 mL). The title compound (2.20 g, 89%) was yielded as a pale yellow oil and used 










Following general procedure 5: carbamoyl chloride 280a (800 mg, 2.71 mmol) in anhydrous DCM 
(13.6 mL), Et3N (0.44 mL, 3.13 mmol) and 4-(methyl amino) benzonitrile (357 mg, 2.70 mmol). 
The crude product was purified by flash column chromatography (SiO2; Pet.Ether:Diethyl Ether 
100:0 to Pet.Ether:Diethyl ether 60:40) to afford the title compound (1.01 g, 95%) as a white solid. 
Rf (6:4 Pet.Ether:Diethyl Ether) 0.15; mp: 73 – 74 °C; 1H NMR (400 MHz, CDCl3):  7.58 (2H, 
d, J =8.6, Ar-H), 7.45 (3H, dd, J =4.9, 1.9, Ar-H), 7.27 – 7.22 (2H, m, Ar-H), 7.06 (2H, d, J = 8.6, 
Ar-H), 5.51 (1H, s, CHPh), 3.35 (3H, s, NCH3), 1.50 (9H, s, NC(CH3)3); 13C NMR (101 MHz, 
CDCl3): 170.71 (C=O)amide, 152.43 (C=O)urea hydantoin, 151.87 (C=O)urea, 147.46 (CAr), 133.93 (CAr), 
132.77 (2xCArH), 129.75 (CArH), 129.34 (2xCArH), 128.44 (2xCArH), 126.51 (2xCArH), 118.37 
(CN), 110.15 (CAr), 62.29 (CHPh), 59.27 (NC(CH3)3), 38.85 (NCH3), 28.46 (NC(CH3)3); IR 
(vmax/cm-1) (neat): 2978, 2938 (alkyl C-H), 2228 (CN), 1785, 1718, 1683 (C=O); HRMS (ESI): 





Following general procedure 5: carbamoyl chloride 280a (300 mg, 1.02 mmol) in anhydrous DCM 
(4.10 mL), Et3N (0.17 mL, 1.22 mmol) and 3-(methyl amino) benzonitrile (148 mg, 1.12 mmol). 
The crude product was purified by flash column chromatography (SiO2; Pet.Ether:EtOAc 100:0 to 
Pet.Ether:EtOAc 80:20) to afford the title compound (315 mg, 79%) as a white solid. Rf (8:2 
Pet.Ether:EtOAc) 0.19; mp: 113 – 115 °C; 1H NMR (400 MHz, CDCl3):  7.54 – 7.38 (5H, m, Ar-





CHPh), 3.33 (3H, s, NCH3), 1.49 (9H, s, NC(CH3)3); 13C NMR (101 MHz, CDCl3): 170.8 
(C=O)amide, 152.4 (C=O)urea hydantoin,, 152.0 (C=O)urea, 144.2 (CAr), 133.9 (CAr), 131.2 (CAr), 130.4 
(CArH), 129.89 (CArH), 129.87 (CArH), 129.6 (2xCArH), 129.8 (CArH), 128.5 (2xCArH), 117.9 (CN), 
112.8 (CAr), 62.3 (CHPh), 59.2 (NC(CH3)3), 39.1 (NCH3), 28.4 (NC(CH3)3); IR (vmax/cm-1) 
(neat): 2977, 2937 (alkyl C-H), 1783, 1718, 1688 (C=O); HRMS (ESI): m/z calcd for 




Following similar procedure to general procedure 5: carbamoyl chloride 280a (138 mg, 0.47 
mmol) in anhydrous DCM (2.00 mL), Et3N (0.08 mL, 0.56 mmol) and 2-(methyl amino) 
benzonitrile (61.8 mg, 0.47 mmol). The reaction was stirred for 16 h. The crude product was 
purified by flash column chromatography (SiO2; DCM:MeOH 100:0 to DCM:MeOH 99.5:0.5) to 
afford the title compound (107 mg, 58%) as a pale yellow oil. Rf (9.95:0.05 DCM:MeOH) 0.49; 
1H NMR (400 MHz, CDCl3):  7.69 (1H, dd, J = 7.7, 1.6, Ar-H), 7.50 – 7.38 (4H, m, Ar-H), 7.38 
– 7.33 (1H, m, Ar-H), 7.26 – 7.22 (2H, m, Ar-H), 6.82 (1H, br. s, Ar-H), 5.51 (1H, s, CHPh), 3.40 
(3H, s, NCH3), 1.49 (9H, s, NC(CH3)3); 13C NMR (101 MHz, CDCl3):  170.77 (C=O)amide, 152.16 
(C=O)urea hydantoin,, 146.17 (C=O)urea, 134.10 (CAr), 133.66 (CArH), 133.03 (CArH), 129.58 (CArH), 
129.26 (2xCArH), 128.19 (2xCArH), 128.01 (CArH), 127.75 (CArH), 126.55 (CAr), 116.47 (CN), 
112.81 (CAr), 62.45 (CHPh), 59.20 (NC(CH3)3), 39.22 (NCH3), 28.46 (NC(CH3)3); IR (vmax/cm-
1) (neat): 2977, 2938 (alkyl C-H), 2232 (C≡N), 1785, 1721, 1691 (C=O); HRMS (ESI): m/z calcd 




Following similar procedure to general procedure 5: Carbamoyl chloride 280a (300 mg, 1.02 





(110 mg, 1.02 mmol). The reaction mixture was quenched with water and washed with brine. The 
crude product was purified by flash column chromatography (SiO2; Pet.Ether:EtOAc 100:0 to 
Pet.Ether:EtOAc 50:50) to afford the title compound (260 mg, 70%) as a white solid. Rf (5:5 
Pet.Ether:EtOAc) 0.14; mp: 147 – 149 °C; 1H NMR (400 MHz, CDCl3):  8.51 (2H, d, J =6.4 Ar-
H), 7.45 (3H, dd, J =5.2, 2.1, Ar-H), 7.31 – 7.25 (2H, m, Ar-H), 6.95 (2H, d, J =6.4, Ar-H), 5.52 
(1H, s, CHPh), 3.36 (3H, s, NCH3), 1.51 (9H, s, NC(CH3)3); 13C NMR (101 MHz, CDCl3): 170.71 
(C=O)amide, 152.47 (C=O)urea hydantoin, 151.77 (C=O)urea, 150.78 (CAr), 150.65 (2xCArH), 133.89 (CAr), 
129.73 (CArH), 129.38 (2xCArH), 128.40 (2xCArH), 119.12 (2xCArH), 62.32 (CHPh), 59.34 
(NC(CH3)3), 38.06 (NCH3), 28.50 (NC(CH3)3); IR (vmax/cm-1) (neat): 2974, 2936 (alkyl C-H), 





Following general procedure 5: carbamoyl chloride 280a (300 mg, 1.02 mmol) in anhydrous DCM 
(4.10 mL), Et3N (0.17 mL, 1.22 mmol) and 4-nitro-N-methylaniline (139 mg, 0.92 mmol, 0.90 eq.). 
The crude product was purified by flash column chromatography (SiO2; Pet.Ether:Diethyl ether 
100:0 to Pet.Ether:Diethyl ether 60:40) to afford the title compound (326 mg, 78%) as a pale yellow 
crystalline solid. Rf (6:4 Pet.Ether:Diethyl ether) 0.17; mp: 59 – 61; 1H NMR (400 MHz, CDCl3): 
 8.14 (2H, d, J =9.1, Ar-H), 7.46 (3H, dd, J =5.2, 1.9, Ar-H), 7.31 – 7.22 (2H, m, Ar-H), 7.11 (2H, 
d, J =9.0, Ar-H), 5.53 (1H, s, CHPh), 3.38 (3H, s, NCH3), 1.49 (9H, s, NC(CH3)3); 13C NMR (101 
MHz, CDCl3): 170.6 (C=O)amide, 152.3 (C=O)urea hydantoin, 151.8 (C=O)urea, 149.2 (CAr), 145.4 (CAr), 
133.8 (CAr), 129.7 (CArH), 129.3 (2xCArH), 128.3 (2xCArH), 126.0 (2xCArH), 124.2 (2xCArH), 62.2 
(CHPh), 59.2 (NC(CH3)3), 38.8 (NCH3), 28.4 (NC(CH3)3); IR (vmax/cm-1) (neat): 2977, 2938 
(alkyl C-H), 1786, 1720, 1688 (C=O); HRMS (ESI): m/z calcd for C21H22N4O5Na [M+Na]+ 











Following a similar procedure to general procedure 5: carbamoyl chloride 280a (200 mg, 0.68 
mmol) in anhydrous CH3CN (13.0 mL), Et3N (0.12 mL, 0.78 mmol) and N-methyl-2-nitroaniline 
(103 mg, 0.679 mmol). The reaction was refluxed for 16 hours at 100 °C. The crude product was 
purified by flash column chromatography (SiO2; DCM:MeOH 100:0 to DCM:MeOH 99.5:0.5) to 
afford the title compound (116 mg, 42%) as a pale yellow oil. Rf (9.95:0.05 DCM:MeOH) 0.43; 
1H NMR (500 MHz, CDCl3):  8.05 (1H, dd, J =8.1, 1.5, Ar-H), 7.55 (1H, t, J =7.8, Ar-H), 7.49 – 
7.38 (5H, m, Ar-H), 7.24 – 7.18 (2H, m, Ar-H), 5.46 (1H, s, CHPh), 3.39 (3H, s, NCH3), 1.54 (9H, 
s, NC(CH3)3); 13C NMR (126 MHz, CDCl3): 170.8 (C=O)amide,, 153.3 (C=O)urea hydantoin,, 152.3 
(C=O)urea, 137.04 (CAr), 134.16 (CAr), 133.81 (CAr), 129.4 (CArH), 129.2 (2xCArH), 128.9 (CArH), 
127.9 (2xCArH), 125.7 (CArH), 62.6 (CHPh), 59.2 (NC(CH3)3), 40.1 (NCH3), 28.6 (NC(CH3)3); IR 
(vmax/cm-1) (neat): 2988, 2939 (alkyl C-H), 1785, 1718, 1686 (C=O); HRMS (ESI): m/z calcd for 




Following similar procedure to general procedure 5: carbamoyl chloride 280a (100 mg, 0.34 
mmol) in anhydrous CH3CN (1.70 mL), Et3N (0.05 mL, 0.39 mmol) and N-methyl-3-nitroaniline 
(52.0 mg, 0.34 mmol). The reaction was left to stir until TLC analysis showed that the starting 
material was completely consumed. The crude product was purified by flash column 
chromatography (SiO2; Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 70:30) to afford the title 
compound (132 mg, 95%) as a pale yellow solid. Rf (7:3 Pet.Ether:EtOAc) 0.36; mp: 66 – 69 °C; 
1H NMR (400 MHz, CDCl3):  8.10 (1H, ddt, J =8.2, 2.1, 1.0, Ar-H), 7.86 (1H, d, J =2.2, Ar-H), 
7.47 (5H, m, Ar-H), 7.28 (2H, m, Ar-H), 5.53 (1H, s, CHPh), 3.39 (3H, s, NCH3), 1.47 (9H, s, 





(C=O)urea, 148.3 (CAr), 144.6 (CAr), 133.8 (CAr), 132.5 (CArH), 129.8 (CArH), 129.7 (CArH), 129.5 
(2xCArH), 128.4 (2xCArH), 121.6 (CArH), 121.0 (CArH), 62.5 (CHPh), 59.2 (NC(CH3)3), 39.2 
(NCH3), 28.4 (NC(CH3)3); IR (vmax/cm-1) (neat): 2980, 2939 (alkyl C-H), 1784, 1717, 1684 
(C=O); HRMS (ESI): m/z calcd for C21H22N4O5Na [M+Na]+ 433.1482, found 433.1477. 
3-(tert-Butyl)-N-methyl-2,4-dioxo-5-phenyl-N-(4-(trifluoromethyl)phenyl)imidazolidine-1-
carboxamide (273h)  
  
Following general procedure 5: carbamoyl chloride 280a (500 mg, 1.70 mmol) in anhydrous DCM 
(13.0 mL), Et3N (0.27 mL, 1.96 mmol) and 4-(trifluoromethyl)-N-methyl-aniline (0.22 mL, 1.53 
mmol). The crude product was purified by flash column chromatography (SiO2; Pet.Ether:EtOAc 
100:0 to Pet.Ether:EtOAc 80:20) to afford the title compound (487 mg, 66%) as a pale yellow oil. 
Rf (8:2 Pet.Ether:EtOAc) 0.31; 1H NMR (400 MHz, CDCl3):  7.55 (2H, d, J =7.9, Ar-H), 7.45 
(3H, dd, J = 5.0, 1.9, Ar-H), 7.27 – 7.23 (2H, m, Ar-H), 7.08 (2H, d, J =7.8, Ar-H), 5.47 (1H, s, 
CHPh), 3.35 (3H, s, NCH3), 1.49 (9H, s, NC(CH3)3); 13C NMR (126 MHz, CDCl3): 170.78 
(C=O)amide, 152.53 (C=O)urea hydantoin, 151.99 (C=O)urea, 146.46 (CAr), 133.98 (CAr), 129.26 (2xCArH), 
128.43 (2xCArH), 126.44 (2xCArH), 128.82 (q, 
2JC-F = 32.7, CAr), 125.90 (q, 3JC-F = 3.7, 2xAr), 
123.90 (q, 1JC-F = 273.4, CF3), 62.39 (CHPh), 59.10 (NC(CH3)3), 39.02 (NCH3), 28.40 (NC(CH3)3); 
IR (vmax/cm-1) (neat): 2976, 2936 (alkyl C-H), 1785, 1719, 1686 (C=O); HRMS (ESI): m/z calcd 




Following general procedure 5: carbamoyl chloride 280a (200 mg, 0.68 mmol) in anhydrous DCM 
(2.70 mL), Et3N (0.11 mL, 0.81 mmol) and 2-(trifluoromethyl),4-(methyl amino) benzonitrile (136 
mg, 0.68 mmol). The crude product was purified by flash column chromatography (SiO2; 





mg, 79%) as a white solid. Rf (6:4 Pet.Ether:Diethyl ether) 0.13; mp:156 – 158 °C; 1H NMR (400 
MHz, CDCl3):  7.79 (1H, d, J =8.3, Ar-H), 7.51 – 7.41 (3H, m, Ar-H), 7.43 – 7.35 (2H, m, Ar-H), 
7.30 – 7.22 (2H, m, Ar-H), 5.56 (1H, s, CHPh), 3.41 (3H, s, NCH3), 1.49 (9H, s, NC(CH3)3); 13C 
NMR (126 MHz, CDCl3): 170.49 (C=O)amide, 152.38 (C=O)urea hydantoin, 151.58 (C=O)urea, 147.92 
(CAr), 133.75 (CAr), 135.51 (CArH), 133.60 (q, 
2JC-F = 33.1, CAr), 129.89 (CArH), 129.57 (2xCArH), 
128.68 (CArH), 128.44 (2xCArH), 123.29 (q, 3JC-F = 4.6, CAr), 122.09 (q, 
1JC-F = 274.3, CF3), 115.15 
(CN), 107.05 (q, 3JC-F = 2.1, CArH), 62.35 (CHPh), 59.51 (NC(CH3)3), 38.71 (NCH3), 28.41 
(NC(CH3)3); IR (vmax/cm-1) (neat): 2986, 2941 (alkyl C-H), 2234 (CN), 1788, 1717, 1688 (C=O); 
HRMS (ESI): m/z calcd for C23H21F3N4O3Na [M+Na]+ 481.1458, found 481.1467. 
Methyl (tert-Butyl carbamoyl)-L-alaninate (278b) 
 
Following general procedure 2: L-alanine methyl ester hydrochloride (3.00 g, 21.5 mmol) in 
anhydrous DCM (40.0 mL), Et3N (6.00 mL, 43 mmol) and tert-butyl isocyanate (2.7 mL, 23.6 
mmol). The title compound (>99%) was yielded as a white solid and used without further 
purification. Rf (1:1 Pet.Ether:EtOAc) 0.44; mp: 77 – 78 °C; 1H NMR (400 MHz, CDCl3):  4.97 
(1H, d, J =7.8, NHCH), 4.61 (1H, s, (CH3)3CNH), 4.44 (1H, p, J =7.3, NHCHCH3), 3.72 (3H, s, 
OCH3), 1.34 (3H, d, J =7.2, CHCH3), 1.30 (9H, s, (CH3)3CNH); 13C NMR (101 MHz, CDCl3): 
 175.3 (C=O)ester, 156.8 (C=O)urea, 52.4 (OCH3), 50.5 ((CH3)3CNH), 48.6 (NHCHCH3), 29.6 
((CH3)3CNH), 19.2 (CHCH3); IR (vmax/cm-1) (neat): 3341 (N-H), 2961, 2924 (alkyl C-H), 1746 
(ester C=O), 1633 (urea C=O); HRMS (ESI): m/z calcd for C9H18N2O3Na [M+Na]+ 225.1210, 
found 225.1209. Data in agreement with reported values.178 
3-(tert-Butyl)-5-methyl imidazolidine-2, 4-dione (279b) 
 
Following general procedure 3: KOtBu (2.78 g, 24.8 mmol) and urea 278b (4.54 g, 22.4 mmol) in 
anhydrous THF (60 mL). The title compound (3.23 g, 85%) was yielded as a white solid and used 
without further purification. Rf (1:1 Pet.Ether:EtOAc) 0.40; 1H NMR (400 MHz, CDCl3):  6.16 
(1H, s, NH), 3.89 (1H, qd, J =6.9, 1.3, NHCHCH3), 1.58 (9H, s, NC(CH3)3), 1.37 (3H, d, J =6.8, 
CHCH3); 13C NMR (101 MHz, CDCl3):  175.9 (C=O)amide, 158.7 (C=O)urea, 57.7 (NC(CH3)3), 52.1 





C-H), 1770, 1697 (C=O); HRMS (ESI): m/z calcd for C8H14N2O2Na [M+Na]+ 193.0947, found 
193.0951. Data in agreement with reported values.178 
3-(tert-Butyl)-5-methyl-2, 4-dioxoimidazolidine-1-carbonyl chloride (280b) 
 
Following general procedure 4: triphosgene (3.46 g, 11.7 mmol) in DCM (49.0 mL), anhydrous 
pyridine (2.68 mL, 33.1 mmol) and hydantoin 279b (3.86 g, 22.7 mmol) in anhydrous DCM (10 
mL). The title compound (2.83 g, 54%) was yielded as a yellow solid and used without further 
purification. 1H NMR (400 MHz, CDCl3):  4.39 (1H, q, J = 6.8, CHCH3),  (, s, NC(CH3)3), 
1.63 (3H, d, J = 6.8, CHCH3). Data in agreement with reported values.180 
3-(tert-Butyl)-N-(4-chlorophenyl)-N, 5-dimethyl-2, 4-dioxoimidazolidine-1-carboxamide 
(273j) 
 
Following general procedure 5: carbamoyl chloride 280b (750 mg, 3.23 mmol) in anhydrous DCM 
(13.0 mL), Et3N (0.52 mL, 3.73 mmol) and 4-chloro-N-methyl aniline (0.39 mL, 3.22 mmol). The 
crude product was purified by flash column chromatography (SiO2; Pet.Ether:EtOAc 100:0 to 
Pet.Ether:EtOAc 70:30) to afford the title compound (661 mg, 61%) as a yellow oil. Rf (7:3 Pet. 
ether: EtOAc) 0.23; 1H NMR (400 MHz, CDCl3):  7.34 – 7.29 (2H, m, Ar-H), 7.18 – 7.12 (2H, 
m, Ar-H), 4.48 (1H, q, J =6.8, CHCH3), 3.38 (3H, s, NCH3), 1.47 (3H, d, J =6.9, CHCH3), 1.43 
(9H, s, NC(CH3)3); 13C NMR (101 MHz, CDCl3):  172.9 (C=O)amide, 152.34 (C=O)urea hydantoin, 
152.30 (C=O)urea, 142.2 (CAr), 132.49 (CAr), 129.15 (2xCArH), 127.38 (2xCArH), 58.66 (NC(CH3)3), 
54.72 (CHCH3), 39.32 (NCH3), 28.43 (NC(CH3)3), 15.74 (CHCH3); IR (vmax/cm-1) (neat): 
1681.90 (C=O), 1715.58 (C=O), 1783.78 (C=O), 2979.84 (C-H); HRMS (ESI): m/z calcd for 











Following general procedure 5: carbamoyl chloride 280b (500 mg, 2.15 mmol) in anhydrous DCM 
(9.00 mL), Et3N (0.36 mL, 2.58 mmol) and 4-(methyl amino) benzonitrile (284 mg, 2.15 mmol). 
The crude product was purified by flash column chromatography (SiO2; Pet.Ether:Diethyl ether 
100:0 to Pet.Ether:Diethyl ether 60:40) to afford the title compound (540 mg, 76%) as a yellow 
crystal like solid. Rf (6:4 Pet.Ether:Diethyl ether) 0.13; mp: 126 – 128 °C; 1H NMR (400 MHz, 
CDCl3):  7.63 (2H, d, J = 8.2, Ar-H), 7.31 (2H, d, J = 8.2, Ar-H), 4.53 (1H, q, J = 6.8 , CHCH3), 
3.42 (3H, s, NCH3), 1.50 (3H, d, J = 6.8, CHCH3), 1.40 (9H, s, NC(CH3)3); 13C NMR (101 MHz, 
CDCl3): 172.42 (C=O)amide, 152.01 (C=O)urea hydantoin, 151.82 (C=O)urea, 147.87 (CAr), 132.85 
(2xCArH), 125.72 (2xCArH), 118.26 (CN), 109.63 (CAr), 54.58 (CHCH3), 58.68 (NC(CH3)3), 38.65 
(NCH3), 28.26 (NC(CH3)3), 15.54 (CHCH3); IR (vmax/cm-1) (neat): 2982, 2901 (alkyl C-H), 2231 
(C≡N), 1786, 1720, 1683 (C=O); HRMS (ESI): m/z calcd for C17H20N4O3Na [M+Na]+ 351.1428, 
found 351.1420. 
Methyl 2-(3-(tert-butyl)ureido)-2-(4-chlorophenyl)acetate (278c) 
 
Following general procedure 2: methyl 2-amino-2-(4-chlorophenyl)acetate hydrochloride 277c 
(1.00 g, 4.24 mmol) in anhydrous DCM (7.70 mL), Et3N (1.20 mL, 8.47 mmol) and tert-butyl 
isocyanate (0.53 mL, 4.66 mmol). The title compound (1.32 g, >99%) was yielded as a white solid 
and used without further purification. mp: 163 – 165 ° C; 1H NMR (400 MHz, CDCl3): 
  − 7.28 (4H, br. m, Ar-H), 5.44 (1H, d, J =6.9, CHPh), 5.27 (1H, d, J =6.9, NHCH), 4.40 
(1H, s, (CH3)3CNH), 3.71 (3H, s, OCH3), 1.30 (9H, s, (CH3)3CNH); 13C NMR (101 MHz, CDCl3): 
 (C=O)ester, 155.95 (C=O)urea, 136.40 (CAr), 134.28 (CAr), 129.16 (2xCArH), 128.69 (2xCArH), 
56.43 (CHPh), 52.98 (OCH3), 50.86 ( (CH3)3C), 29.53 ((CH3)3C); IR (vmax/cm-1) (neat): 3349 
(NH), 2968, 2929 (alkyl C-H), 1746 (ester C=O), 1635 (urea C=O); HRMS (ESI): m/z calcd for 







Following similar procedure to general procedure 3: KOtBu (539 mg, 4.80 mmol) and urea 278c 
(1.30 g, 4.37 mmol) in anhydrous THF (14.0 mL) at 0 °C. The reaction was quenched with water. 
The crude product was purified by flash column chromatography (SiO2; Pet.Ether:Diethyl ether 
100:0 to Pet.Ether:Diethyl ether 50:50) to afford the title compound (753 mg, 65%) as a white solid. 
Rf (5:5 Pet.Ether:Diethyl ether) 0.30; mp: 135 – 137 °C; 1H NMR (400 MHz, CDCl3):  7.38 (2H, 
d, J =8.6, Ar-H), 7.30 (2H, d, J =8.6, Ar-H), 5.74 (1H, br. s, NH), 4.86 (1H, d, J =1.6, CHPh), 1.59 
(9H, s, NC(CH3)3); 13C NMR (101 MHz, CDCl3): 172.50 (C=O)amide, 158.32 (C=O)urea, 135.13 
(CAr), 133.67 (CAr), 129.44 (2xCArH), 127.85 (2xCArH), 59.40 (CHPh), 58.39 (NC(CH3)3), 28.66 
(NC(CH3)3); IR (vmax/cm-1) (neat): 3306 (NH), 2974, 2905 (alkyl C-H), 1773, 1704 (C=O); 
HRMS (ESI): m/z calcd for C13H15ClN2O2Na [M+Na]+ 289.0714, found 289.0707. 
3-(tert-Butyl)-5-(4-chlorophenyl)-2,4-dioxoimidazolidine-1-carbonyl chloride (280c) 
 
Following general procedure 4: triphosgene (111 mg, 0.37 mmol) in anhydrous DCM (1.60 mL), 
anhydrous pyridine (0.09 mL, 1.12 mmol) and hydantoin 279c (200 mg, 0.75 mmol). The title 
compound (282 mg, >99%) was yielded as an orange oil and used without further purification. 1H 
NMR (400 MHz, CDCl3):  7.42 (2H, J = 8.5, Ar-H), 7.25 (2H, d, J =8.5, Ar-H), 5.29 (1H, s, 











Following general procedure 5: carbamoyl chloride 280c (253 mg, 0.77 mmol) in anhydrous DCM 
(3.10 mL), Et3N (0.13 mL, 0.92 mmol) and 4-(methyl amino) benzonitrile (102 mg, 0.77 mmol). 
The crude product was purified by flash column chromatography (SiO2; Pet.Ether:Diethyl ether 
100:0 to Pet.Ether:Diethyl ether 60:40) to afford the title compound (196 mg, 60%) as a colourless 
oil. Rf (6:4 Pet.Ether:Diethyl ether) 0.14; 1H NMR (400 MHz, CDCl3):  7.61 (2H, d, J =8.6, Ar-
H), 7.44 (2H, d, J =8.5, Ar-H), 7.19 (2H, J =8.5, Ar-H), 7.11 (2H, d, J = 8.6, Ar-H), 5.49 (1H, s, 
CHPh), 3.36 (3H, s, NCH3), 1.49 (9H, s, NC(CH3)3); 13C NMR (101 MHz, CDCl3): 170.32 
(C=O)amide, 152.40 (C=O)urea hydantoin, 151.82 (C=O)urea, 147.40 (CAr), 135.89 (CAr), 132.89 (2xCArH), 
132.39 (CAr), 129.82 (2xCArH), 129.65 (2xCArH), 126.52 (2xCArH), 118.32 (CN), 110.36 (CAr), 
61.67 (CHPh), 59.47 (NC(CH3)3), 39.00 (NCH3), 28.46 (NC(CH 3)3); IR (vmax/cm-1) (neat): 2981, 
2941 (alkyl C-H), 2229 (CN), 1786, 1721, 1689 (C=O); HRMS (ESI): m/z calcd for 
C22H21ClN4O3Na [M+Na]+ 447.119439, found 447.120202. 
Methyl (tert-butyl carbamoyl)glycinate (278e) 
 
Following general procedure 2: glycine methyl ester hydrochloride (3.00 g, 23.9 mmol) in 
anhydrous DCM (44.0 mL), Et3N (6.70 mL, 47.8 mmol) and tert-butyl isocyanate (3.00 mL, 26.3 
mmol). The title compound (3.92 g, 87%) was yielded as an orange oil and used without further 
purification. 1H NMR (400 MHz, CDCl3):  5.20 (1H, t, J =5.6, NHCH2), 4.88 (1H, s, (CH3)3CNH), 
3.94 (2H, d, J =5.5, NHCH2), 3.71 (3H, s, OCH3), 1.30 (9H, s, (CH3)3CNH); 13C NMR (101 MHz, 
CDCl3):  172.25 (C=O)ester, 157.39 (C=O)urea, 52.23 (OCH3), 50.48 ((CH3)3CNH), 41.90 (NHCH2), 
29.55 ((CH3)3CNH); IR (vmax/cm-1) (neat): 3345 (N-H), 2964, 2931 (alkyl C-H), 1747 (ester 









Following general procedure 3: KOtBu (2.51 g, 22.4 mmol) and urea 278e (3.83 g, 20.3 mmol) in 
anhydrous THF (54.0 mL). The title compound (1.80 g, 57%) was yielded as a white solid and used 
without further purification. mp: 89 – 91 °C; 1HNMR (400 MHz, CDCl3):  6.14 (1H, s, NH), 3.82 
(2H, s, CH2), 1.60 (9H, s, NC(CH3)3); 13C NMR (101 MHz, CDCl3):  72.43 (C=O)amide, 159.70 
(C=O)urea, 57.96 (NC(CH3)3), 46.18 (CH2), 28.70 (NC(CH3)3); IR (vmax/cm-1) (neat): 3290 (NH), 
2972, 2934 (alkyl C-H), 1768, 1696 (C=O); MS (ESI): m/z calcd for C7H13N2O2 [M+H]+, found 
157.0984. 
3-(tert-Butyl)-2,4-dioxoimidazolidine-1-carbonyl chloride (280e) 
 
Following general procedure 4: triphosgene (1.69 g, 5.70 mmol) in anhydrous DCM (25.0 mL), 
anhydrous pyridine (1.40 mL, 17.1 mmol) and hydantoin 279e (1.78 g, 11.4 mmol). The title 
compound (2.32 g, 93%) was yielded as a yellow solid and used without further purification. mp: 
126 – 128 °C (decomposed); 1H NMR (400 MHz, CDCl3):  4.29 (2H, s, CH2), 1.62 (9H, s, 
NC(CH3)3); 13C NMR (101 MHz, CDCl3):   (C=O), 150.94 (C=O), 143.11 (C=O), 60.51 
(NC(CH3)3), 50.23 (CH2), 28.45 (NC(CH3)3). 
3-(tert-Butyl)-N-methyl-2,4-dioxo-N-phenylimidazolidine-1-carboxamide (273m) 
 
Following general procedure 5: carbamoyl chloride 280e (200 mg, 0.91 mmol) in anhydrous DCM 
(4.00 mL), Et3N (0.15 mL, 1.10 mmol) and N-methyl aniline (0.10 mL, 0.91 mmol). The crude 
product was purified by flash column chromatography (SiO2; Pet.Ether:EtOAc 100:0 to 
Pet.Ether:EtOAc 80:20) to afford the title compound (212 mg, 80%) as a white solid. Rf (8:2 
Pet.Ether:EtOAc) 0.16; mp: 123 – 125 °C; 1H NMR (400 MHz, CDCl3):  7.36 (2H, t, J = 7.8, Ar-
H), 7.25 – 7.15 (3H, m, Ar-H), 4.08 (2H, s, CH2), 3.41 (3H, s, NCH3), 1.41 (9H, s, NC(CH3)3); 13C 
NMR (101 MHz, CDCl3): 169.42 (C=O)amide, 152.88 (C=O)urea hydantoin, 152.51 (CAr), 143.75 





39.33 (NCH3), 28.37 (NC(CH3)3); IR (vmax/cm-1) (neat): 2975, 2941 (alkyl C-H), 1788, 1721, 
1662 (C=O); HRMS (ESI): m/z calcd for C15H19N3O3Na [M+Na]+ 312.1319, found 312.1314. 
Methyl 2-(3-(tert-butyl)ureido)-2-(4-methoxyphenyl)acetate (278d) 
 
Following general procedure 2: methyl 2-amino-2-(4-methoxyphenyl)acetate hydrochloride 277d 
(700 mg, 3.02 mmol) in anhydrous DCM (5.50 mL), Et3N (0.84 mL, 6.04 mmol) and tert-butyl 
isocyanate (0.38 mL, 3.32 mmol). The title compound (857 mg, 96%) was yielded as an off-white 
solid and used without further purification. mp: 134 – 136 °C; 1H NMR (400 MHz, CDCl3):  7.27 
(2H, d, J =8.7, Ar-H), 6.86 (2H, d, J =8.7, Ar-H), 5.38 (1H, d, J =7.1, CHPh), 5.20 (1H, d, J =7.1, 
NHCH), 4.41 (1H, s, (CH3)3CNH), 3.79 (3H, s, p-OCH3), 3.70 (3H, s, OCH3), 1.30 (9H, s, 
(CH3)3CNH); 13C NMR (101 MHz, CDCl3):  (C=O)ester, 159.67 (C=O)urea, 156.23 (CAr), 
129.68 (CAr), 128.58 (2xCArH), 114.41 (2xCArH), 56.52 (CHPh), 55.43 (p-OCH3), 52.75 (OCH3), 
50.73 ( (CH3)3C), 29.54 ((CH3)3C); IR (vmax/cm-1) (neat): 3355 (NH), 2963, 2911 (alkyl C-H), 
1744 (ester C=O), 1635 (urea C=O); HRMS (ESI): m/z calcd for C15H22N2O4Na [M+Na]+ 
317.147178, found 317.146472. 
3-(tert-Butyl)-5-(4-methoxyphenyl)imidazolidine-2,4-dione (279d) 
 
Following a similar procedure to general procedure 3: NaH (6.79 mg, 0.17 mmol, 1.00 eq.) was 
added to a solution of urea 278d (50.0 mg, 0.17 mmol, 1.00 eq.) in anhydrous THF (0.60 mL) at 0 
°C and the mixture was stirred for 1 hour at 0 °C. The reaction was quenched with water and the 
solvent removed under reduced pressure. The residue was dissolved in EtOAc and washed with 
brine. Afterwards, it was dried over MgSO4, filtered and the solvent removed under reduced 
pressure. The crude product was purified by flash column chromatography (SiO2; DCM:MeOH 
100:0 to DCM:MeOH 99:1) to afford the title compound (37.5 mg, 84%) as a white solid. Rf 
(9.9:0.1 DCM:MeOH) 0.24; mp: 103 – 105 °C; 1H NMR (400 MHz, CDCl3):  7.25 (2H, d, J =8.8, 





OCH3), 1.61 (9H, s, NC(CH3)3); 13C NMR (101 MHz, CDCl3): 173.41 (C=O)amide, 160.16 (C=O)urea, 
158.57 (CAr), 127.72 (2xCArH), 127.28 (CAr), 114.57 (2xCArH), 59.58 (CHPh), 58.03 (NC(CH3)3), 
55.44 (OCH3), 28.66 (NC(CH3)3); IR (vmax/cm-1) (neat): 3216 (NH), 2963, 2927 (alkyl C-H), 
1771, 1704 (C=O); HRMS (ESI): m/z calcd for C14H19N2O3 [M+H]+ 263.1390, found 263.1390. 
Methyl 2-(3-benzylureido)-2-phenylacetate (338) 
 
Following general procedure 2: [R]-[-]-2-phenylglycine methyl ester hydrochloride (1.50 g, 7.44 
mmol) in anhydrous DCM (14.0 mL), Et3N (2.10 mL, 14.9 mmol) and benzyl isocyanate (1.00 mL, 
8.18 mmol). The title compound (1.87 g, 84%) was yielded as a white solid and used without further 
purification. Rf (7:3 Pet.Ether:EtOAc) 0.14; mp: 132 – 135 °C; 1H NMR (400 MHz, CDCl3):  7.28 
– 7.15 (10H, m, Ar-H), 5.73 (1H, d, J =7.4, NHCH), 5.45 (1H, d, J =7.3, CHPh), 5.13 (1H, t, J 
=5.6, (CH2NH), 4.26 (2H, d, J =5.6, CH2NH), 3.59 (3H, s, OCH3); 13C NMR (101 MHz, CDCl3): 
  (C=O)ester, 157.19 (C=O)urea, 139.10 (CAr), 137.41 (CAr), 129.02 (2xCArH), 128.72 
(2xCArH), 128.46 (CArH), 127.64 (2xCArH), 127.42 (CArH), 127.31 (2xCArH), 57.39 (CHPh), 52.79 
(OCH3), 44.62 (CH2NH); IR (vmax/cm-1) (neat): 3163 (NH), 2954, 2923 (alkyl C-H), 1741 (ester 
C=O), 1630 (urea C=O); HRMS (ESI): m/z calcd for C17H18N2O3Na [M+Na]+ 321.1210, found 
321.1206. 
Methyl 2-(3-ethylureido)-2-phenylacetate (344) 
 
Following general procedure 2: [R]-[-]-2-phenylglycine methyl ester hydrochloride (3.08 g, 15.3 
mmol) in anhydrous DCM (28.0 mL), Et3N (4.30 mL, 30.5 mmol) and ethyl isocyanate (1.3 mL, 
16.8 mmol). The title compound (2.85 g, 79%) was yielded as a white solid and used without further 
purification. mp: 106 – 108 °C; 1H NMR (400 MHz, CDCl3):  7.39 – 7.27 (5H, m, Ar-H), 5.66 
(1H, d, J =7.4, NHCH), 5.50 (1H, d, J =7.3, CHPh), 4.79 (1H, t, J =5.7, CH2NH), 3.17 (2H, qd, J 
=7.2, 5.4, CH3CH2NH), 3.70 (3H, s, OCH3), 1.08 (3H, t, J =7.2, CH3CH2); 13C NMR (101 MHz, 
CDCl3):   (C=O)ester, 157.20 (C=O)urea, 137.51 (CAr), 129.02 (2xCArH), 128.45 (CArH), 





1) (neat): 3360 (N-H), 2977 (alkyl C-H), 1738 (ester C=O), 1646 (urea C=O); HRMS (ESI): m/z 
calcd for C12H16N2O3Na [M+Na]+ 259.1053, found 259.1048. 
3-Ethyl-5-phenylimidazolidine-2,4-dione (346) 
 
Following general procedure 3: KOtBu (1.44 g, 12.9 mmol) and urea 344 (2.76 g, 11.7 mmol) in 
anhydrous THF (31.0 mL). The crude product was purified by flash column chromatography (SiO2; 
DCM:MeOH 100:0 to DCM:MeOH 98:2) to afford the title compound (859 mg, 36%) as a white 
solid. Rf (9.8:0.2 DCM:MeOH) 0.27; mp: 90 – 92 °C; 1H NMR (400 MHz, CDCl3):  7.44 – 7.32 
(5H, m, Ar-H), 6.43 (1H, s, NH), 5.02 (1H, s, CHPh), 3.57 (2H, q, J =7.1, CH2CH3), 1.21 (3H, t, J 
=7.2 CH2CH3); 13C NMR (101 MHz, CDCl3): 172.03 (C=O)amide, 157.80 (C=O)urea, 134.47 (CAr), 
129.26 (2xCArH), 129.18 (CArH), 126.57 (2xCArH), 60.82 (CHPh), 34.01 (CH2), 13.51 (CH3); IR 
(vmax/cm-1) (neat): 3291 (NH), 2980, 2939 (alkyl C-H), 1772, 1701 (C=O); HRMS (ESI): m/z 
calcd for C11H13N2O2 [M+H]+ 205.0972, found 205.0967. 
3-Ethyl-2,4-dioxo-5-phenylimidazolidine-1-carbonyl chloride (348) 
 
Following general procedure 4: triphosgene (624 mg, 2.10 mmol) in anhydrous DCM (9.00 mL), 
anhydrous pyridine (0.50 mL, 6.31 mmol) and hydantoin 346 (859 mg, 4.21 mmol). The title 
compound (1.46 g, >99%) was yielded as a cream solid and used without further purification. mp: 
101 – 103 °C; 1H NMR (400 MHz, CDCl3):  7.47 – 7.40 (3H, m, Ar-H), 7.31 (2H, dd, J =7.4, 2.2, 
Ar-H), 5.48 (1H, s, CHPh), 3.68 (2H, q, J =7.1, CH2CH3), 1.27 (3H, t, J =7.2, CH2CH3); 13C NMR 
(101 MHz, CDCl3):   (C=O), 150.97 (C=O), 143.58 (C=O), 132.23 (CAr), 129.89 (CArH), 








N-(4-Cyanophenyl)-3-ethyl-N-methyl-2,4-dioxo-5-phenylimidazolidine-1-carboxamide (350)  
 
Following general procedure 5: carbamoyl chloride 348 (200 mg, 0.75 mmol) in anhydrous DCM 
(3.00 mL), Et3N (0.13 mL, 0.90 mmol) and 4-(methyl amino) benzonitrile (99.0 mg, 0.75 mmol). 
The crude product was purified by flash column chromatography (SiO2; Pet.Ether:EtOAc 100:0 to 
Pet.Ether:EtOAc 70:30) to afford the title compound (271 mg, >99%) as a pale yellow solid. Rf 
(7:3 Pet.Ether:EtOAc) 0.21; mp: 86 – 88 °C; 1H NMR (400 MHz, CDCl3):  7.57 (2H, d, J =8.6, 
Ar-H), 7.49 – 7.44 (3H, dd, m, Ar-H), 7.31 – 7.21 (3H, m, Ar-H), 7.02 (2H, d, J = 8.6, Ar-H), 5.69 
(1H, s, CHPh), 3.53 (2H, q, J =7.0, CH2CH3), 3.35 (3H, s, NCH3), 1.15 (3H, t, J =7.2, CH2CH3); 
13C NMR (101 MHz, CDCl3): 169.93 (C=O)amide, 151.83 (C=O)urea hydantoin, 151.58 (C=O)urea, 147.51 
(CAr), 133.08 (CAr), 132.94 (2xCArH), 129.99 (CArH), 129.42 (2xCArH), 128.70 (2xCArH), 126.50 
(2xCArH), 118.32 (CN), 110.32 (CAr), 63.21 (CHPh), 39.09 (NCH3), 34.66 (CH2), 13.32 (CH3); IR 
(vmax/cm-1) (neat): 2978, 2938 (alkyl C-H), 2228 (CN), 1785, 1718, 1683 (C=O); HRMS (ESI): 
m/z calcd for C20H18N4O3Na [M+Na]+ 385.1271, found 385.1268. 
Methyl (R)-2-phenyl-2-(3-(2,4,4-trimethylpentan-2-yl)ureido)acetate (345) 
 
Following general procedure 2: [R]-[-]-2-phenylglycine methyl ester hydrochloride (3.00 g, 14.9 
mmol) in anhydrous DCM (27.0 mL), Et3N (4.10 mL, 29.8 mmol) and 1,1,3,3-tetramethylbutyl 
isocyanate (3.00 mL, 16.4 mmol). The title compound (6.37 g, >99%) was yielded as a viscous 
colourless oil and used without further purification. 1H NMR (400 MHz, CDCl3):  7.36 – 7.27 
(5H, m, Ar-H), 5.46 (2H, s, NHCH + CHPh overlap), 4.57 (1H, s, (CH3)2CNH), 3.69 (3H, s, OCH3), 
1.69 (2H, d, J =7.8, CHAHB + CHAHB overlap), 1.33 (3H, s, (CH3)A(CH3)B), 1.33 (3H, s, 
(CH3)A(CH3)B), 0.95 (9H, s, (CH3)3C); 13C NMR (101 MHz, CDCl3):  (C=O)ester, 156.08 
(C=O)urea, 137.68 (CAr), 128.94 (2xCArH), 128.33 (CArH), 127.34 (2xCArH), 57.08 (CHPh), 54.50 
((CH3)A(CH3)BC), 52.75 (OCH3), 51.75 (CH2), 31.66 ((CH3)3C), 31.57 ((CH3)3C), 30.17 
((CH3)A(CH3)B), 30.13 ((CH3)A(CH3)B); IR (vmax/cm-1) (neat): 3355 (NH), 2952, 2908 (alkyl C-








Following a similar procedure to general procedure 3: KOtBu (2.20 g, 19.7 mmol) and urea 345 
(5.73 g, 17.9 mmol) in anhydrous THF (57.0 mL) at 0 °C. The reaction was quenched with water. 
The crude product was purified by flash column chromatography (SiO2; Pet.Ether:EtOAc 100:0 to 
Pet.Ether:EtOAc 80:20) to afford the title compound (3.50 g, 68%) as a yellow gum. Rf (8:2 
Pet.Ether:EtOAc) 0.39; 1H NMR (400 MHz, CDCl3):  7.42 – 7.33 (5H, m, Ar-H), 6.44 (1H, s, 
NH), 4.87 (1H, s, CHPh), 1.92 (2H, d, J =8.0, CHAHB + CHAHB overlap), 1.66 (3H, s, 
(CH3)A(CH3)B), 1.63 (3H, s, (CH3)A(CH3)B), 0.94 (9H, s, (CH3)3C); 13C NMR (101 MHz, CDCl3): 
173.32 (C=O)amide, 159.13 (C=O)urea, 134.96 (CAr), 129.05 (2xCArH), 128.90 (CArH), 126.54 
(2xCArH), 61.81 ((CH3)A(CH3)BC), 59.99 (CHPh), 50.34 (CH2), 31.71 ((CH3)3C), 31.19 ((CH3)3C), 
29.75 ((CH3)A(CH3)B), 29.68 ((CH3)A(CH3)B); IR (vmax/cm-1) (neat): 3298 (NH), 2955, 2904 
(alkyl C-H), 1771 (C=O), 1698 (C=O). 
2,4-Dioxo-5-phenyl-3-(2,4,4-trimethylpentan-2-yl)imidazolidine-1-carbonyl chloride (349) 
 
Following general procedure 4: triphosgene (1.38 g, 4.65 mmol) in anhydrous DCM (20.0 mL), 
anhydrous pyridine (1.10 mL, 13.9 mmol) and hydantoin 347 (2.68 g, 9.30 mmol). The title 
compound (3.02 g, 92%) was yielded as a yellow oil and used without further purification. 1H NMR 
(400 MHz, CDCl3):  7.46 – 7.39 (3H, m, Ar-H), 7.32 – 7.28 (2H, m, Ar-H), 5.31 (1H, s, CHPh), 
1.96 (2H, s, CH2), 1.72 (3H, s, (CH3)A(CH3)B), 1.67 (3H, s, (CH3)A(CH3)B), 0.96 (9H, s, (CH3)3C); 
13C NMR (101 MHz, CDCl3):   (C=O), 151.50 (C=O), 143.52 (C=O), 132.75 (CAr), 129.64 
(CArH), 129.50 (2xCArH), 126.20 (2xCArH), 64.48 ((CH3)A(CH3)BC), 64.13 (CHPh), 50.18 (CH2), 










Following general procedure 5: carbamoyl chloride 349 (300 mg, 0.86 mmol) in anhydrous DCM 
(3.40 mL), Et3N (0.14 mL, 1.03 mmol) and 4-(methyl amino) benzonitrile (113 mg, 0.86 mmol). 
The crude product was purified by flash column chromatography (SiO2; DCM:Acetone 100:0 to 
DCM:Acetone 99:1) to afford the title compound (280 mg, 73%) as a colourless oil. Rf (9.9:0.1 
DCM:Acetone) 0.33; 1H NMR (400 MHz, CDCl3):  7.58 (2H, d, J =8.6, Ar-H), 7.47 – 7.43 (3H, 
m, Ar-H), 7.27 – 7.23 (2H, m, Ar-H), 7.07 (2H, d, J = 8.6, Ar-H), 5.49 (1H, s, CHPh), 3.35 (3H, s, 
NCH3), 1.97 (1H, d, J =15.2, CHAHB), 1.66 (1H, d, J =15.2, CHAHB), 1.57 (3H, s, (CH3)A(CH3)B), 
1.56 (3H, s, (CH3)A(CH3)B), 0.85 (9H, s, (CH3)3C); 13C NMR (101 MHz, CDCl3): 171.28 
(C=O)amide, 152.95 (C=O)urea hydantoin, 151.99 (C=O)urea, 147.43 (CAr), 133.66 (CAr), 132.82 (2xCArH), 
129.74 (CArH), 129.29 (2xCArH), 128.85 (2xCArH), 127.06 (2xCArH), 118.28 (CN), 110.43 (CAr), 
63.08 ((CH3)A(CH3)BC), 62.56 (CHPh), 49.96 (CH2), 38.90 (NCH3), 31.56 ((CH3)3C), 31.12 
((CH3)3C), 29.92 ((CH3)A(CH3)B), 29.27 ((CH3)A(CH3)B); IR (vmax/cm-1) (neat): 2953, 2908 (alkyl 
C-H), 2229 (CN), 1785, 1718, 1690 (C=O). 




Following general procedure 6: hydantoin urea 273a (50.0 mg, 0.128 mmol) was stirred in CHCl3 
(1.00 mL) at −20 °C. PTC 322 (14.0 mg, 0.026 mmol, 0.20 eq.) and Cs2CO3 (211 mg, 0.65 mmol) 
were added and the reaction stirred for 40 h. The crude product was purified by flash column 
chromatography (SiO2; Pet.Ether:Diethyl ether 100:0 to Pet.Ether:Diethyl ether 60:40) to afford the 
title compound (33.4 mg, 67%) as a white solid. Rf (6:4 Pet.Ether:Diethyl ether) 0.25; mp: 95 – 98 





d, J =8.5, Ar-H), 7.42 – 7.35(5H, m, Ar-H), 2.79 (3H, d, J =4.7, NHCH3), 1.65 (9H, s, NC(CH3)3); 
13C NMR (101 MHz, CDCl3):  172.4 (C=O)amide, 156.4 (C=O)urea hydantoin, 151.0 (C=O)urea, 142.2 
(CAr), 136.0 (CAr), 131.9 (2xCArH), 129.5 (2xCArH), 129.1 (CArH), 128.5 (2xCArH), 128.4 (2xCArH), 
118.5 (CN), 112.5 (CAr), 72.4 (NCPh), 60.4 (NC(CH3)3), 28.7 (NC(CH3)3), 26.7 (NHCH3); HPLC: 
er = ~85:15, (R,R) whelk-01, Hexane:EtOAc = 90:10, flow = 1 mL/min, λ = 254 nm, tR = 31.3 min 
(major), 35.9 min (minor); IR (vmax/cm-1) (neat): 3362 (NH), 2922 (alkyl C-H), 2229 (C≡N), 
1778, 1727, 1701 (C=O); HRMS (ESI): m/z calcd for C22H22N4O3Na [M+Na]+ 413.1585, found 




Following general procedure 6: hydantoin urea 273c (46.0 mg, 0.12 mmol) was stirred in CHCl3 
(1.00 mL) at −20 °C. PTC 322 (13.0 mg, 0.02 mmol, 0.20 eq.) and Cs2CO3 (192 mg, 0.59 mmol) 
were added and the reaction stirred for 100 hours (monitored by TLC). The crude product was 
purified by flash column chromatography (SiO2; Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 80:20) 
to afford the title compound (18 mg, 39%) as a white solid. Rf (8:2 Pet.Ether:EtOAc) 0.26; mp: 
144 – 147 °C; 1H NMR (400 MHz, CDCl3):  8.25 (1H, br. q, J = 4.4, NH), 7.70 (1H, dd, J =7.5, 
1.6, Ar-H), 7.58 – 7.48 (2H, m, Ar-H), 7.48 (1H, dd, J =7.9, 1.5, Ar-H), 7.46 – 7.39 (4H, m, Ar-
H), 7.32 (1H, d, J =8.0, Ar-H), 2.83 (3H, d, J =4.7, NHCH3), 1.60 (9H, s, NC(CH3)3); 13C NMR 
(101 MHz, CDCl3):  171.77 (C=O)amide,, 156.42 (C=O)urea hydantoin,, 151.73 (C=O)urea, 141.78 (CAr), 
134.63 (CAr), 134.59 (CArH), 132.72 (CArH), 132.24 (CArH), 129.23 (CArH), 128.85 (CArH), 128.74 
(2xCArH), 127.87 (2xCArH), 117.71 (CN), 110.65 (CAr), 71.72 (NCPh), 60.31 (NC(CH3)3), 28.39 
(NC(CH3)3), 26.78 (NHCH3); HPLC: er = ~52:48, Chiralpak® IA, Hexane:IPA = 99:1, flow = 1 
mL/min, λ = 254 nm, tR = 15.1 min (major), 17.2 min (minor); IR (vmax/cm-1) (neat): 3358 (NH), 
2979, 2904 (alkyl C-H), 2253 (C≡N), 1779, 1725, 1698 (C=O); HRMS (ESI): m/z calcd for 











Following general procedure 6: hydantoin urea 273d (25.0 mg, 0.07 mmol) was stirred in CHCl3 
(0.50 mL) at −20 °C. PTC 322 (7.50 mg, 0.01 mmol, 0.20 eq.) and KOH (11.5 mg, 0.20 mmol) 
were added and the reaction mixture stirred for 25 h. The crude product was purified by flash 
column chromatography (SiO2; Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 30:70) to afford the title 
compound (1H NMR yield: 51%) as a yellow oil. Rf (3:7 Pet.Ether:EtOAc) 0.19; 1H NMR (400 
MHz, CDCl3):  8.63 (2H, d, J = 6.3, Ar-H), 8.18 – 8.09 (1H, br. m, NH), 7.40 – 7.36 (3H, m, Ar-
H), 7.36 – 7.27 (4H, m, Ar-H), 2.80 (3H, d, J =4.7, NHCH3), 1.65 (9H, s, NC(CH3)3); Chiral SFC: 
er = ~30:70, Chiralpak® IB, 10% co-solvent (IPA), flow = 4.0 mL/min, 125 bar, 40 °C, tR = 2.8 min 





Following general procedure 6: hydantoin urea 273e (87.0 mg, 0.21 mmol) was stirred in a 
PhMe/CHCl3 system (1.:0.7, 2.00 mL) at 0 °C. PTC 276 (12.8 mg, 0.021 mmol, 0.10 eq.) and 
Cs2CO3 (349 mg, 1.07 mmol) were added and the reaction stirred for 17 h. The crude product was 
purified by flash column chromatography (SiO2; Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 80:20) 
to afford the title compound (42 mg, 48%) as a colourless oil. Rf (8:2 Pet.Ether:EtOAc) 0.29; 1H 
NMR (400 MHz, CDCl3):  8.22 (2H, d, J =9.0, Ar-H), 7.55 (2H, d, J =8.9, Ar-H), 7.39 (3H, m, 
Ar-H), 7.35 (2H, m, Ar-H), 2.80 (3H, d, J =4.7, NHCH3), 1.66 (9H, s, NC(CH3)3); 13C NMR (101 
MHz, CDCl3): 172.3 (C=O)amide, 156.3 (C=O)urea hydantoin,, 150.9 (C=O)urea, 147.8 (CAr), 144.1 (CAr), 
136.0 (CAr), 129.8 (2xCArH), 129.2 (CArH), 128.6 (2xCArH), 128.4 (2xCArH), 123.3 (2xCArH), 72.3 
(NCPh), 60.4 (NC(CH3)3), ( 28.7 (NC(CH3)3), 26.7 (NHCH3); HPLC: er = ~55:45, (R,R) whelk-01 





(vmax/cm-1) (neat): 3361 (NH), 2941 (alkyl C-H), 1778, 1722, 1699 (C=O); HRMS (ESI): m/z 




Following general procedure 6: hydantoin urea 273h (100 mg, 0.23 mmol), was stirred in PhMe 
(2.00 mL) at room temperature. PTC 276 (14 mg, 0.023 mmol, 0.1 eq.) and CsOH (196 mg, 1.17 
mmol) were added and the reaction stirred for 24 h. The crude product was purified by flash column 
chromatography (SiO2; Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 90:10) to afford the title 
compound (34.2 mg, 39%) as a pale oil. Rf (9:1 Pet.Ether:EtOAc) 0.27; 1H NMR (400 MHz, 
CDCl3):  7.62 (2H, dt, J = 8.3, 0.7, Ar-H), 7.53 (2H, dt, J = 8.2, 0.7, Ar-H), 7.40 – 7.34 (3H, m, 
Ar-H), 7.30 – 7.27 (2H, m, Ar-H), 6.60 (1H, br. s, NH), 1.63 ( 9H, s, NC(CH3)3); 13C NMR (126 
MHz, CDCl3): 173.6 (C=O)amide, 157.4 (C=O)urea, 143.6 (CAr), 139.6 (CAr), 130.8 (q, 
2JC-F = 32.8, 
CAr), 129.2 (2xCArH), 128.9 (CArH), 127.6 (2xCArH), 126.9 (2xCArH), 125.8 (q, 3JC-F = 3.8, 2xCArH), 
124.0(q, 1JC-F = 272.6, CF3), 68.6 (NHCPh), 58.8 (NC(CH3)3), 28.7 (NC(CH3)3); 19F NMR (377 
MHz, CDCl3) δF −62.73 (3F, s); IR (vmax/cm-1) (neat): 3246 (NH), 2925 (alkyl C-H), 1771, 1707 




Following general procedure 6: hydantoin urea 273i (25.0 mg, 0.055 mmol) was stirred in CHCl3 
(0.50 mL) at −20 °C. PTC 322 (6.00 mg, 0.01 mmol, 0.20 eq.) and Cs2CO3 (88.8 mg, 0.27 mmol) 
were added and the reaction mixture stirred for 22 hours (monitored by TLC). The crude product 
was purified by flash column chromatography (SiO2; Pet.Ether:Diethyl ether 100:0 to 
Pet.Ether:Diethyl ether 60:40) to afford the title compound (15.0 mg, 59%) as a white solid. Rf (6:4 





= 4.1, NH), 7.84 (1H, d, J =8.1, Ar-H), 7.76 – 7.68 (2H, m, Ar-H), 7.46 – 7.36 (3H, Ar-H), 7.30 – 
7.27 (2H, m, Ar-H), 2.80 (3H, d, J =4.8, NHCH3), 1.66 (9H, s, NC(CH3)3; 13C NMR (126 MHz, 
CDCl3): 171.88 (C=O)amide, 156.14 (C=O)urea hydantoin, 150.87 (C=O)urea, 143.13 (CAr), 135.44 (CAr), 
134.43 (CArH), 132.93 (CArH), 132.70 (q, 
2JC-F = 32.9, CAr), 129.41 (CArH), 128.81 (2xCArH), 128.12 
(2xCArH), 126.98 (q, 3JC-F = 4.7, CAr), 122.30 (q, 
1JC-F = 274.1, CF3), 115.27 (CN), 110.24 (q, 3JC-F 
= 1.9, CArH), 72.09 (NCPh), 60.71 (NC(CH3)3), 28.64 (NC(CH3)3), 26.74 (NHCH3); IR (vmax/cm-
1) (neat): 3365 (NH), 2988, 2905 (alkyl C-H), 2235 (C≡N), 1781, 1728, 1707 (C=O); HRMS (ESI): 




Following general procedure 6: hydantoin urea 273l (50.0 mg, 0.118 mmol) was stirred in CHCl3 
(1.00 mL) at −20 °C. PTC 322 (12.9 mg, 0.024 mmol, 0.20 eq.) and Cs2CO3 (192 mg, 0.59 mmol) 
were added and the reaction mixture stirred for 48 hours (monitored by TLC). The crude product 
was purified by flash column chromatography (SiO2; Pet.Ether:Diethyl ether 100:0 to 
Pet.Ether:Diethyl ether 60:40) to afford the title compound (33.2 mg, 66%) as a colourless oil. Rf 
(6:4 Pet.Ether:Diethyl ether) 0.27; 1H NMR (400 MHz, CDCl3):  8.12 (1H, br. q, J = 4.7, NH),7.66 
(2H, d, J =8.8, Ar-H), 7.46 (2H, d, J =8.8, Ar-H), 7.36 (2H, d, J =8.8, Ar-H), 7.26 (2H, d, J =8.8, 
Ar-H), 2.80 (3H, d, J =4.7, NHCH3), 1.64 (9H, s, NC(CH3)3); 13C NMR (101 MHz, CDCl3):  
172.08 (C=O)amide, 156.19 (C=O)urea hydantoin, 150.91 (C=O)urea, 141.81 (CAr), 135.26 (CAr), 134.65 
(CAr), 132.09 (2xCArH), 129.98 (2xCArH), 129.35 (2xCArH), 128.76 (2xCArH), 118.42 (CN), 112.78 
(CAr), 71.98 (NCPh), 60.57 (NC(CH3)3), 28.66 (NC(CH3)3), 26.71 (NHCH3); HPLC: er = ~77:23, 













Following general procedure 6: hydantoin urea 350 (50.0 mg, 0.138 mmol) was stirred in CHCl3 
(1.00 mL) at −20 °C. PTC 322 (15.2 mg, 0.03 mmol, 0.20 eq.) and Cs2CO3 (225 mg, 0.69 mmol) 
were added and the reaction mixture stirred for 48 hours (monitored by TLC). The crude product 
was purified by flash column chromatography (SiO2; Pet.Ether:Diethyl ether 100:0 to 
Pet.Ether:Diethyl ether 60:40) to afford the title compound (30.4 mg, 61%) as a yellow oil. Rf (6:4 
Pet.Ether:Diethyl ether) 0.16; 1H NMR (400 MHz, CDCl3):  8.04 (1H, br. q, J = 4.7, NH),7.67 
(2H, d, J =8.5, Ar-H), 7.50 (2H, d, J =8.5, Ar-H), 7.44 – 7.34 (3H, m, Ar-H), 7.35 – 7.29 (2H, m, 
Ar-H), 3.70 (2H, q, J =7.2, CH2CH3), 2.82 (3H, d, J =4.7, NHCH3), 1.30 (3H, t, J =7.2, CH2CH3); 
13C NMR (101 MHz, CDCl3):  171.46 (C=O)amide, 155.57 (C=O)urea hydantoin,, 150.74 (C=O)urea, 
141.51 (CAr), 135.39 (CAr), 132.04 (2xCArH), 129.55 (2xCArH), 129.29 (CArH), 128.62 (2xCArH), 
128.46 (2xCArH), 118.47 (CN), 112.75 (CAr), 73.73 (NCPh), 35.09 (CH2), 26.78 (NHCH3), 13.31 
(CH3); HPLC: er = ~77:23, (R,R) whelk-01, Hexane:EtOAc = 85:15, flow = 1 mL/min, λ = 254 
nm, tR = 23.9 min (major), 26.0 min (minor); IR (vmax/cm-1) (neat): 3365 (NH), 2984, 2940 (alkyl 
C-H), 2229 (C≡N), 1783, 1723, 1699 (C=O); HRMS (ESI): m/z calcd for C20H19N4O3 [M+H]+ 




Following general procedure 6: hydantoin urea 351 (62.3 mg, 0.14 mmol) was stirred in CHCl3 
(1.00 mL) at −20 °C. PTC 322 (15.3 mg, 0.03 mmol, 0.20 eq.) and Cs2CO3 (227 mg, 0.70 mmol) 
were added and the reaction mixture stirred for 144 hours (monitored by TLC). The crude product 
was purified by flash column chromatography (SiO2; Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 
70:30) to afford the title compound (1H NMR yield: 36%) as a colourless oil. Rf (7:3 





J =8.7, Ar-H), 7.48 (2H, d, J =8.7, Ar-H), 7.39 – 7.35 (3H, m, Ar-H), 7.35 – 7.30 (2H, m, Ar-H), 
2.80 (3H, d, J =4.7, NHCH3), 1.95 (2H, d, J =7.5, CHAHB + CHAHB overlap), 1.73 (6H, s, (CH3)2), 
0.83 (9H, s, (CH3)3C); HPLC: er = ~72:28, (R,R) whelk-01 Hexane:EtOAc = 90:10, flow = 1 
mL/min, λ = 254 nm, tR = 21 min (major), 24 min (minor); 13C NMR (101 MHz, CDCl3):  172.57 
(C=O)amide, 156.74 (C=O)urea hydantoin, 151.04 (C=O)urea, 142.18 (CAr), 136.04 (CAr), 131.83 (2xCArH), 
129.64 (2xCArH), 129.05 (CArH), 128.57 (2xCArH), 128.42 (2xCArH), 118.60 (CN), 112.46 (CAr), 
72.42 (NCPh), 64.38 ((CH3)A(CH3)BC), 50.29 (CH2), 31.63 ((CH3)3C), 31.17 ((CH3)3C), 29.87 
((CH3)A(CH3)B), 29.70 ((CH3)A(CH3)B), 26.70 (NHCH3); IR (vmax/cm-1) (neat): 3359 (NH), 2954, 
2911 (alkyl C-H), 2228 (C≡N), 1778, 1717, 1607 (C=O); HRMS (ESI): m/z calcd for 
C26H30N4O3Na [M+Na]+ 469.221012, found 469.223058. 
4.3.2 Photoredox-Catalysed Alkylarylation of Dehydroalanine Derivatives for the 
Preparation of Enantiopure -Quaternary Amino Acids 
4.3.2.1 Synthesis of Vinyl Ureas 
(R)-2-amino-3-(benzylthio)-N-methylpropanamide (411) 
 
Following general procedure 7: MeNH2 (33% w/w solution in EtOH, 16.1 mL, 129 mmol) and (S)-
benzyl-L-cysteine methyl ester hydrochloride 410 (4.82 g, 18.4 mmol). The title compound (>99%) 
was yielded as a yellow oil and used without further purification. Rf (9.5:0.5 DCM:MeOH) 0.22; 
1H NMR (400 MHz, CDCl3):  7.33 – 7.29 (4H, m, Ar-H), 7.26 – 7.21 (1H, m, Ar-H), 3.71 (2H, s, 
PhCH2), 3.42 (1H, dd, J =8.6, 3.8, CHNH2), 2.99 (1H, dd, J =13.7, 3.8, CHAHB), 2.79 (3H, d, J 
=5.1, NHCH3), 2.65 (1H, dd, J =13.7, 8.6, CHAHB); 13C NMR (101 MHz, CDCl3):  173.94 (C=O), 
138.28 (CAr), 129.00 (2xCArH), 128.70 (2xCArH), 127.28 (CArH), 54.06 (CHNH2), 37.49 (CHAHB), 
36.56 (PhCH2), 25.97 (NHCH3); IR (vmax/cm-1) (neat): 3360, 3298 (NH), 2915 (alkyl C-H), 1654 











Following general procedure 8: N-methylamide 411 (2.00 g, 8.92 mmol), MgSO4 (1.07 g, 8.92 
mmol) and pivalaldehyde (1.30 mL, 11.6 mmol) in anhydrous DCM (4.50 mL). The title compound 
(2.59 g, 99%) was yielded as a yellow oil and used without further purification. 1H NMR (400 
MHz, CDCl3):  7.46 (1H, s, CN=CH), 7.35 – 7.25 (4H, m, Ar-H), 7.27 – 7.17 (1H, m, Ar-H), 6.81 
(1H, br. s, NH), 3.68 (2H, d, J =4.8, PhCHAHB + PhCHAHB overlap), 3.61 (1H, dd, J =9.8, 2.9, 
CHAHBCH), 3.03 (1H, dd, J =13.7, 2.9, CHAHBCH), 2.82 (3H, d, J =5.0, NHCH3), 2.62 (1H, dd, J 
=13.7, 9.8, CHAHBCH), 1.10 (9H, s, C(CH3)3); 13C NMR (101 MHz, CDCl3):   (CN=CH), 
172.53 (C=O), 138.39 (CAr), 129.09 (2xCArH), 128.64 (2xCArH), 127.16 (CArH), 72.29 (CH2CH), 
36.93 (PhCH2), 36.84 (C(CH3)3), 36.67 (CH2CH), 26.94 (C(CH3)3), 26.02 (NHCH3); IR (vmax/cm-
1) (neat): 3326 (NH), 2958, 2932 (alkyl C-H), 1667 (C=O); MS (ESI): m/z calcd for C16H25N2OS 




Following general procedure 10: DMAP (52.9 mg, 0.43 mmol), N-methyl-N-phenylcarbamoyl 
chloride (2.20 g, 13.0 mmol) and N-Methylamide imine 412 (2.53 g, 8.65 mmol) in anhydrous 
toluene (43.0 mL) were stirred to reflux. The crude product was purified by flash column 
chromatography (SiO2; Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 60:40) to afford the title 
compound (1.28 g, 35%) as a yellow oil. Rf (6:4 Pet.Ether:EtOAc) 0.30; 1H NMR (400 MHz, 
CDCl3):  7.44 – 7.38 (2H, m, Ar-H), 7.34 – 7.27 (1H, m, Ar-H), 7.23 – 7.21 (2H, m, Ar-H), 7.20 
– 7.16 (5H, m, Ar-H), 5.46 (1H, s, CHC(CH3)3), 4.13 (1H, dd, J =10.6, 2.4, CHCHAHB, ), 3.78 (1H, 
d, J =12.6, PhCHAHB), 3.62 (1H, d, J =12.6, PhCHAHB), 3.17 (3H, s, PhNCH3), 2.95 (3H, s, NCH3), 
2.15 (1H, dd, J =13.6, 10.6, CHCHAHB), 0.96 (1H, dd, J =13.6, 2.4, CHCHAHB), 0.89 (9H, s, 
C(CH3)3); 13C NMR (101 MHz, CDCl3):   (C=O)amide, 163.29 (C=O)urea, 145.63 (CAr), 
138.52 (CAr), 130.50 (2xCArH), 129.33 (2xCArH), 128.39 (2xCArH), 127.34 (2xCArH), 127.19 





36.66 (C(CH3)3), 33.32 (CHCH2), 31.66 (NCH3), 26.80 (C(CH3)3); IR (vmax/cm-1) (neat): 2973, 
2934 (alkyl C-H), 1699, 1658 (C=O); MS (ESI): m/z calcd for C24H32N3O2S [M+H]+, found 




Following general procedure 11: KHMDS (1.0 M/THF, 3.30 mL, 3.27 mmol, 1.20 eq.) and 
imidazolidinone urea 414a (1.16 g, 2.73 mmol) in anhydrous THF (27.3 mL) were stirred for 65 
mins (monitored by TLC). The crude product was purified by flash column chromatography (SiO2; 
Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 60:40) to afford the title compound (700 mg, 85%) as 
a yellow solid. Rf (6:4 Pet.Ether:EtOAc) 0.33; 1H NMR (400 MHz, CDCl3):  7.39 – 7.33 (2H, m, 
Ar-H), 7.25 – 7.20 (1H, m, Ar-H), 7.11 – 7.06 (2H, m, Ar-H), 5.24 (1H, d, J =0.9, C=CHACHB), 
5.13 (1H, d, J =0.9, C=CHACHB), 4.39 (1H, s, CHC(CH3)3), 3.36 (3H, s, PhNCH3), 2.80 (3H, s, 
NCH3), 0.90 (9H, s, C(CH3)3); 13C NMR (101 MHz, CDCl3):   (C=O)amide, 156.96 
(C=O)urea, 143.95 (CAr), 137.27 (C=CH2), 129.77 (2xCArH), 126.30 (CArH), 123.94 (2xCArH), 92.70 
(C=CH2), 80.96 (CHC(CH3)3), 38.89 (PhNCH3), 39.59 (C(CH3)3), 31.85 (NCH3), 25.58 (C(CH3)3); 
IR (vmax/cm-1) (neat): 3064 (alkene CH), 2965, 2911 (alkyl C-H), 1704, 1674 (C=O); MS (ESI): 




Following general procedure 10: DMAP (31.2 mg, 0.26 mmol), N-(4-cyanophenyl)-N-
methylcarbamoyl chloride (1.29 g, 6.64 mmol, 1.30 eq.) and N-Methylamide imine 412 (1.49 g, 
5.11 mmol) in anhydrous toluene (26.0 mL) were stirred to reflux. The crude product was purified 
by flash column chromatography (SiO2; Pet.Ether:Diethyl ether 100:0 to Pet.Ether:Diethyl ether 
10:90) to afford the title compound (930 mg, 40%) as white amorphous solid. Rf (1:9 





7.21 (2H, m, Ar-H), 7.21 – 7.16 (5H, m, Ar-H), 5.34 (1H, s, CHC(CH3)3), 4.12 (1H, dd, J =9.6, 2.4, 
CHCHAHB), 3.80 (1H, d, J =13.0, PhCHAHB), 3.67 (1H, d, J =13.0, PhCHAHB), 3.15 (3H, s, 
ArNCH3), 2.94 (3H, s, NCH3), 2.31 (1H, dd, J =13.9, 9.6, CHCHAHB), 1.40 (1H, dd, J =13.9, 2.4, 
CHCHAHB), 0.89 (9H, s, C(CH3)3); 13C NMR (101 MHz, CDCl3):   (C=O)amide, 162.51 
(C=O)urea, 149.56 (CAr), 138.06 (CAr), 134.14 (2xCArH), 129.22 (2xCArH), 128.50 (2xCArH), 127.06 
(CArH), 125.86 (2xCArH), 118.22 (CN), 109.61 (CAr), 82.42 (CHC(CH3)3), 65.00 (CHCH2), 40.56 
(PhNCH3), 37.23 (PhCH2), 36.80 (C(CH3)3), 33.84 (CHCH2), 31.68 (NCH3), 26.74 (C(CH3)3); IR 
(vmax/cm-1) (neat): 2967, 2934 (alkyl C-H), 1700 (C=O), 1663 (C=O); HRMS (ESI): m/z calcd 




Following general procedure 11: KHMDS (1.0 M/THF, 4.10 mL, 4.06 mmol, 2.00 eq.) and 
imidazolidinone urea 414b (915 mg, 2.03 mmol) in anhydrous THF (20.0 mL) were stirred for 2.5 
hours (monitored by TLC). The crude product was purified by flash column chromatography (SiO2; 
Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 50:50) to afford the title compound (411 mg, 62%) as 
a yellow solid. Rf (5:5 Pet.Ether:EtOAc) 0.31; mp: 180 – 182 °C; 1H NMR (400 MHz, CDCl3):  
7.64 (2H, d, J =8.6, Ar-H), 7.23 (2H, d, J =8.6, Ar-H), 5.32 (1H, s, C=CHACHB), 4.89 (1H, s, 
C=CHACHB), 4.82 (1H, s, CHC(CH3)3), 3.41 (3H, s, PhNCH3), 2.99 (3H, s, NCH3), 0.94 (9H, s, 
C(CH3)3); 13C NMR (101 MHz, CDCl3):   (C=O)amide, 157.20 (C=O)urea, 147.39 (CAr), 
136.45 (C=CH2), 133.46 (2xCArH), 122.83 (2xCArH), 118.39 (CN), 108.69 (CAr), 93.66 (C=CH2), 
80.93 (CHC(CH3)3), 39.24 (C(CH3)3), 38.12 (PhNCH3), 32.05 (NCH3), 25.67 (C(CH3)3); IR 
(vmax/cm-1) (neat): 3071 (alkene CH), 2969, 2942 (alkyl C-H), 1701, 1679 (C=O); HRMS (ESI): 












Following general procedure 9: triphosgene (1.87 g, 6.31 mmol) in anhydrous DCM (15.8 mL), 
anhydrous pyridine (1.00 mL, 12.6 mmol) and 4-trifluoromethyl-N-methylaniline (1.80 mL, 12.6 
mmol). The reaction yielded 260c (>99%) as a white solid, which was used in the next step without 
further purification. 260c: 1H NMR (400 MHz, CDCl3):  7.70 (2H, d, J =8.3, Ar-H), 7.41 (2H, d, 
J =8.3, Ar-H), 3.43 (3H, br. s, NCH3); IR (vmax/cm-1) (neat): 1728 (C=O); MS (ESI): m/z calcd 
for C9H7ClF3NONa [M+Na]+, found 260. Data in agreement with reported values.295 Following 
general procedure 10: DMAP (57.1 mg, 0.47 mmol), 260c (3.33 g, 14.0 mmol) and N-Methylamide 
imine 412 (2.73 g, 9.35 mmol) in anhydrous toluene (46.5 mL) were stirred to reflux. The crude 
product was purified by flash column chromatography (SiO2; Pet.Ether:EtOAc 100:0 to 
Pet.Ether:EtOAc 60:40) to afford the title compound (1.79 g, 39%) as an orange oil. Rf (6:4 
Pet.Ether:EtOAc) 0.36; 1H NMR (400 MHz, CDCl3):  7.68 (2H, d, J =8.1, Ar-H), 7.33 – 7.27 
(2H, m, Ar-H), 7.24 – 7.21 (2H, m, Ar-H), 7.21 – 7.15 (3H, m, Ar-H), 5.39 (1H, s, CHC(CH3)3), 
4.14 (1H, dd, J =10.2, 2.4, CHCHAHB), 3.76 (1H, d, J =12.8, PhCHAHB), 3.60 (1H, d, J =12.8, 
PhCHAHB), 3.18 (3H, s, ArNCH3), 2.95 (3H, s, NCH3), 2.27 (1H, dd, J =13.5, 10.2, CHCHAHB), 
1.22 (1H, dd, J =13.5, 2.4, CHCHAHB), 0.90 (9H, s, C(CH3)3); 13C NMR (126 MHz, CDCl3): 
  (C=O)amide, 162.91 (C=O)urea, 148.86 (br. q, 
5JC-F = 1.4, CAr), 138.13 (CAr), 129.19 
(2xCArH), 128.82 (q, 
2JC-F = 33.0, Ar), 128.42 (2xCArH), 127.50 (q, 
3JC-F = 3.6, 2xCArH), 126.95 
(CArH), 126.74 (2xCArH), 123.82 (q, 
1JC-F = 272.2, CF3), 82.34 (CHC(CH3)3), 64.91 (CHCH2), 41.10 
(PhNCH3), 37.35 (PhCH2), 36.73 (C(CH3)3), 33.79 (CHCH2), 31.67 (NCH3), 26.75 (C(CH3)3); IR 
(vmax/cm-1) (neat): 2976, 2874 (alkyl C-H), 1703, 1666 (C=O); HRMS (ESI): m/z calcd for 












Following a similar procedure to general procedure 11: KHMDS (1.0 M/THF, 5.60 mL, 5.60 
mmol, 2.00 eq.) was added to a solution of imidazolidinone urea 414c (1.37 g, 2.78 mmol) in 
anhydrous THF (26.6 mL) at 0 °C under nitrogen. The reaction was allowed to warm to room 
temperature and then heated to 75 °C. The reaction was left stirring until TLC analysis showed the 
starting material had been completely consumed. The crude product was purified by flash column 
chromatography (SiO2; Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 70:30) to afford the title 
compound (246 mg, 24%). Rf (7:3 Pet.Ether:EtOAc) 0.36; 1H NMR (400 MHz, CDCl3):  7.63 
(2H, d, J =8.3, Ar-H), 7.25 (1H, d, J =8.3, Ar-H), 5.31 (1H, d, J =1.3, C=CHACHB), 4.97 (1H, d, J 
=1.3, C=CHACHB), 4.70 (1H, s, CHC(CH3)3), 3.42 (3H, s, PhNCH3), 2.94 (3H, s, NCH3), 0.94 (9H, 
s, C(CH3)3); 13C NMR (126 MHz, CDCl3):   (C=O)amide, 157.31 (C=O)urea, 146.72 (q, 
5JC-F 
= 1.2, CAr), 136.80 (C=CH2), 127.87 (q, 
2JC-F = 33.0, CAr), 126.77 (q, 
3JC-F = 3.8, 2xCArH), 123.91 
(q, 1JC-F = 271.9, CF3), 123.33 (2xCArH), 93.16 (C=CH2), 80.99 (CHC(CH3)3), 39.33 (C(CH3)3), 
38.50 (PhNCH3), 31.98 (NCH3), 25.68 (C(CH3)3); IR (vmax/cm-1) (neat): 3082 (alkene CH), 2973, 
2924 (alkyl C-H), 1698, 1615 (C=O); HRMS (ESI): m/z calcd for C18H22F3N3O2Na [M+Na]+ 




Following general procedure 9: triphosgene (1.93 g, 6.50 mmol) in anhydrous DCM (16.3 mL), 
anhydrous pyridine (1.10 mL, 13.0 mmol) and 4-chloro-N-methylaniline (1.60 mL, 13.0 mmol). 
The reaction yielded 260d (2.69 g, >99%) as a yellow solid, which was used in the next step without 
further purification. 260d: 1H NMR (400 MHz, CDCl3):  7.40 (2H, d, J =8.1, Ar-H), 7.20 (2H, d, 
J =8.1, Ar-H), 3.36 (3H, s, NCH3); IR (vmax/cm-1) (neat): 1740 (C=O), 2939, 2906 (alkyl C-H). 





mmol), 260d (1.99 g, 9.75 mmol) and N-Methylamide imine 412 (1.90 g, 6.50 mmol) in anhydrous 
toluene (32.0 mL) were stirred to reflux. The crude product was purified by flash column 
chromatography (SiO2; Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 60:40) to afford the title 
compound (1.57 g, 53%) as a dark orange oil. Rf (6:4 Pet.Ether:EtOAc) 0.28; 1H NMR (400 MHz, 
CDCl3):  7.39 (2H, d, J =8.7, Ar-H), 7.25 – 7.21 (4H, m, Ar-H), 7.21 – 7.17 (1H, m, Ar-H), 7.13 
(2H, d, J =8.7, Ar-H), 5.46 (1H, s, CHC(CH3)3), 4.07 (1H, dd, J =10.5, 2.3, CHCHAHB, ), 3.78 (1H, 
d, J =12.8, PhCHAHB), 3.63 (1H, d, J =12.8, PhCHAHB), 3.14 (3H, s, PhNCH3), 2.95 (3H, s, NCH3), 
2.23 (1H, dd, J =13.4, 10.5, CHCHAHB), 1.09 (1H, dd, J =13.4, 2.3, CHCHAHB), 0.89 (9H, s, 
C(CH3)3); 13C NMR (101 MHz, CDCl3):   (C=O)amide, 163.13 (C=O)urea, 144.20 (CAr), 
138.29 (CAr), 132.83 (CAr), 130.63 (2xCArH), 129.27 (2xCArH), 128.58 (2xCArH), 128.45 (2xCArH), 
126.95 (CArH), 82.26 (CHC(CH3)3), 65.07 (CHCH2), 41.49 (PhNCH3), 37.55 (PhCH2), 36.67 
(C(CH3)3), 33.79 (CHCH2), 31.67 (NCH3), 26.78 (C(CH3)3); IR (vmax/cm-1) (neat): 2967, 2929 





Following general procedure 11: KHMDS (1.0 M/THF, 4.10 mL, 4.11 mmol, 1.20 eq.) was added 
to imidazolidinone urea 414d (1.57 g, 3.42 mmol) in anhydrous THF (34.0 mL) at 0 °C under 
nitrogen. The reaction was stirred at room temperature for 2 hours, after which it was cooled to 0 
°C and an additional 0.8 equivalents of KHMDS (1.0 M/THF, 2.7 mL, 2.74 mmol) was added. The 
reaction was then stirred at room temperature for 2.5 hours (monitored by TLC). The crude product 
was purified by flash column chromatography (SiO2; Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 
60:40) to afford the title compound (814 mg, 71%) as a yellow solid. Rf (6:4 Pet.Ether:EtOAc) 
0.44; mp: 150 – 152 °C; 1H NMR (400 MHz, CDCl3):  7.34 (2H, d, J =8.8, Ar-H), 7.07 (2H, d, J 
=8.8, Ar-H), 5.27 (1H, d, J =1.2, C=CHACHB), 4.97 (1H, d, J =1.2, C=CHACHB), 4.65 (1H, s, 
CHC(CH3)3), 3.36 (3H, s, PhNCH3), 2.93 (3H, s, NCH3), 0.93 (9H, s, C(CH3)3); 13C NMR (101 
MHz, CDCl3):   (C=O)amide, 157.20 (C=O)urea, 142.24 ( CAr), 137.09 (C=CH2), 131.82 ( CAr), 
129.78 (2xCArH), 125.26 (2xCArH), 92.53 (C=CH2), 80.97 (CHC(CH3)3), 39.35 (C(CH3)3), 38.99 
(PhNCH3), 31.96 (NCH3), 25.64 (C(CH3)3); IR (vmax/cm-1) (neat): 3050 (alkene CH), 2972, 2925 
(alkyl C-H), 1714, 1699 (C=O); HRMS (ESI): m/z calcd for C17H22ClN3O2Na [M+Na]+ 








Following general procedure 10: DMAP (21.4 mg, 0.18 mmol), N-(methyl)-N-(4-methylphenyl)-
carbamoyl chloride (965 mg, 5.23 mmol) and N-Methylamide imine 412 (1.02 g, 3.50 mmol) in 
anhydrous toluene (17.5 mL) were stirred to reflux. The crude product was purified by flash column 
chromatography (SiO2; DCM:Acetone 100:0 to DCM:Acetone 95:5) to afford the title compound 
(695 mg, 45%) as an orange oil. Rf (9.5:0.5 DCM:Acetone) 0.31; 1H NMR (400 MHz, CDCl3):  
7.24 – 7.20 (4H, m, Ar-H), 7.20 – 7.15 (3H, m, Ar-H), 7.10 – 7.05 (2H, m, Ar-H), 5.48 (1H, s, 
CHC(CH3)3), 4.11 (1H, dd, J =10.7, 2.4, CHCHAHB, ), 3.77 (1H, d, J =12.7, PhCHAHB), 3.59 (1H, 
d, J =12.7, PhCHAHB), 3.14 (3H, s, ArNCH3), 2.95 (3H, s, NCH3), 2.37 (3H, s, CH3), 2.15 (1H, dd, 
J =13.5, 10.7, CHCHAHB), 0.96 (1H, dd, J =13.5, 2.4, CHCHAHB), 0.89 (9H, s, C(CH3)3); 13C NMR 
(101 MHz, CDCl3):   (C=O)amide, 163.38 (C=O)urea, 142.97 (CAr), 138.57 (CAr), 137.16 (CAr), 
131.09 (2xCArH), 129.27 (2xCArH), 128.39 (2xCArH), 127.23 (2xCArH), 126.85 (CArH), 82.13 
(CHC(CH3)3), 65.29 (CHCH2), 41.55 (PhNCH3), 37.51 (PhCH2), 36.63 (C(CH3)3), 33.38 (CHCH2), 
31.65 (NCH3), 26.78 (C(CH3)3), 21.23 (CH3); IR (vmax/cm-1) (neat): 2965, 2926 (alkyl C-H), 





Following general procedure 11: KHMDS (1.0 M/THF, 4.50 mL, 4.49 mmol, 2.00 eq.) and 
imidazolidinone urea 414e (988 mg, 2.26 mmol) in anhydrous THF (23.0 mL) were stirred for 65 
mins (monitored by TLC). The crude product was purified by flash column chromatography (SiO2; 
Pet.Ether:Diethyl ether 100:0 to Pet.Ether:Diethyl ether 40:60) to afford the title compound (518 
mg, 73%) as a yellow solid. Rf (4:6 Pet.Ether:Diethyl ether) 0.22; mp: 158 – 159 °C; 1H NMR 





C=CHACHB), 5.08 (1H, d, J =1.0, C=CHACHB), 4.47 (1H, s, CHC(CH3)3), 3.34 (3H, s, PhNCH3), 
2.83 (3H, s, NCH3), 2.34 (CH3), 0.92 (9H, s, C(CH3)3); 13C NMR (101 MHz, CDCl3): 
  (C=O)amide, 157.12 (C=O)urea, 141.36 (CAr), 137.40 (C=CH2), 136.31 (CAr), 130.32 
(2xCArH), 124.00 (2xCArH), 92.36 (C=CH2), 80.95 (CHC(CH3)3), 39.55 (C(CH3)3), 39.10 
(PhNCH3), 31.88 (NCH3), 25.63 (C(CH3)3), 21.05 (CH3); IR (vmax/cm-1) (neat): 3032 (alkene 
CH), 2969, 2926 (alkyl C-H), 1705, 1674 (C=O); HRMS (ESI): m/z calcd for C18H26N3O2 [M+H]+ 




Following general procedure 11: KHMDS (1.0 M/THF, 4.20 mL, 4.24 mmol, 1.20 eq.) was added 
to imidazolidinone urea 414f (1.51 g, 3.53 mmol) in anhydrous THF (35.0 mL) at 0 °C under 
nitrogen. The reaction was stirred for 2 hours at room temperature, after which it was cooled down 
to 0 °C and an additional 0.8 equivalents of KHMDS (1.0 M/THF, 2.8mL, 2.80 mmol) was added. 
The reaction was then stirred at room temperature for 1 hour (monitored by TLC). The crude 
product was purified by flash column chromatography (SiO2; Pet.Ether:EtOAc 100:0 to 
Pet.Ether:EtOAc 20:80) to afford the title compound (1.09 g, >99%) as a dark viscous oil. Rf (2:8 
Pet.Ether:EtOAc) 0.43; 1H NMR (400 MHz, CDCl3):  8.39 (1H, ddd, J =4.9, 2.0, 1.0, Ar-H), 7.63 
(1H, ddd, J =8.4, 7.3, 2.0, Ar-H), 7.19 (1H, dt, J =8.4, 1.0, Ar-H), 7.04 (1H, ddd, J =7.3, 4.9, 1.0, 
Ar-H), 5.27 (1H, d, J =1.3, C=CHACHB), 4.93 (1H, s, CHC(CH3)3), 4.85 (1H, d, J =1.3, 
C=CHACHB), 3.48 (3H, s, PhNCH3), 3.02 (3H, s, NCH3), 0.97 (9H, s, C(CH3)3); 13C NMR (101 
MHz, CDCl3):   (C=O)amide, 157.79 (C=O)urea, 155.49 (CAr), 148.37 (CArH), 137.81 (CArH), 
136.49 (C=CH2), 119.76 (CArH), 116.80 (CArH), 93.83 (C=CH2), 81.06 (CHC(CH3)3), 39.29 
(C(CH3)3), 36.31 (PhNCH3), 32.08 (NCH3), 25.77 (C(CH3)3); IR (vmax/cm-1) (neat): 2967, 2925 











Following general procedure 7: MeNH2 (33% w/w solution in EtOH, 89.0 mL, 712 mmol) and O-
benzyl-L-serine methyl ester hydrochloride 418 (25.0 g, 102 mmol). The title compound (20.7 g, 
98%) was yielded as a yellow oil and used without further purification. 1H NMR (400 MHz, 
CDCl3):  7.37 – 7.26 (5H, m, Ar-H), 4.53 (2H, s, PhCH2), 3.74 (1H, dd, J =9.2, 4.0, CHAHB), 3.64 
(1H, dd, J =9.2, 6.7, CHAHB) ), 3.58 (1H, dd, J =6.7, 4.0, CHNH2), 2.81 (3H, d, J =5.0, NHCH3); 
13C NMR (101 MHz, CDCl3):  173.31 (C=O), 137.98 (CAr), 128.59 (2xCArH), 127.95 (CArH), 
127.92 (2xCArH), 73.39 (PhCH2), 72.44 (CHAHB), 55.19 (CHNH2), 25.95 (NHCH3); IR (vmax/cm-
1) (neat): 3371, 3305, 3094 (NH), 2906 (alkyl C-H), 1651 (C=O); HRMS (ESI): m/z calcd for 
C11H17N2O2 [M+NH]+ 209.128454, found 209.128466. 
(S)-3-(Benzyloxy)-2-((2,2-dimethylpropylidene)amino)-N-methylpropanamide (420) 
 
Following general procedure 8: N-methylamide 420 (2.46 g, 11.8 mmol), MgSO4 (1.42 g, 11.8 
mmol) and pivalaldehyde (1.67 mL, 15.3 mmol) in anhydrous DCM (5.90 mL). The title compound 
(2.62 g, 80%) was yielded as a yellow oil and used without further purification. 1H NMR (400 
MHz, CDCl3):  7.55 (1H, d, J = 0.6, CN=CH), 7.33 – 7.28 (2H, m, Ar-H), 7.27 – 7.22 (3H, m, Ar-
H), 7.03 (1H, br. s, NH), 4.54 – 4.43 (2H, m, PhCHAHB + PhCHAHB overlap), 3.89 – 3.82 (2H, m, 
CHAHBCH + CHAHBCH), 3.54 (1H, dd, J =10.2, 9.2, CHAHBCH), 2.83 (3H, d, J =5.0, NHCH3), 
1.08 (9H, s, C(CH3)3); 13C NMR (101 MHz, CDCl3):   (CN=CH), 171.43 (C=O), 138.22 
(CAr), 129.39 (2xCArH), 127.63 (CArH), 127.54 (2xCArH), 73.02 (PhCH2), 72.42 (CH2CH), 36.72 
(C(CH3)3), 71.74 (CH2CH), 26.85 (C(CH3)3), 25.97 (NHCH3); IR (vmax/cm-1) (neat): 3395 (NH), 












Following general procedure 9: triphosgene (1.96 g, 6.61 mmol) in anhydrous DCM (16.5 mL), 
anhydrous pyridine (1.10 mL, 13.2 mmol) and 4-bromo-N-methylaniline (1.70 mL, 13.2 mmol). 
The reaction yielded 260g (3.19 g, 97%) as a yellow solid, which was used in the next step without 
further purification. 260g: 1H NMR (400 MHz, CDCl3):  7.56 (2H, d, J =8.6, Ar-H), 7.14 (2H, d, 
J =8.6, Ar-H), 3.36 (3H, s, NCH3). Data in agreement with reported values.295 Following general 
procedure 10: DMAP (57.3 mg, 0.47 mmol), 260g (3.49 g, 14.1 mmol) and N-Methylamide imine 
420 (2.59 g, 9.38 mmol) in anhydrous toluene (47.0 mL) were stirred to reflux. The crude product 
was purified by flash column chromatography (SiO2; nHexane:Acetone 100:0 to nHexane:Acetone 
60:40) to afford the title compound (1.88 g, 41%) as a yellow oil. Rf (6:4 nHexane:Acetone) 0.42; 
1H NMR (400 MHz, CDCl3):  7.47 (2H, d, J = 8.7, Ar-H), 7.35 – 7.29 (2H, m, Ar-H), 7.28 – 7.23 
(3H, m, Ar-H), 7.07 (2H, d, J = 8.7, Ar-H), 5.50 (1H, s, CHC(CH3)3), 4.15 (2H, s, PhCH2), 4.05 
(1H, dd, J =7.0, 2.4, CHCHAHB), 3.14 (3H, s, ArNCH3), 2.96 (3H, s, NCH3), 2.92 (1H, dd, J =9.4, 
7.0, CHCHAHB), 2.38 (1H, dd, J =9.4, 2.4, CHCHAHB), 0.92 (9H, s, C(CH3)3); 13C NMR (101 
MHz, CDCl3):   (C=O)amide, 163.39 (C=O)urea, 144.77 (CAr), 137.87 (CAr), 133.16 (2xCArH), 
129.06 (2xCArH), 128.41 (2xCArH), 127.63 (2xCArH), 127.60 (CArH), 120.42 (CAr), 82.25 
(CHC(CH3)3), 73.28 (PhCH2), 70.77 (CHCH2), 63.27 (CHCH2), 41.45 (PhNCH3), 36.86 (C(CH3)3), 
31.56 (NCH3), 26.68 (C(CH3)3); IR (vmax/cm-1) (neat): 2973, 2870 (alkyl C-H), 1703, 1658 




Following general procedure 11: KHMDS (1.0 M/THF, 6.00 mL, 5.99 mmol, 1.60 eq.) and 
imidazolidinone urea 421g (1.85 g, 3.79 mmol) in anhydrous THF (38.0 mL) were stirred for 2.75 
hours (monitored by TLC). The crude product was purified by flash column chromatography (SiO2; 





a light brown solid. Rf (6:4 Pet.Ether:EtOAc) 0.40; 1H NMR (400 MHz, CDCl3):  7.49 (2H, d, J 
=8.8, Ar-H), 7.01 (2H, d, J =8.8, Ar-H), 5.27 (1H, d, J =1.2, C=CHACHB), 4.96 (1H, d, J =1.2, 
C=CHACHB), 4.65 (1H, s, CHC(CH3)3), 3.35 (3H, s, PhNCH3), 2.93 (3H, s, NCH3), 0.93 (9H, s, 
C(CH3)3); 13C NMR (101 MHz, CDCl3):   (C=O)amide, 157.17 (C=O)urea, 142.77 (CAr), 
137.07 (C=CH2), 132.76 (2xCArH), 125.55 (2xCArH), 119.53 (CAr), 92.63 (C=CH2), 80.99 
(CHC(CH3)3), 39.36 (C(CH3)3), 38.90 (PhNCH3), 31.98 (NCH3), 25.65 (C(CH3)3); IR (vmax/cm-
1) (neat): 2968, 2927 (alkyl C-H), 1714, 1679 (C=O); HRMS (ESI): m/z calcd for C17H22BrN3O2Na 
[M+Na]+ 402.0788, found 402.0791. 




Following general procedure 12: vinyl urea 400b (65.3 mg, 0.20 mmol), caesium carbonate (97.7 
mg, 0.30 mmol), 4CzIPN (7.9 mg, 0.01 mmol) and C2H3F2SO2Na (60.8 mg, 0.40 mmol, 2.00 eq.) 
in anhydrous CH3CN (2.00 mL). The crude product was purified by flash column chromatography 
(SiO2; DCM:Acetone 100:0 to DCM:Acetone 90:10) to afford the title compound (25.4 mg, 32%) 
as a white solid. Rf (9:1 DCM:Acetone) 0.48; 1H NMR (400 MHz, CDCl3):  7.62 (2H, d, J =8.7, 
Ar-H), 7.32 – 7.27 (2H, m, Ar-H), 5.80 (1H, s, CHC(CH3)3), 4.82 (1H, br. s, NHCH3), 3.27 (1H, 
ddd, J =31.2, 16.6, 2.5, CHAHB), 3.04 (3H, s, NCH3), 2.68 (1H, ddd, J =31.2, 16.6, 7.5, CHAHB), 
2.37 (3H, d, J =4.6, NHCH3), 1.85 (3H, t, J =18.7, CH3F2), 1.07 (9H, s, C(CH3)3); 13C NMR (126 
MHz, CDCl3):   (C=O)amide, 158.51 (C=O)urea, 144.88 (CAr), 132.46 (2xCArH), 126.94 
(2xCArH), 124.62 (dd, 
1JC-F = 242.8, 237.0, CF2), 118.32 (CN), 112.23 (CAr), 81.50 (CHC(CH3)3), 
67.93 ( NC(Ar)), 40.91 (t, 2JC-F = 22.7, NCCH2), 38.19 (C(CH3)3), 32.12 (NCH3), 27.08 (NHCH3), 
26.77 (C(CH3)3), 26.05 (t, 
2JC-F = 27.2, CH3F2); 19F NMR (377 MHz, CDCl3) δF −84.50 to −85.28 
(1F, m), δF −89.27 to −90.02 (1F, m); IR (vmax/cm-1) (neat): 3668 (NH), 2969, 2916 (alkyl C-H), 










Following general procedure 12: vinyl urea 400b (196 mg, 0.60 mmol), caesium carbonate (293 
mg, 0.90 mmol), 4CzIPN (23.7 mg, 0.03 mmol) and CHF2SO2Na (166 mg, 1.2 mmol, 2.00 eq.) in 
anhydrous CH3CN (6.00 mL). The crude product was purified by flash column chromatography 
(SiO2; DCM:Acetone 100:0 to DCM:Acetone 90:10) to afford the title compound (94.8 mg, 42%) 
as a yellow oil; Rf (9:1 DCM:Acetone) 0.46; 1H NMR (400 MHz, CDCl3):  7.64 (2H, d, J =8.6, 
Ar-H), 7.30 (2H, d, J =8.6, Ar-H), 6.29 (1H, tt, J = 55.1, 4.7, CHF2), 5.57 (1H, s, CHC(CH3)3), 
4.43 (1H, br. s, NHCH3), 3.08 (3H, s, NCH3), 3.06 – 2.93 (2H, m, NCCH2), 2.42 (3H, d, J =4.4, 
NHCH3), 1.07 (9H, s, C(CH3)3); 13C NMR (126 MHz, CDCl3):   (C=O)amide, 158.40 
(C=O)urea, 145.00 (CAr), 132.79 (2xCArH), 126.45 (2xCArH), 118.15 (CN), 115.33 (t, 
1JC-F = 238.8, 
CHF2), 112.64 (CAr), 81.39 (CHC(CH3)3), 66.94 (dd, 
3JC-F = 8.9, 3.2, NC(Ar)), 40.48 (t, 2JC-F = 22.5, 
NCCH2), 38.23 (C(CH3)3), 32.21 (NCH3), 27.26 (NHCH3), 26.78 (C(CH3)3); 19F NMR (377 MHz, 
CDCl3) δF −110.14 to −111.26 (1F, m), δF −111.34 to −112.46 (1F, m); IR (vmax/cm-1) (neat): 
3403 (NH), 2972, 2907 (alkyl C-H), 1703 (C=O), 1668 (C=O); HRMS (ESI): m/z calcd for 




Following general procedure 12: vinyl urea 400a (30.0 mg, 0.10 mmol), caesium carbonate (48.9 
mg, 0.15 mmol), 4CzIPN (3.9 mg, 5 x 10⁻3 mmol) and CF3SO2Na (46.8 mg, 0.30 mmol, 3.00 eq.) 
in anhydrous CH3CN (1.00 mL). The crude product was purified by flash column chromatography 
(SiO2; Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 60:40) to afford the title compound (19F NMR 
yield: 66%) as a yellow oil. Rf (6:4 Pet.Ether:EtOAc) 0.33; 1H NMR (400 MHz, CDCl3):  7.46 – 
7.40 (2H, m, Ar-H), 7.33 – 7.28 (1H, m, Ar-H), 7.18 – 7.14 (2H, m, Ar-H), 5.36 (1H, s, 





2.14 – 1.98 (1H, m, CHCHAHB), 1.04 – 1.00 (1H, m, CHCHAHB), 0.96 (9H, s, C(CH3)3); 13C NMR 
(126 MHz, CDCl3):   (C=O)amide, 163.00 (C=O)urea, 145.34 (CAr), 130.42 (2xCArH), 127.26 
(CArH), 126.71 (2xCArH), 124.77 (q, 
1JC-F = 277.7, CF3), 82.45 (CHC(CH3)3), 57.24 (q, 
3JC-F = 3.3, 
CHCH2), 41.32 (PhNCH3), 37.09 (q, 
2JC-F = 29.1, CHCH2), 36.90 (C(CH3)3), 31.90 (NCH3), 26.86 
(C(CH3)3); 19F NMR (377 MHz, CDCl3) δF −60.67 (3F, dd, J = 11.9, 9.2); IR (vmax/cm-1) (neat): 
2976, 2907 (alkyl C-H), 1715, 1661 (C=O); HRMS (ESI): m/z calcd for C18H24F3N3O2Na [M+Na]+ 




Following general procedure 12: vinyl urea 400a (30.0 mg, 0.10 mmol), caesium carbonate (48.9 
mg, 0.15 mmol), 4CzIPN (3.9 mg, 5 x 10⁻3 mmol) and C2H3F2SO2Na (30.4 mg, 0.20 mmol, 2.00 
eq.) in anhydrous CH3CN (1.00 mL). The crude product was purified by flash column 
chromatography (SiO2; Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 60:40) to afford the title 
compound (23.6 mg, 64%) as a yellow oil. Rf (6:4 Pet.Ether:EtOAc) 0.33; 1H NMR (400 MHz, 
CDCl3):  7.40 (2H, t, J =7.8, Ar-H), 7.29 – 7.22 (1H, m, Ar-H), 7.13 (2H, d, J =7.5, Ar-H), 5.18 
(1H, s, CHC(CH3)3), 4.21 (1H, dd, J =10.8, 2.7, CHCHAHB), 3.18 (3H, s, PhNCH3), 2.86 (3H, s, 
NCH3), 1.93 (1H, tdd, J =15.3, 12.3, 10.8, CHCHAHB), 1.57 (3H, t, J =18.9, CF2CH3), 1.31 – 1.16 
(1H, m, CHCHAHB), 0.96 (9H, s, C(CH3)3); 13C NMR (126 MHz, CDCl3):   (C=O)amide, 
163.00 (C=O)urea, 145.65 (CAr), 130.15 (2xCArH), 126.62 (CArH), 126.09 (2xCArH), 122.31 (t, 
1JC-F 
= 240.1, CF2), 82.29 (CHC(CH3)3), 57.87 (dd, 
3JC-F = 6.6, 4.8, CHCH2), 41.15 (PhNCH3), 36.91 
(C(CH3)3), 41.33 (t, 
2JC-F = 26.4, CHCH2), 31.78 (NCH3), 26.92 (C(CH3)3), 24.26 (t, 
1JC-F = 27.1, 
CH3); 19F NMR (377 MHz, CDCl3) δF −82.86 to −83.74 (1F, m), δF −86.13 to −87.01 (1F, m); IR 
(vmax/cm-1) (neat): 2969, 2874 (alkyl C-H), 1705, 1658 (C=O); HRMS (ESI): m/z calcd for 











Following general procedure 12: vinyl urea 400a (30.0 mg, 0.10 mmol), caesium carbonate (48.9 
mg, 0.15 mmol), 4CzIPN (3.9 mg, 5 x 10⁻3 mmol) and CHF2SO2Na (27.6 mg, 0.20 mmol, 2.00 eq.) 
in anhydrous CH3CN (1.00 mL). The crude product was purified by flash column chromatography 
(SiO2; Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 60:40) to afford the title compound (32.2 mg, 
91%) as a colourless oil. Rf (6:4 Pet.Ether:EtOAc) 0.33; 1H NMR (400 MHz, CDCl3):  7.46 – 
7.40 (2H, m, Ar-H), 7.33 – 7.27 (1H, m, Ar-H), 7.19 – 7.15 (2H, m, Ar-H), 6.08 (1H, tdd, J = 56.9, 
8.1, 2.7, CHF2), 5.51 (1H, s, CHC(CH3)3), 4.03 (1H, ddd, J =11.9, 3.4, 2.1, CHCHAHB), 3.19 (3H, 
s, PhNCH3), 2.92 (3H, s, NCH3), 1.73 – 1.53 (1H, m, CHCHAHB), 0.97 (9H, s, C(CH3)3), 0.59 – 
0.46 (1H, m, CHCHAHB); 13C NMR (126 MHz, CDCl3):   (C=O)amide, 163.38 (C=O)urea, 
145.29 (CAr), 130.33 (2xCArH), 127.22 (2xCArH), 127.19 (CArH), 114.67 (dd, 
1JC-F = 240.6, 238.5, 
CHF2), 82.71 (CHC(CH3)3), 58.40 (dd, 
3JC-F = 11.5, 3.1, CHCH2), 41.47 (PhNCH3), 36.90 
(C(CH3)3), 36.81 (t, 
2JC-F = 22.7, CHCH2), 31.68 (NCH3), 26.86 (C(CH3)3); 19F NMR (377 MHz, 
CDCl3) δF −114.66 to −115.76 (1F, m), δF −119.26 (1F, dddd, J = 287.8, 57.0, 30.4, 10.4); IR 
(vmax/cm-1) (neat): 2969, 2933 (alkyl C-H), 1704, 1663 (C=O); HRMS (ESI): m/z calcd for 




Following general procedure 12: vinyl urea 400c (36.9 mg, 0.10 mmol), caesium carbonate (48.9 
mg, 0.15 mmol), 4CzIPN (3.9 mg, 5 x 10⁻3 mmol) and CHF2SO2Na (27.6 mg, 0.20 mmol, 2.00 eq.) 
in anhydrous CH3CN (1.00 mL). The crude product was purified by flash column chromatography 
(SiO2; Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 70:30) to afford the title compound (19F NMR 
yield: 67%) as yellow oil. Rf (7:3 Pet.Ether:EtOAc) 0.17; 1H NMR (400 MHz, CDCl3):  7.70 (2H, 





CHC(CH3)3), 4.05 (1H, dt, J =11.5, 2.5, CHCHAHB), 3.21 (3H, s, PhNCH3), 2.93 (3H, s, NCH3), 
1.75 (1H, dddt, J = 26.4, 13.9, 4.8, 2.5, CHCHAHB), 0.98 (9H, s, C(CH3)3), 0.72 – 0.58 (1H, m, 
CHCHAHB); 13C NMR (126 MHz, CDCl3):   (C=O)amide, 163.00 (C=O)urea, 148.56 (CAr), 
129.10 (q, 2JC-F = 33.2, CAr), 127.43 (q, 
3JC-F = 3.7, 2xCArH), 126.86 (2xCArH), 123.75 (q, 
1JC-F = 
272.1, CF3), 114.41 (t, 
1JC-F = 239.8, CHF2), 82.88 (CHC(CH3)3), 58.13 (dd, 
3JC-F = 11.6, 3.1, 
CHCH2), 41.14 (PhNCH3), 36.98 (C(CH3)3), 37.01 (t, 
2JC-F = 22.3, CHCH2), 31.70 (NCH3), 26.87 
(C(CH3)3); 19F NMR (377 MHz, CDCl3) δF −62.56 (3F, s), −114.83 to −115.85 (1F, m), −119.45 
(1F, dddd, J = 288.5, 57.2, 30.6, 10.5); IR (vmax/cm-1) (neat): 2964, 2933 (alkyl C-H), 1704, 1671 




Following general procedure 12: vinyl urea 400d (33.6 mg, 0.10 mmol), caesium carbonate (48.9 
mg, 0.15 mmol), 4CzIPN (3.90 mg, 5 x 10⁻3 mmol) and CF3SO2Na (31.2 mg, 0.20 mmol, 2.00 eq.) 
in anhydrous CH3CN (1.00 mL). The crude product was purified by flash column chromatography 
(SiO2; Diethyl ether:Acetone 100:0 to Diethyl ether:Acetone 99:1) to afford the title compound 
(22.7 mg, 56%) as a yellow oil. Rf (9.9:0.1 Diethyl ether:Acetone) 0.35; 1H NMR (400 MHz, 
CDCl3):  7.40 (2H, d, J = 8.7, Ar-H), 7.09 (2H, d, J =8.7, Ar-H), 5.33 (1H, s, CHC(CH3)3), 4.19 
(1H, dd, J =10.9, 2.6, CHCHAHB), 3.16 (3H, s, PhNCH3), 2.92 (3H, s, NCH3), 2.22 – 2.11 (1H, m, 
CHCHAHB), 1.27 – 1.18 (1H, m, CHCHAHB), 0.96 (9H, s, C(CH3)3); 13C NMR (126 MHz, CDCl3): 
  (C=O)amide, 162.76 (C=O)urea, 143.88 (CAr), 132.92 (CAr), 130.53 (2xCArH), 127.72 
(2xCArH), 124.73 (q, 
1JC-F = 277.8, CF3), 82.51 (CHC(CH3)3), 57.02 (q, 
3JC-F = 3.3, CHCH2), 41.29 
(PhNCH3), 37.43 (q, 
2JC-F = 29.3, CHCH2), 36.93 (C(CH3)3), 31.90 (NCH3), 26.85 (C(CH3)3); 19F 
NMR (377 MHz, CDCl3) δF −60.94 (3F, dd, J =11.7, 9.2); IR (vmax/cm-1) (neat): 2971, 2929 
(alkyl C-H), 1713, 1661 (C=O); HRMS (ESI): m/z calcd for C18H23ClF3N3O2Na [M+Na]+ 











Following general procedure 12: vinyl urea 400d (33.6 mg, 0.10 mmol), caesium carbonate (48.9 
mg, 0.15 mmol), 4CzIPN (3.90 mg, 5 x 10⁻3 mmol) and C2H3F2SO2Na (30.4 mg, 0.20 mmol, 2.00 
eq.) in anhydrous CH3CN (1.00 mL). The crude product was purified by flash column 
chromatography (SiO2; Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 60:40) to afford the title 
compound (19F NMR yield: 67%) as a yellow oil. Rf (6:4 Pet.Ether:EtOAc) 0.38; 1H NMR (400 
MHz, CDCl3):  7.37 (2H, d, J =8.7, Ar-H), 7.07 (2H, d, J =8.7, Ar-H), 5.25 (1H, s, CHC(CH3)3), 
4.20 (1H, dd, J =10.7, 2.9, CHCHAHB), 3.16 (3H, s, PhNCH3), 2.90 (3H, s, NCH3), 2.06 – 1.90 
(1H, m, CHCHAHB), 1.59 (3H, t, J =18.9, CF2CH3), 1.39 – 1.24 (1H, m, CHCHAHB), 0.97 (9H, s, 
C(CH3)3); 13C NMR (126 MHz, CDCl3):   (C=O)amide, 163.01 (C=O)urea, 144.14 (CAr), 
132.21 (CAr), 130.23 (2xCArH), 127.37 (2xCArH), 122.21 (t, 
1JC-F = 240.8, CF2), 82.37 
(CHC(CH3)3), 57.76 (dd, 
3JC-F = 7.5, 3.7, CHCH2), 41.57 (dd, 
2JC-F = 27.4, 25.3, CHCH2), 41.19 
(PhNCH3), 36.94 (C(CH3)3), 31.87 (NCH3), 26.94 (C(CH3)3), 24.59 (t, 
1JC-F = 27.2, CF2CH3); 19F 
NMR (377 MHz, CDCl3) δF −82.47 to −83.44 (1F, m), δF −88.16 (1F, ddq, J = 244.6, 35.3, 18.0); 
IR (vmax/cm-1) (neat): 2976, 2934 (alkyl C-H), 1707, 1662 (C=O); HRMS (ESI): m/z calcd for 




Following general procedure 12: vinyl urea 400d (33.6 mg, 0.10 mmol), caesium carbonate (48.9 
mg, 0.15 mmol), 4CzIPN (3.90 mg, 5 x 10⁻3 mmol) and CHF2SO2Na (27.6 mg, 0.20 mmol, 2.00 
eq.) in anhydrous CH3CN (1.00 mL). The crude product was purified by flash column 
chromatography (SiO2; Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 60:40) to afford the title 
compound (34.1 mg, 88%) as a yellow solid; mp: 87 – 89 °C; Rf (6:4 Pet.Ether:EtOAc) 0.35; 1H 
NMR (400 MHz, CDCl3):  7.35 (2H, d, J =8.7, Ar-H), 7.04 (2H, d, J =8.7, Ar-H), 6.07 (1H, tdd, 





(3H, s, PhNCH3), 2.87 (3H, s, NCH3), 1.75 – 1.56 (1H, m, CHCHAHB), 0.90 (9H, s, C(CH3)3), 0.68 
– 0.54 (1H, m, CHCHAHB); 13C NMR (126 MHz, CDCl3):   (C=O)amide, 163.26 (C=O)urea, 
143.87 (CAr), 132.90 (CAr), 130.45 (2xCArH), 128.43 (2xCArH), 114.58 (dd, 
1JC-F = 240.0 CHF2), 
82.76 (CHC(CH3)3), 58.26 (dd, 
3JC-F = 11.7, 2.9, CHCH2), 41.49 (PhNCH3), 36.91 (C(CH3)3), 37.00 
(dd, 2JC-F = 23.0, 21.4, CHCH2), 31.70 (NCH3), 26.86 (C(CH3)3); 19F NMR (377 MHz, CDCl3) δF 
−114.57 to −115.63 (1F, m), δF −119.44 (1F, dddd, J = 288.3, 57.2, 30.9, 10.5); IR (vmax/cm-1) 
(neat): 2974, 2929 (alkyl C-H), 1702, 1663 (C=O); HRMS (ESI): m/z calcd for C18H24ClF2N3O2Na 




Following general procedure 12: vinyl urea 400e (126 mg, 0.40 mmol), caesium carbonate (195 
mg, 0.60 mmol), 4CzIPN (15.8 mg, 0.02 mmol) and C2H3F2SO2Na (122 mg, 0.80 mmol, 2.00 eq.) 
in anhydrous CH3CN (2.00 mL). The crude product was purified by flash column chromatography 
(SiO2; Pet.Ether:Diethyl ether 100:0 to Pet.Ether:Diethyl ether 40:60) to afford the title compound 
(87.0 mg, 57%) as a yellow oil. Rf (4:6:Pet.Ether:Diethyl ether) 0.21; 1H NMR (400 MHz, CDCl3): 
 7.20 (2H, d, J =8.3, Ar-H), 7.02 (2H, d, J =8.3, Ar-H), 5.26 (1H, s, CHC(CH3)3), 4.18 (1H, dd, J 
=10.9, 2.8, CHCHAHB), 3.16 (3H, s, PhNCH3), 2.88 (3H, s, NCH3), 2.35 (CH3), 1.98 – 1.81 (1H, 
m, CHCHAHB), 1.56 (3H, t, J =18.9, CF2CH3), 1.22 – 1.07 (1H, m, CHCHAHB), 0.96 (9H, s, 
C(CH3)3); 13C NMR (126 MHz, CDCl3):   (C=O)amide, 163.21 (C=O)urea, 142.97 (CAr), 
136.82 (CAr), 130.73 (2xCArH), 126.28 (2xCArH), 122.31 (t, 
1JC-F = 240.2, CF2), 82.27 
(CHC(CH3)3), 58.00 (dd, 
3JC-F = 6.4, 4.9, CHCH2), 41.31 (PhNCH3), 41.20 (t, 
2JC-F = 26.5, CHCH2), 
36.87 (C(CH3)3), 31.81 (NCH3), 26.97 (C(CH3)3), 24.27 (t, 
1JC-F = 27.2, CF2CH3), 21.03 (CH3); 19F 
NMR (377 MHz, CDCl3) δF −82.50 to −83.55 (1F, m), δF −85.94 to −86.99 (1F, m); IR (vmax/cm-
1) (neat): 2969, 2931 (alkyl C-H), 1710 (C=O), 1660 (C=O); HRMS (ESI): m/z calcd for 











Following general procedure 12: vinyl urea 400e (126 mg, 0.40 mmol), caesium carbonate (195 
mg, 0.60 mmol), 4CzIPN (15.8 mg, 0.02 mmol) and CHF2SO2Na (110 mg, 0.80 mmol, 2.00 eq.) in 
anhydrous CH3CN (2.00 mL). The crude product was purified by flash column chromatography 
(SiO2; Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 60:40) to afford the title compound (111 mg, 
75%) as a yellow oil. 1H NMR (400 MHz, CDCl3):  7.22 (2H, d, J =8.6, Ar-H), 7.04 (2H, d, J 
=8.6, Ar-H), 6.06 (1H, tdd, J = 56.7, 8.0, 2.7, CHF2), 5.53 (1H, s, CHC(CH3)3), 4.00 (1H, ddd, J 
=11.9, 3.3, 1.9, CHCHAHB), 3.15 (3H, s, PhNCH3), 2.92 (3H, s, NCH3), 2.35 (CH3), 1.70 – 1.51 
(1H, m, CHCHAHB), 0.96 (9H, s, C(CH3)3), 0.58 – 0.45 (1H, m, CHCHAHB); 13C NMR (126 MHz, 
CDCl3):   (C=O)amide, 163.43 (C=O)urea, 142.57 (CAr), 137.32 (CAr), 130.84 (2xCArH), 
127.09 (2xCArH), 114.70 (dd, 
1JC-F = 240.0 CHF2), 82.64 (CHC(CH3)3), 58.42 (dd, 
3JC-F = 11.5, 3.3, 
CHCH2), 41.48 (PhNCH3), 36.86 (C(CH3)3), 36.77 (t, 
2JC-F = 22.3, CHCH2), 31.64 (NCH3), 26.84 
(C(CH3)3), 21.02 (CH3); 19F NMR (377 MHz, CDCl3) δF −114.43 to −115.70 (1F, m), δF −119.08 
(1F, dddd, J = 288.7, 56.7, 30.2, 10.2); IR (vmax/cm-1) (neat): 2965, 2926 (alkyl C-H), 1699, 1657 




Following general procedure 12: vinyl urea 400g (202 mg, 0.54 mmol), caesium carbonate (259 
mg, 0.81 mmol), 4CzIPN (21.3 mg, 0.027 mmol) and CF3SO2Na (248 mg, 1.59 mmol, 3.00 eq.) in 
anhydrous CH3CN (5.40 mL). The crude product was purified by flash column chromatography 
(SiO2; Diethyl ether:Acetone 100:0 to Diethyl ether:Acetone 99:1) to afford the title compound 
(158 mg, 65%) as a yellow oil. Rf (9.9:0.1 Diethyl ether:Acetone) 0.43; 1H NMR (400 MHz, 
CDCl3):  7.56 (2H, d, J =8.7, Ar-H), 7.03 (2H, d, J =8.7, Ar-H), 5.34 (1H, s, CHC(CH3)3), 4.19 
(1H, dd, J =10.8, 2.6, CHCHAHB), 3.17 (3H, s, PhNCH3), 2.93 (3H, s, NCH3), 2.22 – 2.11 (1H, m, 





  (C=O)amide, 162.71 (C=O)urea, 144.41 (CAr), 133.54 (2xCArH), 128.02 (2xCArH), 124.74 (q, 
1JC-F = 277.6, CF3), 120.58 (CAr), 82.53 (CHC(CH3)3), 57.02 (q, 
3JC-F = 3.3, CHCH2), 41.22 
(PhNCH3), 37.44 (q, 
2JC-F = 29.2, CHCH2), 36.96 (C(CH3)3), 31.92 (NCH3), 26.87 (C(CH3)3); 19F 
NMR (377 MHz, CDCl3) δF −60.74 to −60.91(3F, m); IR (vmax/cm-1) (neat): 2971, 2935 (alkyl 
C-H), 1715, 1662 (C=O); HRMS (ESI): m/z calcd for C18H23BrF3N3O2Na [M+Na]+ 472.0818, 
found 472.0807. 




Following general procedure 13: LiHMDS (1.0 M/THF, 70 L, 0.07 mmol) and conjugate addition 
product 427af (16.2 mg, 0.046 mmol) in anhydrous THF (0.50 mL). The reaction was complete 
after 1 hour (monitored by TLC). The crude product was purified by flash column chromatography 
(SiO2; Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 60:40) to afford the title compound (9.9 mg, 
61%) as a yellow oil. Rf (6:4 Pet.Ether:EtOAc) 0.35; 1H NMR (400 MHz, CDCl3):  7.39 – 7.33 
(2H, m, Ar-H), 7.33 – 7.27 (1H, m, Ar-H), 7.20 – 7.16 (2H, m, Ar-H), 6.31 (1H, tdd, J = 55.0, 6.5, 
2.5, CHF2), 5.64 (1H, s, CHC(CH3)3), 4.20 (1H, br. s, NHCH3), 3.09 (3H, s, NCH3), 3.08 – 2.87 
(2H, m, NCCH2), 2.35 (3H, d, J =4.7, NHCH3), 1.08 (9H, s, C(CH3)3); 13C NMR (126 MHz, 
CDCl3):   (C=O)amide, 158.87 (C=O)urea, 139.53 (CAr), 129.30 (2xCArH), 128.81 (CArH), 
125.56 (2xCArH), 115.67 (t, 
1JC-F = 238.7, CHF2), 81.31 (CHC(CH3)3), 66.72 (dd, 
3JC-F = 9.6, 2.4, 
NC(Ar)), 40.60 (t, 2JC-F = 22.4, NCCH2), 38.22 (C(CH3)3), 32.17 (NCH3), 27.23 (NHCH3), 26.93 
(C(CH3)3); 19F NMR (377 MHz, CDCl3) δF −109.98 to −111.09 (1F, m), δF −111.62 to −112.68 (1F, 
m); IR (vmax/cm-1) (neat): 3396 (NH), 2971, 2906 (alkyl C-H), 1704, 1666 (C=O); HRMS (ESI): 












Following general procedure 13: LiHMDS (1.0 M/THF, 160 L, 0.15 mmol) and conjugate 
addition product 427da (42.0 mg, 0.104 mmol) in anhydrous THF (1.00 mL). The reaction was 
complete after 2 hours (monitored by TLC). The crude product was purified by flash column 
chromatography (SiO2; Pentane:Diethyl ether 100:0 to Pentane:Diethyl ether 30:70) to afford the 
title compound (22.8 mg, 54%) as a yellow oil. Rf (3:7 Pentane:Diethyl ether) 0.28; 1H NMR (400 
MHz, CDCl3):  7.33 (2H, d, J =8.8, Ar-H), 7.10 (2H, d, J =8.8, Ar-H), 5.68 (1H, s, CHC(CH3)3), 
4.33 (1H, br. s, NHCH3), 3.36 – 3.25 (1H, m, CHAHB), 3.19 – 3.08 (1H, m, CHAHB), 3.07 (3H, s, 
NCH3), 2.45 (3H, d, J =4.7, NHCH3), 1.07 (9H, s, C(CH3)3); 13C NMR (126 MHz, CDCl3): 
  (C=O)amide, 158.85 (C=O)urea, 137.35 (CAr), 134.96 (CAr), 129.34 (2xCArH), 127.02 
(2xCArH), 125.81 (q, 
1JC-F = 277.7, CF3), 81.50 (CHC(CH3)3), 66.54 (q, 
3JC-F = 2.4, NC(Ar)), 38.30 
(q, 2JC-F = 27.5, NCCH2), 38.01 (C(CH3)3), 32.11 (NCH3), 27.38 (NHCH3), 26.82 (C(CH3)3); 19F 
NMR (377 MHz, CDCl3) δF −58.54 (3F, t, J = 10.7); IR (vmax/cm-1) (neat): 3423 (NH), 2969, 
2907 (alkyl C-H), 1761, 1676 (C=O); HRMS (ESI): m/z calcd for [C18H23ClF3N3O2Na [M+Na]+ 




Following general procedure 13: LiHMDS (1.0 M/THF, 80 L, 0.08 mmol) and conjugate addition 
product 427de (22.6 mg, 0.056 mmol) in anhydrous THF (0.60 mL). The reaction was complete 
after 1 hour (monitored by TLC). The crude product was purified by flash column chromatography 
(SiO2; Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 60:40) to afford the title compound (11.2 mg, 
50%) as a white solid. Rf (6:4 Pet.Ether:EtOAc) 0.25; 1H NMR (400 MHz, CDCl3):  7.29 (2H, d, 





(1H, ddd, J =30.1, 16.5, 2.9, CHAHB), 3.04 (3H, s, NCH3), 2.65 (1H, , ddd, J =30.1, 16.5, 8.3, 
CHAHB), 2.40 (3H, d, J =4.6, NHCH3), 1.84 (3H, t, J =18.9, CH3F2), 1.07 (9H, s, C(CH3)3); 13C 
NMR (126 MHz, CDCl3):   (C=O)amide, 158.79 (C=O)urea, 138.10 (CAr), 134.30 (CAr), 
128.97 (2xCArH), 127.49 (2xCArH), 124.58 (dd, 
1JC-F = 242.8, 237.2, CF2), 81.40 (CHC(CH3)3), 
67.58 ( NC(Ar)), 40.94 (t, 2JC-F = 22.8, NCCH2), 38.21 (C(CH3)3), 32.08 (NCH3), 27.15 (NHCH3), 
26.83 (C(CH3)3), 26.08 (t, 
2JC-F = 27.3, CH3F2); 19F NMR (377 MHz, CDCl3) δF −84.42 to −85.15 
(1F, m), δF −89.58 to −90.20 (1F, m); IR (vmax/cm-1) (neat): 3660 (NH), 2977, 2903 (alkyl C-H), 





Following general procedure 13: LiHMDS (1.0 M/THF, 120 L, 0.12 mmol) and conjugate 
addition product 427df (30.0 mg, 0.08 mmol) in anhydrous THF (0.80 mL). The reaction was 
complete after 2 hours (monitored by TLC). The crude product was purified by flash column 
chromatography (SiO2; Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 60:40) to afford the title 
compound (16.3 mg, 53%) as a yellow oil. Rf (6:4 Pet.Ether:EtOAc) 0.42; 1H NMR (400 MHz, 
CDCl3):  7.33 (2H, d, J =8.8, Ar-H), 7.11 (2H, d, J =8.8, Ar-H), 6.27 (1H, tdd, J = 55.0, 6.1, 3.0, 
CHF2), 5.59 (1H, s, CHC(CH3)3), 4.32 (1H, br. s, NHCH3), 3.08 (3H, s, NCH3), 3.03 – 2.86 (2H, 
m, NCCH2), 2.42 (3H, d, J =4.6, NHCH3), 1.06 (9H, s, C(CH3)3); 13C NMR (126 MHz, CDCl3): 
  (C=O)amide, 158.73 (C=O)urea, 138.18 (CAr), 134.83 (CAr), 129.38 (2xCArH), 127.03 
(2xCArH), 115.53 (t, 
1JC-F = 239.4, CHF2), 81.25 (CHC(CH3)3), 66.52 (dd, 
3JC-F = 9.4, 2.6, NC(Ar)), 
40.58 (t, 2JC-F = 22.4, NCCH2), 38.21 (C(CH3)3), 32.18 (NCH3), 27.31 (NHCH3), 26.85 (C(CH3)3); 
19F NMR (377 MHz, CDCl3) δF −110.15 to −111.26 (1F, m), δF −112.11 (1F, ddt, J = 287.7, 55.0, 
12.2); IR (vmax/cm-1) (neat): 3396 (NH), 2973, 2906 (alkyl C-H), 1698 (C=O), 1662 (C=O); 










Following general procedure 13: LiHMDS (1.0 M/THF, 0.82 mL, 0.82 mmol, 2.5 eq.) and 
conjugate addition product 427ga (147 mg, 0.33 mmol) in anhydrous THF (3.30 mL). The reaction 
was complete after 3 hours (monitored by TLC). The crude product was purified by flash column 
chromatography (SiO2; Pentane:Diethyl ether 100:0 to Pentane:Diethyl ether 40:60) to afford the 
title compound (78.4 mg, 53%) as a white foam. Rf (4:6 Pentane:Diethyl ether) 0.35; 1H NMR 
(400 MHz, CDCl3):  7.48 (2H, d, J =8.7, Ar-H), 7.04 (2H, d, J =8.7, Ar-H), 5.68 (1H, s, 
CHC(CH3)3), 4.33 (1H, br. s, NHCH3), 3.36 – 3.24 (1H, m, CHAHB), 3.19 – 3.08 (1H, m, CHAHB), 
3.07 (3H, s, NCH3), 2.45 (3H, d, J =4.6, NHCH3), 1.07 (9H, s, C(CH3)3); 13C NMR (126 MHz, 
CDCl3):   (C=O)amide, 158.83 (C=O)urea, 137.90 (CAr), 132.31 (2xCArH), 127.30 (2xCArH), 
123.16 (CAr), 125.66 (q, 
1JC-F = 278.0, CF3), 81.52 (CHC(CH3)3), 66.63 (q, 
3JC-F = 2.1, NC(Ar)), 
38.26 (q, 2JC-F = 27.2, NCCH2), 38.02 (C(CH3)3), 32.12 (NCH3), 27.40 (NHCH3), 26.83 (C(CH3)3); 
19F NMR (377 MHz, CDCl3) δF −58.53 (3F, t, J = 10.7); IR (vmax/cm-1) (neat): 3391 (NH), 2964, 
2920 (alkyl C-H), 1708 (C=O), 1678 (C=O); HRMS (ESI): m/z calcd for C18H23BrF3N3O2Na 
[M+Na]+ 472.0818, found 472.0814. 





Following general procedure 14: KHMDS (1.0 M/THF, 100 L, 0.09 mmol, 1.50 eq.) and 
conjugate addition product 427ae (23.6 mg, 0.06 mmol) in anhydrous THF (0.60 mL). The reaction 





chromatography (SiO2; Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 60:40) to afford the title 
compound (5.4 mg, 26%) as an orange oil. Rf (6:4 Pet.Ether:EtOAc) 0.30; 1H NMR (400 MHz, 
CDCl3):  7.36 – 7.30 (2H, m, Ar-H), 7.28 – 7.23 (1H, m, Ar-H), 7.20 – 7.15 (2H, m, Ar-H), 5.77 
(1H, s, CHC(CH3)3), 5.29 (1H, dq, J =39.2, 0.9, CH=CFCH3), 4.16 (1H, br. q, J = 4.6, NH), 3.09 
(3H, s, NCH3), 2.24 (3H, d, J = 4.6, NHCH3), 2.12 (3H, dd, J =17.1, 0.9, CH=CFCH3), 1.02 (9H, 
s, C(CH3)3); 13C NMR (126 MHz, CDCl3):   (C=O)amide, 158.44 (C=O)urea, 158.01 (d, 
1JC-F 
= 260.4, CH=CFCH3), 140.70 (d, 
4JC-F = 2.1, CAr), 129.09 (2xCArH), 128.48 (CArH), 125.98 
(2xCArH), 105.14 (d, 
2JC-F = 6.0, CH=CFCH3), 80.69 (CHC(CH3)3), 69.20 (NCPh), 38.57 
(C(CH3)3), 32.13 (NCH3), 26.91 (NHCH3), 26.27 (C(CH3)3), 19.30 (d, 
2JC-F = 29.6, CH=CFCH3); 
19F NMR (377 MHz, CDCl3) δF −94.42 (1F, dqd, J = 34.2, 17.1, 6.1); IR (vmax/cm-1) (neat): 3419 
(NH), 3061 (alkene C-H), 2959, 2922 (alkyl C-H), 1704, 1667 (C=O); MS (ESI): m/z calcd for 




Following general procedure 14: KHMDS (1.0 M/THF, 140 L, 0.14 mmol, 1.50 eq.) and 
conjugate addition product 427af (32.2 mg, 0.091 mmol) in anhydrous THF (0.91 mL). The reaction 
was complete after 2 hours (monitored by TLC). The crude product was purified by flash column 
chromatography (SiO2; Pet.Ether:Diethyl ether 100:0 to Pet.Ether:Diethyl ether 40:60) to afford the 
title compound (16.5 mg, 54%) as a yellow oil. Rf (6:4 Pet.Ether:EtOAc) 0.18; 1H NMR (400 MHz, 
CDCl3):  7.40 – 7.33 (2H, m, Ar-H), 7.32 – 7.27 (1H, m, Ar-H), 7.20 – 7.17 (2H, m, Ar-H), 7.05 
(1H, dd, J = 82.5, 11.2, CH=CHF), 6.21 (1H, dd, J = 19.3, 11.2, CH=CHF), 5.68 (1H, s, 
CHC(CH3)3), 3.88 (1H, br. q, J = 4.8, NH), 3.08 (3H, s, NCH3), 2.25 (3H, d, J = 4.8, NHCH3), 1.06 
(9H, s, C(CH3)3); 13C NMR (126 MHz, CDCl3):   (d, 
4JC-F = 2.2, C=O)amide, 158.01 
(C=O)urea, 153.19 (d, 
1JC-F = 261.7, CH=CHF), 140.92 (d, 4JC-F = 2.4, CAr), 129.50 (2xCArH), 128.88 
(CArH), 125.66 (2xCArH), 112.15 (d, 
2JC-F = 14.9, CH=CHF), 80.65 (CHC(CH3)3), 67.40 (d, 
3JC-F = 
10.1, NCPh), 38.66 (C(CH3)3), 32.12 (NCH3), 27.02 (NHCH3), 26.75 (C(CH3)3); 19F NMR (377 
MHz, CDCl3) δF −126.04 (1F, dd, J = 82.5, 19.3); IR (vmax/cm-1) (neat): 3408 (NH), 3065 (alkene 
C-H), 2969, 2909 (alkyl C-H), 1698, 1659 (C=O); HRMS (ESI): m/z calcd for C18H24FN3O2Na 








Following general procedure 14: KHMDS (1.0 M/THF, 270 L, 0.27 mmol, 2.50 eq.) and 
conjugate addition product 427df (42.1 mg, 0.108 mmol) in anhydrous THF (1.10 mL). The 
reaction was complete after 2.45 hours (monitored by TLC). The crude product was purified by 
flash column chromatography (SiO2; Pentane:Diethyl ether 100:0 to Pentane:Diethyl ether 30:70) 
to afford the title compound (32.3 mg, 81%) as a yellow oil. Rf (7:3 Pentane:Diethyl ether) 0.24; 
1H NMR (400 MHz, CDCl3):  7.34 (2H, d, J = 8.7, Ar-H), 7.13 (2H, J = 8.7, Ar-H), 7.06 (1H, 
dd, J = 82.1, 11.2, CH=CHF), 6.15 (1H, dd, J = 19.0, 11.2, CH=CHF), 5.66 (1H, s, CHC(CH3)3), 
3.90 (1H, br. s, NH), 3.07 (3H, s, NCH3), 2.34 (3H, d, J = 4.7, NHCH3), 1.05 (9H, s, C(CH3)3); 13C 
NMR (126 MHz, CDCl3):   (d, 
4JC-F = 2.1, C=O)amide, 157.70 (C=O)urea, 153.44 (d, 
1JC-F = 
262.7, CH=CHF), 139.50 (d, 4JC-F = 2.6, CAr), 134.95 (CAr), 129.63 (2xCArH), 127.12 (2xCArH), 
111.86 (d, 2JC-F = 15.1, CH=CHF), 80.63 (CHC(CH3)3), 67.03 (d, 
3JC-F = 10.2, NCPh), 38.67 
(C(CH3)3), 32.17 (NCH3), 27.12 (NHCH3), 26.72 (C(CH3)3); 19F NMR (377 MHz, CDCl3) δF 
−125.16 (1F, dd, J = 82.1, 19.0); IR (vmax/cm-1) (neat): 3403 (NH), 3103 (alkene C-H), 2971, 
2932 (alkyl C-H), 1703, 1662 (C=O); HRMS (ESI): m/z calcd for [C18H23ClFN3O2Na [M+Na]+ 




Following general procedure 14: KHMDS (1.0 M/THF, 400 L, 0.37 mmol, 2.50 eq.) and 
conjugate addition product 427ef (53.8 mg, 0.146 mmol) in anhydrous THF (1.50 mL). The reaction 
was complete after 2 hours (monitored by TLC). The crude product was purified by flash column 
chromatography (SiO2; Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 60:40) to afford the title 





CDCl3):  7.16 (2H, d, J = 8.6, Ar-H), 7.06 (2H, J = 8.6, Ar-H), 7.04 (1H, dd, J = 82.7, 11.2, 
CH=CHF), 6.18 (1H, dd, J = 19.3, 11.2, CH=CHF), 5.66 (1H, s, CHC(CH3)3), 3.89 (1H, br. q, J = 
4.8, NH), 3.07 (3H, s, NCH3), 2.31 (CH3), 2.28 (3H, d, J = 4.8, NHCH3), 1.05 (9H, s, C(CH3)3); 
13C NMR (126 MHz, CDCl3):   (d, 
4JC-F = 2.2, C=O)amide, 158.10 (C=O)urea, 153.12 (d, 
1JC-
F = 261.4, CH=CHF), 138.82 (CAr), 137.89 (d, 
4JC-F = 2.5, CAr), 130.20 (2xCArH), 125.56 (2xCArH), 
112.19 (d, 2JC-F = 14.8, CH=CHF), 80.60 (CHC(CH3)3), 67.19 (d, 
3JC-F = 10.2, NCPh), 38.69 
(C(CH3)3), 32.14 (NCH3), 27.10 (NHCH3), 26.78 (C(CH3)3), 21.17 (CH3); 19F NMR (377 MHz, 
CDCl3) δF −126.26 (1F, dd, J = 82.7, 19.3); IR (vmax/cm-1) (neat): 3406 (NH), 3171 (alkene C-
H), 2965, 2932 (alkyl C-H), 1703, 1662 (C=O); HRMS (ESI): m/z calcd for C19H27FN3O2 [M+H]+ 
348.208182, found 348.208386. 




Following general procedure 15: conjugate addition product 427da (137 mg, 0.34 mmol) was 
dissolved in anhydrous THF (3.40 mL) at 0 °C. LiHMDS (1 M/THF, 0.51 mL, 0.51 mmol, 1.50 
eq.) was added and the reaction stirred for 2 hours at 0 °C. An additional 1.50 eq. of LiHMDS (1 
M/THF, 0.51 mL, 0.51 mmol ) was added and the reaction stirred for 45 mins at 0 °C, after which 
MeI (110 L, 1.69 mmol, 5.0 eq.) was added. The reaction was allowed to warm to room 
temperature and left to stir for 16 hours. The crude product was purified by flash column 
chromatography (SiO2; Pentane:Diethyl ether 100:0 to Pentane:Diethyl ether 30:70) to afford the 
title compound (54.8 mg, 38%) as a white solid. 1H NMR (400 MHz, CDCl3):  7.28 (2H, d, J 
=8.3, Ar-H), 6.98 (2H, d, J =8.3, Ar-H), 5.42 (1H, s, CHC(CH3)3), 3.31 (2H, q, J = 10.1, NCCH2), 
3.21 (3H, s, NCH3), 2.71 (6H, s, br., N(CH3)2), 1.01 (9H, s, C(CH3)3); 13C NMR (126 MHz, CDCl3): 
  (C=O)amide, 163.22 (C=O)urea, 136.16 (CAr), 134.83 (CAr), 128.46 (2xCArH), 127.69 
(2xCArH), 125.17 (t, 
1JC-F = 278.5, CF3), 82.01 (CHC(CH3)3), 68.71 (NC(Ar)), 38.76 (q, 
2JC-F = 28.5, 
NCCH2), 38.23 (N(CH3)2), 36.68 (C(CH3)3), 31.73 (NCH3), 26.49 (C(CH3)3); 19F NMR (377 MHz, 
CDCl3) δF −57.61 (3F, 10.1); IR (vmax/cm-1) (neat): 2967, 2928 (alkyl C-H), 1713 (C=O), 1667 








Following general procedure 15: conjugate addition product 427df (160 mg, 0.41 mmol) was 
dissolved in anhydrous THF (4.10 mL) at 0 °C. LiHMDS (1 M/THF, 0.62 mL, 0.62 mmol, 1.50 
eq.) was added and the reaction stirred for 4.5 hours at 0 °C. An additional 1.50 eq. of LiHMDS (1 
M/THF, 0.62 mL, 0.62 mmol) was added and the reaction stirred for 45 mins at 0 °C, after which 
MeI (51 L, 0.82 mmol, 2.00 eq.) was added. The reaction was allowed to warm to room 
temperature and left to stir for 16 hours. The crude product was purified by flash column 
chromatography (SiO2; Pet.Ether:EtOAc 100:0 to Pet.Ether:EtOAc 70:30) to afford the title 
compound (54.8 mg, 38%) as a white solid. Rf (7:3 Pet.Ether:EtOAc) 0.28; 1H NMR (400 MHz, 
CDCl3):  7.29 (2H, d, J =8.7, Ar-H), 7.05 (2H, d, J =8.3, Ar-H), 6.31 (1H, tt, J = 55.6, 4.0, CHF2), 
5.40 (1H, s, CHC(CH3)3), 3.36 – 3.20 (1H, m, NCCHAHB), 3.18 (3H, s, NCH3), 2.81 (1H, qd, J = 
15.4, 14.2, NCCHAHB), 2.68 (6H, s, br., N(CH3)2), 1.00 (9H, s, C(CH3)3); 13C NMR (126 MHz, 
CDCl3):   (C=O)amide, 162.65 (C=O)urea, 135.14 (CAr), 134.81 (CAr), 128.44 (2xCArH), 
128.41 (2xCArH), 115.05 (t, 
1JC-F = 239.1, CHF2), 82.07 (CHC(CH3)3), 68.97 (t, 
3JC-F = 6.8, 
NC(Ar)), 41.55 (t, 2JC-F = 23.2, NCCH2), 38.21 (N(CH3)2), 36.95 (C(CH3)3), 31.92 (NCH3), 26.30 
(C(CH3)3); 19F NMR (377 MHz, CDCl3) δF −109.73 (2F, dtd, J = 55.5, 15.8, 10.8); IR (vmax/cm-
1) (neat): 2965, 2910 (alkyl C-H), 1700 (C=O), 1659 (C=O); HRMS (ESI): m/z calcd for 
C19H26ClF2N3O2Na [M+Na]+ 424.1574, found 424.1583. 
4.3.3 Decarboxylative Arylation of Urea Malonic Acid Half Esters 
4.3.3.1 Synthesis of Urea Malonic Acid Half Esters 
Diethyl 2-(3-methyl-3-phenylureido)malonate (477a) 
 
Following general procedure 16: N-methyl-N-phenylcarbamoyl chloride (73.0 mg, 0.43 mmol) in 
anhydrous CH3CN (4.30 mL), diethyl amino malonate hydrochloride salt (100 mg, 0.47 mmol) and 





(SiO2; Pet.Ether:EtOAc 100:0 to Pet: EtOAc 60:40) to afford the title compound (100 mg, 75%) as 
a colourless oil. Rf (6:4 Pet.Ether:EtOAc) 0.27; 1H NMR (400 MHz, CDCl3):  7.46 – 7.40 (2H, 
m, 2xAr-H), 7.34 – 7.28 (3H, m, 3xAr-H), 5.37 (1H, br. d, J = 7.4, NH), 5.11 (1H, d, J = 7.4, CH), 
4.20 (4H, qq, J = 10.8, 7.2, 2xOCH2), 3.27 (3H, s, NCH3), 1.25 (6H, t, J = 7.1, 2xCH2CH3); 13C 
NMR (101 MHz, CDCl3): 167.21 (2xC=O), 155.94 (C=O), 142.75 (CAr), 130.18 (2xCArH), 127.71 
(CArH), 127.17 (2xCArH), 62.40 (2xOCH2), 57.87 (CH), 37.36 (NCH3), 14.07 (2xCH2CH3); (IR 
(vmax/cm-1) (neat): 3428 (NH), 2982, 2939 (alkyl C-H), 1753, 1737 (C=Oester), 1665(C=O); 
HRMS (ESI): m/z calcd for C15H21N2O5 [M+H]+ 309.144498.Found 309.145197. 
Diethyl 2-(1,3-dimethyl-3-phenylureido)-2-methylmalonate (478a) 
 
Following general procedure 17: urea malonic acid ester 477a (772 mg, 2.50 mmol) in anhydrous 
DMF (25.0 mL), NaH (60% in mineral oil, 300 mg, 7.51 mmol) and MeI (0.78 mL, 12.5 mmol). 
The crude product was purified by flash column chromatography (SiO2; Pet.Ether:EtOAc 100:0 to 
Pet.Ether:EtOAc 60:40) to afford the title compound (751 mg, 89%) as a colourless oil. Rf (6:4 
Pet.Ether:EtOAc) 0.36; 1H NMR (400 MHz, CDCl3):  7.34 (4H, d, J = 4.2, 2xAr-H), 7.12 (1H, q, 
J = 4.3, Ar-H), 4.25 (4H, qd, J = 7.1, 1.4, 2xOCH2), 3.24 (3H, s, NCH3), 2.41 (3H, s, NCH3), 1.70 
(3H, s, CCH3), 1.29 (6H, t, J = 7.1, 2xCH2CH3); 13C NMR (101 MHz, CDCl3): 169.12 (2xC=O), 
161.66 (C=O), 146.25 (CAr), 129.44 (2xCArH), 124.77 (CArH), 124.50 (2xCArH), 69.86 (CCH3), 
62.01 (2xOCH2), 39.25 (NCH3), 35.02 (NCH3), 20.25 (CCH3), 14.18 (2xCH2CH3); (IR (vmax/cm-
1) (neat): 2980, 2907 (alkyl C-H), 1746 (C=Oester), 1651 (C=O); HRMS (ESI): m/z calcd for 
C17H25N2O5 [M+H]+ 337.1758, found 337.1768. 
2-(1,3-Dimethyl-3-phenylureido)-3-ethoxy-2-methyl-3-oxopropanoic acid (469a) 
 
Following general procedure 18: alkylated urea malonic acid ester 478a (707 mg, 2.10 mmol) in 
ethanol:water (10:1, 3.00 mL) and KOH (236 mg, 4.21 mmol). The crude product was purified by 
flash column chromatography (SiO2; DCM:MeOH 100:0 to DCM:MeOH 93:7) to afford the title 
compound 55a (357 mg, 55%) as a cream solid. Rf (9.3:0.7 DCM:MeOH) 0.30; mp: 68 – 70 °C; 
1H NMR (400 MHz, CDCl3):  7.48 – 7.44 (2H, m, 2xAr-H), 7.43 – 7.37 (2H, m, 2xAr-H), 7.25 – 
7.20 (1H, m, Ar-H) 4.33 (2H, q, J = 7.1, OCH2), 3.34 (3H, s, NCH3), 2.38 (3H, s, NCH3), 1.55 (3H, 
s, CCH3), 1.34 (3H, t, J = 7.1, CH2CH3); 13C NMR (101 MHz, CDCl3): 170.62 (C=O), 170.24 





(CCH3), 62.90 (OCH2), 39.65 (NCH3), 34.10 (NCH3), 20.68 (CCH3), 14.12 (CH2CH3); (IR 
(vmax/cm-1) (neat): 3300 – 2300 (OH), 2982, 2940 (alkyl C-H), 1788 (C=O), 1739 (C=O) 1646 
(C=O); HRMS (ESI): m/z calcd for C15H21N2O5 [M+H]+ 309.144498, found 309.143533. 
Diethyl 2-(3-(4-cyanophenyl)-3-methylureido)malonate (477b) 
 
Following general procedure 16: N-(4-cyanophenyl)-N-methylcarbamoyl chloride (575 mg, 2.95 
mmol) in anhydrous CH3CN (29.6 mL), diethyl amino malonate hydrochloride salt (688 mg, 3.25 
mmol) and Et3N (0.91 mL, 6.50 mmol). The crude product was purified by flash column 
chromatography (SiO2; Pet.Ether:EtOAc 100:0 to Pet: EtOAc 60:40) to afford the title compound 
(984 mg, >99%) as a yellow oil. Rf (6:4 Pet.Ether:EtOAc) 0.20; 1H NMR (400 MHz, CDCl3): 
 7.73 (2H, d, J = 8.7, 2xAr-H), 7.49 (2H, d, J = 8.8, 2xAr-H), 5.59 (1H, br. d, J = 7.1, NH), 5.13 
(1H, d, J = 7.1, CH), 4.27 (4H, dddd, J = 17.8, 10.7, 7.1, 3.6, 2xOCH2), 3.35 (3H, s, NCH3), 1.31 
(6H, t, J = 7.1, 2xCH2CH3); 13C NMR (101 MHz, CDCl3): 166.95 (2xC=O), 155.09 (C=O), 147.30 
(C≡N), 133.85 (2xCArH), 126.64 (2xCArH), 118.31 (CAr), 110.22 (CAr), 62.76 (2xOCH2), 57.86 
(CH), 37.07 (NCH3), 14.12 (2xCH2CH3); (IR (vmax/cm-1) (neat): 3426 (NH), 2965, 2901 (alkyl 
C-H), 2232 (C≡N), 1753 (C=Oester), 1667 (C=O); HRMS (ESI): m/z calcd for C16H20N3O5 [M+H]+ 
334.1397, found 334.1390. 
Diethyl 2-(3-(4-cyanophenyl)-1,3-dimethylureido)malonate (478b) 
 
Following general procedure 17: urea malonic acid ester 477b (899 mg, 2.70 mmol) in anhydrous 
DMF (27.0 mL), NaH (60% in mineral oil, 324 mg, 8.09 mmol) and MeI (0.84 mL, 13.5 mmol). 
The crude product was purified by flash column chromatography (SiO2; Pet.Ether:EtOAc 100:0 to 
Pet.Ether:EtOAc 60:40) to afford the title compound (684 mg, 70%) as a colourless oil. Rf (6:4 
Pet.Ether:EtOAc) 0.30; 1H NMR (400 MHz, CDCl3):  7.62 (2H, d, J = 8.7, 2xAr-H), 7.43 (2H, d, 
J = 8.8, 2xAr-H), 4.26 (4H, qd, J = 7.2, 1.6, 2xOCH2), 3.28 (3H, s, NCH3), 2.52 (3H, s, NCH3), 
1.73 (3H, s, CH3), 1.30 (6H, t, J = 7.1, 2xCH2CH3); 13C NMR (101 MHz, CDCl3): 168.58 (2xC=O), 
160.78 (C=O), 149.75 (C≡N), 133.51 (2xCArH), 122.60 (2xCArH), 118.93 (CAr), 106.80 (CAr), 69.87 
(CCH3), 62.34 (2xOCH2), 37.96 (NCH3), 34.83 (NCH3), 19.99 (CH3), 14.17 (2xCH2CH3); (IR 
(vmax/cm-1) (neat): 2982, 2939 (alkyl C-H), 2224 (C≡N), 1742 (C=O), 1660 (C=O); HRMS (ESI): 







Following general procedure 18: alkylated urea malonic acid ester 478a (653 mg, 1.81 mmol) in 
ethanol:water (10:1, 2.50 mL) and KOH (203 mg, 3.61 mmol). The title compound (429 mg, 71%) 
was yielded as a white solid and used without further purification. Rf (9.3:0.7 DCM:MeOH) 0.15; 
mp: 110 – 112 °C; 1H NMR (400 MHz, CDCl3):  7.69 (2H, d, J = 8.7, 2xAr-H), 7.58 (2H, d, J = 
8.8, 2xAr-H), 4.34 (2H, q, J = 7.1, OCH2), 3.36 (3H, s, NCH3), 2.51 (3H, s, NCH3), 1.61 (3H, s, 
CH3), 1.34 (3H, t, J = 7.1, CH2CH3); 13C NMR (101 MHz, CDCl3): 171.54 (C=O), 169.76 (C=O), 
163.73 (C=O), 148.52 (C≡N), 133.89 (2xCArH), 124.43 (2xCArH), 118.34 (CAr), 109.10 (CAr), 68.57 
(CCH3), 63.36 (OCH2), 38.94 (NCH3), 34.26 (NCH3), 20.86 (CH3), 14.08 (CH2CH3); (IR 
(vmax/cm-1) (neat): 3378 (OH), 2984, 2936 (alkyl C-H), 2211 (C≡N), 1736 (C=O), 1652 (C=O), 
1606 (C=O); MS (ESI): m/z calcd for [C15H20N3O3]+ [M+H−CO2]+, found 290.15. 
4.3.3.2 Aryl Migration of Urea Malonic Acid Half Ester 
4-(1,3,4-Trimethyl-2,5-dioxoimidazolidin-4-yl)benzonitrile (470b) 
 
To a solution of 469b (50.0 mg, 0.15 mmol, 1.00 eq.) and LiCl (19.1 mg, 0.45 mmol, 3.00 eq.) in 
THF (3 mL), was added cinchonidine (4.42 mg, 0.02 mmol, 0.10 eq.). The reaction was left to stir 
for 20 hours at room temperature. The reaction was quenched by the drop wise addition of HCl (1.0 
M, aq.) to ensure pH was acidic. It was then extracted 3 times with EtOAc, and the combined 
organic layer dried over MgSO4, filtered and the solvent removed under reduced pressure. The 
crude product was purified by flash column chromatography (SiO2; Pet.Ether:EtOAc 100:0 to 
Pet.Ether:EtOAc 60:40) to afford the title compound (7.30 mg, 20%) as a colourless oil. Rf (6:4 
Pet.Ether:EtOAc) 0.19; 1H NMR (400 MHz, CDCl3):  7.71 (2H, d, J = 8.6, Ar-H), 7.43 (2H, d, J 
= 8.7, Ar-H), 3.06 (3H, s, NCH3), 2.88 (3H, s, NCH3), 1.83 (3H, s, CH3), 13C NMR (101 MHz, 
CDCl3): 173.88 (C=O), 156.28 (C=O), 141.92 (CAr), 133.03 (2xCArH), 127.02 (2xCArH), 118.20 
(C≡N), 113.02 (CAr), 66.72 (CCH3), 25.79 (NCH3), 25.53 (NCH3), 20.67 (CH3); HPLC: er = 
~48:52, Chiralcel® OD-H, Hexane:IPA = 80:20, flow = 1 mL/min, λ = 254 nm, tR = 18 min (major), 
21 min (minor); (IR (vmax/cm-1) (neat): 2929, 2858 (alkyl C-H), 2229 (C≡N), 1772, 1710 (C=O); 





4.3.4 Diastereoselective Arylation of -Amino Nitriles 
4.3.4.1 Synthesis of -Amino Nitrile Ureas 
2-(Furan-3-yl)-2-(((1R,2R)-2-hydroxycyclohexyl)amino)acetonitrile (493a) 
 
Following general procedure 19: (1R,2R)-2-aminocyclohexanol (1.13 g, 9.79 mmol), 3-
furaldehyde (0.93 mL, 10.8 mmol) and TMSCN (1.47 mL, 11.7 mmol) in MeOH (56.0 mL). The 
crude product was purified by flash column chromatography (SiO2; Pet.Ether:EtOAc 100:0 to 
Pet.Ether:EtOAc 60:40) to afford the title compound (1.3 g, 61%; 65:35 dr) as a white solid. Rf 
(6:4 Pet.Ether:EtOAc) 0.34; 1H NMR (400 MHz, CDCl3) (mixture of diast A:B in a 0.65:0.35 
ratio):  7.60 (0.65H, dt, J =1.8, 1.0, Ar-H, diast. A), 7.58 (0.35H, dt, J =1.8, 1.0, Ar-H, diast. B), 
7.44 (0.65H, t, J =1.7, Ar-H, diast. A), 7.43 – 7.39 (0.35H, m, Ar-H, diast. B), 6.50 (1H, dt, J =1.9, 
1.0, Ar-H, diast. A+B), 4.92 (0.35H, s, NCH(Ar)CN, diast. B), 4.79 (0.65H, s, NCH(Ar)CN, diast. 
A), 3.31 (1H, ddt, J =13.7, 9.1, 4.1, NHCHCHOH, diast. A+B), 2.65 (0.65H, ddd, J =11.1, 9.1, 
4.1, NHCHCHOH, diast. A), 2.55 (0.35H, ddd, J =11.2, 9.0, 4.2, NHCHCHOH, diast. B), 2.47 – 
1.93 (3H, m (overlapping), NH, diast. A+B, 2xCH, diast. A+B), 1.94 – 1.53 (3H, m (overlapping), 
OH, diast. A+B, 2xCH, diast. A+B), 1.41 – 1.22 (3H, m, 3xCH, diast. A+B), 1.21 – 1.02 (1H, m, 
CH, diast. A+B); 13C NMR (126 MHz, CDCl3): 144.3 (CArH, diast. A), 144.2 (CArH, diast. B), 
140.8 (CArH, diast. A), 140.6 (CArH, diast. B), 121.8 (CAr, diast. B), 121.3 (CAr, diast. A), 120.0 
(C≡N, diast. B), 118.8 (C≡N, diast. A), 109.4 (CArH, diast. A), 109.3 (CArH, diast. B), 75.5 
(NHCHCHOH, diast. B), 74.1 (NHCHCHOH, diast. A), 62.8 (NHCHCHOH, diast. B), 61.3 
(NHCHCHOH, diast. A), 46.0 (NCH(Ar)CN, diast. B), 43.6 (NCH(Ar)CN, diast. A), 34.3 (CH2, 
diast. A), 33.9 (CH2, diast. B), 31.6 (CH2, diast. B), 29.9 (CH2, diast. A), 25.0 (CH2, diast. B), 24.5 
(CH2, diast. A), 24.4 (CH2, diast. A), 24.3 (CH2, diast. B); IR (vmax/cm-1) (neat): 3600 – 3200 
(OH, br.), 3323 (NH), 2932, 2859 (alkyl C-H), 2233 (C ≡ N); HRMS (ESI): m/z calcd for 











Following general procedure 20: 2,6-lutidine (0.08 mL, 0.68 mmol), -amino nitrile 493a (100 
mg, 0.45 mmol) in anhydrous DCM (2.00 mL) and TBDMSOTf (0.13 mL, 0.55 mmol). The crude 
product was purified by flash column chromatography (SiO2; nHexane:EtOAc 100:0 to 
nHexane:EtOAc 90:10) to afford the title compound (79.7 mg, 52%; 65:35 dr) as a yellow oil. Rf 
(9:1 nHexane:EtOAc) 0.29; 1H NMR (400 MHz, CDCl3) (mixture of diast A:B in a 0.65:0.35 ratio): 
 7.60 – 7.53 (1H, m (overlapping), Ar-H, diast. A+B), 7.43 (0.65H, dq, J =2.6, 1.6, Ar-H, diast. 
A), 7.40 (0.35H, 1d, J =1.7, Ar-H, diast. B), 6.58 – 6.39 (1H, m, Ar-H, diast. A+B), 4.93 (0.35H, 
s, NCH(Ar)CN, diast. B), 4.72 (0.65H, s, NCH(Ar)CN, diast. A), 3.50 – 3.34 (1H, m, 
NHCHCHOTBS, diast. A+B), 2.76 (0.65H, ddd, J =11.9, 8.8, 3.9, NHCHCHOTBS, diast. A), 2.63 
(0.35H, ddd, J =9.9, 8.9, 4.0, NHCHCHOTBS, diast. B), 2.34 (0.65H, br. d, J =11.4, NH, diast. 
A), 2.05 – 1.82 (1.65H, m, 2xCH, diast. A; CH, diast. B), 1.81 – 1.59 (2.70H, m, 2xCH, diast. A; 
2xCH + CH2, diast. B), 1.48 – 1.15 (3.35H, 3xCH, diast. A; 3xCH + NH, diast. B), 1.07 (0.65H, 
qd, J =13.2, 12.7, CH, diast. A), 0.86 (5.85H, s, SiC(CH3)3, diast. A), 0.79 (3.15H, s, SiC(CH3)3, 
diast. B), 0.07 (1.95H, s, Si(CH3,A)(CH3,B), diast. A), 0.05 (1.05H, s, Si(CH3,A)(CH3,B), diast. B), 
0.03 (1.95H, s, Si(CH3,A)(CH3,B), diast. A), 0.01 (1.05H, Si(CH3,A)(CH3,B), diast. B); 13C NMR 
(101 MHz, CDCl3): 144.15 (CArH, diast. A), 143.92 (CArH, diast. B), 140.48 (CArH, diast. B), 140.40 
(CArH, diast. A), 121.8 (CAr, diast. B), 121.6 (CAr, diast. A), 120.0 (C≡N, diast. B), 118.4 (C≡N, 
diast. A), 109.22 (2xCArH, diast. A+B), 76.8 (NHCHCHOTBS, diast. B), 75.3 (NHCHCHOTBS, 
diast. A), 61.8 (NHCHCHOTBS, diast. B), 61.1 (NHCHCHOTBS, diast. A), 46.1 (NCH(Ar)CN, 
diast. B), 43.6 (NCH(Ar)CN, diast. A), 34.3 (CH2, diast. A), 32.8 (CH2, diast. B), 31.4 (CH2, diast. 
B), 29.1 (CH2, diast. A), 25.96 (SiC(CH3)3 diast. B), 25.91 (SiC(CH3)3, diast. A), 24.8 (CH2, diast. 
B), 24.5 (CH2, diast. A), 24.3 (CH2, diast. B), 24.1 (CH2, diast. A), 18.09 (SiC(CH3)3, diast. A), 
18.07 (SiC(CH3)3, diast. B), −3.66 (Si(CH3,A)(CH3,B), diast. A), −3.85 (Si(CH3,A)(CH3,B), diast. B), 
−4.43 (Si(CH3,A)(CH3,B), diast. B), −4.67 (Si(CH3,A)(CH3,B), diast. A); IR (vmax/cm-1) (neat): 
3329 (NH), 2929, 2857 (alkyl C-H), 2346 (C≡N); HRMS (ESI): m/z calcd for C18H31N2O2Si 









Following general procedure 21: triphosgene (347 mg, 1.17 mmol) in anhydrous DCM (13.4 mL), 
2,6-lutidine (0.40 mL, 3.51 mmol) and N-alkyl-OTBS amino nitrile 494a (978 mg, 2.92 mmol). 
The crude carbamoyl chloride 495a was yielded as a dark brown oil and used without further 
purification. Following general procedure 22 method A: 2,6-lutidine (0.61 mL, 5.23 mmol), N-
methyl aniline (0.52 mL, 4.79 mmol), KI (868 mg, 5.23 mmol) and carbamoyl chloride 495a (1.73 
g, 4.36 mmol) in anhydrous CH3CN (11.0 mL). The crude product was purified by flash column 
chromatography (SiO2; nHexane:Diethyl ether 100:0 to nHexane:Diethyl ether 70:30) to afford the 
title compound ( 228 mg, 17% over 2 steps; 50:50 dr, relative stereochemistry undetermined) as the 
two separated diastereoisomers A:B. 
Diast. A: Yellow solid; Rf (7:3 nHexane:Diethyl ether) 0.34; mp: 119 – 121 °C; 1H NMR (400 
MHz, CDCl3):  7.61 (1H, dt, J =1.8, 0.9, Ar-H), 7.37 (1H, t, J =1.7, Ar-H), 7.36 – 7.31 (2H, m, 
2xAr-H), 7.17 (1H, ddt, J = 7.9, 7.0, 1.2, Ar-H), 7.14 – 7.10 (2H, m, Ar-H), 6.50 (1H, dd, J =1.9, 
0.9, Ar-H), 5.77 (1H, s, NCH(Ar)CN), 4.02 (1H, d, J =8.1, NCHCHOTBS), 3.22 – 3.15 (1H, m, 
NCHCHOTBS), 3.21 (3H, s, NCH3), 1.98 – 1.89 (1H, m, CH), 1.69 – 1.60 (1H, m, CH), 1.60 – 
1.50 (2H, m, 2xCH), 1.48 – 1.41 (1H, m, CH), 1.17 – 1.09 (1H, m, CH), 1.05 – 0.92 (1H, m, CH), 
0.85 (9H, s, SiC(CH3)3), 0.75 – 0.70 (1H, m, CH), 0.06 (3H, s, Si(CH3,A)(CH3,B)), 0.01 (3H, s, 
Si(CH3,A)(CH3,B)); 13C NMR (101 MHz, CDCl3): 163.36 (C=O), 146.15 (CAr), 143.36 (CArH), 
142.14 (CArH), 129.78 (2xCArH), 125.83 (CArH), 124.94 (2xCArH), 119.44 (CAr), 118.14 (C≡N), 
110.61 (CArH), 71.95 (NCHCHOTBS), 65.14 (NCHCHOTBS), 41.97 (NCH(Ar)CN), 40.38 
(NCH3), 36.98 (CH2), 29.21 (CH2), 26.14 (SiC(CH3)3), 25.75 (CH2), 24.48 (CH2), 18.23 
(SiC(CH3)3), −3.59 (Si(CH3,A)(CH3,B)), −3.82 (Si(CH3,A)(CH3,B)); (IR (vmax/cm-1) (neat): 2929, 
2857 (alkyl C-H), 2243 (C≡N), 1657 (C=O); HRMS (ESI): m/z calcd for C26H38N3O3Si [M+H]+ 
468.2677, found 468.2676. 
Diast. B: Orange oil; Rf (7:3 nHexane:Diethyl ether) 0.21; 1H NMR (400 MHz, CDCl3):  7.71 
(1H, s, Ar-H), 7.42 (1H, t, J =1.7, Ar-H), 7.34 – 7.28 (2H, m, 2xAr-H), 7.19 – 7.14 (1H, m, Ar-H), 
6.97 – 6.93 (2H, m, Ar-H), 6.40 (1H, d, J =1.5, Ar-H), 4.97 (1H, s, NCH(Ar)CN), 3.67 (1H, dt, J 
=10.4, 3.8, NCHCHOTBS), 3.28 (1H, ddd, J =12.9, 9.3, 4.0, NCHCHOTBS), 3.16 (3H, s, NCH3), 





CH), 1.09 – 0.97 (3H, m, 3xCH), 0.95 (9H, s, SiC(CH3)3), 0.57 (1H, td, J = 12.0, 11.6, 5.9, CH), 
0.23 (3H, s, Si(CH3,A)(CH3,B)), 0.14 (3H, s, Si(CH3,A)(CH3,B)); 13C NMR (126 MHz, CDCl3): 160.5 
(C=O), 146.4 (CAr), 143.3 (CArH), 142.7 (CArH), 129.6 (2xCArH), 125.8 (CArH), 125.5 (2xCArH), 
120.0 (CAr), 118.0 (C≡N), 110.1 (CArH), 71.6 (NCHCHOTBS), 64.9 (NCHCHOTBS), 39.8 (NCH3 
+ NCH(Ar)CN overlap), 36.7 (CH2), 29.2 (CH2), 26.3 (SiC(CH3)3), 25.2 (CH2), 24.4 (CH2), 18.3 
(SiC(CH3)3), −3.3 (Si(CH3,A)(CH3,B)), −3.9 (Si(CH3,A)(CH3,B)); (IR (vmax/cm-1) (neat): 2929 
(alkyl C-H), 2857 (alkyl C-H), 2243 (C ≡ N), 1661 (C=O); HRMS (ESI): m/z calcd for 




Following general procedure 19: (1R,2R)-2-aminocyclohexanol (1.18 g, 10.23 mmol), 4-
fluorobenzaldehyde (1.20 mL, 11.3 mmol) and TMSCN (1.50 mL, 12.3 mmol) in MeOH (59.0 
mL). The crude -amino nitrile 493b (2.70 g, 63:37 dr) was yielded as a white solid and used 
without further purification. Following general procedure 20: 2,6-lutidine (1.80 mL, 15.4 mmol), 
-amino nitrile 493b (2.56 g, 10.3 mmol) in anhydrous DCM (47.0 mL) and TBDMSOTf (2.80 
mL, 12.4 mmol). The crude product was purified by flash column chromatography (SiO2; 
nHexane:Diethyl ether 100:0 to nHexane:Diethyl ether 90:10) to afford the title compound ( 1.41 
g, 38% over 2 steps, 75:25 dr) as a pale yellow oil. Rf (7:3 Pet.Ether:EtOAc) 0.23; 1H NMR (400 
MHz, CDCl3) (mixture of diast A:B in a 0.75:0.25 ratio):   7.54 – 7.39 (2H, m (Ar-H, diast. A+B), 
7.08 (2H, ddt, J =8.6, 6.7, 2.0 Ar-H, diast. A+B), 4.93 (0.25H, s, NCH(Ar)CN, diast. B), 4.75 
(0.75H, s, NCH(Ar)CN, diast. A), 3.43 (1H, dddd, J =19.4, 10.8, 8.5, 4.2 NHCHCHOTBS, diast. 
A+B), 2.79 (0.75H, ddd, J = 11.1, 8.6, 4.0, NHCHCHOTBS, diast. A), 2.62 (0.25H, ddd, J =10.4, 
8.3, 3.9, NHCHCHOTBS, diast. B), 2.33 (0.75H, br. d, J = 12.0, NH, diast. A), 2.03 (0.75H, ddt, J 
= 12.6, 5.3, 2.6, CH, diast. A), 1.98 – 1.82 (1.50H, m, CH + NH, diast. B; CH, diast. A+ B), 1.79 – 
1.67 (2H, CH2, diast. A+B), 1.50 – 1.17 (3.25H, m, CH + CH2, diast. A+B; CH, diast. B), 1.18 – 
0.97 (0.75H, m, CH, diast. A), 0.84 (9H, s (overlapping), SiC(CH3)3, diast. A+B), 0.06 (3H, s, 
Si(CH3,A)(CH3,B), diast. A + B), 0.03 (0.75H, s, Si(CH3,A)(CH3,B), diast. B), −0.02 (2.25H, s, 
Si(CH3,A)(CH3,B), diast. A); 13C NMR (101 MHz, CDCl3): 164.16 (CAr, d, J =249.9, diast. B), 





A), 129.08 (2xCArH, d, J =8.4, diast. A), 129.02 (2xCArH, d, J =8.3, diast. B), 120.14 (C≡N, diast. 
B), 118.57 (C≡N, diast. A), 116.05 (2xCArH, d, J = 21.8, diast. A), 115.60 (2xCArH, d, J = 21.7, 
diast. B), 76.29 (NHCHCHOTBS, diast. B), 75.27 (NHCHCHOTBS, diast. A), 62.15 
(NHCHCHOTBS, diast. B), 61.36 (NHCHCHOTBS, diast. A), 53.04 (NCH(Ar)CN, diast. B), 
50.83 (NCH(Ar)CN, diast. A), 34.47 (CH2, diast. B), 34.32 (CH2, diast. A), 31.17 (CH2, diast. B), 
29.20 (CH2, diast. A), 25.91 (SiC(CH3)3 diast. B), 25.88 (SiC(CH3)3, diast. A), 24.49 (CH2, diast. A), 
24.32 (CH2, diast. B), 24.24 (CH2, diast. B), 24.04 (CH2, diast. A), 18.07 (SiC(CH3)3, diast. A), 
18.04 (SiC(CH3)3, diast. B), −3.65 (Si(CH3,A)(CH3,B), diast. A), −3.78 (Si(CH3,A)(CH3,B), diast. B), 
−4.47 (Si(CH3,A)(CH3,B), diast. B), −4.75 (Si(CH3,A)(CH3,B), diast. A); (IR (vmax/cm-1) (neat): 





Following general procedure 21: triphosgene (428 mg, 1.44 mmol) in anhydrous DCM (16.5 mL), 
2,6-lutidine (0.50 mL, 4.32 mmol) and N-alkyl-OTBS amino nitrile 494b (1.31 g, 3.60 mmol). The 
crude carbamoyl chloride 495b (1.39 g) was yielded as a yellow oil and used without further 
purification. Following general procedure 22 method A: 2,6-lutidine (0.42 mL, 3.61 mmol), N-
methyl aniline (0.36 mL, 3.31 mmol), KI (600 mg, 3.61 mmol) and carbamoyl chloride 495b (1.28 
g, 3.01 mmol) in anhydrous CH3CN (8.00 mL). The crude product was purified by flash column 
chromatography (SiO2; Pet.Ether:Diethyl ether 100:0 to Pet.Ether:Diethyl ether 80:20) to afford the 
title compound (194 mg, 11% over 2 steps; 50:50 dr, relative stereochemistry undetermined) as the 
two separated diastereoisomers A:B. 
Diast. A: pale yellow oil. Rf (8:2 Pet.Ether:Diethyl ether) 0.3; 1H NMR (500 MHz, CDCl3):  7.59 
– 7.54 (2H, m, 2xAr-H), 7.37 – 7.31 (2H, m, 2xAr-H), 7.22 – 7.16 (1H, m, Ar-H), 7.11 – 7.02 (4H, 
m, 4xAr-H), 5.76 (1H, s, NCH(Ar)CN), 4.09 – 3.97 (1H, m, NCHCHOTBS), 3.25 (1H, t, J = 10.4, 
NCHCHOTBS), 3.19 (3H, s, NCH3), 2.02 – 1.93 (1H, m, CH), 1.70 (1H, qd, J = 12.6, 3.5, CH), 
1.59 – 1.50 (3H, m, 3xCH), 1.29 – 1.20 (1H, m, CH), 1.18 1.12 (1H, m, CH ), 0.99 – 0.95 (1H, m, 
CH), 0.85 (9H, s, SiC(CH3)3), 0.08 (3H, s, Si(CH3,A)(CH3,B)), 0.01 (3H, s, Si(CH3,A)(CH3,B)); 13C 





129.79 (2xCArH), 129.67 (2xCArH, d, 3JC-F = 8.3), 126.04 (CArH), 125.17 (2xCArH), 118.58 (C≡N), 
115.55 (2xCArH, d, 2JC-F = 21.8), 72.09 (NCHCHOTBS), 65.37 (NCHCHOTBS), 48.57 
(NCH(Ar)CN), 40.36 (NCH3), 36.92 (CH2), 29.86 (CH2), 26.24 (SiC(CH3)3), 25.74 (CH2), 24.46 
(CH2), 18.37 (SiC(CH3)3), −3.17 (Si(CH3,A)(CH3,B)), −3.48 (Si(CH3,A)(CH3,B)); (IR (vmax/cm-1) 
(neat): 2926 (alkyl C-H), 2855 (alkyl C-H), 2242 (C≡N), 1660 (C=O); HRMS (ESI): m/z calcd for 
C28H39FN3O2Si [M+H]+ 496.2790, found 496.2771. 
Diast. B: pale yellow oil. Rf (8:2 Pet.Ether:Diethyl ether) 0.29; 1H NMR (500 MHz, CDCl3):  7.54 
(2H, dd, J = 8.5, 5.2, 2xAr-H), 7.32 (2H, t, J = 7.7, 2xAr-H), 7.21 – 7.16 (1H, m, Ar-H), 7.10 (2H, 
t, J = 8.5, 2xAr-H), 6.87 (2H, d, J = 7.9, 2xAr-H), 5.05 (1H, s, NCH(Ar)CN), 3.81 – 3.65 (1H, m, 
NCHCHOTBS), 3.33 (1H, ddd, J = 12.9, 9.3, 4.0, NCHCHOTBS), 3.10 (3H, s, NCH3), 2.12 – 1.97 
(1H, m, CH), 1.66 – 1.50 (1H, m, CH), 1.50 – 1.43 (1H, m, CH), 1.31 – 1.21 (1H, m, CH), 1.13 – 
1.01 (3H, m, 3xCH), 0.96 (9H, s, SiC(CH3)3), 0.61 (1H, td, J =16.2, 14.5, 11.0, CH), 0.26 (3H, s, 
Si(CH3,A)(CH3,B)), 0.15 (3H, s, Si(CH3,A)(CH3,B)); 13C NMR (126 MHz, CDCl3): 162.73 (CAr, d, 
1JC-F = 246.9), 160.46 (C=O), 146.19 (CAr), 130.31 (2xCArH, d, 3JC-F = 8.3), 130.10 (CAr, d, 4JC-F = 
3.2), 129.56 (2xCArH), 125.93 (CArH), 125.70 (2xCArH), 118.07 (C≡N), 115.41 (2xCArH, d, 2JC-F = 
21.9), 71.63 (NCHCHOTBS), 65.06 (NCHCHOTBS), 47.11 (NCH(Ar)CN), 39.76 (NCH3), 36.87 
(CH2), 29.86 (CH2), 26.34 (SiC(CH3)3), 25.28 (CH2), 24.35 (CH2), 18.36 (SiC(CH3)3), −3.46 
(Si(CH3,A)(CH3,B)), −3.74 (Si(CH3,A)(CH3,B)); (IR (vmax/cm-1) (neat): 2925, 2854 (alkyl C-H), 




Following general procedure 19: (1R,2R)-2-aminocyclohexanol (1.17 g, 10.1 mmol), 
benzaldehyde (1.10 mL, 11.1 mmol) and TMSCN (1.50 mL, 12.2 mmol) in MeOH (58.0 mL). The 
crude -amino nitrile 493c (2.50 g, >99%, 62:38 dr) was yielded as a white solid and used without 
further purification. Following general procedure 20: 2,6-lutidine (1.90 mL, 16.3 mmol), -amino 
nitrile 493c (2.50 g, 10.9 mmol) in anhydrous DCM (49.0 mL) and TBDMSOTf (3.00 mL, 13.0 
mmol). The crude product was purified by flash column chromatography (SiO2; Pet.Ether:Diethyl 
ether 100:0 to Pet.Ether:Diethyl ether 80:20) to afford the title compound (1.72 g, 49% over 2 steps, 
70:30 dr) as a colourless oil. Rf (8:2 Pet.Ether:Diethyl ether) 0.26; 1H NMR (400 MHz, CDCl3) 





(3H, m, 3xCArH, diast. A+B), 4.93 (0.30H, s, NCH(Ar)CN, diast. B), 4.77 (0.70H, s, NCH(Ar)CN, 
diast A), 3.52 – 3.36 (1H, m, NCHCHOTBS, diast. A+B), 2.81 (0.70H, ddd, J = 11.1, 8.6, 4.0 Hz, 
NCHCHOTBS, diast A), 2.66 – 2.57 (0.30H, m, NCHCHOTBS, diast. B), 2.38 (0.70 H, br. s, NH, 
diast A), 2.10 – 2.01 (0.70H, m, CH, diast A), 2.01 – 1.93 (0.30 H, m, CH, diast. B), 1.93 – 1.82 
(1H, m, CH, diast. A+B), 1.79 – 1.63 (2.30H, m, CH2, diast. A+B; NH, diast. B), 1.49 – 1.22 (3.30H, 
m, CH2+CH, diast. A+B; CH, diast. B), 1.14 – 1.04 (0.70H, m, CH, diast. A), 0.85 (6.30 H, s, 
SiC(CH3)3, diast A), 0.84 (2.70 H, s, SiC(CH3)3, diast B), 0.06 (3 H, s, Si(CH3,A)(CH3,B), diast A+B), 
0.03 (0.90 H, s, Si(CH3,A)(CH3,B), diast B), −0.01 (2.10 H, s, Si(CH3,A)(CH3,B), diast A); 13C NMR 
(101 MHz, CDCl3) δC = 136.02 (CArH, diast B), 135.74 (CArH, diast A), 129.12 (2xCArH, diast A), 
128.97 (2xCArH, diast B), 128.53 (CAr, diast B), 128.31 (CAr, diast A), 127.25 (2xCArH, diast A), 
127.22 (2xCArH, diast B), 120.36 (C≡N, diast B), 118.78 (C≡N, diast A), 76.20 (NCHCHOTBS, 
diast B), 75.25 (NCHCHOTBS, diast A), 62.18 (NCHCHOTBS, diast B), 61.37 (NCHCHOTBS, 
diast A), 53.67 (NCH(Ar)CN, diast B), 51.51 (NCH(Ar)CN, diast A), 34.45 (CH2, diast B), 34.35 
(CH2, diast A), 31.07 (CH2, diast. B), 29.21 (CH2, diast. A), 25.92 (SiC(CH3)3, diast B), 25.90 
(SiC(CH3)3, diast A), 24.51 (CH2, diast A), 24.31 (CH2, diast B), 24.26 (CH2, diast B), 24.06 (CH2, 
diast A), 18.07 (SiC(CH3)3, diast A), 18.04 (SiC(CH3)3, diast B), −3.64 (Si(CH3,A)(CH3,B), diast A), 
−3.79 (Si(CH3,A)(CH3,B), diast B), −4.48 (Si(CH3,A)(CH3,B), diast B), −4.74 (Si(CH3,A)(CH3,B), diast 
A); IR (neat, cm-1): 3323 (NH), 2929 (alkyl C-H), 2243 (C≡N); HRMS (EI+): m/z calcd for 




Following general procedure 21: triphosgene (187 mg, 0.63 mmol) in anhydrous DCM (7.30 mL), 
2,6-lutidine (0.22 mL, 1.90 mmol) and N-alkyl-OTBS amino nitrile 494c (542 mg, 1.57 mmol). The 
crude carbamoyl chloride 495c (558 mg) was yielded as a yellow oil and used without further 
purification. Following general procedure 22 method B: 2,6-lutidine (0.18 mL, 1.56 mmol), 
deuterated-N-methyl aniline (160 mg, 1.43 mmol) and carbamoyl chloride 495c (528 mg, 1.30 
mmol) in anhydrous CH3CN (3.20 mL). The crude product was purified by flash column 
chromatography (Pet.Ether:Diethyl ether 100:0 to Pet.Ether:Diethyl ether 80:20) to afford the title 
compound (391 mg, 51% over 2 steps; 50:50 dr, relative stereochemistry undetermined) as the two 





Diast. A: Yellow oil. Rf (8:2 Pet.Ether:Diethyl ether) 0.24; 1H NMR (400 MHz, CDCl3):  7.57 
(2H, d, J =7.2, 2xAr-H), 7.40 – 7.29 (3H, m, 3xAr-H), 5.89 (1H, s, NCH(Ar)CN), 4.09 (1H, td, J 
=9.8, 4.2, NCHCHOTBS), 3.31 – 3.22 (1H, m, NCHCHOTBS), 3.20 (3H, s, NCH3), 2.01 – 1.91 
(1H, m, CH), 1.77 – 1.63 (1H, m, CH), 1.61 – 1.44 (3H, m, 3xCH), 1.19 – 1.12 (1H, m, CH), 1.03 
– 0.97 (1H, m, CH), 0.86 (9H, s, SiC(CH3)3), 0.79 (1H, d, J =12.4, CH), 0.09 (3H, s, 
Si(CH3,A)(CH3,B)), 0.03 (3H, s, Si(CH3,A)(CH3,B)); 13C NMR (126 MHz, CDCl3): 161.49 (C=O), 
145.74 (CAr), 134.83 (CAr), 129.21 (2xCArD, t, 1JC-D = 23.94), 125.59 – 124.43 (3xCArD, m), 128.59 
(2xCArH), 128.55 (CArH), 127.76 (2xCArH), 118.70 (C ≡ N), 71.98 (NCHCHOTBS), 65.40 
(NCHCHOTBS), 49.21 (NCH(Ar)CN), 40.31 (NCH3), 36.97 (CH2), 29.79 (CH2), 26.25 
(SiC(CH3)3), 25.78 (CH2), 24.45 (CH2), 18.34 (SiC(CH3)3), −3.25 (Si(CH3,A)(CH3,B)), −3.62 
(Si(CH3,A)(CH3,B)); IR (vmax/cm-1) (neat): 2929 (alkyl C-H), 2856 (alkyl C-H), 2250 (C≡N), 
1661 (C=O); HRMS (ESI): m/z calcd for C28H34D5N3O2SiNa [M+Na]+ 505.3018, found 505.3014. 
Diast. B: yellow oil. Rf (8:2 Pet.Ether:Diethyl ether) 0.17; 1H NMR (400 MHz, CDCl3):  7.57 
(2H, d, J =7.8, 2xAr-H), 7.45 – 7.32 (3H, m, 3xAr-H), 5.11 (1H, s, NCH(Ar)CN), 3.82 – 3.65 (1H, 
m, NCHCHOTBS), 3.34 (1H, ddd, J =12.8, 9.2, 4.0, NCHCHOTBS), 3.11 (3H, s, NCH3), 2.11 – 
1.97 (1H, m, CH), 1.61 – 1.52 (1H, m, CH), 1.52 – 1.43 (1H, m, CH), 1.39 – 1.20 (1H, m, CH), 
1.15 – 1.03 (3H, m, CH), 0.96 (9H, s, SiC(CH3)3), 0.67 – 0.55 (1H, m, CH), 0.27 (3H, s, 
Si(CH3,A)(CH3,B)), 0.16 (3H, s, Si(CH3,A)(CH3,B)); 13C NMR (126 MHz, CDCl3): 160.48 (C=O), 
146.13 (CAr), 129.01 (2xCArD, t, 1JC-D=23.94), 125.51 – 125.01 (3xCArD), 134.22 (CAr), 128.53 
(CArH), 128.45 (2xCArH), 128.37 (2xCArH), 118.18 (C ≡ N) 71.64 (NCHCHOTBS), 65.05 
(NCHCHOTBS), 47.79 (NCH(Ar)CN), 39.71 (NCH3), 36.90 (CH2), 29.61 (CH2), 26.36 
(SiC(CH3)3), 25.30 (CH2), 24.36 (CH2), 18.37 (SiC(CH3)3), −3.51 (Si(CH3,A)(CH3,B)), −3.69 
(Si(CH3,A)(CH3,B)); (IR (vmax/cm-1) (neat): 2930, 2856 (alkyl C-H), 2278 (C≡N), 1659 (C=O); 




Following general procedure 21: triphosgene (134 mg, 0.45 mmol) in anhydrous DCM (5.20 mL), 
2,6-lutidine (0.16 mL, 1.35 mmol) and N-alkyl-OTBS amino nitrile 494c (389 mg, 1.13 mmol). The 
crude carbamoyl chloride 495c (359 mg) was yielded as a yellow oil which was used immediately 





1.06 mmol), 4-fluoro-N-methyl aniline (0.12 mL, 0.97 mmol) and carbamoyl chloride 495c (359 
mg, 0.88 mmol) in anhydrous CH3CN (1.00 mL). The crude product was purified by flash column 
chromatography (Pet.Ether:Diethyl ether 100:0 to Pet.Ether:Diethyl ether 80:20) to afford the title 
compound (317 mg, 58% over 2 steps; 50:50 dr, relative stereochemistry undetermined) as the two 
separated diastereoisomers A:B.  
Diast. A: orange oil. Rf (8:2 Pet.Ether:Diethyl ether) 0.25; 1H NMR (500 MHz, CDCl3):  7.58 – 
7.51 (2H, m, 2xAr-H), 7.39 – 7.32 (3H, m, 3xAr-H), 7.08 – 6.98 (4H, m, 4xAr-H), 5.83 (1H, s, 
NCH(Ar)CN), 4.08 (1H, td, J = 9.9, 4.3, NCHCHOTBS), 3.28 (1H, td, J = 9.9, 3.5, 
NCHCHOTBS), 3.16 (3H, s, NCH3), 2.04 – 1.95 (1H, m, CH), 1.83 – 1.68 (1H, m, CH), 1.65 – 
1.46 (3H, m, 3xCH), 1.33 – 1.11 (2H, m, 2xCH), 1.07 – 0.98 (1H, m, CH), 0.87 (9H, s, SiC(CH3)3), 
0.09 (3H, s, Si(CH3,A)(CH3,B)), 0.04 (3H, s, Si(CH3,A)(CH3,B)); 13C NMR (126 MHz, CDCl3): 
161.57 (C=O), 160.57 (CAr, d, 1JC-F = 246.2), 141.84 (CAr, d, 4JC-F = 3.1), 134.71 (CAr), 128.62 
(3xCArH, overlap), 127.67 (2xCArH), 126.98 (2xCArH, d, 3JC-F = 8.3), 118.68 (C≡N), 116.47 
(2xCArH, d, 2JC-F = 22.6), 71.98 (NCHCHOTBS), 65.71 (NCHCHOTBS), 49.23 (NCH(Ar)CN), 
40.57 (NCH3), 37.00 (CH2), 29.86 (CH2), 26.24 (SiC(CH3)3), 25.88 (CH2), 24.44 (CH2), 18.34 
(SiC(CH3)3), −3.26 (Si(CH3,A)(CH3,B)), −3.53 (Si(CH3,A)(CH3,B)); (IR (vmax/cm-1) (neat): 2926, 
2855 (alkyl C-H), 2253 (C≡N), 1661 (C=O); HRMS (ESI): m/z calcd for C28H38FN3O2SiNa 
[M+Na]+ 518.260953, found 518.259538.  
Diast. B: yellow oil. Rf (8:2 Pet.Ether:Diethyl ether) 0.22; 1H NMR (500 MHz, CDCl3):  7.56 – 
7.52 (2H, m, 2xAr-H), 7.44 – 7.33 (3H, m, 3xAr-H), 7.04 – 6.98 (2H, m, 2xAr-H), 6.87 – 6.81 (2H, 
m, 2xAr-H), 5.09 (1H, s, NCH(Ar)CN), 3.76 (1H, td, J = 9.5, 4.7, NCHCHOTBS), 3.34 (1H, ddd, 
J = 12.9, 9.3, 4.0, NCHCHOTBS), 3.05 (3H, s, NCH3), 2.12 – 2.02 (1H, m, CH), 1.64 – 1.49 (2H, 
m, 2xCH), 1.32 – 1.18 (1H, m, CH), 1.12 – 1.05 (3H, m, 3xCH), 0.95 (9H, s, SiC(CH3)3), 0.74 – 
0.66 (1H, m, CH), 0.26 (3H, s, Si(CH3,A)(CH3,B)), 0.16 (3H, s, Si(CH3,A)(CH3,B)); 13C NMR (126 
MHz, CDCl3): 160.58 (C=O), 160.47 (CAr, d, 1JC-F = 246.10), 142.34 (CAr, d, 4JC-F = 3.2), 134.08 
(CAr), 128.63 (CArH), 128.47 (2xCArH), 128.39 (2xCArH), 127.42 (2xCArH, d, 3JC-F = 8.2), 118.07 
(C≡N), 116.31 (2xCArH, d, 2JC-F = 22.6), 71.63 (NCHCHOTBS), 65.23 (NCHCHOTBS), 47.71 
(NCH(Ar)CN), 40.00 (NCH3), 36.92 (CH2), 29.72 (CH2), 26.34 (SiC(CH3)3), 25.42 (CH2), 24.33 
(CH2), 18.36 (SiC(CH3)3), −3.44 (Si(CH3,A)(CH3,B)), −3.76 (Si(CH3,A)(CH3,B)); (IR (vmax/cm-1) 
(neat): 2926, 2855 (alkyl C-H), 2240 (C ≡ N), 1662 (C=O); HRMS (ESI): m/z calcd for 












Following general procedure 23 method A: LDA (2.0 M in THF/heptane/ethylbenzene, 0.16 mL, 
0.32 mmol) and -amino nitrile urea 488ea (50.0 mg, 0.107 mmol; diast. A) in anhydrous THF 
(0.94 mL). The crude product (>95:5 dr by NMR) was purified by flash column chromatography 
(SiO2; nHexane:EtOAc 100:0 to nHexane:EtOAc 70:30) to afford the title compound (33.8 mg, 
68%; >95:5 dr) as a yellow oil. The same diastereoisomer 489ea was obtained (85%, >95:5 dr by 1 
HNMR) after performing the reaction from 488ea (diast. B). Rf (7:3 nHexane:EtOAc) 0.19; 1H 
NMR (400 MHz, CDCl3):  7.83 – 7.77 (2H, m, 2xAr-H), 7.45 (1H, t, =1.7, Ar-H), 7.41 – 7.33 
(4H, m, 4xAr-H), 6.25 (1H, dd, J = 2.0, 0.9, Ar-H), 4.76 (1H, br. s, NCHCHOTBS), 3.11 (3H, s, 
NCH3), 3.00 – 2.86 (1H, m, NCHCHOTBS), 1.98 – 1.89 (1H, m, CH), 1.63 – 1.53 (2H, m, 2xCH), 
1.50 – 1.40 (1H, m, CH), 1.31 – 1.24 (1H, m, CH), 1.23 – 1.15 (1H, m, CH), 1.06 – 0.95 (1H, m, 
CH), 0.94 (9H, s, SiC(CH3)3), 0.91 – 0.87 (1H, m, CH), 0.19 (3H, s, Si(CH3,A)(CH3,B)), 0.08 (3H, 
Si(CH3,A)(CH3,B)); 13C NMR (101 MHz, CDCl3): 167.26 (C=N), 155.86 (C=O), 143.85 (CArH), 
142.47 (2xCArH), 137.84 (CAr), 128.85 (2xCArH), 128.27 (2xCArH), 126.20 (CAr), 110.96 (CArH), 
69.05 (NC(Ar)Ph), 72.48 (NCHCHOTBS), 61.16 (NCHCHOTBS), 37.48 (CH2), 29.87 (CH2), 
26.23 (SiC(CH3)3), 25.7 (NCH3), 25.48 (CH2), 24.76 (CH2), 18.33 (SiC(CH3)3), −3.75 
(Si(CH3,A)(CH3,B)), −5.54 (Si(CH3,A)(CH3,B)); (IR (vmax/cm-1) (neat): 3311 (NH), 2929 (alkyl C-
H), 2856 (alkyl C-H), 1732 (C=N), 1659 (C=O); HRMS (ESI): m/z calcd for C26H38N3O3Si [M+H]+ 








Following general procedure 23 method A: LDA (2.0 M in THF/heptane/ethylbenzene, 0.20 mL, 
0.40 mmol) and -amino nitrile urea 488ed (65.0 mg, 0.135 mmol) in anhydrous THF (1.20 mL). 
The crude product was purified by flash column chromatography (SiO2; Pet.Ether:Diethyl ether 
100:0 to Pet.Ether:Diethyl ether 50:50) to afford the title compound (49.0 mg, 75%; >95:5 dr by 
2D-NMR) as an orange oil. Rf (5:5 Pet.Ether:Diethyl ether) 0.17; 1H NMR (400 MHz, CDCl3): 
 7.39 – 7.31 (3H, m, 3xAr-H), 7.27 – 7.23 (2H, m, 2xAr-H), 4.87 – 4.68 (1H, m, NCHCHOTBS), 
3.14 (3H, s, NCH3), 2.91 (1H, ddd, J = 11.9, 9.6, 3.0, NCHCHOTBS), 1.97 – 1.87 (1H, m, CH), 
1.57 – 1.46 (1H, m, CH), 1.32 – 1.28 (1H, m, CH), 1.22 – 1.18 (3H, m, 3xCH), 0.97 (9H, s, 
SiC(CH3)3), 0.73 – 0.64 (1H, m, CH), 0.20 (3H, s, Si(CH3,A)(CH3,B)), 0.09 (3H, Si(CH3,A)(CH3,B)), 
0.06 to −0.01 (1H, m, CH); 13C NMR (126 MHz, CDCl3): 167.99 (C=N), 155.80 (C=O), 128.77 – 
127.69 (5xCArD, m), 140.99 (CAr), 138.35 (CAr), 129.11 (2xCArH), 129.07 (CArH), 128.83 (2xCArH), 
75.28 (NC(Ar)Ph), 72.52 (NCHCHOTBS), 61.11 (NCHCHOTBS), 37.59 (CH2), 29.36 (CH2), 
26.22 (SiC(CH3)3), 25.61 (NCH3), 25.37 (CH2) 24.72 (CH2), 18.35 (SiC(CH3)3), −3.79 
(Si(CH3,A)(CH3,B)), −5.61 (Si(CH3,A)(CH3,B)); (IR (vmax/cm-1) (neat): 3314 (NH), 2928 (alkyl C-
H), 2855 (alkyl C-H), 1731 (C=N), 1658 (C=O); HRMS (ESI): m/z calcd for C28H35D5N3O2Si 




Following general procedure 23 method B: DMPU (0.10 mL), -amino nitrile urea 488ec (53.3 
mg, 0.107 mmol) in anhydrous THF (1.00 mL) and LDA (2.0 M in THF/heptane/ethylbenzene, 
0.13 mL, 0.27 mmol). The crude product (94:6 dr by 19F NMR) was purified by flash column 
chromatography (SiO2; Pet.Ether:Diethyl ether 100:0 to Pet.Ether:Diethyl ether 70:30) to afford the 
title compound (27.0 mg, 51%; 94:6 dr) as a yellow oil. Rf (7:3 Pet.Ether:Diethyl ether) 0.25; 1H 
NMR (400 MHz, CDCl3):  7.89 – 7.83 (2H, m, 2xAr-H), 7.40 – 7.32 (3H, m, 3xAr-H), 7.25 – 7.21 





(3H, s, NCH3), 2.87 (1H, ddd, J = 11.9, 9.7, 3.0 NCHCHOTBS), 1.97 – 1.88 (1H, m, CH), 1.57 – 
1.48 (1H, m, CH), 1.33 – 1.27 (1H, m, CH), 1.24 – 1.17 (3H, m, 3xCH), 0.96 (9H, s, SiC(CH3)3), 
0.76 – 0.64 (1H, m, CH), 0.20 (3H, s, Si(CH3,A)(CH3,B)), 0.07 (3H, Si(CH3,A)(CH3,B)), 0.06 to −0.03 
(1H, m, CH); 13C NMR (101 MHz, CDCl3): 167.83 (C=N), 162.91 (CAr, d, 1JC-F = 248.0), 155.67 
(C=O), 140.82 (CAr), 134.32 (CAr, d, 4JC-F = 3.1), 130.78 (2xCArH, d, 3JC-F = 8.0), 129.22 (CArH), 
129.00 (2xCArH), 128.95 (2xCArH), 115.58 (2xCArH, d, 2JC-F = 21.4), 74.81 (NC(Ar)Ph), 72.56 
(NCHCHOTBS), 61.15 (NCHCHOTBS), 37.59 (CH2), 29.34 (CH2), 26.21 (SiC(CH3)3), 25.59 
(NCH3), 25.37 (CH2), 24.71 (CH2), 18.36 (SiC(CH3)3), −3.77 (Si(CH3,A)(CH3,B)), −5.61 
(Si(CH3,A)(CH3,B)); 19F NMR (377 MHz, CDCl3) δF −114.09; (IR (vmax/cm-1) (neat): 3321 (NH), 
2930 (alkyl C-H), 2856 (alkyl C-H), 1737 (C=N), 1660 (C=O); HRMS (ESI): m/z calcd for 




Following general procedure 23 method A: LDA (2.00 M in THF/heptane/ethylbenzene, 0.14 mL, 
0.29 mmol) and -amino nitrile urea 488eb (47.5 mg, 0.096 mmol) in anhydrous THF (0.84 mL). 
The crude product (98:2 dr by 19F NMR) was purified by flash column chromatography (SiO2; 
Pet.Ether:Diethyl ether 100:0 to Pet.Ether:Diethyl ether 60:40) to afford the title compound (44.1 
mg, 93%; 98:2 dr) as a colourless oil. Rf (6:4 Pet.Ether:Diethyl ether) 0.17; 1H NMR (400 MHz, 
CDCl3):  7.86 – 7.81 (2H, m, 2xAr-H), 7.43 – 7.33 (3H, m, 3xAr-H), 7.26 – 7.21 (2H, m, 2xAr-
H), 7.08 – 7.01 (2H, m, 2xAr-H), 4.83 – 4.74 (1H, m, NCHCHOTBS), 3.13 (3H, s, NCH3), 2.89 
(1H, ddd, J = 11.9, 9.6, 3.0 NCHCHOTBS), 1.97 – 1.89 (1H, m, CH), 1.58 – 1.51 (1H, m, CH), 
1.39 – 1.21 (2H, m, 2xCH), 1.23 – 1.15 (2H, m, 2xCH), 0.96 (9H, s, SiC(CH3)3), 0.78 – 0.66 (1H, 
m, CH), 0.20 (3H, s, Si(CH3,A)(CH3,B)), 0.12 (1H, br. s, CH), 0.08 (3H, Si(CH3,A)(CH3,B)); 13C 
NMR (101 MHz, CDCl3): 167.79 (C=N), 162.95 (CAr, d, 1JC-F = 249.8), 155.69 (C=O), 138.35 (CAr), 
137.06 (CAr, ), 131.05 (2xCArH, d, 3JC-F = 8.2), 128.80 (2xCArH), 128.70 (2xCArH), 128.53 (CArH), 
115.84 (2xCArH, d, 2JC-F = 21.5), 74.67 (NC(Ar)Ph), 72.52 (NCHCHOTBS), 61.09 
(NCHCHOTBS), 37.59 (CH2), 29.56 (CH2), 26.23 (SiC(CH3)3), 25.63 (NCH3), 25.40 (CH2), 24.70 
(CH2), 18.35 (SiC(CH3)3), −3.78 (Si(CH3,A)(CH3,B)), −5.59 (Si(CH3,A)(CH3,B)); 19F NMR (377 
MHz, CDCl3) δF −112.09; (IR (vmax/cm-1) (neat): 3315 (NH), 2929, 2856 (alkyl C-H), 1732 















To a solution of the hydantoin urea 273a (100 mg, 0.256 mmol, 1.00 eq.), in anhydrous CH3CN 
(3.00 mL) was added Boc anhydride (118 mg, 0.54 mmol, 2.08 eq.) and DMAP (6.3 mg, 0.05 mmol, 
0.20 eq.). The reaction mixture was stirred at room temperature for 15 hours. The solvent was then 
removed under reduced pressure and the residue dissolved in ethyl acetate and washed with water. 
The organic layer was dried over MgSO4, filtered and the solvent removed under reduced pressure. 
The crude product was purified by flash column chromatography (SiO2; Pet.Ether:EtOAc 100:0 to 
Pet.Ether:EtOAc 80:20) to afford the title compound (72 mg, 65%) as a cloudy oil. Rf (8:2 
Pet.Ether:EtOAc) 0.39; 1H NMR (500 MHz, CDCl3):  7.73 – 7.66 (2H, m, Ar-H), 7.59 – 7.53 (2H, 
m, Ar-H), 7.42 – 7.36 (3H, m, Ar-H), 7.32 – 7.28 (2H, m, Ar-H), 1.63 (9H, s, NC(CH3)3), 1.19 (9H, 
s, OC(CH3)3); 13C NMR (125 MHz, CDCl3): 172.03 (C=O)boc, 152.55 (C=O), 147.87, (C=O), 
141.60 (CAr), 136.03 (CAr), 131.94 (2xCArH), 129.40 (2xCArH), 129.23 (CArH), 128.56 (2xCArH), 
128.30 (2xCArH), 118.39 (CN), 112.75 (CAr), 84.86 (OC(CH3)3), 72.33 (NCPh), 60.21 (NC(CH3)3), 
28.63 (NC(CH3)3), 27.78 (OC(CH3)3)); IR (vmax/cm-1) (neat): 2980, 2931 (alkyl C-H), 2230 









To a solution of the hydantoin urea 273e (277 mg, 0.68 mmol, 1.00 eq.) in anhydrous CH3CN was 
added Boc anhydride (309 mg, 1.41 mmol, 2.08 eq.) and DMAP (17.0 mg, 0.14 mmol, 0.20 eq.). 
The reaction mixture was stirred at room temperature for 15 hours. The solvent was then removed 
under reduced pressure and the residue dissolved in ethyl acetate and washed with water. The 
organic layer was dried over MgSO4, filtered and the solvent removed under reduced pressure. The 
crude product was purified by flash column chromatography (SiO2; Pet.Ether:EtOAc 100:0 to 
Pet.Ether:EtOAc 90:10) to afford the title compound (100 mg, 32%) as a white solid. Rf (9:1 
Pet.Ether:EtOAc) 0.29; mp: 170 – 173 °C; 1H NMR (400 MHz, CDCl3):  8.25 (2H, d, J = 8.9, Ar-
H), 7.64 (2H, d, J = 8.9, Ar-H), 7.40 (3H, dt, J = 4.6, 2.9, Ar-H), 7.33 – 7.28 (2H, m, Ar-H), 1.64 
(9H, s, NC(CH3)3), 1.20 (9H, s, OC(CH3)3); 13C NMR (100 MHz, CDCl3): 171.76 (C=O)boc, 152.34 
(C=O)urea, 147.82 (C=O)amide, 147.70 (CAr), 143.14 (CAr), 136.01 (CAr), 129.53 (2xCArH) 129.14 
(CArH), 128.45 (2xCArH), 128.13 (2xCArH), 123.12 (2xCArH), 84.81 (OC(CH3)3), 72.12 (NCPh), 
60.11 (NC(CH3)3), 28.47 (NC(CH3)3), 27.63 (OC(CH3)3); IR (vmax/cm-1) (neat): 2980, 2932 (alkyl 
C-H), 1808, 1747, 1737 (C=O); HRMS (ESI): m/z calcd for C24H27N3O6Na [M+Na]+ 476.1792, 
found 476.1796. 
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